<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus - Shepherd, ES - 2024 | Cochrane Library</title> <meta content="Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus - Shepherd, ES - 2024 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004661.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus - Shepherd, ES - 2024 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004661.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004661.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus" name="citation_title"/> <meta content="Emily S Shepherd" name="citation_author"/> <meta content="emily.shepherd@adelaide.edu.au" name="citation_author_email"/> <meta content="Shona Goldsmith" name="citation_author"/> <meta content="The University of Sydney" name="citation_author_institution"/> <meta content="Lex W Doyle" name="citation_author"/> <meta content="The University of Melbourne" name="citation_author_institution"/> <meta content="Philippa Middleton" name="citation_author"/> <meta content="Stéphane Marret" name="citation_author"/> <meta content="Dwight J Rouse" name="citation_author"/> <meta content="The Alpert Medical School of Brown University" name="citation_author_institution"/> <meta content="Peter Pryde" name="citation_author"/> <meta content="The University of Wisconsin School of Medicine and Public Health" name="citation_author_institution"/> <meta content="Hanne T Wolf" name="citation_author"/> <meta content="Hvidovre University Hospital" name="citation_author_institution"/> <meta content="Caroline A Crowther" name="citation_author"/> <meta content="The University of Auckland" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD004661.pub4" name="citation_doi"/> <meta content="2024" name="citation_date"/> <meta content="2024/05/10" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004661.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004661.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004661.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Bias; *Cerebral Palsy [prevention &amp; control]; *Magnesium Sulfate [adverse effects, therapeutic use]; *Neuroprotective Agents [therapeutic use]; *Premature Birth [prevention &amp; control]; *Randomized Controlled Trials as Topic; Tocolytic Agents [therapeutic use]" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004661.pub4&amp;doi=10.1002/14651858.CD004661.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004661.pub4&amp;doi=10.1002/14651858.CD004661.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004661.pub4&amp;doi=10.1002/14651858.CD004661.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004661.pub4&amp;doi=10.1002/14651858.CD004661.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004661.pub4&amp;doi=10.1002/14651858.CD004661.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004661.pub4&amp;doi=10.1002/14651858.CD004661.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004661.pub4&amp;doi=10.1002/14651858.CD004661.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004661.pub4&amp;doi=10.1002/14651858.CD004661.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004661.pub4&amp;doi=10.1002/14651858.CD004661.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004661.pub4&amp;doi=10.1002/14651858.CD004661.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004661.pub4&amp;doi=10.1002/14651858.CD004661.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004661.pub4&amp;doi=10.1002/14651858.CD004661.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004661.pub4&amp;doi=10.1002/14651858.CD004661.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004661.pub4&amp;doi=10.1002/14651858.CD004661.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004661.pub4&amp;doi=10.1002/14651858.CD004661.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004661.pub4&amp;doi=10.1002/14651858.CD004661.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004661.pub4&amp;doi=10.1002/14651858.CD004661.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004661.pub4&amp;doi=10.1002/14651858.CD004661.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004661.pub4&amp;doi=10.1002/14651858.CD004661.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004661.pub4&amp;doi=10.1002/14651858.CD004661.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004661.pub4&amp;doi=10.1002/14651858.CD004661.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004661.pub4&amp;doi=10.1002/14651858.CD004661.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004661.pub4&amp;doi=10.1002/14651858.CD004661.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="xcg9958b";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004661\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004661\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004661\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004661\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ru","ko","ms","hr","fa","fr","pl"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD004661.pub4",title:"Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus",firstPublishedDate:"May 10, 2024 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Z_INACTIVE_Pregnancy and Childbirth Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xcg9958b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004661.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004661.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004661.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004661.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004661.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004661.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004661.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004661.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004661.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004661.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>17575 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004661.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004661.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004661.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004661.pub4/full#CD004661-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004661.pub4/full#CD004661-sec-0177"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004661.pub4/full#CD004661-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004661.pub4/full#CD004661-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004661.pub4/full#CD004661-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004661.pub4/full#CD004661-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004661.pub4/full#CD004661-sec-0066"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004661.pub4/full#CD004661-sec-0171"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004661.pub4/appendices#CD004661-sec-0183"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/supinfo/CD004661-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/supinfo/CD004661-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004661.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004661.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004661.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004661.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004661.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004661.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2024 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004661.pub4/information#CD004661-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Emily S Shepherd</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004661.pub4/information#CD004661-cr-0005">Shona Goldsmith</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004661.pub4/information#CD004661-cr-0006">Lex W Doyle</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004661.pub4/information#CD004661-cr-0007">Philippa Middleton</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004661.pub4/information#CD004661-cr-0008">Stéphane Marret</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004661.pub4/information#CD004661-cr-0009">Dwight J Rouse</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004661.pub4/information#CD004661-cr-0010">Peter Pryde</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004661.pub4/information#CD004661-cr-0011">Hanne T Wolf</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004661.pub4/information#CD004661-cr-0012">Caroline A Crowther</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/information/en#CD004661-sec-0194">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 10 May 2024 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004661.pub4">https://doi.org/10.1002/14651858.CD004661.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004661-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004661-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004661-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004661-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004661-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD004661-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004661-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004661-abs-0001" lang="en"> <section id="CD004661-sec-0001"> <h3 class="title" id="CD004661-sec-0001">Background</h3> <p>Magnesium sulphate is a common therapy in perinatal care. Its benefits when given to women at risk of preterm birth for fetal neuroprotection (prevention of cerebral palsy for children) were shown in a 2009 Cochrane review. Internationally, use of magnesium sulphate for preterm cerebral palsy prevention is now recommended practice. As new randomised controlled trials (RCTs) and longer‐term follow‐up of prior RCTs have since been conducted, this review updates the previously published version. </p> </section> <section id="CD004661-sec-0002"> <h3 class="title" id="CD004661-sec-0002">Objectives</h3> <p>To assess the effectiveness and safety of magnesium sulphate as a fetal neuroprotective agent when given to women considered to be at risk of preterm birth. </p> </section> <section id="CD004661-sec-0003"> <h3 class="title" id="CD004661-sec-0003">Search methods</h3> <p>We searched Cochrane Pregnancy and Childbirth's Trials Register, ClinicalTrials.gov, and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) on 17 March 2023, as well as reference lists of retrieved studies. </p> </section> <section id="CD004661-sec-0004"> <h3 class="title" id="CD004661-sec-0004">Selection criteria</h3> <p>We included RCTs and cluster‐RCTs of women at risk of preterm birth that assessed prenatal magnesium sulphate for fetal neuroprotection compared with placebo or no treatment. All methods of administration (intravenous, intramuscular, and oral) were eligible. We did not include studies where magnesium sulphate was used with the primary aim of preterm labour tocolysis, or the prevention and/or treatment of eclampsia. </p> </section> <section id="CD004661-sec-0005"> <h3 class="title" id="CD004661-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed RCTs for inclusion, extracted data, and assessed risk of bias and trustworthiness. Dichotomous data were presented as summary risk ratios (RR) with 95% confidence intervals (CI), and continuous data were presented as mean differences with 95% CI. We assessed the certainty of the evidence using the GRADE approach. </p> </section> <section id="CD004661-sec-0006"> <h3 class="title" id="CD004661-sec-0006">Main results</h3> <p>We included six RCTs (5917 women and their 6759 fetuses alive at randomisation). All RCTs were conducted in high‐income countries. The RCTs compared magnesium sulphate with placebo in women at risk of preterm birth at less than 34 weeks' gestation; however, treatment regimens and inclusion/exclusion criteria varied. Though the RCTs were at an overall low risk of bias, the certainty of evidence ranged from high to very low, due to concerns regarding study limitations, imprecision, and inconsistency. </p> <p><b>Primary outcomes for infants/children:</b><i>Up to two years’ corrected age</i>, magnesium sulphate compared with placebo reduced cerebral palsy (RR 0.71, 95% CI 0.57 to 0.89; 6 RCTs, 6107 children; number needed to treat for additional beneficial outcome (NNTB) 60, 95% CI 41 to 158) and death or cerebral palsy (RR 0.87, 95% CI 0.77 to 0.98; 6 RCTs, 6481 children; NNTB 56, 95% CI 32 to 363) (both high‐certainty evidence). Magnesium sulphate probably resulted in little to no difference in death (fetal, neonatal, or later) (RR 0.96, 95% CI 0.82 to 1.13; 6 RCTs, 6759 children); major neurodevelopmental disability (RR 1.09, 95% CI 0.83 to 1.44; 1 RCT, 987 children); or death or major neurodevelopmental disability (RR 0.95, 95% CI 0.85 to 1.07; 3 RCTs, 4279 children) (all moderate‐certainty evidence). <i>At early school age</i>, magnesium sulphate may have resulted in little to no difference in death (fetal, neonatal, or later) (RR 0.82, 95% CI 0.66 to 1.02; 2 RCTs, 1758 children); cerebral palsy (RR 0.99, 95% CI 0.69 to 1.41; 2 RCTs, 1038 children); death or cerebral palsy (RR 0.90, 95% CI 0.67 to 1.20; 1 RCT, 503 children); and death or major neurodevelopmental disability (RR 0.81, 95% CI 0.59 to 1.12; 1 RCT, 503 children) (all low‐certainty evidence). Magnesium sulphate may also have resulted in little to no difference in major neurodevelopmental disability, but the evidence is very uncertain (average RR 0.92, 95% CI 0.53 to 1.62; 2 RCTs, 940 children; very low‐certainty evidence). </p> <p><b>Secondary outcomes for infants/children:</b> Magnesium sulphate probably reduced severe intraventricular haemorrhage (grade 3 or 4) (RR 0.76, 95% CI 0.60 to 0.98; 5 RCTs, 5885 infants; NNTB 92, 95% CI 55 to 1102; moderate‐certainty evidence) and may have resulted in little to no difference in chronic lung disease/bronchopulmonary dysplasia (average RR 0.92, 95% CI 0.77 to 1.10; 5 RCTs, 6689 infants; low‐certainty evidence). </p> <p><b>Primary outcomes for women:</b> Magnesium sulphate may have resulted in little or no difference in severe maternal outcomes potentially related to treatment (death, cardiac arrest, respiratory arrest) (RR 0.32, 95% CI 0.01 to 7.92; 4 RCTs, 5300 women; low‐certainty evidence). However, magnesium sulphate probably increased maternal adverse effects severe enough to stop treatment (average RR 3.21, 95% CI 1.88 to 5.48; 3 RCTs, 4736 women; moderate‐certainty evidence). </p> <p><b>Secondary outcomes for women:</b> Magnesium sulphate probably resulted in little to no difference in caesarean section (RR 0.96, 95% CI 0.91 to 1.02; 5 RCTs, 5861 women) and postpartum haemorrhage (RR 0.94, 95% CI 0.80 to 1.09; 2 RCTs, 2495 women) (both moderate‐certainty evidence). Breastfeeding at hospital discharge and women’s views of treatment were not reported. </p> </section> <section id="CD004661-sec-0007"> <h3 class="title" id="CD004661-sec-0007">Authors' conclusions</h3> <p>The currently available evidence indicates that magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus, compared with placebo, reduces cerebral palsy, and death or cerebral palsy, in children up to two years' corrected age, and probably reduces severe intraventricular haemorrhage for infants. Magnesium sulphate may result in little to no difference in outcomes in children at school age. </p> <p>While magnesium sulphate may result in little to no difference in severe maternal outcomes (death, cardiac arrest, respiratory arrest), it probably increases maternal adverse effects severe enough to stop treatment. </p> <p>Further research is needed on the longer‐term benefits and harms for children, into adolescence and adulthood. Additional studies to determine variation in effects by characteristics of women treated and magnesium sulphate regimens used, along with the generalisability of findings to low‐ and middle‐income countries, should be considered. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004661-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004661-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD004661-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD004661-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004661-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004661-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD004661-abs-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD004661-abs-0009">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD004661-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD004661-abs-0016">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD004661-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004661-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD004661-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004661-abs-0002" lang="en"> <h3>Is magnesium sulphate for women at risk of preterm birth better than placebo for protecting their babies' brains? </h3> <p><b>Key messages</b> </p> <p>Magnesium sulphate given to women at risk of preterm birth for protecting their babies' brains reduces cerebral palsy, and the combined outcome of death or cerebral palsy, in their children up to two years of age, when compared with placebo. </p> <p>Future research in this area should focus on the effects of treatment:</p> <p>• on children when they are adolescents and adults; and</p> <p>• for different groups of women at risk of preterm birth, and with different ways of giving magnesium sulphate. </p> <p><b>What is magnesium sulphate?</b> </p> <p>Magnesium sulphate is a common medicine used across the world for different complications in pregnancy. </p> <p><b>Why is this important for women at risk of preterm birth and their babies?</b> </p> <p>Babies born early (preterm, before 37 weeks of pregnancy) have a higher risk of complications including death and disabilities, such as cerebral palsy. In recent years, magnesium sulphate has been given to women who are likely to have their babies preterm (because of spontaneous preterm labour, or a medical indication to plan an induction of labour or caesarean birth early) to help protect their babies' brains and prevent these complications. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to find out if magnesium sulphate is better than placebo (a 'dummy' treatment that does not contain any medicine but appears identical to the medicine being tested) at protecting the brains of babies likely to be born preterm. </p> <p>We were interested in the effect of magnesium sulphate on important outcomes, including: death (of the babies, or later as children), cerebral palsy, and major 'neurodevelopmental disability' (which might include serious outcomes like cerebral palsy, blindness, deafness, or global cognitive or intellectual impairment). We were also interested in the effect on important outcomes for women, including serious complications of magnesium sulphate (death, respiratory or cardiac arrest), and stopping treatment because of side effects. </p> <p><b>What did we do?</b> </p> <p>We searched for studies that looked at whether magnesium sulphate caused benefits or harms for women and their preterm babies when compared to placebo or no treatment. We compared and summarised results and rated our confidence in the evidence, based on factors such as study methods and sizes. </p> <p><b>What did we find?</b> </p> <p>We found six studies involving 5917 women at less than 34 weeks of pregnancy and their 6759 babies. The studies were all conducted in high‐income countries. The included studies compared magnesium sulphate with placebo. </p> <p><b>Main results</b> </p> <p>Compared with placebo, magnesium sulphate in women at risk of having their babies preterm: </p> <p>• reduces cerebral palsy (evidence from 6 studies with 6107 children) and the combined outcome of death or cerebral palsy (6 studies, 6481 children) for children up to two years of age; </p> <p>• probably makes little to no difference in death (6 studies, 6759 children), major neurodevelopmental disability (1 study, 987 children), or the combined outcome of death or major neurodevelopmental disability (3 studies, 4279 children), for children up to two years of age; </p> <p>• may make little to no difference in the above‐mentioned outcomes for children at early school age; </p> <p>• may make little to no difference in serious complications of treatment for women (4 studies, 5300 women), but probably increases women stopping treatment because of side effects (3 studies, 4736 women). </p> <p><b>What are the limitations of the evidence?</b> </p> <p>We are confident in our finding that magnesium sulphate reduces cerebral palsy, and the combined outcome of death or cerebral palsy, in children up to two years of age. </p> <p>We have little confidence in the evidence for outcomes of children at school age, as studies could not provide data for all children, and there are not yet enough studies/data to be certain about the results. </p> <p>We have little confidence in our finding that magnesium sulphate makes little to no difference in serious complications of treatment for women, as there was only one complication reported in one study. We have moderate confidence in our findings that magnesium sulphate probably increases women stopping treatment because of side effects, as the findings differed across studies, probably because of different decision‐making processes for stopping treatment. </p> <p>The results of further research for the outcomes in which we have limited confidence could differ from the results of this review. </p> <p><b>How up‐to‐date is this evidence?</b> </p> <p>The evidence is current to 17 March 2023.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004661-sec-0177" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004661-sec-0177"></div> <h3 class="title" id="CD004661-sec-0178">Implications for practice</h3> <section id="CD004661-sec-0178"> <p>There is high‐certainty evidence that magnesium sulphate given to women at risk of preterm birth for neuroprotection of the fetus reduces cerebral palsy, and death or cerebral palsy, for children up to two years' corrected age when compared to placebo. There is moderate‐certainty evidence that magnesium sulphate probably reduces severe intraventricular haemorrhage for neonates. There is low‐ to very low‐certainty evidence that magnesium sulphate may result in little to no difference in outcomes at school age. </p> <p>While there is low‐certainty evidence that magnesium sulphate may result in little to no difference in severe maternal outcomes (death, cardiac arrest, respiratory arrest), there is moderate‐certainty evidence that magnesium sulphate probably increases adverse effects severe enough to stop treatment. </p> <p>The available data are from six randomised controlled trials that randomised women at less than 34 weeks' gestation and were conducted in high‐income countries. </p> </section> <h3 class="title" id="CD004661-sec-0179">Implications for research</h3> <section id="CD004661-sec-0179"> <p>Further research is needed on the longer‐term benefits and harms of magnesium sulphate when given to women at risk of preterm birth for neuroprotection of the fetus, including follow‐up of children into adolescence and adulthood. Any future studies should use robust methodology, and aim for consistency in outcome measurement and reporting (using standardised, ideally contemporary assessment methods), to facilitate pooling of data. </p> <p>As the available evidence does not support clear variation in treatment effects according to characteristics of women treated and treatment regimens used, further studies addressing persisting uncertainties regarding which women to treat, when, and how, should be prioritised. This will help to ensure that women whose children are likely to benefit from exposure are not denied treatment; and that women whose children will likely not benefit from treatment are not exposed unnecessarily. Research to address the generalisability of review findings to low‐ and middle‐income countries should also be considered. </p> <p>The <a href="./references#CD004661-bbs1-0003" title="">Studies awaiting classification</a> and <a href="./references#CD004661-bbs1-0004" title="">Ongoing studies</a> may contribute to addressing some of these gaps. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004661-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004661-sec-0008"></div> <div class="table" id="CD004661-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Magnesium sulphate versus placebo (outcomes for infants/children, up to 2 years' corrected age)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Magnesium sulphate versus placebo (outcomes for infants/children, up to 2 years' corrected age)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> women at risk of preterm birth (&lt; 34 weeks' gestation)<br/><b>Setting:</b> hospitals in high‐income countries<br/><b>Intervention:</b> magnesium sulphate<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with magnesium sulphate</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death (fetal, neonatal, or later (up to 2 years' corrected age))**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>78 per 1000 (66 to 92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.96</b> (0.82 to 1.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6759 (6 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy (up to 2 years' corrected age)**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000 (33 to 52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.71</b> (0.57 to 0.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6107 (6 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death or cerebral palsy (up to 2 years' corrected age)**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>138 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 per 1000 (106 to 135)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.87</b> (0.77 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6481 (6 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major neurodevelopmental disability (up to 2 years' corrected age)**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>162 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>177 per 1000 (135 to 233)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.09</b> (0.83 to 1.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>987 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death or major neurodevelopmental disability (up to 2 years' corrected age)**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>223 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>212 per 1000 (190 to 239)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b> (0.85 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4279 (3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe intraventricular haemorrhage (grade 3 or 4) (newborn/infant)**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000 (27 to 44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.76</b> (0.60 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5885 (5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic lung disease/bronchopulmonary dysplasia (newborn/infant)**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>183 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>168 per 1000 (141 to 201)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.92</b> (0.77 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6689 (5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>**Outcomes as defined by RCT authors.<br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded 1 level due to imprecision, as the 95% CI includes both benefit and harm.<br/><sup>b</sup>Not downgraded for risk of bias; however, data from 1 RCT from secondary analysis (result remained similar when this RCT was excluded from meta‐analysis).<br/><sup>c</sup>Downgraded 1 level due to risk of bias, as when data from 1 RCT with potential methodological concerns were excluded from the meta‐analysis the 95% CI includes the null value. <br/><sup>d</sup>Downgraded 1 level due to inconsistency as evidenced by statistical heterogeneity that could be due to variations in outcome definitions. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004661-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Magnesium sulphate versus placebo (outcomes for infants/children, up to school age)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Magnesium sulphate versus placebo (outcomes for infants/children, up to school age)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> women at risk of preterm birth (&lt; 34 weeks' gestation)<br/><b>Setting:</b> hospitals in high‐income countries<br/><b>Intervention:</b> magnesium sulphate<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with magnesium sulphate</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death (fetal, neonatal, or later (up to school age))**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>169 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>139 per 1000 (112 to 172)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.82</b> (0.66 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1758 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy (school age)**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>103 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>102 per 1000 (71 to 145)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b> (0.69 to 1.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1038 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death or cerebral palsy (up to school age)**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>283 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>255 per 1000 (190 to 340)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.90</b> (0.67 to 1.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>503 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major neurodevelopmental disability (school age)**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>116 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>107 per 1000 (62 to 188)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.92</b> (0.53 to 1.62) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>940 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death or major neurodevelopmental disability (up to school age)**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>259 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>210 per 1000 (153 to 290)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.81</b> (0.59 to 1.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>503 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>**Outcomes as defined by RCT authors.<br/><b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded 1 level due to risk of bias, as the included RCTs were judged to have some limitations due to missing outcome data at school age follow‐up.<br/><sup>b</sup>Downgraded 1 level due to imprecision, as the 95% CI includes both benefit and harm.<br/><sup>c</sup>Downgraded 1 level due to inconsistency as evidenced by statistical heterogeneity that could be due to variations in outcome definitions. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004661-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Magnesium sulphate versus placebo (outcomes for women)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Magnesium sulphate versus placebo (outcomes for women)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> women at risk of preterm birth (&lt; 34 weeks' gestation)<br/><b>Setting:</b> hospitals in high‐income countries<br/><b>Intervention:</b> magnesium sulphate<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with magnesium sulphate</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest)** </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/>(0 to 8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.32</b> (0.01 to 7.92) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5300 (4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects severe enough to stop treatment**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1000 (36 to 104)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.21</b> (1.88 to 5.48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4736 (3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mode of birth (caesarean section)**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>476 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>457 per 1000 (433 to 486)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.96</b> (0.91 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5861 (5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Postpartum haemorrhage**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>216 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>203 per 1000 (173 to 235)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b> (0.80 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2495 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Breastfeeding at hospital discharge**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No RCTs reported data for this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women’s views of treatment**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No RCTs reported data for this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>**Outcomes as defined by RCT authors.<br/><b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded 2 levels due to imprecision, as there was only 1 event and a wide 95% CI includes both benefit and harm.<br/><sup>b</sup>Downgraded 1 level due to inconsistency as evidenced by statistical heterogeneity that could be due to differences in protocols for stopping treatment.<br/><sup>c</sup>Downgraded 1 level due to inconsistency as evidenced by statistical heterogeneity that could be due to differences in birth intervention practices.<br/><sup>d</sup>Downgraded 1 level due to imprecision, as the 95% CI includes both benefit and harm. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004661-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004661-sec-0009"></div> <section id="CD004661-sec-0010"> <h3 class="title" id="CD004661-sec-0010">Description of the condition</h3> <p>Cerebral palsy is a heterogeneous group of disorders of movement and posture, causing activity limitation, attributed to a non‐progressive maldevelopment or insult to the developing brain. It is commonly accompanied by disorders of sensation, perception, cognition, communication, and behaviour (<a href="./references#CD004661-bbs2-0027" title="BekteshiS , MonbaliuE , McIntyreS , SaloojeeG , HilberinkSR , TatishviliN , et al. Towards functional improvement of motor disorders associated with cerebral palsy. Lancet Neurology2023;22:229-43.">Bekteshi 2023</a>; <a href="./references#CD004661-bbs2-0054" title="RosenbaumP , PanethN , LevitonA , GoldsteinM , BaxM , DamianoD , DanB , JacobssonB . A report: the definition and classification of cerebral palsy April 2006. Developmental Medicine &amp; Child Neurology2007;109:8-14.">Rosenbaum 2007</a>). Despite variation in definitions and classifications of cerebral palsy, there is wide agreement that it is the most prevalent physical disability in childhood. Though recent evidence suggests that the birth prevalence of cerebral palsy in high‐income countries is declining, it continues to affect approximately one in 600 babies (1.6 per 1000 live births; 95% confidence interval (CI) 1.5 to 1.7). While limited, available cerebral palsy data from low‐ and middle‐income countries suggest a markedly higher birth prevalence (up to 3.4 per 1000; 95% CI 3.0 to 3.9 live births) (<a href="./references#CD004661-bbs2-0050" title="McIntyreS , GoldsmithS , WebbA , EhlingerV , HollungSJ , McConnellK , ArnaudC , Smithers-SheedyH , OskouiM , KhandakerG , HimmelmannK . Global prevalence of cerebral palsy: A systematic analysis. Developmental Medicine &amp; Child Neurology2022;64(12):1494-506.">McIntyre 2022</a>). </p> <p>For approximately 94% of individuals with cerebral palsy, their maldevelopment or brain insult is believed to have occurred in utero or the neonatal period (<a href="./references#CD004661-bbs2-0025" title="ACPR Group. Australian Cerebral Palsy Register Report 2023. cpregister.com/wp-content/uploads/2023/01/2023-ACPR-Report.pdf (accessed 18 October 2023).">ACPR 2023</a>). The causal pathways to cerebral palsy are complex, resulting from multiple interacting pre‐, peri‐, and/or postnatal environmental factors, and influenced by genetic background (summarised in <a href="./references#CD004661-bbs2-0056" title="ShepherdE , SalamRA , MiddletonP , MakridesM , McIntyreS , BadawiN , CrowtherCA . Antenatal and intrapartum interventions for preventing cerebral palsy: an overview of Cochrane systematic reviews. Cochrane Database of Systematic Reviews2017, Issue 8. Art. No: CD012077. [DOI: 10.1002/14651858.CD012077.pub2]">Shepherd 2017</a>; <a href="./references#CD004661-bbs2-0057" title="ShepherdE , SalamRA , MiddletonP , HanS , MakridesM , McIntyreS , BadawiN , CrowtherCA . Neonatal interventions for preventing cerebral palsy: an overview of Cochrane Systematic Reviews. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD012409. [DOI: 10.1002/14651858.CD012409.pub2]">Shepherd 2018</a>). For many individuals, the exact cause(s) remains unknown (<a href="./references#CD004661-bbs2-0046" title="KorzeniewskiSJ , SlaughterJ , LenskiM , HaakP , PanethN . The complex aetiology of cerebral palsy. Nature Reviews Neurology2018;14(9):528-43.">Korzeniewski 2018</a>). Despite there being many risk factors for cerebral palsy (e.g. preterm birth, at less than 37 weeks’ gestation, with over 40% of individuals with cerebral palsy born preterm versus ~8% to 9% of the general population (<a href="./references#CD004661-bbs2-0025" title="ACPR Group. Australian Cerebral Palsy Register Report 2023. cpregister.com/wp-content/uploads/2023/01/2023-ACPR-Report.pdf (accessed 18 October 2023).">ACPR 2023</a>)), there is no cure. Prevention remains crucial. </p> </section> <section id="CD004661-sec-0011"> <h3 class="title" id="CD004661-sec-0011">Description of the intervention</h3> <p>Magnesium sulphate is a common therapy in perinatal care, with longstanding use globally for preventing and treating eclampsia and pre‐eclampsia (<a href="./references#CD004661-bbs2-0034" title="DuleyL , GülmezogluAM , Henderson-SmartDJ , ChouD . Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database of Systematic Reviews2010, Issue 11. Art. No: CD000025. [DOI: 10.1002/14651858.CD000025.pub2]">Duley 2010</a>; <a href="./references#CD004661-bbs2-0039" title="Fishel BartalM , SibaiBM . Eclampsia in the 21st century. American Journal of Obstetrics and Gynecology2022;226(2s):S1237-53.">Fishel 2022</a>), preterm labour tocolysis (though controversial) (<a href="./references#CD004661-bbs2-0038" title="ElliottJP , MorrisonJC , BofillJA . Risks and benefits of magnesium sulfate tocolysis in preterm labor (PTL). AIMS Public Health2016;3(2):348-56.">Elliott 2016</a>), and, in the last decade, for preterm fetal neuroprotection, or cerebral palsy prevention (<a href="./references#CD004661-bbs2-0067" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. Art. No: CD004661. [DOI: 10.1002/14651858.CD004661.pub3]">Doyle 2009</a>). </p> <p>Two landmark observational studies in the 1990s first reported reduced risks of perinatal brain injury and cerebral palsy among infants who were exposed to magnesium sulphate in utero, when given to their mothers for pre‐eclampsia treatment (<a href="./references#CD004661-bbs2-0047" title="KubanK , LevitonA , PaganoM , FentonT , StrasfeldR , WolffM . Maternal toxemia is associated with reduced incidence of germinal matrix hemorrhage in premature babies. Journal of Child Neurology1992;7:70-6.">Kuban 1992</a>; <a href="./references#CD004661-bbs2-0051" title="NelsonKB , GretherJK . Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants?Pediatrics1995;95:1-10.">Nelson 1995</a>). Subsequent to these, and further observational studies (<a href="./references#CD004661-bbs2-0062" title="WolfHT , HegaardHK , GreisenG , HuusomL , HedegaardM . Treatment with magnesium sulphate in pre-term birth: a systematic review and meta-analysis of observational studies. Journal of Obstetrics and Gynaecology2012;32(2):135-40.">Wolf 2012</a>), five randomised controlled trials (RCTs) (conducted from 1995 to 2004) assessed prenatal magnesium sulphate and outcomes associated with preterm fetal neuroprotection, including cerebral palsy (<a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a>; <a href="./references#CD004661-bbs2-0010" title="DuleyL . The Magpie Trial follow up study: Outcome after discharge from hospital for women and children recruited to a trial comparing magnesium sulphate with placebo for pre-eclampsia [ISRCTN86938761]. BMC Pregnancy and Childbirth2004;4(1):5. Magpie Trial Follow Up Study Collaborative Group. The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months. BJOG: an international journal of obstetrics and gynaecology2007;114(3):289-99. ">Magpie 2006</a>; <a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a>; <a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a>; <a href="./references#CD004661-bbs2-0005" title="BrookfieldKF , O'MalleyK , Yeaton-MasseyA , ButwickAJ . Does magnesium sulfate exposure attenuate the effect of steroids administered for fetal lung maturation? In: Society for Obstetric Anesthesia and Perinatology (SOAP) 48th Annual Meeting; 2016 May 18-22; Boston USA. 2016:SA-32. BuhimschiCS , JablonskiKA , RouseDJ , VarnerMW , ReddyUM , MercerBM , et al. Cord blood haptoglobin, cerebral palsy and death in infants of women at risk for preterm birth: a secondary analysis of a randomised controlled trial. Eclinicalmedicine2019;9:11-8. CostantineMM , WeinerSJ , RouseDJ , HirtzDG , VarnerMW , SpongCY , et al. Umbilical cord blood biomarkers of neurologic injury and the risk of cerebral palsy or infant death. International Journal of Developmental Neuroscience2011;29(8):917-22. CostantineMM . Cord blood biomarkers and the risk of cerebral palsy or death. Reproductive Sciences2010;17(3 Suppl 1):65A. DeihlTE , SimhanHN . Antenatal magnesium sulfate and ponderal index from birth to age 2 in preterm male and female infants. Reproductive Sciences2017;24(Suppl 1):130A. DeihlTE , SimhanHN . Antenatal magnesium sulfate exposure and ponderal index in preterm infants. American Journal of Perinatology2019;36(3):329-34. DenobleAE , WuJ , MitchellCJ , HughesBL , Dotters-KatzSK . Chorioamnionitis versus intraamniotic infection among preterm deliveries-is postpartum infectious morbidity different?American Journal of Obstetrics and Gynecology MFM2020;2(3):100176. DrassinowerD , FriedmanAM , LevinH , ObicanSG , Gyamfi-BannermanC . Does magnesium exposure affect neonatal resuscitation? Presented as a poster at the 35th annual meeting of the society for maternal-fetal medicine, San Diego, CA, Feb. 2-7, 2015. American Journal of Obstetrics and Gynecology2015;213(3):424e1-5. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm prelabour rupture of membranes and neurodevelopmental outcomes: a secondary analysis. BJOG: an international journal of obstetrics and gynaecology2016;123(10):1629-35. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of cerebral palsy. Journal of Maternal-Fetal &amp; Neonatal Medicine2016;29(17):2748-52. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of neonatal sepsis. American Journal of Obstetrics and Gynecology2016;214(6):743.e1-6. DrassinowerD , LevinH , ObicanS , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on cerebral palsy. American Journal of Obstetrics and Gynecology2015;212(1):S310-1. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . Immediate neonatal outcomes in infants exposed to magnesium sulfate at the time of delivery. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S90. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1):S161-2. EdwardsJ , EdwardsL , SwamyG , GrotegutC . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S215-6. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Effect of cord blood magnesium level at birth on non-neurologic neonatal outcomes. American Journal of Perinatology2019;36(1):3-7. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. Journal of Maternal-Fetal &amp; Neonatal Medicine2018;31(9):1156-60. FaucettAM , MetzTD , DeWittPE , GibbsRS . Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2016;214(2):287.e1-5. HaarEV , Gyamfi-BannermanC , Coletta-LucasJ . Sepsis but not chorioamnionitis is associated with cerebral palsy. Reproductive Sciences2015;22:372A. HaarEV , Gyamfi-BannermanC , RandisTM . Abnormal brain imaging in infants exposed to chorioamnionitis and sepsis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl. 1):S11-2. HaarEV , LucasJC , D'AltonM , Gyamfi-BannermanC . The effect of chorioamnionitis on neurocognitive development at age 2. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S139-40. HerreraC , SilverRM , MajorH , VarnerMW , ClarkEAS . Triple I criteria and adverse neonatal and childhood outcomes after early preterm birth. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S250. HirtzDG , WeinerSJ , BulasD , DiPietroM , SeibertJ , RouseDJ , et al. Antenatal magnesium and cerebral palsy in preterm infants. Journal of Pediatrics2015;167(4):834-9.e3. HirtzDG . Effect of prenatal MgSO4 on head ultrasound imaging in preterm infants. Annals of Neurology2011;70(Suppl 15):S110. HortonA . The effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S209. HortonL , YingleiL , RouseJ , SpongY , LevenoJ , VarnerW , et al. Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Perinatology2015;32(4):387-92. JohnsonLH , MappDC , RouseDJ , SpongCY , MercerBM , LevenoKJ , et al. Association of cord blood magnesium concentration and neonatal resuscitation. Journal of Pediatrics2012;160(4):573-7.e1. KachikisA , WalkerC , McAdamsR , WaldorfKA , Gyamfi-BannermanC . Influence of preterm premature rupture of membranes on neonatal respiratory complications. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S215. KachikisA , WalkerCL , McAdamsRM , Gyamfi-BannermanC , Adams WaldorfKM . Phenotypic overlap in neonatal respiratory morbidity following preterm premature rupture of membranes versus spontaneous preterm labor. Journal of Maternal-fetal &amp; Neonatal Medicine2021;34(12):1941-8. KamyarM , ClarkEA , YoderBA , VarnerMW , ManuckTA . Antenatal magnesium sulfate, necrotizing enterocolitis, and death among neonates &lt; 28 weeks gestation. AJP Reports2016;6(1):e148-54. KamyarM , ClarkEAS , VarnerMW , ManuckTA . Chorioamnionitis prevents protective effect of magnesium sulfate in the preterm infant. Reproductive Sciences2014;21(3 Suppl 1):78A. KamyarM , ManuckTA , StoddardGJ , VarnerMW , ClarkEAS . Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. BJOG: an international journal of obstetrics and gynaecology2016;123(7):1161-6. KamyarM , VarnerM , ClarkE . Magnesium sulfate neuroprophylaxis and the effect of infant sex. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S144. ManuckA , ShengX , YoderA , VarnerW . Correlation between initial neonatal and early childhood outcomes following preterm birth. American Journal of Obstetrics &amp; Gynecology2014;210(5):426.e1-9. ManuckT , ShengX , YoderB , VarnerM . Correlation between initial neonatal and early childhood outcomes among children delivered &lt;34 weeks gestation. American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S23. ManuckT , VarnerM . Is bigger better? Neonatal and childhood outcomes of large for gestational age (LGA) infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341-2. ManuckT , VarnerM . Neonatal and childhood outcomes following early vs later preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S340-1. ManuckT , VarnerM . Neonatal and childhood outcomes of small for gestational age infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341. ManuckTA , VarnerMW . Neonatal and early childhood outcomes following early vs later preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2014;211(3):308.e1-6. MarrsC , Mendez-FigueroaH , ChauhanS . Periventricular leukomalacia with PPROM: Obstetric antecedents and infants' outcomes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S85. MarrsCC , Mendez-FigueroaH , HammadIA , ChauhanSP . Differential morbidity in preterm small versus appropriate for gestational age: perhaps unverifiable. American Journal of Perinatology2015;32(13):1251-6. McPhersonJ , SmileyS , StamiloD . Magnesium sulfate neuroprotection and obesity: Is efficacy affected by obesity. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S218. McPhersonJA , RouseDJ , GrobmanWA , PalatnikA , StamilioDM . Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. Obstetrics and Gynecology2014;124(4):749-55. McPhersonJA , SmileyS , StamilioDM . Maternal obesity and neuroprotective magnesium sulfate. American Journal of Obstetrics and Gynecology2015;213(4):582.e1–6. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate &lt; 12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S252. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate for &gt;12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S104-5. Mendez-FigueroaH , ChauhanSP , PedrozaC , RefuerzoJS , DahlkeJD , RouseDJ . Preterm cesarean delivery for nonreassuring fetal heart rate: neonatal and neurologic morbidity. Obstetrics and Gynecology2015;125(3):636-42. Mendez-FigueroaH , DahlkeJD , ViteriOA , ChauhanSP , RouseDJ , SibaiBM , et al. Neonatal and infant outcomes in twin gestations with preterm premature rupture of membranes at 24-31 weeks of gestation. Obstetrics and Gynecology2014;124(2 Pt 1):323-31. MoussaH , Hosseini NasabS , FournieD , OntiverosA , AlkawasR , ChauhanS , et al. The impact of time of delivery on gestations complicated by preterm premature rupture of membranes: daytime versus nighttime. Journal of Maternal-Fetal &amp; Neonatal Medicine2019;32(20):3319-24. NCT00014989. Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) [Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)]. clinicaltrials.gov/show/NCT00014989 (first received 18 April 2001). NussEE , SpiegelmanJ , TuritzAL , Gyamfi-BannermanC . Childhood neurodevelopment after spontaneous versus indicated preterm birth. American Journal of Obstetrics and Gynecology MFM2020;2(2):100082. ObicanS , DrassinowerD , LevinH , Gyamfi-BannermanC . Mode of delivery at periviability and early childhood neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S124. OvertonE , BaptisteC , Gyamfi-BannermanC . 546: neurodevelopmental outcomes in late preterm and early term deliveries following antenatal corticosteroid exposure. American Journal of Obstetrics and Gynecology2019;220(1):S365-6. PalatnikA , RouseD , StamiloD , McPhersonJ , GrobmanW . The association between cerebral palsy or death and umbilical cord magnesium concentration. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S302. RobbinsLS , BlanchardCT , BiasiniFJ , PowellMF , CaseyBM , TitaAT , et al. General anesthesia for cesarean delivery and childhood neurodevelopmental and perinatal outcomes: a secondary analysis of a randomized controlled trial. International Journal of Obstetric Anesthesia2020;45:34-40. RobbinsLS , BlanchardCT , SinkeyRG , HarrisSL , TitaAT , HarperLM . Prenatal tobacco exposure and childhood neurodevelopment among infants born prematurely. American Journal of Perinatology2020;38(3):218-23. RobertsR , Ankumah N-A, ViteriO , Mendez-FigueroaH , ChauhanS , SibaiB . Significance of the absence of amniotic fluid from the cervical os with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S223. RouseD , HirtzD , ThomE , VarnerM , AlexanderJ , SpongC , et al. Magnesium sulfate for the prevention of cerebral palsy. New England Journal of Medicine2008;359:895-905. RouseD . A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. American Journal of Obstetrics and Gynecology2007;197(6):S2. RouseD . Magnesium sulfate (MGSO4) dose and timing, umbilical cord MG++ concentration: relationship to cerebral palsy. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S46. SagaramD , HaarEV , MillerR , Gyamfi-BannermanC . Birth order does not offer a neurologic advantage in twin pregnancy. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S427. SiegelAM , HeineRP , Dotters-KatzSK . The effect of non-penicillin antibiotic regimens on neonatal outcomes in preterm prelabor rupture of membranes. American Journal of Obstetrics and Gynecology2018;219(6):637. SonM , GrobmanWA , MillerES . Is mode of delivery associated with the risk of necrotizing enterocolitis?American Journal of Obstetrics and Gynecology2016;214(1 Suppl 1):S204-5. TuritzAL , TooGT , Gyamfi-BannermanC . Proximity of magnesium exposure to delivery and neonatal outcomes. American Journal of Obstetrics and Gynecology2016;215(4):508.e1-6. TwicklerD , McIntireD , AlexanderJ , LevenoK . Effects of magnesium sulfate on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S112. TwicklerDM , McIntireDD , AlexanderJM , LevenoKJ . Effects of magnesium sulfate on preterm fetal cerebral blood flow using Doppler analysis: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):21-5. Vander HaarE , GoldbergerA , Gyamfi-BannermanC . Mild intraventricular hemorrhage is not associated with low bayley scores at age 2. Reproductive Sciences2017;24(1 Suppl 1):83A. VilchezG , DaiJ , KumarK , MundyD , KontopoulosE , SokolRJ . Racial/ethnic disparities in magnesium sulfate neuroprotection: a subgroup analysis of a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(17):2304-11. VilchezG , DaiJ , LagosM , SokolRJ . Maternal side effects &amp; fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(2):178-83. WoodAM , PostAL , SwamyGK , GrotegutCA . Neonatal outcomes associated with noncephalic presentation at delivery in preterm birth. American Journal of Perinatology2018;35(12):1131-7. YadavaS , GarabedianM , SitA , El-SayedY . Use of magnesium sulfate and labor outcomes in PPROM at less than 37 weeks. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S203. YangM , VarnerMW , YoderB . Cord blood magnesium levels and nonneurologic outcomes in neonates less than 27 weeks gestational age. Journal of Investigative Medicine2019;67(1):86-7. ">Rouse 2008</a>). These RCTs were included in the previous version of this Cochrane review, published in 2009, which confirmed a neuroprotective role for magnesium sulphate. That review reported that 63 babies (95% CI 44 to 155) need to be exposed to prenatal magnesium sulphate to prevent one case of cerebral palsy (risk ratio 0.68, 95% CI 0.54 to 0.87; 5 RCTs, 6145 infants) (<a href="./references#CD004661-bbs2-0067" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. Art. No: CD004661. [DOI: 10.1002/14651858.CD004661.pub3]">Doyle 2009</a>). </p> <p>Subsequent systematic reviews and meta‐analyses reached similar conclusions (<a href="./references#CD004661-bbs2-0030" title="Conde-AgudeloA , RomeroR . Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis. American Journal of Obstetrics and Gynecology2009;200(6):595-609.">Conde‐Agudelo 2009</a>; <a href="./references#CD004661-bbs2-0031" title="CostantineMM , WeinerSJ . Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis. Obstetrics &amp; Gynecology2009;114(2 Pt 1):354-64.">Costantine 2009</a>; <a href="./references#CD004661-bbs2-0033" title="CrowtherCA , MiddletonPF , VoyseyM , AskieL , DuleyL , PrydePG , MarretS , DoyleLW . Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: An individual participant data meta-analysis. PLoS Medicine2017;14(10):e1002398.">Crowther 2017</a>; <a href="./references#CD004661-bbs2-0064" title="ZengX , XueY , TianQ , SunR , AnR . Effects and safety of magnesium sulfate on neuroprotection: A meta-analysis based on PRISMA guidelines. Medicine (Baltimore)2016;95(1):e2451.">Zeng 2016</a>). A systematic review of economic studies supported health gains and cost savings with this treatment (<a href="./references#CD004661-bbs2-0059" title="ShihSTF , TonmukayakulU , ImmsC , ReddihoughD , GrahamHK , CoxL , CarterR . Economic evaluation and cost of interventions for cerebral palsy: a systematic review. Developmental Medicine &amp; Child Neurology2018;60(6):543-58.">Shih 2018</a>). Further, Cochrane overviews of systematic reviews demonstrated it to be one of only two interventions for cerebral palsy prevention supported by high‐certainty evidence (<a href="./references#CD004661-bbs2-0056" title="ShepherdE , SalamRA , MiddletonP , MakridesM , McIntyreS , BadawiN , CrowtherCA . Antenatal and intrapartum interventions for preventing cerebral palsy: an overview of Cochrane systematic reviews. Cochrane Database of Systematic Reviews2017, Issue 8. Art. No: CD012077. [DOI: 10.1002/14651858.CD012077.pub2]">Shepherd 2017</a>; <a href="./references#CD004661-bbs2-0057" title="ShepherdE , SalamRA , MiddletonP , HanS , MakridesM , McIntyreS , BadawiN , CrowtherCA . Neonatal interventions for preventing cerebral palsy: an overview of Cochrane Systematic Reviews. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD012409. [DOI: 10.1002/14651858.CD012409.pub2]">Shepherd 2018</a>). </p> </section> <section id="CD004661-sec-0012"> <h3 class="title" id="CD004661-sec-0012">How the intervention might work</h3> <p>While the exact mechanism(s) by which magnesium sulphate confers preterm fetal neuroprotection remains unclear, recent advances from pre‐clinical and clinical studies suggest that it may be important in modulating brain excitotoxic cell death and inflammatory pathways (<a href="./references#CD004661-bbs2-0029" title="ChollatC , SentilhesL , MarretS . Protection of brain development by antenatal magnesium sulphate for infants born preterm. Developmental Medicine &amp; Child Neurology2019;61(1):25-30.">Chollat 2019</a>; <a href="./references#CD004661-bbs2-0040" title="GalinskyR , DeanJM , LingamI , RobertsonNJ , MallardC , BennetL , GunnAJ . A systematic review of magnesium sulfate for perinatal neuroprotection: What have we learnt from the past decade?Frontiers in Neurology2020;11:449.">Galinsky 2020</a>), both of which are implicated in the pathophysiology of perinatal brain injury and cerebral palsy. </p> </section> <section id="CD004661-sec-0013"> <h3 class="title" id="CD004661-sec-0013">Why it is important to do this review</h3> <p>In response to the compelling Cochrane review findings (<a href="./references#CD004661-bbs2-0067" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. Art. No: CD004661. [DOI: 10.1002/14651858.CD004661.pub3]">Doyle 2009</a>), professional bodies in many high‐income countries began recommending prenatal magnesium sulphate for preterm fetal neuroprotection in clinical practice guidelines (<a href="./references#CD004661-bbs2-0044" title="JayaramPM , MohanMK , FaridI , LindowS . Antenatal magnesium sulfate for fetal neuroprotection: a critical appraisal and systematic review of clinical practice guidelines. Journal of Perinatal Medicine2019;47(3):262-9.">Jayaram 2019</a>). In its 2015 guidelines on interventions to improve preterm birth outcomes, the World Health Organization provided a strong recommendation supporting the use of magnesium sulphate (<a href="./references#CD004661-bbs2-0061" title="World Health Organization. WHO recommendations on interventions to improve preterm birth outcomes. www.who.int/publications/i/item/9789241508988;(accessed 18 October 2023).">WHO 2015</a>). Over the last decade, international adoption of prenatal magnesium sulphate for preterm cerebral palsy prevention has ensued. </p> <p>In recent years, further RCTs and longer‐term follow‐up from the RCTs included in the <a href="./references#CD004661-bbs2-0067" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. Art. No: CD004661. [DOI: 10.1002/14651858.CD004661.pub3]">Doyle 2009</a> Cochrane review have been published, which may be eligible for inclusion in this review update. </p> <p>Over a decade into the knowledge translation on prenatal magnesium sulphate for neuroprotection, this update will support future clinical practice guideline review and revision and/or the continued implementation of this evidence‐based practice. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004661-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004661-sec-0014"></div> <p>To assess the effectiveness and safety of magnesium sulphate as a fetal neuroprotective agent when given to women considered to be at risk of preterm birth. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004661-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004661-sec-0015"></div> <section id="CD004661-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004661-sec-0017"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) and cluster‐RCTs were eligible. Both RCTs published in full‐text and those in abstract form only were eligible. Quasi‐RCTs (with a quasi‐random method of allocation, such as alternation) and cross‐over trials were not eligible. </p> </section> <section id="CD004661-sec-0018"> <h4 class="title">Types of participants</h4> <p>RCTs of women at risk of preterm birth (at less than 37 weeks' gestation) were eligible, irrespective of the reason(s) women were considered at risk of preterm birth (and how risk of preterm birth was determined), the number of babies in utero, gestational age, socio‐demographic factors, setting and location. </p> <p>We included RCTs with some 'eligible' and some 'ineligible' participants only if data from the 'eligible' participants could be retrieved. </p> </section> <section id="CD004661-sec-0019"> <h4 class="title">Types of interventions</h4> <p>RCTs assessing magnesium sulphate given for fetal neuroprotection compared with placebo or no treatment were eligible, irrespective of treatment regimen used, considering mode of administration (intravenous, intramuscular, oral), dose (loading and/or maintenance used), and timing of treatment prior to anticipated preterm birth. </p> <p>RCTs where magnesium sulphate was used with the primary aim of tocolysis (<a href="./references#CD004661-bbs2-0032" title="CrowtherCA , BrownJ , McKinlayCJD , MiddletonP . Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews2014, Issue 8. Art. No: CD001060. [DOI: 10.1002/14651858.CD001060.pub2]">Crowther 2014</a>) (including maintenance therapy after preterm labour (<a href="./references#CD004661-bbs2-0041" title="HanS , CrowtherCA , MooreV . Magnesium maintenance therapy for preventing preterm birth after threatened preterm labour. Cochrane Database of Systematic Reviews2013, Issue 5. Art. No: CD000940. [DOI: 10.1002/14651858.CD000940.pub3]">Han 2013</a>)), prevention and treatment of eclampsia and pre‐eclampsia (<a href="./references#CD004661-bbs2-0034" title="DuleyL , GülmezogluAM , Henderson-SmartDJ , ChouD . Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database of Systematic Reviews2010, Issue 11. Art. No: CD000025. [DOI: 10.1002/14651858.CD000025.pub2]">Duley 2010</a>; <a href="./references#CD004661-bbs2-0035" title="DuleyL , GulmezogluAM , ChouD . Magnesium sulphate versus lytic cocktail for eclampsia. Cochrane Database of Systematic Reviews2010, Issue 10. Art. No: CD002960. [DOI: 10.1002/14651858.CD002960.pub2]">Duley 2010a</a>; <a href="./references#CD004661-bbs2-0036" title="DuleyL , Henderson-SmartD , ChouD . Magnesium sulphate versus diazepam for eclampsia. Cochrane Database of Systematic Reviews2010, Issue 10. Art. No: CD000128. [DOI: 10.1002/14651858.CD000128.pub2]">Duley 2010b</a>; <a href="./references#CD004661-bbs2-0037" title="DuleyL , Henderson-SmartD . Magnesium sulphate versus phenytoin for eclampsia. Cochrane Database of Systematic Reviews2010, Issue 10. Art. No: CD000128. [DOI: 10.1002/14651858.CD000128.pub2]">Duley 2010c</a>), or as a dietary supplement in pregnancy were not eligible (<a href="./references#CD004661-bbs2-0049" title="MakridesM , CrosbyDD , ShepherdE , CrowtherCA . Magnesium supplementation in pregnancy. Cochrane Database of Systematic Reviews2014, Issue 4. Art. No: CD000937. [DOI: 10.1002/14651858.CD000937.pub2]">Makrides 2014</a>). These RCTs are covered in separate Cochrane reviews. </p> </section> <section id="CD004661-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>Reporting the outcome measures listed below was not an eligibility criterion.</p> <p>Considering time points, where relevant, we planned to synthesise outcomes from infancy/childhood/adulthood.</p> <p>We did not restrict outcomes according to measurement methods or tools used, and planned wherever possible to synthesise different measures of the same outcome (or outcome domain). </p> <section id="CD004661-sec-0021"> <h5 class="title">Primary outcomes</h5> <section id="CD004661-sec-0022"> <h6 class="title">For infants/children/adults</h6> <p> <ul id="CD004661-list-0001"> <li> <p>Death (fetal, neonatal, or later)</p> </li> <li> <p>Cerebral palsy</p> </li> <li> <p>Death or cerebral palsy</p> </li> <li> <p>Major neurodevelopmental disability (defined as any of: moderate to severe cerebral palsy (Gross Motor Function Classification System (GMFCS) levels II to V, or as defined by trialists), legal blindness, sensorineural deafness requiring amplification or worse, or developmental delay/intellectual impairment (standardised score more than 2 standard deviations (SD) below the mean)) </p> </li> <li> <p>Death or major neurodevelopmental disability</p> </li> </ul> </p> </section> <section id="CD004661-sec-0023"> <h6 class="title">For women</h6> <p> <ul id="CD004661-list-0002"> <li> <p>Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest) </p> </li> <li> <p>Adverse effects severe enough to stop treatment</p> </li> </ul> </p> </section> </section> <section id="CD004661-sec-0024"> <h5 class="title">Secondary outcomes</h5> <section id="CD004661-sec-0025"> <h6 class="title">For infants</h6> <p> <ul id="CD004661-list-0003"> <li> <p>Fetal death</p> </li> <li> <p>Neonatal death</p> </li> <li> <p>Body size at birth (weight, length, head circumference z‐scores)</p> </li> <li> <p>Gestational age at birth</p> </li> <li> <p>Apgar score less than seven at five minutes</p> </li> <li> <p>Use of active resuscitation at birth</p> </li> <li> <p>Intraventricular haemorrhage</p> </li> <li> <p>Severe intraventricular haemorrhage (grade 3 or 4)</p> </li> <li> <p>Cystic periventricular leukomalacia</p> </li> <li> <p>Post‐haemorrhagic hydrocephalus or ventriculomegaly</p> </li> <li> <p>Neonatal encephalopathy</p> </li> <li> <p>Neonatal convulsions</p> </li> <li> <p>Neonatal hypoglycaemia</p> </li> <li> <p>Neonatal hypotonia</p> </li> <li> <p>Necrotising enterocolitis</p> </li> <li> <p>Intestinal perforation</p> </li> <li> <p>Retinopathy of prematurity</p> </li> <li> <p>Patent ductus arteriosus</p> </li> <li> <p>Respiratory distress syndrome</p> </li> <li> <p>Chronic lung disease/bronchopulmonary dysplasia</p> </li> <li> <p>Use of respiratory support (mechanical ventilation or continuous positive airway pressure)</p> </li> <li> <p>Use of postnatal corticosteroids to prevent or treat chronic lung disease/bronchopulmonary dysplasia </p> </li> <li> <p>Use of inotropic support</p> </li> <li> <p>Air leak syndrome</p> </li> <li> <p>Early‐ and late‐onset sepsis</p> </li> <li> <p>Severe adverse neonatal outcome composite (e.g. death, severe intraventricular haemorrhage, neonatal encephalopathy, necrotising enterocolitis, stage 3 or worse retinopathy of prematurity, patent ductus arteriosus requiring treatment, chronic lung disease/bronchopulmonary dysplasia; or as defined by trialists) </p> </li> </ul> </p> </section> <section id="CD004661-sec-0026"> <h6 class="title">For infants/children/adults</h6> <p> <ul id="CD004661-list-0004"> <li> <p>Later death</p> </li> <li> <p>Cerebral palsy severity</p> </li> <li> <p>Any neurodevelopmental disability (defined as any of: cerebral palsy (GMFCS level I to V, or as defined by trialists), blindness (corrected visual acuity worse than 6/60 in the better eye), deafness (hearing loss requiring amplification or worse), or developmental delay/intellectual impairment (standardised score more than 1 SD below the mean)) </p> </li> <li> <p>Death or any neurodevelopmental disability</p> </li> <li> <p>Blindness</p> </li> <li> <p>Deafness</p> </li> <li> <p>Developmental delay/intellectual impairment</p> </li> <li> <p>Gross motor dysfunction</p> </li> <li> <p>Psychomotor dysfunction</p> </li> <li> <p>Death or substantial gross motor dysfunction</p> </li> <li> <p>Growth (weight, head circumference, length/height)</p> </li> <li> <p>Respiratory function</p> </li> <li> <p>Blood pressure</p> </li> <li> <p>Behaviour</p> </li> <li> <p>Educational achievement</p> </li> </ul> </p> </section> <section id="CD004661-sec-0027"> <h6 class="title">For women</h6> <p> <ul id="CD004661-list-0005"> <li> <p>Individual components of severe maternal outcome potentially related to treatment</p> </li> <li> <p>Maternal side effects of treatment (including nausea, vomiting, flushing, infusion arm discomfort, mouth dryness, sweating, dizziness, blurred vision, changes in blood pressure, respiratory rate, or pulse) </p> </li> <li> <p>Time between randomisation and birth</p> </li> <li> <p>Mode of birth (caesarean section)</p> </li> <li> <p>Chorioamnionitis</p> </li> <li> <p>Postpartum haemorrhage</p> </li> <li> <p>Breastfeeding at hospital discharge</p> </li> <li> <p>Women's views of treatment</p> </li> </ul> </p> </section> <section id="CD004661-sec-0028"> <h6 class="title">Use of health services</h6> <p> <ul id="CD004661-list-0006"> <li> <p>Maternal admission to the intensive care unit</p> </li> <li> <p>Length of postnatal hospitalisation for women</p> </li> <li> <p>Admission to the neonatal intensive care unit</p> </li> <li> <p>Length of stay in neonatal intensive care unit</p> </li> <li> <p>Length of neonatal/infant hospitalisation</p> </li> <li> <p>Costs of maternal care</p> </li> <li> <p>Costs of neonatal care</p> </li> <li> <p>Use and costs of care for infant/child/adult (e.g. related to neurodevelopmental disability)</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD004661-sec-0029"> <h3 class="title">Search methods for identification of studies</h3> <p>The following methods section is based on a standard template used by Cochrane Pregnancy and Childbirth. </p> <section id="CD004661-sec-0030"> <h4 class="title">Electronic searches</h4> <p>For this update, we searched Cochrane Pregnancy and Childbirth's Trials Register by contacting their Information Specialist (17 March 2023). </p> <p>The Register was a database containing over 34,000 reports of controlled trials in the field of pregnancy and childbirth. It represented over 30 years of searching, including handsearched journals and conference proceedings, and journals reviewed via a current awareness service. For the detailed search strategies used to populate Cochrane Pregnancy and Childbirth's Trials Register for the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and CINAHL (Cumulative Index to Nursing and Allied Health Literature), see <a href="./appendices#CD004661-sec-0184">Appendix 1</a>; <a href="./appendices#CD004661-sec-0185">Appendix 2</a>; <a href="./appendices#CD004661-sec-0186">Appendix 3</a>; <a href="./appendices#CD004661-sec-0187">Appendix 4</a>. </p> <p>Briefly, Cochrane Pregnancy and Childbirth's Trials Register was maintained by their Information Specialist and contains trials identified from: </p> <p> <ul id="CD004661-list-0007"> <li> <p>monthly searches of CENTRAL;</p> </li> <li> <p>weekly searches of MEDLINE (Ovid);</p> </li> <li> <p>weekly searches of Embase (Ovid);</p> </li> <li> <p>monthly searches of CINAHL (EBSCO);</p> </li> <li> <p>handsearches of 30 journals and the proceedings of major conferences;</p> </li> <li> <p>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts. </p> </li> </ul> </p> <p>All search results were screened by two people, and the full texts of all relevant RCT reports were reviewed. Based on the intervention described, each trial report was assigned a number that corresponds to a specific Pregnancy and Childbirth review topic (or topics), and was then added to the Register. The Information Specialist searched the Register for each review using this topic number rather than keywords. This resulted in a more specific search set that has been fully accounted for in the relevant review sections (Included studies; Excluded studies; Studies awaiting classification; Ongoing studies). </p> <p>We also searched ClinicalTrials.gov (<a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="https://trialsearch.who.int/" target="_blank">trialsearch.who.int</a>) on 17 March 2023 for unpublished, planned, and ongoing trial reports using the search methods detailed in <a href="./appendices#CD004661-sec-0188">Appendix 5</a>. </p> </section> <section id="CD004661-sec-0031"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of included studies, and Google Scholar (<a href="https://scholar.google.com/" target="_blank">scholar.google.com</a>). </p> <p>We did not apply any language or date restrictions. We also revisited all records identified through searching from the previously published version of this review. </p> </section> </section> <section id="CD004661-sec-0032"> <h3 class="title" id="CD004661-sec-0032">Data collection and analysis</h3> <p>For the methods used in the previous version of this review, see <a href="./references#CD004661-bbs2-0067" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. Art. No: CD004661. [DOI: 10.1002/14651858.CD004661.pub3]">Doyle 2009</a>. </p> <p>For this update, we used the following methods to assess the reports that were identified as a result of the updated search. </p> <section id="CD004661-sec-0033"> <h4 class="title">Selection of studies</h4> <p>Two review authors (ES and one of HW, PP, PM, CC, or LD) independently assessed all studies identified as a result of the search strategy for inclusion in the review. We resolved any disagreements through discussion. </p> <section id="CD004661-sec-0034"> <h5 class="title">Screening eligible studies for scientific integrity/trustworthiness</h5> <p>Two review authors (ES and SG) evaluated all studies meeting our inclusion criteria against predefined criteria to select studies that, based on the available information, were deemed to be sufficiently trustworthy to be included in the analysis. The criteria were as follows. </p> <section id="CD004661-sec-0035"> <h6 class="title">Research governance</h6> <p> <ul id="CD004661-list-0008"> <li> <p>Are there any retraction notices or expressions of concern listed on the Retraction Watch Database relating to this RCT? </p> </li> <li> <p>Was the RCT prospectively registered (for those studies published after 2010)? If not, was there a plausible reason? </p> </li> <li> <p>If requested, did the RCT authors provide/share the protocol or ethics approval letter (or both)? </p> </li> <li> <p>Did the RCT authors engage in communication with the Cochrane review authors within the agreed timelines? </p> </li> <li> <p>Did the RCT authors provide individual participant data if requested? If not, was there a plausible reason? </p> </li> </ul> </p> </section> <section id="CD004661-sec-0036"> <h6 class="title">Baseline characteristics</h6> <p> <ul id="CD004661-list-0009"> <li> <p>Is the RCT free from characteristics of the study participants that appear too similar (e.g. distribution of the mean (SD) excessively narrow or excessively wide, as noted by <a href="./references#CD004661-bbs2-0028" title="CarlisleJB . Data fabrication and other reasons for non-random sampling in 5087 randomised, controlled trial in anaesthetic and general medical journals. Anaesthesia2017;72:944-52.">Carlisle 2017</a>)? </p> </li> </ul> </p> </section> <section id="CD004661-sec-0037"> <h6 class="title">Feasibility</h6> <p> <ul id="CD004661-list-0010"> <li> <p>Is the RCT free from characteristics that could be implausible (e.g. large numbers of women with a rare condition (such as severe cholestasis in pregnancy) recruited within 12 months)? </p> </li> <li> <p>In cases with (close to) zero losses to follow‐up, is there a plausible explanation?</p> </li> </ul> </p> </section> <section id="CD004661-sec-0038"> <h6 class="title">Results</h6> <p> <ul id="CD004661-list-0011"> <li> <p>Is the RCT free from results that could be implausible (e.g. massive risk reduction for main outcomes with small sample size)? </p> </li> <li> <p>Do the numbers randomised to each group suggest that adequate randomisation methods were used (e.g. is the RCT free from issues such as unexpectedly even numbers of women 'randomised' including a mismatch between the numbers and the methods, if the authors say 'no blocking was used' but still end up with equal numbers, or if the authors say they used 'blocks of 4' but the final numbers differ by six)? </p> </li> </ul> </p> <p>Where a study was classified as potentially 'high risk' based on the above criteria, it was added to <a href="./references#CD004661-bbs1-0003" title="">Studies awaiting classification</a>, and the reasons and communications with the author(s) (or lack thereof) were described in detail. The process is described in <a href="#CD004661-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD004661-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Process for screening eligible studies for scientific integrity/trustworthiness. Figure produced with permission from Cochrane Pregnancy and Childbirth." data-id="CD004661-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Process for screening eligible studies for scientific integrity/trustworthiness.<br/>Figure produced with permission from Cochrane Pregnancy and Childbirth. </p> </div> </div> </div> </section> <section id="CD004661-sec-0039"> <h6 class="title">Abstracts</h6> <p>We planned to include data from abstracts only if, in addition to the trustworthiness assessment, the RCT authors confirmed in writing that the data to be included in the review had come from the final analysis and would not change. If such information was not available/provided, we added the study to <a href="./references#CD004661-bbs1-0003" title="">Studies awaiting classification</a> (as above). </p> </section> </section> </section> <section id="CD004661-sec-0040"> <h4 class="title">Data extraction and management</h4> <p>We designed a data extraction form. Two review authors (ES and SG) independently extracted data from the included studies using the agreed‐upon form. We resolved any discrepancies through discussion. We entered data into RevMan software (<a href="./references#CD004661-bbs2-0053" title="Review Manager (RevMan). Version 7.2.0. The Cochrane Collaboration, 2024. Available at revman.cochrane.org.">RevMan 2024</a>), which we checked for accuracy. </p> </section> <section id="CD004661-sec-0041"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (ES and SG) independently assessed the risk of bias for each RCT using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004661-bbs2-0042" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). We resolved any disagreements by discussion. </p> <section id="CD004661-sec-0042"> <h5 class="title">(1) Random sequence generation (checking for possible selection bias)</h5> <p>We described for each included RCT the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. </p> <p>We have assessed the method as:</p> <p> <ul id="CD004661-list-0012"> <li> <p>low risk of bias (any truly random process, e.g. random number table; computer random number generator); </p> </li> <li> <p>high risk of bias (any non‐random process, e.g. odd or even date of birth; hospital or clinic record number); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD004661-sec-0043"> <h5 class="title">(2) Allocation concealment (checking for possible selection bias)</h5> <p>We described for each included RCT the method used to conceal allocation to interventions prior to assignment and assessed whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. </p> <p>We have assessed the methods as:</p> <p> <ul id="CD004661-list-0013"> <li> <p>low risk of bias (e.g. telephone or central randomisation; consecutively numbered, sealed, opaque envelopes); </p> </li> <li> <p>high risk of bias (open random allocation; unsealed or non‐opaque envelopes, alternation; date of birth); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD004661-sec-0044"> <h5 class="title">(3.1) Blinding of participants and personnel (checking for possible performance bias)</h5> <p>We described for each included RCT the methods used, if any, to blind participants and personnel from knowledge of which intervention a participant received. We considered RCTs to be at low risk of bias if they were blinded, or if we judged that the lack of blinding was unlikely to have affected the results. We assessed blinding separately for different outcomes or classes of outcomes. </p> <p>We assessed the methods as:</p> <p> <ul id="CD004661-list-0014"> <li> <p>low, high, or unclear risk of bias for participants;</p> </li> <li> <p>low, high, or unclear risk of bias for personnel.</p> </li> </ul> </p> </section> <section id="CD004661-sec-0045"> <h5 class="title">(3.2) Blinding of outcome assessment (checking for possible detection bias)</h5> <p>We described for each included RCT the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes. </p> <p>We assessed the methods used to blind outcome assessment as:</p> <p> <ul id="CD004661-list-0015"> <li> <p>low, high, or unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD004661-sec-0046"> <h5 class="title">(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature, and handling of incomplete outcome data) </h5> <p>We described for each included RCT the completeness of data, including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported and the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported, or could be supplied by the study authors, we planned to re‐include missing data in the analyses we undertook. </p> <p>We assessed the methods as:</p> <p> <ul id="CD004661-list-0016"> <li> <p>low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups); </p> </li> <li> <p>high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; ‘as treated’ analysis done with substantial departure of intervention received from that assigned at randomisation); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD004661-sec-0047"> <h5 class="title">(5) Selective reporting (checking for reporting bias)</h5> <p>We described for each included RCT how we investigated the possibility of selective outcome reporting bias and what we found. </p> <p>We have assessed the methods as:</p> <p> <ul id="CD004661-list-0017"> <li> <p>low risk of bias (where it was clear that all of the RCT's prespecified outcomes and all expected outcomes of interest to the review have been reported); </p> </li> <li> <p>high risk of bias (where not all of the RCT's prespecified outcomes have been reported; one or more reported primary outcomes were not prespecified; outcomes of interest were reported incompletely and so could not be used; the RCT failed to include results of a key outcome that would be expected to have been reported); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD004661-sec-0048"> <h5 class="title">(6) Other bias (checking for bias due to problems not covered by (1) to (5) above)</h5> <p>We described for each included RCT any important concerns we had about other possible sources of bias. </p> </section> <section id="CD004661-sec-0049"> <h5 class="title">(7) Overall risk of bias</h5> <p>We made explicit judgements about whether RCTs were at high risk of bias, according to the criteria given in the <i>Cochrane Handbook</i> (<a href="./references#CD004661-bbs2-0042" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias, and whether we considered it likely to impact on the findings. We explored the impact of the level of bias through sensitivity analyses (see <a href="#CD004661-sec-0062">Sensitivity analysis</a>). </p> </section> </section> <section id="CD004661-sec-0050"> <h4 class="title">Measures of treatment effect</h4> <section id="CD004661-sec-0051"> <h5 class="title">Dichotomous data</h5> <p>For dichotomous data, we presented results as summary risk ratios (RR) with 95% confidence intervals (CI). </p> </section> <section id="CD004661-sec-0052"> <h5 class="title">Continuous data</h5> <p>For continuous data measured on the same scale, we used the mean difference (MD) with 95% CIs. For studies that measured the same outcome on different scales, we planned to report the standardised mean difference (SMD) with 95% CIs. </p> </section> </section> <section id="CD004661-sec-0053"> <h4 class="title">Unit of analysis issues</h4> <section id="CD004661-sec-0054"> <h5 class="title">Cluster‐RCTs</h5> <p>Had we found cluster‐RCTs, we would have included them in the analyses along with individual RCTs. We planned to adjust the sample sizes of cluster‐RCTs using the methods described in the <i>Cochrane Handbook</i> (<a href="./references#CD004661-bbs2-0043" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v6.3.">Higgins 2022</a>), employing an estimate of the intracluster correlation coefficient (ICC) derived from the RCT (if possible), from a similar RCT, or from a study of a similar population. Had we used ICCs from other sources, we would have reported this and conducted sensitivity analyses to investigate the effect of variation in the ICC. In future updates, if we identify both cluster‐RCTs and individually randomised RCTs, we will synthesise the relevant information. We will consider it reasonable to combine the results from both types of studies if there is little heterogeneity between study designs, and the interaction between the effect of intervention and the choice of randomisation unit is considered to be unlikely. We will also acknowledge heterogeneity in the randomisation unit and perform a sensitivity analysis to investigate the effects of the randomisation unit. </p> </section> <section id="CD004661-sec-0055"> <h5 class="title">Multiple pregnancy</h5> <p>There may be unit of analysis issues that arise when women randomised have a multiple pregnancy. We have presented maternal data as per woman randomised, and fetal/neonatal/infant/child data as per fetus/neonate/infant/child. </p> </section> <section id="CD004661-sec-0056"> <h5 class="title">Multiple‐arm RCTs</h5> <p>In future updates of this review, if an RCT has multiple intervention arms, we will avoid 'double‐counting' of participants by combining groups to create a single pairwise comparison if possible. Where this is not possible, we will split the 'shared' group into two or more groups with smaller sample size and include two or more (reasonably independent) comparisons. </p> </section> </section> <section id="CD004661-sec-0057"> <h4 class="title">Dealing with missing data</h4> <p>We noted levels of attrition in the included studies. We planned to explore the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis. </p> <p>For all outcomes, we carried out analyses, to the greatest degree possible, on an intention‐to‐treat (ITT) basis, that is we attempted to include all participants randomised to each group in the analyses, and all participants were analysed in the group to which they were allocated, regardless of whether they received the allocated intervention. The denominator for each outcome in each study was the number randomised minus any participants whose outcomes were known to be missing. </p> </section> <section id="CD004661-sec-0058"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity in each meta‐analysis using the Tau², I², and Chi² statistics. We regarded heterogeneity as substantial if I² was greater than 30%, and either Tau² was greater than zero, or there was a low P value (less than 0.10) in the Chi² test for heterogeneity. </p> </section> <section id="CD004661-sec-0059"> <h4 class="title">Assessment of reporting biases</h4> <p>In future updates of this review, if 10 or more RCTs are included in a given meta‐analysis, we will investigate reporting biases (such as publication bias) using funnel plots. We will assess funnel plot asymmetry visually. If asymmetry is suggested by a visual assessment, we will perform exploratory analyses to investigate it. </p> </section> <section id="CD004661-sec-0060"> <h4 class="title">Data synthesis</h4> <p>We carried out statistical analysis using RevMan software (<a href="./references#CD004661-bbs2-0053" title="Review Manager (RevMan). Version 7.2.0. The Cochrane Collaboration, 2024. Available at revman.cochrane.org.">RevMan 2024</a>). We used fixed‐effect meta‐analyses for combining data where it was reasonable to assume that RCTs were estimating the same underlying treatment effect (i.e. where RCTs were examining the same intervention, and the RCTs’ populations and methods were judged to be sufficiently similar). Where we detected substantial statistical heterogeneity, we used random‐effects meta‐analysis to produce an overall summary, as we considered an average treatment effect across RCTs to be clinically meaningful. We treated the random‐effects summary as the average of the range of possible treatment effects, and we have discussed the clinical implications of treatment effects differing between RCTs. </p> <p>Where we used random‐effects analyses, we have presented the results as the average treatment effect with 95% CIs, and the estimates of Tau² and I². </p> </section> <section id="CD004661-sec-0061"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>For this update, where data were available, we performed the following subgroup analyses for our primary outcomes: </p> <p> <ul id="CD004661-list-0018"> <li> <p>gestational age at randomisation (we prespecified the following groups: &lt; 26; 26 to &lt; 28; 28 to &lt; 30; 30 to &lt; 32; 32 to &lt; 34 completed weeks at randomisation; however, groups were combined, as RCTs did not present stratified results); </p> </li> <li> <p>loading‐dose regimen (4 g; &gt; 4 g);</p> </li> <li> <p>maintenance dose regimen (no; 1 g/hour; &gt; 1 g/hour);</p> </li> <li> <p>repeat treatment permitted (yes; no).</p> </li> </ul> </p> <p>We assessed subgroup differences by interaction tests available within RevMan (<a href="./references#CD004661-bbs2-0053" title="Review Manager (RevMan). Version 7.2.0. The Cochrane Collaboration, 2024. Available at revman.cochrane.org.">RevMan 2024</a>). </p> <p>We also planned to conduct the following subgroup analyses for our primary outcomes:</p> <p> <ul id="CD004661-list-0019"> <li> <p>primary reason the woman was considered at high risk of preterm birth (e.g. preterm labour; prelabour rupture of membranes; chorioamnionitis; pre‐eclampsia; antepartum haemorrhage; fetal distress; intrauterine growth restriction; other); </p> </li> <li> <p>number of babies in utero (singleton; multiple)</p> </li> <li> <p>mode of administration (intravenous; intramuscular);</p> </li> <li> <p>time treatment was intended to be started prior to preterm birth (0 to &lt; 4 hours; 4 to &lt; 8 hours; 8 to &lt; 12 hours; 12 to &lt; 24 hours; we planned to combine groups if data were insufficient). </p> </li> </ul> </p> <p>However, we were unable to undertake meaningful subgroup analyses for these characteristics, as for most RCTs their inclusion/exclusion criteria did not enable allocation to one or the other subgroup, or the results were not presented stratified by the relevant characteristic, or both; or all included RCTs were eligible for the same subgroup. </p> </section> <section id="CD004661-sec-0062"> <h4 class="title">Sensitivity analysis</h4> <p>We carried out sensitivity analyses to explore the impact of risk of bias on our primary outcomes. Specifically, we explored the impact restricting the primary outcome analyses to those RCTs judged to be at low risk of selection bias. </p> <p>During data collection and analysis, it appeared that most RCTs reported adjusted effect size(s) (RRs or odds ratios (ORs) with 95% CIs) for at least one of the primary outcomes for the infants/children (death (fetal, neonatal, later), cerebral palsy, death or cerebral palsy, major neurodevelopmental disability, or death or major neurodevelopmental disability), including to account for clustering due to multiple births. We therefore decided to perform post hoc sensitivity analyses for our primary outcomes for the infant/child/adult (where at least one RCT reported an adjusted effect size for that outcome), using the generic inverse variance method to pool results. </p> </section> <section id="CD004661-sec-0063"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>Two review authors (ES and SG) assessed the certainty of the evidence using the GRADE approach, as outlined in the GRADE Handbook (<a href="./references#CD004661-bbs2-0055" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). Handbook for grading the quality of evidence and the strengthof recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">Schünemann 2013</a>), for the outcomes for our main comparison ('magnesium sulphate versus placebo'), as described below. </p> <section id="CD004661-sec-0064"> <h5 class="title">For infants/children</h5> <p> <ul id="CD004661-list-0020"> <li> <p>Death (fetal, neonatal, or later)</p> </li> <li> <p>Cerebral palsy</p> </li> <li> <p>Death or cerebral palsy</p> </li> <li> <p>Major neurodevelopmental disability</p> </li> <li> <p>Death or major neurodevelopmental disability</p> </li> <li> <p>Severe intraventricular haemorrhage (grade 3 or 4)*</p> </li> <li> <p>Chronic lung disease/bronchopulmonary dysplasia*</p> </li> </ul> </p> <p>*These outcomes are not relevant to children up to school age and so were not included in <a href="./full#CD004661-tbl-0002">summary of findings Table 2</a>. </p> </section> <section id="CD004661-sec-0065"> <h5 class="title">For women</h5> <p> <ul id="CD004661-list-0021"> <li> <p>Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest) </p> </li> <li> <p>Adverse effects severe enough to stop treatment</p> </li> <li> <p>Mode of birth (caesarean section)</p> </li> <li> <p>Postpartum haemorrhage</p> </li> <li> <p>Breastfeeding at hospital discharge</p> </li> <li> <p>Women’s views of treatment</p> </li> </ul> </p> <p>We created summary of findings tables in RevMan (<a href="./references#CD004661-bbs2-0053" title="Review Manager (RevMan). Version 7.2.0. The Cochrane Collaboration, 2024. Available at revman.cochrane.org.">RevMan 2024</a>). The GRADE approach uses five considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of the body of evidence for each outcome. The evidence can be downgraded from high certainty by one level for serious (or two levels for very serious) limitations, depending on the assessment of these factors. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004661-sec-0066" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004661-sec-0066"></div> <section id="CD004661-sec-0067"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD004661-sec-0213" title="">Characteristics of included studies</a>. </p> <section id="CD004661-sec-0068"> <h4 class="title">Results of the search</h4> <p>See <a href="#CD004661-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD004661-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD004661-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>The previous version of this review included five RCTs (29 records). We reassessed these records, along with 215 new records identified through database searching and other sources. Following removal of duplicate and irrelevant records, we assessed 137 records in full. We included two new RCTs (10 records), and excluded five new studies (five records). Eight studies (10 records) are awaiting classification, and four studies (four records) are ongoing. The remaining 78 records were additional records for four previously included RCTs. </p> <p>Following prespecified revision to the <a href="#CD004661-sec-0016">Criteria for considering studies for this review</a> for this update, we also excluded one previously included RCT (two records). We included a total of six RCTs (116 records). </p> <section id="CD004661-sec-0069"> <h5 class="title">Screening eligible studies for trustworthiness</h5> <p>We categorised eight studies as awaiting classification as they did not fulfil our trustworthiness criteria (see <a href="./references#CD004661-sec-0215" title="">Characteristics of studies awaiting classification</a>). At the time of publication, the study authors had not responded to our various queries/concerns (<a href="./references#CD004661-bbs2-0013" title="BachnasMA , MoseJC , EffendiJS , AndonotopoW . Influence of antenatal magnesium sulfate application on cord blood levels of brain-derived neurotrophic factor in premature infants. Journal of Perinatal Medicine2014;42(1):129-34. ">Bachnas 2014</a>; <a href="./references#CD004661-bbs2-0014" title="GuptaN , GargR , GuptaA , MishraS . Magnesium sulfate for fetal neuroprotection in women at risk of preterm birth: analysis of its effect on cerebral palsy [Magnesium sulfate for fetal neuroprotection in women at risk of preterm birth: Analysis of its effect on cerebral palsy]. Journal of SAFOG2021;13(3):90-3. ">Gupta 2021</a>; <a href="./references#CD004661-bbs2-0015" title="ManojVC , MenonB , SankarA , AnandM , ManikothP . Randomized controlled trial of antenatal magnesium sulfate for short-term neuroprotection in premature neonates. Indian Journal of Child Health2017;4(2):199-202. ">Manoj 2017</a>; <a href="./references#CD004661-bbs2-0016" title="MuhammedHO , MuradSJ . Effect of prenatal infusion of magnesium sulphate on neurological complication in preterm infant. International Journal of Pharmaceutical Research2019;11(3):29-34. ">Muhammed 2019</a>; <a href="./references#CD004661-bbs2-0017" title="IRCT2016080729223N1. The survey of magnesium sulfate in prevention of intraventricular hemorrhage in premature infants [The survey of magnesium sulfate in prevention of intraventricular hemorrhage in premature infants: randomization clinical trial]. trialsearch.who.int/Trial2.aspx?TrialID=IRCT2016080729223N1 (first received 3 October 2016). ParashiS , BordbarA , MahmoodiY , JafariMR . The survey of magnesium sulfate in prevention of intraventricular hemorrhage in premature infants: a randomized clinical trial. Shiraz e Medical Journal2017;18(11):e55094. ">Parashi 2017</a>; <a href="./references#CD004661-bbs2-0018" title="PetrovV , LupascuA , EtscoL , PavlencoA . Maternal and new born hemodinamics after antenatal administration of magnesium sulfate (MGSO4), as a neuroprotective drug in preterm birth. Journal of Perinatal Medicine2013;41:RU350. PetrovV , LupascuA , PavlencoA , PadureV , BurlacuA . The results of antenatal administration of magnesium sulfate (MGSO4), as a neuroprotective drug in preterm birth, at infants after one year follow up program. Journal of Perinatal Medicine2013;41:RU369. ">Petrov 2013</a>; <a href="./references#CD004661-bbs2-0019" title="SharmaK , RanideepaA , AnamikaB . To study the effect of antenatal magnesium sulphate for neuroprotection in preterm babies. International Journal of Advanced Research2021;9(4):628-33. ">Sharma 2021</a>; <a href="./references#CD004661-bbs2-0020" title="SheebaLM , NamboodiripadA , VaranattuMC . Efficacy of maternal magnesium sulfate administration on the neurodevelopmental outcome of preterm babies: a randomised controlled trial. Journal of Clinical and Diagnostic Research2022;16(12):6-9. ">Sheeba 2022</a>). </p> </section> </section> <section id="CD004661-sec-0070"> <h4 class="title">Included studies</h4> <p>Six RCTs met our eligibility and trustworthiness criteria (<a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a>; <a href="./references#CD004661-bbs2-0002" title="ACTRN12611000491965. MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: neuroprotection trial [Does antenatal magnesium sulphate given to women at risk of imminent preterm birth (defined as planned or definitely expected in the next 24 hours) between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children at 2 years corrected age? - a randomised controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000491965 (first received 11 May 2011). CrowtherCA , AshwoodP , MiddletonPF , McPheeA , TranT , HardineJE , et al. Prenatal intravenous magnesium at 30-34 weeks’ gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial. JAMA2023;330(7):603-14. CrowtherCA , MiddletonPF , WilkinsonD , AshwoodP , HaslamR . Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) - study protocol. BMC Pregnancy and Childbirth2013;13(1):91. PoppeT , ThompsonB , BoardmanJP , BastinME , AlsweilerJ , DeibG , et al. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: the MagNUM Study. EBioMedicine2022;78:103923. ">Crowther 2023</a>; <a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a>; <a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a>; <a href="./references#CD004661-bbs2-0005" title="BrookfieldKF , O'MalleyK , Yeaton-MasseyA , ButwickAJ . Does magnesium sulfate exposure attenuate the effect of steroids administered for fetal lung maturation? In: Society for Obstetric Anesthesia and Perinatology (SOAP) 48th Annual Meeting; 2016 May 18-22; Boston USA. 2016:SA-32. BuhimschiCS , JablonskiKA , RouseDJ , VarnerMW , ReddyUM , MercerBM , et al. Cord blood haptoglobin, cerebral palsy and death in infants of women at risk for preterm birth: a secondary analysis of a randomised controlled trial. Eclinicalmedicine2019;9:11-8. CostantineMM , WeinerSJ , RouseDJ , HirtzDG , VarnerMW , SpongCY , et al. Umbilical cord blood biomarkers of neurologic injury and the risk of cerebral palsy or infant death. International Journal of Developmental Neuroscience2011;29(8):917-22. CostantineMM . Cord blood biomarkers and the risk of cerebral palsy or death. Reproductive Sciences2010;17(3 Suppl 1):65A. DeihlTE , SimhanHN . Antenatal magnesium sulfate and ponderal index from birth to age 2 in preterm male and female infants. Reproductive Sciences2017;24(Suppl 1):130A. DeihlTE , SimhanHN . Antenatal magnesium sulfate exposure and ponderal index in preterm infants. American Journal of Perinatology2019;36(3):329-34. DenobleAE , WuJ , MitchellCJ , HughesBL , Dotters-KatzSK . Chorioamnionitis versus intraamniotic infection among preterm deliveries-is postpartum infectious morbidity different?American Journal of Obstetrics and Gynecology MFM2020;2(3):100176. DrassinowerD , FriedmanAM , LevinH , ObicanSG , Gyamfi-BannermanC . Does magnesium exposure affect neonatal resuscitation? Presented as a poster at the 35th annual meeting of the society for maternal-fetal medicine, San Diego, CA, Feb. 2-7, 2015. American Journal of Obstetrics and Gynecology2015;213(3):424e1-5. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm prelabour rupture of membranes and neurodevelopmental outcomes: a secondary analysis. BJOG: an international journal of obstetrics and gynaecology2016;123(10):1629-35. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of cerebral palsy. Journal of Maternal-Fetal &amp; Neonatal Medicine2016;29(17):2748-52. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of neonatal sepsis. American Journal of Obstetrics and Gynecology2016;214(6):743.e1-6. DrassinowerD , LevinH , ObicanS , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on cerebral palsy. American Journal of Obstetrics and Gynecology2015;212(1):S310-1. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . Immediate neonatal outcomes in infants exposed to magnesium sulfate at the time of delivery. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S90. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1):S161-2. EdwardsJ , EdwardsL , SwamyG , GrotegutC . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S215-6. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Effect of cord blood magnesium level at birth on non-neurologic neonatal outcomes. American Journal of Perinatology2019;36(1):3-7. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. Journal of Maternal-Fetal &amp; Neonatal Medicine2018;31(9):1156-60. FaucettAM , MetzTD , DeWittPE , GibbsRS . Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2016;214(2):287.e1-5. HaarEV , Gyamfi-BannermanC , Coletta-LucasJ . Sepsis but not chorioamnionitis is associated with cerebral palsy. Reproductive Sciences2015;22:372A. HaarEV , Gyamfi-BannermanC , RandisTM . Abnormal brain imaging in infants exposed to chorioamnionitis and sepsis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl. 1):S11-2. HaarEV , LucasJC , D'AltonM , Gyamfi-BannermanC . The effect of chorioamnionitis on neurocognitive development at age 2. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S139-40. HerreraC , SilverRM , MajorH , VarnerMW , ClarkEAS . Triple I criteria and adverse neonatal and childhood outcomes after early preterm birth. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S250. HirtzDG , WeinerSJ , BulasD , DiPietroM , SeibertJ , RouseDJ , et al. Antenatal magnesium and cerebral palsy in preterm infants. Journal of Pediatrics2015;167(4):834-9.e3. HirtzDG . Effect of prenatal MgSO4 on head ultrasound imaging in preterm infants. Annals of Neurology2011;70(Suppl 15):S110. HortonA . The effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S209. HortonL , YingleiL , RouseJ , SpongY , LevenoJ , VarnerW , et al. Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Perinatology2015;32(4):387-92. JohnsonLH , MappDC , RouseDJ , SpongCY , MercerBM , LevenoKJ , et al. Association of cord blood magnesium concentration and neonatal resuscitation. Journal of Pediatrics2012;160(4):573-7.e1. KachikisA , WalkerC , McAdamsR , WaldorfKA , Gyamfi-BannermanC . Influence of preterm premature rupture of membranes on neonatal respiratory complications. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S215. KachikisA , WalkerCL , McAdamsRM , Gyamfi-BannermanC , Adams WaldorfKM . Phenotypic overlap in neonatal respiratory morbidity following preterm premature rupture of membranes versus spontaneous preterm labor. Journal of Maternal-fetal &amp; Neonatal Medicine2021;34(12):1941-8. KamyarM , ClarkEA , YoderBA , VarnerMW , ManuckTA . Antenatal magnesium sulfate, necrotizing enterocolitis, and death among neonates &lt; 28 weeks gestation. AJP Reports2016;6(1):e148-54. KamyarM , ClarkEAS , VarnerMW , ManuckTA . Chorioamnionitis prevents protective effect of magnesium sulfate in the preterm infant. Reproductive Sciences2014;21(3 Suppl 1):78A. KamyarM , ManuckTA , StoddardGJ , VarnerMW , ClarkEAS . Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. BJOG: an international journal of obstetrics and gynaecology2016;123(7):1161-6. KamyarM , VarnerM , ClarkE . Magnesium sulfate neuroprophylaxis and the effect of infant sex. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S144. ManuckA , ShengX , YoderA , VarnerW . Correlation between initial neonatal and early childhood outcomes following preterm birth. American Journal of Obstetrics &amp; Gynecology2014;210(5):426.e1-9. ManuckT , ShengX , YoderB , VarnerM . Correlation between initial neonatal and early childhood outcomes among children delivered &lt;34 weeks gestation. American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S23. ManuckT , VarnerM . Is bigger better? Neonatal and childhood outcomes of large for gestational age (LGA) infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341-2. ManuckT , VarnerM . Neonatal and childhood outcomes following early vs later preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S340-1. ManuckT , VarnerM . Neonatal and childhood outcomes of small for gestational age infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341. ManuckTA , VarnerMW . Neonatal and early childhood outcomes following early vs later preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2014;211(3):308.e1-6. MarrsC , Mendez-FigueroaH , ChauhanS . Periventricular leukomalacia with PPROM: Obstetric antecedents and infants' outcomes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S85. MarrsCC , Mendez-FigueroaH , HammadIA , ChauhanSP . Differential morbidity in preterm small versus appropriate for gestational age: perhaps unverifiable. American Journal of Perinatology2015;32(13):1251-6. McPhersonJ , SmileyS , StamiloD . Magnesium sulfate neuroprotection and obesity: Is efficacy affected by obesity. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S218. McPhersonJA , RouseDJ , GrobmanWA , PalatnikA , StamilioDM . Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. Obstetrics and Gynecology2014;124(4):749-55. McPhersonJA , SmileyS , StamilioDM . Maternal obesity and neuroprotective magnesium sulfate. American Journal of Obstetrics and Gynecology2015;213(4):582.e1–6. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate &lt; 12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S252. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate for &gt;12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S104-5. Mendez-FigueroaH , ChauhanSP , PedrozaC , RefuerzoJS , DahlkeJD , RouseDJ . Preterm cesarean delivery for nonreassuring fetal heart rate: neonatal and neurologic morbidity. Obstetrics and Gynecology2015;125(3):636-42. Mendez-FigueroaH , DahlkeJD , ViteriOA , ChauhanSP , RouseDJ , SibaiBM , et al. Neonatal and infant outcomes in twin gestations with preterm premature rupture of membranes at 24-31 weeks of gestation. Obstetrics and Gynecology2014;124(2 Pt 1):323-31. MoussaH , Hosseini NasabS , FournieD , OntiverosA , AlkawasR , ChauhanS , et al. The impact of time of delivery on gestations complicated by preterm premature rupture of membranes: daytime versus nighttime. Journal of Maternal-Fetal &amp; Neonatal Medicine2019;32(20):3319-24. NCT00014989. Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) [Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)]. clinicaltrials.gov/show/NCT00014989 (first received 18 April 2001). NussEE , SpiegelmanJ , TuritzAL , Gyamfi-BannermanC . Childhood neurodevelopment after spontaneous versus indicated preterm birth. American Journal of Obstetrics and Gynecology MFM2020;2(2):100082. ObicanS , DrassinowerD , LevinH , Gyamfi-BannermanC . Mode of delivery at periviability and early childhood neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S124. OvertonE , BaptisteC , Gyamfi-BannermanC . 546: neurodevelopmental outcomes in late preterm and early term deliveries following antenatal corticosteroid exposure. American Journal of Obstetrics and Gynecology2019;220(1):S365-6. PalatnikA , RouseD , StamiloD , McPhersonJ , GrobmanW . The association between cerebral palsy or death and umbilical cord magnesium concentration. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S302. RobbinsLS , BlanchardCT , BiasiniFJ , PowellMF , CaseyBM , TitaAT , et al. General anesthesia for cesarean delivery and childhood neurodevelopmental and perinatal outcomes: a secondary analysis of a randomized controlled trial. International Journal of Obstetric Anesthesia2020;45:34-40. RobbinsLS , BlanchardCT , SinkeyRG , HarrisSL , TitaAT , HarperLM . Prenatal tobacco exposure and childhood neurodevelopment among infants born prematurely. American Journal of Perinatology2020;38(3):218-23. RobertsR , Ankumah N-A, ViteriO , Mendez-FigueroaH , ChauhanS , SibaiB . Significance of the absence of amniotic fluid from the cervical os with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S223. RouseD , HirtzD , ThomE , VarnerM , AlexanderJ , SpongC , et al. Magnesium sulfate for the prevention of cerebral palsy. New England Journal of Medicine2008;359:895-905. RouseD . A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. American Journal of Obstetrics and Gynecology2007;197(6):S2. RouseD . Magnesium sulfate (MGSO4) dose and timing, umbilical cord MG++ concentration: relationship to cerebral palsy. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S46. SagaramD , HaarEV , MillerR , Gyamfi-BannermanC . Birth order does not offer a neurologic advantage in twin pregnancy. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S427. SiegelAM , HeineRP , Dotters-KatzSK . The effect of non-penicillin antibiotic regimens on neonatal outcomes in preterm prelabor rupture of membranes. American Journal of Obstetrics and Gynecology2018;219(6):637. SonM , GrobmanWA , MillerES . Is mode of delivery associated with the risk of necrotizing enterocolitis?American Journal of Obstetrics and Gynecology2016;214(1 Suppl 1):S204-5. TuritzAL , TooGT , Gyamfi-BannermanC . Proximity of magnesium exposure to delivery and neonatal outcomes. American Journal of Obstetrics and Gynecology2016;215(4):508.e1-6. TwicklerD , McIntireD , AlexanderJ , LevenoK . Effects of magnesium sulfate on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S112. TwicklerDM , McIntireDD , AlexanderJM , LevenoKJ . Effects of magnesium sulfate on preterm fetal cerebral blood flow using Doppler analysis: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):21-5. Vander HaarE , GoldbergerA , Gyamfi-BannermanC . Mild intraventricular hemorrhage is not associated with low bayley scores at age 2. Reproductive Sciences2017;24(1 Suppl 1):83A. VilchezG , DaiJ , KumarK , MundyD , KontopoulosE , SokolRJ . Racial/ethnic disparities in magnesium sulfate neuroprotection: a subgroup analysis of a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(17):2304-11. VilchezG , DaiJ , LagosM , SokolRJ . Maternal side effects &amp; fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(2):178-83. WoodAM , PostAL , SwamyGK , GrotegutCA . Neonatal outcomes associated with noncephalic presentation at delivery in preterm birth. American Journal of Perinatology2018;35(12):1131-7. YadavaS , GarabedianM , SitA , El-SayedY . Use of magnesium sulfate and labor outcomes in PPROM at less than 37 weeks. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S203. YangM , VarnerMW , YoderB . Cord blood magnesium levels and nonneurologic outcomes in neonates less than 27 weeks gestational age. Journal of Investigative Medicine2019;67(1):86-7. ">Rouse 2008</a>; <a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a>). For further details, see <a href="./references#CD004661-sec-0213" title="">Characteristics of included studies</a>. </p> <section id="CD004661-sec-0071"> <h5 class="title">Study design</h5> <p>The included RCTs were all individually randomised (<a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a>; <a href="./references#CD004661-bbs2-0002" title="ACTRN12611000491965. MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: neuroprotection trial [Does antenatal magnesium sulphate given to women at risk of imminent preterm birth (defined as planned or definitely expected in the next 24 hours) between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children at 2 years corrected age? - a randomised controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000491965 (first received 11 May 2011). CrowtherCA , AshwoodP , MiddletonPF , McPheeA , TranT , HardineJE , et al. Prenatal intravenous magnesium at 30-34 weeks’ gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial. JAMA2023;330(7):603-14. CrowtherCA , MiddletonPF , WilkinsonD , AshwoodP , HaslamR . Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) - study protocol. BMC Pregnancy and Childbirth2013;13(1):91. PoppeT , ThompsonB , BoardmanJP , BastinME , AlsweilerJ , DeibG , et al. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: the MagNUM Study. EBioMedicine2022;78:103923. ">Crowther 2023</a>; <a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a>; <a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a>; <a href="./references#CD004661-bbs2-0005" title="BrookfieldKF , O'MalleyK , Yeaton-MasseyA , ButwickAJ . Does magnesium sulfate exposure attenuate the effect of steroids administered for fetal lung maturation? In: Society for Obstetric Anesthesia and Perinatology (SOAP) 48th Annual Meeting; 2016 May 18-22; Boston USA. 2016:SA-32. BuhimschiCS , JablonskiKA , RouseDJ , VarnerMW , ReddyUM , MercerBM , et al. Cord blood haptoglobin, cerebral palsy and death in infants of women at risk for preterm birth: a secondary analysis of a randomised controlled trial. Eclinicalmedicine2019;9:11-8. CostantineMM , WeinerSJ , RouseDJ , HirtzDG , VarnerMW , SpongCY , et al. Umbilical cord blood biomarkers of neurologic injury and the risk of cerebral palsy or infant death. International Journal of Developmental Neuroscience2011;29(8):917-22. CostantineMM . Cord blood biomarkers and the risk of cerebral palsy or death. Reproductive Sciences2010;17(3 Suppl 1):65A. DeihlTE , SimhanHN . Antenatal magnesium sulfate and ponderal index from birth to age 2 in preterm male and female infants. Reproductive Sciences2017;24(Suppl 1):130A. DeihlTE , SimhanHN . Antenatal magnesium sulfate exposure and ponderal index in preterm infants. American Journal of Perinatology2019;36(3):329-34. DenobleAE , WuJ , MitchellCJ , HughesBL , Dotters-KatzSK . Chorioamnionitis versus intraamniotic infection among preterm deliveries-is postpartum infectious morbidity different?American Journal of Obstetrics and Gynecology MFM2020;2(3):100176. DrassinowerD , FriedmanAM , LevinH , ObicanSG , Gyamfi-BannermanC . Does magnesium exposure affect neonatal resuscitation? Presented as a poster at the 35th annual meeting of the society for maternal-fetal medicine, San Diego, CA, Feb. 2-7, 2015. American Journal of Obstetrics and Gynecology2015;213(3):424e1-5. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm prelabour rupture of membranes and neurodevelopmental outcomes: a secondary analysis. BJOG: an international journal of obstetrics and gynaecology2016;123(10):1629-35. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of cerebral palsy. Journal of Maternal-Fetal &amp; Neonatal Medicine2016;29(17):2748-52. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of neonatal sepsis. American Journal of Obstetrics and Gynecology2016;214(6):743.e1-6. DrassinowerD , LevinH , ObicanS , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on cerebral palsy. American Journal of Obstetrics and Gynecology2015;212(1):S310-1. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . Immediate neonatal outcomes in infants exposed to magnesium sulfate at the time of delivery. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S90. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1):S161-2. EdwardsJ , EdwardsL , SwamyG , GrotegutC . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S215-6. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Effect of cord blood magnesium level at birth on non-neurologic neonatal outcomes. American Journal of Perinatology2019;36(1):3-7. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. Journal of Maternal-Fetal &amp; Neonatal Medicine2018;31(9):1156-60. FaucettAM , MetzTD , DeWittPE , GibbsRS . Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2016;214(2):287.e1-5. HaarEV , Gyamfi-BannermanC , Coletta-LucasJ . Sepsis but not chorioamnionitis is associated with cerebral palsy. Reproductive Sciences2015;22:372A. HaarEV , Gyamfi-BannermanC , RandisTM . Abnormal brain imaging in infants exposed to chorioamnionitis and sepsis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl. 1):S11-2. HaarEV , LucasJC , D'AltonM , Gyamfi-BannermanC . The effect of chorioamnionitis on neurocognitive development at age 2. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S139-40. HerreraC , SilverRM , MajorH , VarnerMW , ClarkEAS . Triple I criteria and adverse neonatal and childhood outcomes after early preterm birth. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S250. HirtzDG , WeinerSJ , BulasD , DiPietroM , SeibertJ , RouseDJ , et al. Antenatal magnesium and cerebral palsy in preterm infants. Journal of Pediatrics2015;167(4):834-9.e3. HirtzDG . Effect of prenatal MgSO4 on head ultrasound imaging in preterm infants. Annals of Neurology2011;70(Suppl 15):S110. HortonA . The effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S209. HortonL , YingleiL , RouseJ , SpongY , LevenoJ , VarnerW , et al. Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Perinatology2015;32(4):387-92. JohnsonLH , MappDC , RouseDJ , SpongCY , MercerBM , LevenoKJ , et al. Association of cord blood magnesium concentration and neonatal resuscitation. Journal of Pediatrics2012;160(4):573-7.e1. KachikisA , WalkerC , McAdamsR , WaldorfKA , Gyamfi-BannermanC . Influence of preterm premature rupture of membranes on neonatal respiratory complications. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S215. KachikisA , WalkerCL , McAdamsRM , Gyamfi-BannermanC , Adams WaldorfKM . Phenotypic overlap in neonatal respiratory morbidity following preterm premature rupture of membranes versus spontaneous preterm labor. Journal of Maternal-fetal &amp; Neonatal Medicine2021;34(12):1941-8. KamyarM , ClarkEA , YoderBA , VarnerMW , ManuckTA . Antenatal magnesium sulfate, necrotizing enterocolitis, and death among neonates &lt; 28 weeks gestation. AJP Reports2016;6(1):e148-54. KamyarM , ClarkEAS , VarnerMW , ManuckTA . Chorioamnionitis prevents protective effect of magnesium sulfate in the preterm infant. Reproductive Sciences2014;21(3 Suppl 1):78A. KamyarM , ManuckTA , StoddardGJ , VarnerMW , ClarkEAS . Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. BJOG: an international journal of obstetrics and gynaecology2016;123(7):1161-6. KamyarM , VarnerM , ClarkE . Magnesium sulfate neuroprophylaxis and the effect of infant sex. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S144. ManuckA , ShengX , YoderA , VarnerW . Correlation between initial neonatal and early childhood outcomes following preterm birth. American Journal of Obstetrics &amp; Gynecology2014;210(5):426.e1-9. ManuckT , ShengX , YoderB , VarnerM . Correlation between initial neonatal and early childhood outcomes among children delivered &lt;34 weeks gestation. American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S23. ManuckT , VarnerM . Is bigger better? Neonatal and childhood outcomes of large for gestational age (LGA) infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341-2. ManuckT , VarnerM . Neonatal and childhood outcomes following early vs later preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S340-1. ManuckT , VarnerM . Neonatal and childhood outcomes of small for gestational age infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341. ManuckTA , VarnerMW . Neonatal and early childhood outcomes following early vs later preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2014;211(3):308.e1-6. MarrsC , Mendez-FigueroaH , ChauhanS . Periventricular leukomalacia with PPROM: Obstetric antecedents and infants' outcomes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S85. MarrsCC , Mendez-FigueroaH , HammadIA , ChauhanSP . Differential morbidity in preterm small versus appropriate for gestational age: perhaps unverifiable. American Journal of Perinatology2015;32(13):1251-6. McPhersonJ , SmileyS , StamiloD . Magnesium sulfate neuroprotection and obesity: Is efficacy affected by obesity. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S218. McPhersonJA , RouseDJ , GrobmanWA , PalatnikA , StamilioDM . Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. Obstetrics and Gynecology2014;124(4):749-55. McPhersonJA , SmileyS , StamilioDM . Maternal obesity and neuroprotective magnesium sulfate. American Journal of Obstetrics and Gynecology2015;213(4):582.e1–6. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate &lt; 12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S252. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate for &gt;12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S104-5. Mendez-FigueroaH , ChauhanSP , PedrozaC , RefuerzoJS , DahlkeJD , RouseDJ . Preterm cesarean delivery for nonreassuring fetal heart rate: neonatal and neurologic morbidity. Obstetrics and Gynecology2015;125(3):636-42. Mendez-FigueroaH , DahlkeJD , ViteriOA , ChauhanSP , RouseDJ , SibaiBM , et al. Neonatal and infant outcomes in twin gestations with preterm premature rupture of membranes at 24-31 weeks of gestation. Obstetrics and Gynecology2014;124(2 Pt 1):323-31. MoussaH , Hosseini NasabS , FournieD , OntiverosA , AlkawasR , ChauhanS , et al. The impact of time of delivery on gestations complicated by preterm premature rupture of membranes: daytime versus nighttime. Journal of Maternal-Fetal &amp; Neonatal Medicine2019;32(20):3319-24. NCT00014989. Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) [Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)]. clinicaltrials.gov/show/NCT00014989 (first received 18 April 2001). NussEE , SpiegelmanJ , TuritzAL , Gyamfi-BannermanC . Childhood neurodevelopment after spontaneous versus indicated preterm birth. American Journal of Obstetrics and Gynecology MFM2020;2(2):100082. ObicanS , DrassinowerD , LevinH , Gyamfi-BannermanC . Mode of delivery at periviability and early childhood neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S124. OvertonE , BaptisteC , Gyamfi-BannermanC . 546: neurodevelopmental outcomes in late preterm and early term deliveries following antenatal corticosteroid exposure. American Journal of Obstetrics and Gynecology2019;220(1):S365-6. PalatnikA , RouseD , StamiloD , McPhersonJ , GrobmanW . The association between cerebral palsy or death and umbilical cord magnesium concentration. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S302. RobbinsLS , BlanchardCT , BiasiniFJ , PowellMF , CaseyBM , TitaAT , et al. General anesthesia for cesarean delivery and childhood neurodevelopmental and perinatal outcomes: a secondary analysis of a randomized controlled trial. International Journal of Obstetric Anesthesia2020;45:34-40. RobbinsLS , BlanchardCT , SinkeyRG , HarrisSL , TitaAT , HarperLM . Prenatal tobacco exposure and childhood neurodevelopment among infants born prematurely. American Journal of Perinatology2020;38(3):218-23. RobertsR , Ankumah N-A, ViteriO , Mendez-FigueroaH , ChauhanS , SibaiB . Significance of the absence of amniotic fluid from the cervical os with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S223. RouseD , HirtzD , ThomE , VarnerM , AlexanderJ , SpongC , et al. Magnesium sulfate for the prevention of cerebral palsy. New England Journal of Medicine2008;359:895-905. RouseD . A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. American Journal of Obstetrics and Gynecology2007;197(6):S2. RouseD . Magnesium sulfate (MGSO4) dose and timing, umbilical cord MG++ concentration: relationship to cerebral palsy. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S46. SagaramD , HaarEV , MillerR , Gyamfi-BannermanC . Birth order does not offer a neurologic advantage in twin pregnancy. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S427. SiegelAM , HeineRP , Dotters-KatzSK . The effect of non-penicillin antibiotic regimens on neonatal outcomes in preterm prelabor rupture of membranes. American Journal of Obstetrics and Gynecology2018;219(6):637. SonM , GrobmanWA , MillerES . Is mode of delivery associated with the risk of necrotizing enterocolitis?American Journal of Obstetrics and Gynecology2016;214(1 Suppl 1):S204-5. TuritzAL , TooGT , Gyamfi-BannermanC . Proximity of magnesium exposure to delivery and neonatal outcomes. American Journal of Obstetrics and Gynecology2016;215(4):508.e1-6. TwicklerD , McIntireD , AlexanderJ , LevenoK . Effects of magnesium sulfate on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S112. TwicklerDM , McIntireDD , AlexanderJM , LevenoKJ . Effects of magnesium sulfate on preterm fetal cerebral blood flow using Doppler analysis: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):21-5. Vander HaarE , GoldbergerA , Gyamfi-BannermanC . Mild intraventricular hemorrhage is not associated with low bayley scores at age 2. Reproductive Sciences2017;24(1 Suppl 1):83A. VilchezG , DaiJ , KumarK , MundyD , KontopoulosE , SokolRJ . Racial/ethnic disparities in magnesium sulfate neuroprotection: a subgroup analysis of a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(17):2304-11. VilchezG , DaiJ , LagosM , SokolRJ . Maternal side effects &amp; fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(2):178-83. WoodAM , PostAL , SwamyGK , GrotegutCA . Neonatal outcomes associated with noncephalic presentation at delivery in preterm birth. American Journal of Perinatology2018;35(12):1131-7. YadavaS , GarabedianM , SitA , El-SayedY . Use of magnesium sulfate and labor outcomes in PPROM at less than 37 weeks. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S203. YangM , VarnerMW , YoderB . Cord blood magnesium levels and nonneurologic outcomes in neonates less than 27 weeks gestational age. Journal of Investigative Medicine2019;67(1):86-7. ">Rouse 2008</a>; <a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a>). </p> </section> <section id="CD004661-sec-0072"> <h5 class="title">Setting</h5> <p>All RCTs were conducted in high‐income countries: two in the USA (<a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a>; <a href="./references#CD004661-bbs2-0005" title="BrookfieldKF , O'MalleyK , Yeaton-MasseyA , ButwickAJ . Does magnesium sulfate exposure attenuate the effect of steroids administered for fetal lung maturation? In: Society for Obstetric Anesthesia and Perinatology (SOAP) 48th Annual Meeting; 2016 May 18-22; Boston USA. 2016:SA-32. BuhimschiCS , JablonskiKA , RouseDJ , VarnerMW , ReddyUM , MercerBM , et al. Cord blood haptoglobin, cerebral palsy and death in infants of women at risk for preterm birth: a secondary analysis of a randomised controlled trial. Eclinicalmedicine2019;9:11-8. CostantineMM , WeinerSJ , RouseDJ , HirtzDG , VarnerMW , SpongCY , et al. Umbilical cord blood biomarkers of neurologic injury and the risk of cerebral palsy or infant death. International Journal of Developmental Neuroscience2011;29(8):917-22. CostantineMM . Cord blood biomarkers and the risk of cerebral palsy or death. Reproductive Sciences2010;17(3 Suppl 1):65A. DeihlTE , SimhanHN . Antenatal magnesium sulfate and ponderal index from birth to age 2 in preterm male and female infants. Reproductive Sciences2017;24(Suppl 1):130A. DeihlTE , SimhanHN . Antenatal magnesium sulfate exposure and ponderal index in preterm infants. American Journal of Perinatology2019;36(3):329-34. DenobleAE , WuJ , MitchellCJ , HughesBL , Dotters-KatzSK . Chorioamnionitis versus intraamniotic infection among preterm deliveries-is postpartum infectious morbidity different?American Journal of Obstetrics and Gynecology MFM2020;2(3):100176. DrassinowerD , FriedmanAM , LevinH , ObicanSG , Gyamfi-BannermanC . Does magnesium exposure affect neonatal resuscitation? Presented as a poster at the 35th annual meeting of the society for maternal-fetal medicine, San Diego, CA, Feb. 2-7, 2015. American Journal of Obstetrics and Gynecology2015;213(3):424e1-5. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm prelabour rupture of membranes and neurodevelopmental outcomes: a secondary analysis. BJOG: an international journal of obstetrics and gynaecology2016;123(10):1629-35. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of cerebral palsy. Journal of Maternal-Fetal &amp; Neonatal Medicine2016;29(17):2748-52. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of neonatal sepsis. American Journal of Obstetrics and Gynecology2016;214(6):743.e1-6. DrassinowerD , LevinH , ObicanS , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on cerebral palsy. American Journal of Obstetrics and Gynecology2015;212(1):S310-1. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . Immediate neonatal outcomes in infants exposed to magnesium sulfate at the time of delivery. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S90. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1):S161-2. EdwardsJ , EdwardsL , SwamyG , GrotegutC . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S215-6. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Effect of cord blood magnesium level at birth on non-neurologic neonatal outcomes. American Journal of Perinatology2019;36(1):3-7. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. Journal of Maternal-Fetal &amp; Neonatal Medicine2018;31(9):1156-60. FaucettAM , MetzTD , DeWittPE , GibbsRS . Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2016;214(2):287.e1-5. HaarEV , Gyamfi-BannermanC , Coletta-LucasJ . Sepsis but not chorioamnionitis is associated with cerebral palsy. Reproductive Sciences2015;22:372A. HaarEV , Gyamfi-BannermanC , RandisTM . Abnormal brain imaging in infants exposed to chorioamnionitis and sepsis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl. 1):S11-2. HaarEV , LucasJC , D'AltonM , Gyamfi-BannermanC . The effect of chorioamnionitis on neurocognitive development at age 2. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S139-40. HerreraC , SilverRM , MajorH , VarnerMW , ClarkEAS . Triple I criteria and adverse neonatal and childhood outcomes after early preterm birth. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S250. HirtzDG , WeinerSJ , BulasD , DiPietroM , SeibertJ , RouseDJ , et al. Antenatal magnesium and cerebral palsy in preterm infants. Journal of Pediatrics2015;167(4):834-9.e3. HirtzDG . Effect of prenatal MgSO4 on head ultrasound imaging in preterm infants. Annals of Neurology2011;70(Suppl 15):S110. HortonA . The effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S209. HortonL , YingleiL , RouseJ , SpongY , LevenoJ , VarnerW , et al. Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Perinatology2015;32(4):387-92. JohnsonLH , MappDC , RouseDJ , SpongCY , MercerBM , LevenoKJ , et al. Association of cord blood magnesium concentration and neonatal resuscitation. Journal of Pediatrics2012;160(4):573-7.e1. KachikisA , WalkerC , McAdamsR , WaldorfKA , Gyamfi-BannermanC . Influence of preterm premature rupture of membranes on neonatal respiratory complications. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S215. KachikisA , WalkerCL , McAdamsRM , Gyamfi-BannermanC , Adams WaldorfKM . Phenotypic overlap in neonatal respiratory morbidity following preterm premature rupture of membranes versus spontaneous preterm labor. Journal of Maternal-fetal &amp; Neonatal Medicine2021;34(12):1941-8. KamyarM , ClarkEA , YoderBA , VarnerMW , ManuckTA . Antenatal magnesium sulfate, necrotizing enterocolitis, and death among neonates &lt; 28 weeks gestation. AJP Reports2016;6(1):e148-54. KamyarM , ClarkEAS , VarnerMW , ManuckTA . Chorioamnionitis prevents protective effect of magnesium sulfate in the preterm infant. Reproductive Sciences2014;21(3 Suppl 1):78A. KamyarM , ManuckTA , StoddardGJ , VarnerMW , ClarkEAS . Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. BJOG: an international journal of obstetrics and gynaecology2016;123(7):1161-6. KamyarM , VarnerM , ClarkE . Magnesium sulfate neuroprophylaxis and the effect of infant sex. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S144. ManuckA , ShengX , YoderA , VarnerW . Correlation between initial neonatal and early childhood outcomes following preterm birth. American Journal of Obstetrics &amp; Gynecology2014;210(5):426.e1-9. ManuckT , ShengX , YoderB , VarnerM . Correlation between initial neonatal and early childhood outcomes among children delivered &lt;34 weeks gestation. American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S23. ManuckT , VarnerM . Is bigger better? Neonatal and childhood outcomes of large for gestational age (LGA) infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341-2. ManuckT , VarnerM . Neonatal and childhood outcomes following early vs later preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S340-1. ManuckT , VarnerM . Neonatal and childhood outcomes of small for gestational age infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341. ManuckTA , VarnerMW . Neonatal and early childhood outcomes following early vs later preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2014;211(3):308.e1-6. MarrsC , Mendez-FigueroaH , ChauhanS . Periventricular leukomalacia with PPROM: Obstetric antecedents and infants' outcomes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S85. MarrsCC , Mendez-FigueroaH , HammadIA , ChauhanSP . Differential morbidity in preterm small versus appropriate for gestational age: perhaps unverifiable. American Journal of Perinatology2015;32(13):1251-6. McPhersonJ , SmileyS , StamiloD . Magnesium sulfate neuroprotection and obesity: Is efficacy affected by obesity. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S218. McPhersonJA , RouseDJ , GrobmanWA , PalatnikA , StamilioDM . Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. Obstetrics and Gynecology2014;124(4):749-55. McPhersonJA , SmileyS , StamilioDM . Maternal obesity and neuroprotective magnesium sulfate. American Journal of Obstetrics and Gynecology2015;213(4):582.e1–6. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate &lt; 12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S252. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate for &gt;12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S104-5. Mendez-FigueroaH , ChauhanSP , PedrozaC , RefuerzoJS , DahlkeJD , RouseDJ . Preterm cesarean delivery for nonreassuring fetal heart rate: neonatal and neurologic morbidity. Obstetrics and Gynecology2015;125(3):636-42. Mendez-FigueroaH , DahlkeJD , ViteriOA , ChauhanSP , RouseDJ , SibaiBM , et al. Neonatal and infant outcomes in twin gestations with preterm premature rupture of membranes at 24-31 weeks of gestation. Obstetrics and Gynecology2014;124(2 Pt 1):323-31. MoussaH , Hosseini NasabS , FournieD , OntiverosA , AlkawasR , ChauhanS , et al. The impact of time of delivery on gestations complicated by preterm premature rupture of membranes: daytime versus nighttime. Journal of Maternal-Fetal &amp; Neonatal Medicine2019;32(20):3319-24. NCT00014989. Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) [Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)]. clinicaltrials.gov/show/NCT00014989 (first received 18 April 2001). NussEE , SpiegelmanJ , TuritzAL , Gyamfi-BannermanC . Childhood neurodevelopment after spontaneous versus indicated preterm birth. American Journal of Obstetrics and Gynecology MFM2020;2(2):100082. ObicanS , DrassinowerD , LevinH , Gyamfi-BannermanC . Mode of delivery at periviability and early childhood neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S124. OvertonE , BaptisteC , Gyamfi-BannermanC . 546: neurodevelopmental outcomes in late preterm and early term deliveries following antenatal corticosteroid exposure. American Journal of Obstetrics and Gynecology2019;220(1):S365-6. PalatnikA , RouseD , StamiloD , McPhersonJ , GrobmanW . The association between cerebral palsy or death and umbilical cord magnesium concentration. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S302. RobbinsLS , BlanchardCT , BiasiniFJ , PowellMF , CaseyBM , TitaAT , et al. General anesthesia for cesarean delivery and childhood neurodevelopmental and perinatal outcomes: a secondary analysis of a randomized controlled trial. International Journal of Obstetric Anesthesia2020;45:34-40. RobbinsLS , BlanchardCT , SinkeyRG , HarrisSL , TitaAT , HarperLM . Prenatal tobacco exposure and childhood neurodevelopment among infants born prematurely. American Journal of Perinatology2020;38(3):218-23. RobertsR , Ankumah N-A, ViteriO , Mendez-FigueroaH , ChauhanS , SibaiB . Significance of the absence of amniotic fluid from the cervical os with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S223. RouseD , HirtzD , ThomE , VarnerM , AlexanderJ , SpongC , et al. Magnesium sulfate for the prevention of cerebral palsy. New England Journal of Medicine2008;359:895-905. RouseD . A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. American Journal of Obstetrics and Gynecology2007;197(6):S2. RouseD . Magnesium sulfate (MGSO4) dose and timing, umbilical cord MG++ concentration: relationship to cerebral palsy. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S46. SagaramD , HaarEV , MillerR , Gyamfi-BannermanC . Birth order does not offer a neurologic advantage in twin pregnancy. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S427. SiegelAM , HeineRP , Dotters-KatzSK . The effect of non-penicillin antibiotic regimens on neonatal outcomes in preterm prelabor rupture of membranes. American Journal of Obstetrics and Gynecology2018;219(6):637. SonM , GrobmanWA , MillerES . Is mode of delivery associated with the risk of necrotizing enterocolitis?American Journal of Obstetrics and Gynecology2016;214(1 Suppl 1):S204-5. TuritzAL , TooGT , Gyamfi-BannermanC . Proximity of magnesium exposure to delivery and neonatal outcomes. American Journal of Obstetrics and Gynecology2016;215(4):508.e1-6. TwicklerD , McIntireD , AlexanderJ , LevenoK . Effects of magnesium sulfate on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S112. TwicklerDM , McIntireDD , AlexanderJM , LevenoKJ . Effects of magnesium sulfate on preterm fetal cerebral blood flow using Doppler analysis: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):21-5. Vander HaarE , GoldbergerA , Gyamfi-BannermanC . Mild intraventricular hemorrhage is not associated with low bayley scores at age 2. Reproductive Sciences2017;24(1 Suppl 1):83A. VilchezG , DaiJ , KumarK , MundyD , KontopoulosE , SokolRJ . Racial/ethnic disparities in magnesium sulfate neuroprotection: a subgroup analysis of a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(17):2304-11. VilchezG , DaiJ , LagosM , SokolRJ . Maternal side effects &amp; fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(2):178-83. WoodAM , PostAL , SwamyGK , GrotegutCA . Neonatal outcomes associated with noncephalic presentation at delivery in preterm birth. American Journal of Perinatology2018;35(12):1131-7. YadavaS , GarabedianM , SitA , El-SayedY . Use of magnesium sulfate and labor outcomes in PPROM at less than 37 weeks. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S203. YangM , VarnerMW , YoderB . Cord blood magnesium levels and nonneurologic outcomes in neonates less than 27 weeks gestational age. Journal of Investigative Medicine2019;67(1):86-7. ">Rouse 2008</a>), two across Australian and New Zealand (<a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a>; <a href="./references#CD004661-bbs2-0002" title="ACTRN12611000491965. MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: neuroprotection trial [Does antenatal magnesium sulphate given to women at risk of imminent preterm birth (defined as planned or definitely expected in the next 24 hours) between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children at 2 years corrected age? - a randomised controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000491965 (first received 11 May 2011). CrowtherCA , AshwoodP , MiddletonPF , McPheeA , TranT , HardineJE , et al. Prenatal intravenous magnesium at 30-34 weeks’ gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial. JAMA2023;330(7):603-14. CrowtherCA , MiddletonPF , WilkinsonD , AshwoodP , HaslamR . Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) - study protocol. BMC Pregnancy and Childbirth2013;13(1):91. PoppeT , ThompsonB , BoardmanJP , BastinME , AlsweilerJ , DeibG , et al. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: the MagNUM Study. EBioMedicine2022;78:103923. ">Crowther 2023</a>), and one each in Denmark (<a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a>) and France (<a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a>). </p> </section> <section id="CD004661-sec-0073"> <h5 class="title">Study dates</h5> <p>The included RCTs commenced between 1995 (<a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a>) and 2018 (<a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a>). </p> </section> <section id="CD004661-sec-0074"> <h5 class="title">Sample sizes</h5> <p>The total number of women randomised ranged from 57 (<a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a>) to 2241 (<a href="./references#CD004661-bbs2-0005" title="BrookfieldKF , O'MalleyK , Yeaton-MasseyA , ButwickAJ . Does magnesium sulfate exposure attenuate the effect of steroids administered for fetal lung maturation? In: Society for Obstetric Anesthesia and Perinatology (SOAP) 48th Annual Meeting; 2016 May 18-22; Boston USA. 2016:SA-32. BuhimschiCS , JablonskiKA , RouseDJ , VarnerMW , ReddyUM , MercerBM , et al. Cord blood haptoglobin, cerebral palsy and death in infants of women at risk for preterm birth: a secondary analysis of a randomised controlled trial. Eclinicalmedicine2019;9:11-8. CostantineMM , WeinerSJ , RouseDJ , HirtzDG , VarnerMW , SpongCY , et al. Umbilical cord blood biomarkers of neurologic injury and the risk of cerebral palsy or infant death. International Journal of Developmental Neuroscience2011;29(8):917-22. CostantineMM . Cord blood biomarkers and the risk of cerebral palsy or death. Reproductive Sciences2010;17(3 Suppl 1):65A. DeihlTE , SimhanHN . Antenatal magnesium sulfate and ponderal index from birth to age 2 in preterm male and female infants. Reproductive Sciences2017;24(Suppl 1):130A. DeihlTE , SimhanHN . Antenatal magnesium sulfate exposure and ponderal index in preterm infants. American Journal of Perinatology2019;36(3):329-34. DenobleAE , WuJ , MitchellCJ , HughesBL , Dotters-KatzSK . Chorioamnionitis versus intraamniotic infection among preterm deliveries-is postpartum infectious morbidity different?American Journal of Obstetrics and Gynecology MFM2020;2(3):100176. DrassinowerD , FriedmanAM , LevinH , ObicanSG , Gyamfi-BannermanC . Does magnesium exposure affect neonatal resuscitation? Presented as a poster at the 35th annual meeting of the society for maternal-fetal medicine, San Diego, CA, Feb. 2-7, 2015. American Journal of Obstetrics and Gynecology2015;213(3):424e1-5. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm prelabour rupture of membranes and neurodevelopmental outcomes: a secondary analysis. BJOG: an international journal of obstetrics and gynaecology2016;123(10):1629-35. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of cerebral palsy. Journal of Maternal-Fetal &amp; Neonatal Medicine2016;29(17):2748-52. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of neonatal sepsis. American Journal of Obstetrics and Gynecology2016;214(6):743.e1-6. DrassinowerD , LevinH , ObicanS , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on cerebral palsy. American Journal of Obstetrics and Gynecology2015;212(1):S310-1. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . Immediate neonatal outcomes in infants exposed to magnesium sulfate at the time of delivery. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S90. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1):S161-2. EdwardsJ , EdwardsL , SwamyG , GrotegutC . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S215-6. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Effect of cord blood magnesium level at birth on non-neurologic neonatal outcomes. American Journal of Perinatology2019;36(1):3-7. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. Journal of Maternal-Fetal &amp; Neonatal Medicine2018;31(9):1156-60. FaucettAM , MetzTD , DeWittPE , GibbsRS . Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2016;214(2):287.e1-5. HaarEV , Gyamfi-BannermanC , Coletta-LucasJ . Sepsis but not chorioamnionitis is associated with cerebral palsy. Reproductive Sciences2015;22:372A. HaarEV , Gyamfi-BannermanC , RandisTM . Abnormal brain imaging in infants exposed to chorioamnionitis and sepsis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl. 1):S11-2. HaarEV , LucasJC , D'AltonM , Gyamfi-BannermanC . The effect of chorioamnionitis on neurocognitive development at age 2. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S139-40. HerreraC , SilverRM , MajorH , VarnerMW , ClarkEAS . Triple I criteria and adverse neonatal and childhood outcomes after early preterm birth. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S250. HirtzDG , WeinerSJ , BulasD , DiPietroM , SeibertJ , RouseDJ , et al. Antenatal magnesium and cerebral palsy in preterm infants. Journal of Pediatrics2015;167(4):834-9.e3. HirtzDG . Effect of prenatal MgSO4 on head ultrasound imaging in preterm infants. Annals of Neurology2011;70(Suppl 15):S110. HortonA . The effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S209. HortonL , YingleiL , RouseJ , SpongY , LevenoJ , VarnerW , et al. Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Perinatology2015;32(4):387-92. JohnsonLH , MappDC , RouseDJ , SpongCY , MercerBM , LevenoKJ , et al. Association of cord blood magnesium concentration and neonatal resuscitation. Journal of Pediatrics2012;160(4):573-7.e1. KachikisA , WalkerC , McAdamsR , WaldorfKA , Gyamfi-BannermanC . Influence of preterm premature rupture of membranes on neonatal respiratory complications. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S215. KachikisA , WalkerCL , McAdamsRM , Gyamfi-BannermanC , Adams WaldorfKM . Phenotypic overlap in neonatal respiratory morbidity following preterm premature rupture of membranes versus spontaneous preterm labor. Journal of Maternal-fetal &amp; Neonatal Medicine2021;34(12):1941-8. KamyarM , ClarkEA , YoderBA , VarnerMW , ManuckTA . Antenatal magnesium sulfate, necrotizing enterocolitis, and death among neonates &lt; 28 weeks gestation. AJP Reports2016;6(1):e148-54. KamyarM , ClarkEAS , VarnerMW , ManuckTA . Chorioamnionitis prevents protective effect of magnesium sulfate in the preterm infant. Reproductive Sciences2014;21(3 Suppl 1):78A. KamyarM , ManuckTA , StoddardGJ , VarnerMW , ClarkEAS . Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. BJOG: an international journal of obstetrics and gynaecology2016;123(7):1161-6. KamyarM , VarnerM , ClarkE . Magnesium sulfate neuroprophylaxis and the effect of infant sex. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S144. ManuckA , ShengX , YoderA , VarnerW . Correlation between initial neonatal and early childhood outcomes following preterm birth. American Journal of Obstetrics &amp; Gynecology2014;210(5):426.e1-9. ManuckT , ShengX , YoderB , VarnerM . Correlation between initial neonatal and early childhood outcomes among children delivered &lt;34 weeks gestation. American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S23. ManuckT , VarnerM . Is bigger better? Neonatal and childhood outcomes of large for gestational age (LGA) infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341-2. ManuckT , VarnerM . Neonatal and childhood outcomes following early vs later preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S340-1. ManuckT , VarnerM . Neonatal and childhood outcomes of small for gestational age infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341. ManuckTA , VarnerMW . Neonatal and early childhood outcomes following early vs later preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2014;211(3):308.e1-6. MarrsC , Mendez-FigueroaH , ChauhanS . Periventricular leukomalacia with PPROM: Obstetric antecedents and infants' outcomes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S85. MarrsCC , Mendez-FigueroaH , HammadIA , ChauhanSP . Differential morbidity in preterm small versus appropriate for gestational age: perhaps unverifiable. American Journal of Perinatology2015;32(13):1251-6. McPhersonJ , SmileyS , StamiloD . Magnesium sulfate neuroprotection and obesity: Is efficacy affected by obesity. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S218. McPhersonJA , RouseDJ , GrobmanWA , PalatnikA , StamilioDM . Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. Obstetrics and Gynecology2014;124(4):749-55. McPhersonJA , SmileyS , StamilioDM . Maternal obesity and neuroprotective magnesium sulfate. American Journal of Obstetrics and Gynecology2015;213(4):582.e1–6. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate &lt; 12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S252. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate for &gt;12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S104-5. Mendez-FigueroaH , ChauhanSP , PedrozaC , RefuerzoJS , DahlkeJD , RouseDJ . Preterm cesarean delivery for nonreassuring fetal heart rate: neonatal and neurologic morbidity. Obstetrics and Gynecology2015;125(3):636-42. Mendez-FigueroaH , DahlkeJD , ViteriOA , ChauhanSP , RouseDJ , SibaiBM , et al. Neonatal and infant outcomes in twin gestations with preterm premature rupture of membranes at 24-31 weeks of gestation. Obstetrics and Gynecology2014;124(2 Pt 1):323-31. MoussaH , Hosseini NasabS , FournieD , OntiverosA , AlkawasR , ChauhanS , et al. The impact of time of delivery on gestations complicated by preterm premature rupture of membranes: daytime versus nighttime. Journal of Maternal-Fetal &amp; Neonatal Medicine2019;32(20):3319-24. NCT00014989. Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) [Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)]. clinicaltrials.gov/show/NCT00014989 (first received 18 April 2001). NussEE , SpiegelmanJ , TuritzAL , Gyamfi-BannermanC . Childhood neurodevelopment after spontaneous versus indicated preterm birth. American Journal of Obstetrics and Gynecology MFM2020;2(2):100082. ObicanS , DrassinowerD , LevinH , Gyamfi-BannermanC . Mode of delivery at periviability and early childhood neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S124. OvertonE , BaptisteC , Gyamfi-BannermanC . 546: neurodevelopmental outcomes in late preterm and early term deliveries following antenatal corticosteroid exposure. American Journal of Obstetrics and Gynecology2019;220(1):S365-6. PalatnikA , RouseD , StamiloD , McPhersonJ , GrobmanW . The association between cerebral palsy or death and umbilical cord magnesium concentration. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S302. RobbinsLS , BlanchardCT , BiasiniFJ , PowellMF , CaseyBM , TitaAT , et al. General anesthesia for cesarean delivery and childhood neurodevelopmental and perinatal outcomes: a secondary analysis of a randomized controlled trial. International Journal of Obstetric Anesthesia2020;45:34-40. RobbinsLS , BlanchardCT , SinkeyRG , HarrisSL , TitaAT , HarperLM . Prenatal tobacco exposure and childhood neurodevelopment among infants born prematurely. American Journal of Perinatology2020;38(3):218-23. RobertsR , Ankumah N-A, ViteriO , Mendez-FigueroaH , ChauhanS , SibaiB . Significance of the absence of amniotic fluid from the cervical os with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S223. RouseD , HirtzD , ThomE , VarnerM , AlexanderJ , SpongC , et al. Magnesium sulfate for the prevention of cerebral palsy. New England Journal of Medicine2008;359:895-905. RouseD . A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. American Journal of Obstetrics and Gynecology2007;197(6):S2. RouseD . Magnesium sulfate (MGSO4) dose and timing, umbilical cord MG++ concentration: relationship to cerebral palsy. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S46. SagaramD , HaarEV , MillerR , Gyamfi-BannermanC . Birth order does not offer a neurologic advantage in twin pregnancy. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S427. SiegelAM , HeineRP , Dotters-KatzSK . The effect of non-penicillin antibiotic regimens on neonatal outcomes in preterm prelabor rupture of membranes. American Journal of Obstetrics and Gynecology2018;219(6):637. SonM , GrobmanWA , MillerES . Is mode of delivery associated with the risk of necrotizing enterocolitis?American Journal of Obstetrics and Gynecology2016;214(1 Suppl 1):S204-5. TuritzAL , TooGT , Gyamfi-BannermanC . Proximity of magnesium exposure to delivery and neonatal outcomes. American Journal of Obstetrics and Gynecology2016;215(4):508.e1-6. TwicklerD , McIntireD , AlexanderJ , LevenoK . Effects of magnesium sulfate on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S112. TwicklerDM , McIntireDD , AlexanderJM , LevenoKJ . Effects of magnesium sulfate on preterm fetal cerebral blood flow using Doppler analysis: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):21-5. Vander HaarE , GoldbergerA , Gyamfi-BannermanC . Mild intraventricular hemorrhage is not associated with low bayley scores at age 2. Reproductive Sciences2017;24(1 Suppl 1):83A. VilchezG , DaiJ , KumarK , MundyD , KontopoulosE , SokolRJ . Racial/ethnic disparities in magnesium sulfate neuroprotection: a subgroup analysis of a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(17):2304-11. VilchezG , DaiJ , LagosM , SokolRJ . Maternal side effects &amp; fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(2):178-83. WoodAM , PostAL , SwamyGK , GrotegutCA . Neonatal outcomes associated with noncephalic presentation at delivery in preterm birth. American Journal of Perinatology2018;35(12):1131-7. YadavaS , GarabedianM , SitA , El-SayedY . Use of magnesium sulfate and labor outcomes in PPROM at less than 37 weeks. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S203. YangM , VarnerMW , YoderB . Cord blood magnesium levels and nonneurologic outcomes in neonates less than 27 weeks gestational age. Journal of Investigative Medicine2019;67(1):86-7. ">Rouse 2008</a>), with a total of 5917 women and their 6759 fetuses alive at randomisation (<a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a>; <a href="./references#CD004661-bbs2-0002" title="ACTRN12611000491965. MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: neuroprotection trial [Does antenatal magnesium sulphate given to women at risk of imminent preterm birth (defined as planned or definitely expected in the next 24 hours) between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children at 2 years corrected age? - a randomised controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000491965 (first received 11 May 2011). CrowtherCA , AshwoodP , MiddletonPF , McPheeA , TranT , HardineJE , et al. Prenatal intravenous magnesium at 30-34 weeks’ gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial. JAMA2023;330(7):603-14. CrowtherCA , MiddletonPF , WilkinsonD , AshwoodP , HaslamR . Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) - study protocol. BMC Pregnancy and Childbirth2013;13(1):91. PoppeT , ThompsonB , BoardmanJP , BastinME , AlsweilerJ , DeibG , et al. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: the MagNUM Study. EBioMedicine2022;78:103923. ">Crowther 2023</a>; <a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a>; <a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a>; <a href="./references#CD004661-bbs2-0005" title="BrookfieldKF , O'MalleyK , Yeaton-MasseyA , ButwickAJ . Does magnesium sulfate exposure attenuate the effect of steroids administered for fetal lung maturation? In: Society for Obstetric Anesthesia and Perinatology (SOAP) 48th Annual Meeting; 2016 May 18-22; Boston USA. 2016:SA-32. BuhimschiCS , JablonskiKA , RouseDJ , VarnerMW , ReddyUM , MercerBM , et al. Cord blood haptoglobin, cerebral palsy and death in infants of women at risk for preterm birth: a secondary analysis of a randomised controlled trial. Eclinicalmedicine2019;9:11-8. CostantineMM , WeinerSJ , RouseDJ , HirtzDG , VarnerMW , SpongCY , et al. Umbilical cord blood biomarkers of neurologic injury and the risk of cerebral palsy or infant death. International Journal of Developmental Neuroscience2011;29(8):917-22. CostantineMM . Cord blood biomarkers and the risk of cerebral palsy or death. Reproductive Sciences2010;17(3 Suppl 1):65A. DeihlTE , SimhanHN . Antenatal magnesium sulfate and ponderal index from birth to age 2 in preterm male and female infants. Reproductive Sciences2017;24(Suppl 1):130A. DeihlTE , SimhanHN . Antenatal magnesium sulfate exposure and ponderal index in preterm infants. American Journal of Perinatology2019;36(3):329-34. DenobleAE , WuJ , MitchellCJ , HughesBL , Dotters-KatzSK . Chorioamnionitis versus intraamniotic infection among preterm deliveries-is postpartum infectious morbidity different?American Journal of Obstetrics and Gynecology MFM2020;2(3):100176. DrassinowerD , FriedmanAM , LevinH , ObicanSG , Gyamfi-BannermanC . Does magnesium exposure affect neonatal resuscitation? Presented as a poster at the 35th annual meeting of the society for maternal-fetal medicine, San Diego, CA, Feb. 2-7, 2015. American Journal of Obstetrics and Gynecology2015;213(3):424e1-5. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm prelabour rupture of membranes and neurodevelopmental outcomes: a secondary analysis. BJOG: an international journal of obstetrics and gynaecology2016;123(10):1629-35. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of cerebral palsy. Journal of Maternal-Fetal &amp; Neonatal Medicine2016;29(17):2748-52. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of neonatal sepsis. American Journal of Obstetrics and Gynecology2016;214(6):743.e1-6. DrassinowerD , LevinH , ObicanS , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on cerebral palsy. American Journal of Obstetrics and Gynecology2015;212(1):S310-1. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . Immediate neonatal outcomes in infants exposed to magnesium sulfate at the time of delivery. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S90. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1):S161-2. EdwardsJ , EdwardsL , SwamyG , GrotegutC . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S215-6. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Effect of cord blood magnesium level at birth on non-neurologic neonatal outcomes. American Journal of Perinatology2019;36(1):3-7. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. Journal of Maternal-Fetal &amp; Neonatal Medicine2018;31(9):1156-60. FaucettAM , MetzTD , DeWittPE , GibbsRS . Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2016;214(2):287.e1-5. HaarEV , Gyamfi-BannermanC , Coletta-LucasJ . Sepsis but not chorioamnionitis is associated with cerebral palsy. Reproductive Sciences2015;22:372A. HaarEV , Gyamfi-BannermanC , RandisTM . Abnormal brain imaging in infants exposed to chorioamnionitis and sepsis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl. 1):S11-2. HaarEV , LucasJC , D'AltonM , Gyamfi-BannermanC . The effect of chorioamnionitis on neurocognitive development at age 2. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S139-40. HerreraC , SilverRM , MajorH , VarnerMW , ClarkEAS . Triple I criteria and adverse neonatal and childhood outcomes after early preterm birth. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S250. HirtzDG , WeinerSJ , BulasD , DiPietroM , SeibertJ , RouseDJ , et al. Antenatal magnesium and cerebral palsy in preterm infants. Journal of Pediatrics2015;167(4):834-9.e3. HirtzDG . Effect of prenatal MgSO4 on head ultrasound imaging in preterm infants. Annals of Neurology2011;70(Suppl 15):S110. HortonA . The effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S209. HortonL , YingleiL , RouseJ , SpongY , LevenoJ , VarnerW , et al. Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Perinatology2015;32(4):387-92. JohnsonLH , MappDC , RouseDJ , SpongCY , MercerBM , LevenoKJ , et al. Association of cord blood magnesium concentration and neonatal resuscitation. Journal of Pediatrics2012;160(4):573-7.e1. KachikisA , WalkerC , McAdamsR , WaldorfKA , Gyamfi-BannermanC . Influence of preterm premature rupture of membranes on neonatal respiratory complications. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S215. KachikisA , WalkerCL , McAdamsRM , Gyamfi-BannermanC , Adams WaldorfKM . Phenotypic overlap in neonatal respiratory morbidity following preterm premature rupture of membranes versus spontaneous preterm labor. Journal of Maternal-fetal &amp; Neonatal Medicine2021;34(12):1941-8. KamyarM , ClarkEA , YoderBA , VarnerMW , ManuckTA . Antenatal magnesium sulfate, necrotizing enterocolitis, and death among neonates &lt; 28 weeks gestation. AJP Reports2016;6(1):e148-54. KamyarM , ClarkEAS , VarnerMW , ManuckTA . Chorioamnionitis prevents protective effect of magnesium sulfate in the preterm infant. Reproductive Sciences2014;21(3 Suppl 1):78A. KamyarM , ManuckTA , StoddardGJ , VarnerMW , ClarkEAS . Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. BJOG: an international journal of obstetrics and gynaecology2016;123(7):1161-6. KamyarM , VarnerM , ClarkE . Magnesium sulfate neuroprophylaxis and the effect of infant sex. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S144. ManuckA , ShengX , YoderA , VarnerW . Correlation between initial neonatal and early childhood outcomes following preterm birth. American Journal of Obstetrics &amp; Gynecology2014;210(5):426.e1-9. ManuckT , ShengX , YoderB , VarnerM . Correlation between initial neonatal and early childhood outcomes among children delivered &lt;34 weeks gestation. American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S23. ManuckT , VarnerM . Is bigger better? Neonatal and childhood outcomes of large for gestational age (LGA) infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341-2. ManuckT , VarnerM . Neonatal and childhood outcomes following early vs later preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S340-1. ManuckT , VarnerM . Neonatal and childhood outcomes of small for gestational age infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341. ManuckTA , VarnerMW . Neonatal and early childhood outcomes following early vs later preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2014;211(3):308.e1-6. MarrsC , Mendez-FigueroaH , ChauhanS . Periventricular leukomalacia with PPROM: Obstetric antecedents and infants' outcomes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S85. MarrsCC , Mendez-FigueroaH , HammadIA , ChauhanSP . Differential morbidity in preterm small versus appropriate for gestational age: perhaps unverifiable. American Journal of Perinatology2015;32(13):1251-6. McPhersonJ , SmileyS , StamiloD . Magnesium sulfate neuroprotection and obesity: Is efficacy affected by obesity. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S218. McPhersonJA , RouseDJ , GrobmanWA , PalatnikA , StamilioDM . Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. Obstetrics and Gynecology2014;124(4):749-55. McPhersonJA , SmileyS , StamilioDM . Maternal obesity and neuroprotective magnesium sulfate. American Journal of Obstetrics and Gynecology2015;213(4):582.e1–6. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate &lt; 12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S252. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate for &gt;12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S104-5. Mendez-FigueroaH , ChauhanSP , PedrozaC , RefuerzoJS , DahlkeJD , RouseDJ . Preterm cesarean delivery for nonreassuring fetal heart rate: neonatal and neurologic morbidity. Obstetrics and Gynecology2015;125(3):636-42. Mendez-FigueroaH , DahlkeJD , ViteriOA , ChauhanSP , RouseDJ , SibaiBM , et al. Neonatal and infant outcomes in twin gestations with preterm premature rupture of membranes at 24-31 weeks of gestation. Obstetrics and Gynecology2014;124(2 Pt 1):323-31. MoussaH , Hosseini NasabS , FournieD , OntiverosA , AlkawasR , ChauhanS , et al. The impact of time of delivery on gestations complicated by preterm premature rupture of membranes: daytime versus nighttime. Journal of Maternal-Fetal &amp; Neonatal Medicine2019;32(20):3319-24. NCT00014989. Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) [Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)]. clinicaltrials.gov/show/NCT00014989 (first received 18 April 2001). NussEE , SpiegelmanJ , TuritzAL , Gyamfi-BannermanC . Childhood neurodevelopment after spontaneous versus indicated preterm birth. American Journal of Obstetrics and Gynecology MFM2020;2(2):100082. ObicanS , DrassinowerD , LevinH , Gyamfi-BannermanC . Mode of delivery at periviability and early childhood neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S124. OvertonE , BaptisteC , Gyamfi-BannermanC . 546: neurodevelopmental outcomes in late preterm and early term deliveries following antenatal corticosteroid exposure. American Journal of Obstetrics and Gynecology2019;220(1):S365-6. PalatnikA , RouseD , StamiloD , McPhersonJ , GrobmanW . The association between cerebral palsy or death and umbilical cord magnesium concentration. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S302. RobbinsLS , BlanchardCT , BiasiniFJ , PowellMF , CaseyBM , TitaAT , et al. General anesthesia for cesarean delivery and childhood neurodevelopmental and perinatal outcomes: a secondary analysis of a randomized controlled trial. International Journal of Obstetric Anesthesia2020;45:34-40. RobbinsLS , BlanchardCT , SinkeyRG , HarrisSL , TitaAT , HarperLM . Prenatal tobacco exposure and childhood neurodevelopment among infants born prematurely. American Journal of Perinatology2020;38(3):218-23. RobertsR , Ankumah N-A, ViteriO , Mendez-FigueroaH , ChauhanS , SibaiB . Significance of the absence of amniotic fluid from the cervical os with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S223. RouseD , HirtzD , ThomE , VarnerM , AlexanderJ , SpongC , et al. Magnesium sulfate for the prevention of cerebral palsy. New England Journal of Medicine2008;359:895-905. RouseD . A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. American Journal of Obstetrics and Gynecology2007;197(6):S2. RouseD . Magnesium sulfate (MGSO4) dose and timing, umbilical cord MG++ concentration: relationship to cerebral palsy. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S46. SagaramD , HaarEV , MillerR , Gyamfi-BannermanC . Birth order does not offer a neurologic advantage in twin pregnancy. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S427. SiegelAM , HeineRP , Dotters-KatzSK . The effect of non-penicillin antibiotic regimens on neonatal outcomes in preterm prelabor rupture of membranes. American Journal of Obstetrics and Gynecology2018;219(6):637. SonM , GrobmanWA , MillerES . Is mode of delivery associated with the risk of necrotizing enterocolitis?American Journal of Obstetrics and Gynecology2016;214(1 Suppl 1):S204-5. TuritzAL , TooGT , Gyamfi-BannermanC . Proximity of magnesium exposure to delivery and neonatal outcomes. American Journal of Obstetrics and Gynecology2016;215(4):508.e1-6. TwicklerD , McIntireD , AlexanderJ , LevenoK . Effects of magnesium sulfate on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S112. TwicklerDM , McIntireDD , AlexanderJM , LevenoKJ . Effects of magnesium sulfate on preterm fetal cerebral blood flow using Doppler analysis: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):21-5. Vander HaarE , GoldbergerA , Gyamfi-BannermanC . Mild intraventricular hemorrhage is not associated with low bayley scores at age 2. Reproductive Sciences2017;24(1 Suppl 1):83A. VilchezG , DaiJ , KumarK , MundyD , KontopoulosE , SokolRJ . Racial/ethnic disparities in magnesium sulfate neuroprotection: a subgroup analysis of a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(17):2304-11. VilchezG , DaiJ , LagosM , SokolRJ . Maternal side effects &amp; fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(2):178-83. WoodAM , PostAL , SwamyGK , GrotegutCA . Neonatal outcomes associated with noncephalic presentation at delivery in preterm birth. American Journal of Perinatology2018;35(12):1131-7. YadavaS , GarabedianM , SitA , El-SayedY . Use of magnesium sulfate and labor outcomes in PPROM at less than 37 weeks. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S203. YangM , VarnerMW , YoderB . Cord blood magnesium levels and nonneurologic outcomes in neonates less than 27 weeks gestational age. Journal of Investigative Medicine2019;67(1):86-7. ">Rouse 2008</a>; <a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a>). </p> </section> <section id="CD004661-sec-0075"> <h5 class="title">Participants</h5> <p>All RCTs included pregnant women in preterm labour or with expected or planned preterm birth. The lower limit of gestational age was 24 weeks' gestation (<a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a>; <a href="./references#CD004661-bbs2-0005" title="BrookfieldKF , O'MalleyK , Yeaton-MasseyA , ButwickAJ . Does magnesium sulfate exposure attenuate the effect of steroids administered for fetal lung maturation? In: Society for Obstetric Anesthesia and Perinatology (SOAP) 48th Annual Meeting; 2016 May 18-22; Boston USA. 2016:SA-32. BuhimschiCS , JablonskiKA , RouseDJ , VarnerMW , ReddyUM , MercerBM , et al. Cord blood haptoglobin, cerebral palsy and death in infants of women at risk for preterm birth: a secondary analysis of a randomised controlled trial. Eclinicalmedicine2019;9:11-8. CostantineMM , WeinerSJ , RouseDJ , HirtzDG , VarnerMW , SpongCY , et al. Umbilical cord blood biomarkers of neurologic injury and the risk of cerebral palsy or infant death. International Journal of Developmental Neuroscience2011;29(8):917-22. CostantineMM . Cord blood biomarkers and the risk of cerebral palsy or death. Reproductive Sciences2010;17(3 Suppl 1):65A. DeihlTE , SimhanHN . Antenatal magnesium sulfate and ponderal index from birth to age 2 in preterm male and female infants. Reproductive Sciences2017;24(Suppl 1):130A. DeihlTE , SimhanHN . Antenatal magnesium sulfate exposure and ponderal index in preterm infants. American Journal of Perinatology2019;36(3):329-34. DenobleAE , WuJ , MitchellCJ , HughesBL , Dotters-KatzSK . Chorioamnionitis versus intraamniotic infection among preterm deliveries-is postpartum infectious morbidity different?American Journal of Obstetrics and Gynecology MFM2020;2(3):100176. DrassinowerD , FriedmanAM , LevinH , ObicanSG , Gyamfi-BannermanC . Does magnesium exposure affect neonatal resuscitation? Presented as a poster at the 35th annual meeting of the society for maternal-fetal medicine, San Diego, CA, Feb. 2-7, 2015. American Journal of Obstetrics and Gynecology2015;213(3):424e1-5. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm prelabour rupture of membranes and neurodevelopmental outcomes: a secondary analysis. BJOG: an international journal of obstetrics and gynaecology2016;123(10):1629-35. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of cerebral palsy. Journal of Maternal-Fetal &amp; Neonatal Medicine2016;29(17):2748-52. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of neonatal sepsis. American Journal of Obstetrics and Gynecology2016;214(6):743.e1-6. DrassinowerD , LevinH , ObicanS , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on cerebral palsy. American Journal of Obstetrics and Gynecology2015;212(1):S310-1. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . Immediate neonatal outcomes in infants exposed to magnesium sulfate at the time of delivery. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S90. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1):S161-2. EdwardsJ , EdwardsL , SwamyG , GrotegutC . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S215-6. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Effect of cord blood magnesium level at birth on non-neurologic neonatal outcomes. American Journal of Perinatology2019;36(1):3-7. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. Journal of Maternal-Fetal &amp; Neonatal Medicine2018;31(9):1156-60. FaucettAM , MetzTD , DeWittPE , GibbsRS . Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2016;214(2):287.e1-5. HaarEV , Gyamfi-BannermanC , Coletta-LucasJ . Sepsis but not chorioamnionitis is associated with cerebral palsy. Reproductive Sciences2015;22:372A. HaarEV , Gyamfi-BannermanC , RandisTM . Abnormal brain imaging in infants exposed to chorioamnionitis and sepsis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl. 1):S11-2. HaarEV , LucasJC , D'AltonM , Gyamfi-BannermanC . The effect of chorioamnionitis on neurocognitive development at age 2. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S139-40. HerreraC , SilverRM , MajorH , VarnerMW , ClarkEAS . Triple I criteria and adverse neonatal and childhood outcomes after early preterm birth. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S250. HirtzDG , WeinerSJ , BulasD , DiPietroM , SeibertJ , RouseDJ , et al. Antenatal magnesium and cerebral palsy in preterm infants. Journal of Pediatrics2015;167(4):834-9.e3. HirtzDG . Effect of prenatal MgSO4 on head ultrasound imaging in preterm infants. Annals of Neurology2011;70(Suppl 15):S110. HortonA . The effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S209. HortonL , YingleiL , RouseJ , SpongY , LevenoJ , VarnerW , et al. Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Perinatology2015;32(4):387-92. JohnsonLH , MappDC , RouseDJ , SpongCY , MercerBM , LevenoKJ , et al. Association of cord blood magnesium concentration and neonatal resuscitation. Journal of Pediatrics2012;160(4):573-7.e1. KachikisA , WalkerC , McAdamsR , WaldorfKA , Gyamfi-BannermanC . Influence of preterm premature rupture of membranes on neonatal respiratory complications. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S215. KachikisA , WalkerCL , McAdamsRM , Gyamfi-BannermanC , Adams WaldorfKM . Phenotypic overlap in neonatal respiratory morbidity following preterm premature rupture of membranes versus spontaneous preterm labor. Journal of Maternal-fetal &amp; Neonatal Medicine2021;34(12):1941-8. KamyarM , ClarkEA , YoderBA , VarnerMW , ManuckTA . Antenatal magnesium sulfate, necrotizing enterocolitis, and death among neonates &lt; 28 weeks gestation. AJP Reports2016;6(1):e148-54. KamyarM , ClarkEAS , VarnerMW , ManuckTA . Chorioamnionitis prevents protective effect of magnesium sulfate in the preterm infant. Reproductive Sciences2014;21(3 Suppl 1):78A. KamyarM , ManuckTA , StoddardGJ , VarnerMW , ClarkEAS . Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. BJOG: an international journal of obstetrics and gynaecology2016;123(7):1161-6. KamyarM , VarnerM , ClarkE . Magnesium sulfate neuroprophylaxis and the effect of infant sex. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S144. ManuckA , ShengX , YoderA , VarnerW . Correlation between initial neonatal and early childhood outcomes following preterm birth. American Journal of Obstetrics &amp; Gynecology2014;210(5):426.e1-9. ManuckT , ShengX , YoderB , VarnerM . Correlation between initial neonatal and early childhood outcomes among children delivered &lt;34 weeks gestation. American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S23. ManuckT , VarnerM . Is bigger better? Neonatal and childhood outcomes of large for gestational age (LGA) infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341-2. ManuckT , VarnerM . Neonatal and childhood outcomes following early vs later preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S340-1. ManuckT , VarnerM . Neonatal and childhood outcomes of small for gestational age infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341. ManuckTA , VarnerMW . Neonatal and early childhood outcomes following early vs later preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2014;211(3):308.e1-6. MarrsC , Mendez-FigueroaH , ChauhanS . Periventricular leukomalacia with PPROM: Obstetric antecedents and infants' outcomes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S85. MarrsCC , Mendez-FigueroaH , HammadIA , ChauhanSP . Differential morbidity in preterm small versus appropriate for gestational age: perhaps unverifiable. American Journal of Perinatology2015;32(13):1251-6. McPhersonJ , SmileyS , StamiloD . Magnesium sulfate neuroprotection and obesity: Is efficacy affected by obesity. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S218. McPhersonJA , RouseDJ , GrobmanWA , PalatnikA , StamilioDM . Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. Obstetrics and Gynecology2014;124(4):749-55. McPhersonJA , SmileyS , StamilioDM . Maternal obesity and neuroprotective magnesium sulfate. American Journal of Obstetrics and Gynecology2015;213(4):582.e1–6. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate &lt; 12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S252. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate for &gt;12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S104-5. Mendez-FigueroaH , ChauhanSP , PedrozaC , RefuerzoJS , DahlkeJD , RouseDJ . Preterm cesarean delivery for nonreassuring fetal heart rate: neonatal and neurologic morbidity. Obstetrics and Gynecology2015;125(3):636-42. Mendez-FigueroaH , DahlkeJD , ViteriOA , ChauhanSP , RouseDJ , SibaiBM , et al. Neonatal and infant outcomes in twin gestations with preterm premature rupture of membranes at 24-31 weeks of gestation. Obstetrics and Gynecology2014;124(2 Pt 1):323-31. MoussaH , Hosseini NasabS , FournieD , OntiverosA , AlkawasR , ChauhanS , et al. The impact of time of delivery on gestations complicated by preterm premature rupture of membranes: daytime versus nighttime. Journal of Maternal-Fetal &amp; Neonatal Medicine2019;32(20):3319-24. NCT00014989. Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) [Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)]. clinicaltrials.gov/show/NCT00014989 (first received 18 April 2001). NussEE , SpiegelmanJ , TuritzAL , Gyamfi-BannermanC . Childhood neurodevelopment after spontaneous versus indicated preterm birth. American Journal of Obstetrics and Gynecology MFM2020;2(2):100082. ObicanS , DrassinowerD , LevinH , Gyamfi-BannermanC . Mode of delivery at periviability and early childhood neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S124. OvertonE , BaptisteC , Gyamfi-BannermanC . 546: neurodevelopmental outcomes in late preterm and early term deliveries following antenatal corticosteroid exposure. American Journal of Obstetrics and Gynecology2019;220(1):S365-6. PalatnikA , RouseD , StamiloD , McPhersonJ , GrobmanW . The association between cerebral palsy or death and umbilical cord magnesium concentration. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S302. RobbinsLS , BlanchardCT , BiasiniFJ , PowellMF , CaseyBM , TitaAT , et al. General anesthesia for cesarean delivery and childhood neurodevelopmental and perinatal outcomes: a secondary analysis of a randomized controlled trial. International Journal of Obstetric Anesthesia2020;45:34-40. RobbinsLS , BlanchardCT , SinkeyRG , HarrisSL , TitaAT , HarperLM . Prenatal tobacco exposure and childhood neurodevelopment among infants born prematurely. American Journal of Perinatology2020;38(3):218-23. RobertsR , Ankumah N-A, ViteriO , Mendez-FigueroaH , ChauhanS , SibaiB . Significance of the absence of amniotic fluid from the cervical os with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S223. RouseD , HirtzD , ThomE , VarnerM , AlexanderJ , SpongC , et al. Magnesium sulfate for the prevention of cerebral palsy. New England Journal of Medicine2008;359:895-905. RouseD . A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. American Journal of Obstetrics and Gynecology2007;197(6):S2. RouseD . Magnesium sulfate (MGSO4) dose and timing, umbilical cord MG++ concentration: relationship to cerebral palsy. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S46. SagaramD , HaarEV , MillerR , Gyamfi-BannermanC . Birth order does not offer a neurologic advantage in twin pregnancy. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S427. SiegelAM , HeineRP , Dotters-KatzSK . The effect of non-penicillin antibiotic regimens on neonatal outcomes in preterm prelabor rupture of membranes. American Journal of Obstetrics and Gynecology2018;219(6):637. SonM , GrobmanWA , MillerES . Is mode of delivery associated with the risk of necrotizing enterocolitis?American Journal of Obstetrics and Gynecology2016;214(1 Suppl 1):S204-5. TuritzAL , TooGT , Gyamfi-BannermanC . Proximity of magnesium exposure to delivery and neonatal outcomes. American Journal of Obstetrics and Gynecology2016;215(4):508.e1-6. TwicklerD , McIntireD , AlexanderJ , LevenoK . Effects of magnesium sulfate on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S112. TwicklerDM , McIntireDD , AlexanderJM , LevenoKJ . Effects of magnesium sulfate on preterm fetal cerebral blood flow using Doppler analysis: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):21-5. Vander HaarE , GoldbergerA , Gyamfi-BannermanC . Mild intraventricular hemorrhage is not associated with low bayley scores at age 2. Reproductive Sciences2017;24(1 Suppl 1):83A. VilchezG , DaiJ , KumarK , MundyD , KontopoulosE , SokolRJ . Racial/ethnic disparities in magnesium sulfate neuroprotection: a subgroup analysis of a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(17):2304-11. VilchezG , DaiJ , LagosM , SokolRJ . Maternal side effects &amp; fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(2):178-83. WoodAM , PostAL , SwamyGK , GrotegutCA . Neonatal outcomes associated with noncephalic presentation at delivery in preterm birth. American Journal of Perinatology2018;35(12):1131-7. YadavaS , GarabedianM , SitA , El-SayedY . Use of magnesium sulfate and labor outcomes in PPROM at less than 37 weeks. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S203. YangM , VarnerMW , YoderB . Cord blood magnesium levels and nonneurologic outcomes in neonates less than 27 weeks gestational age. Journal of Investigative Medicine2019;67(1):86-7. ">Rouse 2008</a>; <a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a>) or above (30 weeks' gestation in <a href="./references#CD004661-bbs2-0002" title="ACTRN12611000491965. MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: neuroprotection trial [Does antenatal magnesium sulphate given to women at risk of imminent preterm birth (defined as planned or definitely expected in the next 24 hours) between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children at 2 years corrected age? - a randomised controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000491965 (first received 11 May 2011). CrowtherCA , AshwoodP , MiddletonPF , McPheeA , TranT , HardineJE , et al. Prenatal intravenous magnesium at 30-34 weeks’ gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial. JAMA2023;330(7):603-14. CrowtherCA , MiddletonPF , WilkinsonD , AshwoodP , HaslamR . Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) - study protocol. BMC Pregnancy and Childbirth2013;13(1):91. PoppeT , ThompsonB , BoardmanJP , BastinME , AlsweilerJ , DeibG , et al. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: the MagNUM Study. EBioMedicine2022;78:103923. ">Crowther 2023</a>), but no lower limit was set for two studies (<a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a>; <a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a>). The upper limit of gestational age ranged from less than 30 to 34 weeks’ gestation (less than 30 weeks’ (<a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a>), less than 32 weeks' (<a href="./references#CD004661-bbs2-0005" title="BrookfieldKF , O'MalleyK , Yeaton-MasseyA , ButwickAJ . Does magnesium sulfate exposure attenuate the effect of steroids administered for fetal lung maturation? In: Society for Obstetric Anesthesia and Perinatology (SOAP) 48th Annual Meeting; 2016 May 18-22; Boston USA. 2016:SA-32. BuhimschiCS , JablonskiKA , RouseDJ , VarnerMW , ReddyUM , MercerBM , et al. Cord blood haptoglobin, cerebral palsy and death in infants of women at risk for preterm birth: a secondary analysis of a randomised controlled trial. Eclinicalmedicine2019;9:11-8. CostantineMM , WeinerSJ , RouseDJ , HirtzDG , VarnerMW , SpongCY , et al. Umbilical cord blood biomarkers of neurologic injury and the risk of cerebral palsy or infant death. International Journal of Developmental Neuroscience2011;29(8):917-22. CostantineMM . Cord blood biomarkers and the risk of cerebral palsy or death. Reproductive Sciences2010;17(3 Suppl 1):65A. DeihlTE , SimhanHN . Antenatal magnesium sulfate and ponderal index from birth to age 2 in preterm male and female infants. Reproductive Sciences2017;24(Suppl 1):130A. DeihlTE , SimhanHN . Antenatal magnesium sulfate exposure and ponderal index in preterm infants. American Journal of Perinatology2019;36(3):329-34. DenobleAE , WuJ , MitchellCJ , HughesBL , Dotters-KatzSK . Chorioamnionitis versus intraamniotic infection among preterm deliveries-is postpartum infectious morbidity different?American Journal of Obstetrics and Gynecology MFM2020;2(3):100176. DrassinowerD , FriedmanAM , LevinH , ObicanSG , Gyamfi-BannermanC . Does magnesium exposure affect neonatal resuscitation? Presented as a poster at the 35th annual meeting of the society for maternal-fetal medicine, San Diego, CA, Feb. 2-7, 2015. American Journal of Obstetrics and Gynecology2015;213(3):424e1-5. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm prelabour rupture of membranes and neurodevelopmental outcomes: a secondary analysis. BJOG: an international journal of obstetrics and gynaecology2016;123(10):1629-35. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of cerebral palsy. Journal of Maternal-Fetal &amp; Neonatal Medicine2016;29(17):2748-52. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of neonatal sepsis. American Journal of Obstetrics and Gynecology2016;214(6):743.e1-6. DrassinowerD , LevinH , ObicanS , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on cerebral palsy. American Journal of Obstetrics and Gynecology2015;212(1):S310-1. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . Immediate neonatal outcomes in infants exposed to magnesium sulfate at the time of delivery. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S90. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1):S161-2. EdwardsJ , EdwardsL , SwamyG , GrotegutC . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S215-6. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Effect of cord blood magnesium level at birth on non-neurologic neonatal outcomes. American Journal of Perinatology2019;36(1):3-7. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. Journal of Maternal-Fetal &amp; Neonatal Medicine2018;31(9):1156-60. FaucettAM , MetzTD , DeWittPE , GibbsRS . Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2016;214(2):287.e1-5. HaarEV , Gyamfi-BannermanC , Coletta-LucasJ . Sepsis but not chorioamnionitis is associated with cerebral palsy. Reproductive Sciences2015;22:372A. HaarEV , Gyamfi-BannermanC , RandisTM . Abnormal brain imaging in infants exposed to chorioamnionitis and sepsis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl. 1):S11-2. HaarEV , LucasJC , D'AltonM , Gyamfi-BannermanC . The effect of chorioamnionitis on neurocognitive development at age 2. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S139-40. HerreraC , SilverRM , MajorH , VarnerMW , ClarkEAS . Triple I criteria and adverse neonatal and childhood outcomes after early preterm birth. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S250. HirtzDG , WeinerSJ , BulasD , DiPietroM , SeibertJ , RouseDJ , et al. Antenatal magnesium and cerebral palsy in preterm infants. Journal of Pediatrics2015;167(4):834-9.e3. HirtzDG . Effect of prenatal MgSO4 on head ultrasound imaging in preterm infants. Annals of Neurology2011;70(Suppl 15):S110. HortonA . The effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S209. HortonL , YingleiL , RouseJ , SpongY , LevenoJ , VarnerW , et al. Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Perinatology2015;32(4):387-92. JohnsonLH , MappDC , RouseDJ , SpongCY , MercerBM , LevenoKJ , et al. Association of cord blood magnesium concentration and neonatal resuscitation. Journal of Pediatrics2012;160(4):573-7.e1. KachikisA , WalkerC , McAdamsR , WaldorfKA , Gyamfi-BannermanC . Influence of preterm premature rupture of membranes on neonatal respiratory complications. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S215. KachikisA , WalkerCL , McAdamsRM , Gyamfi-BannermanC , Adams WaldorfKM . Phenotypic overlap in neonatal respiratory morbidity following preterm premature rupture of membranes versus spontaneous preterm labor. Journal of Maternal-fetal &amp; Neonatal Medicine2021;34(12):1941-8. KamyarM , ClarkEA , YoderBA , VarnerMW , ManuckTA . Antenatal magnesium sulfate, necrotizing enterocolitis, and death among neonates &lt; 28 weeks gestation. AJP Reports2016;6(1):e148-54. KamyarM , ClarkEAS , VarnerMW , ManuckTA . Chorioamnionitis prevents protective effect of magnesium sulfate in the preterm infant. Reproductive Sciences2014;21(3 Suppl 1):78A. KamyarM , ManuckTA , StoddardGJ , VarnerMW , ClarkEAS . Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. BJOG: an international journal of obstetrics and gynaecology2016;123(7):1161-6. KamyarM , VarnerM , ClarkE . Magnesium sulfate neuroprophylaxis and the effect of infant sex. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S144. ManuckA , ShengX , YoderA , VarnerW . Correlation between initial neonatal and early childhood outcomes following preterm birth. American Journal of Obstetrics &amp; Gynecology2014;210(5):426.e1-9. ManuckT , ShengX , YoderB , VarnerM . Correlation between initial neonatal and early childhood outcomes among children delivered &lt;34 weeks gestation. American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S23. ManuckT , VarnerM . Is bigger better? Neonatal and childhood outcomes of large for gestational age (LGA) infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341-2. ManuckT , VarnerM . Neonatal and childhood outcomes following early vs later preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S340-1. ManuckT , VarnerM . Neonatal and childhood outcomes of small for gestational age infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341. ManuckTA , VarnerMW . Neonatal and early childhood outcomes following early vs later preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2014;211(3):308.e1-6. MarrsC , Mendez-FigueroaH , ChauhanS . Periventricular leukomalacia with PPROM: Obstetric antecedents and infants' outcomes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S85. MarrsCC , Mendez-FigueroaH , HammadIA , ChauhanSP . Differential morbidity in preterm small versus appropriate for gestational age: perhaps unverifiable. American Journal of Perinatology2015;32(13):1251-6. McPhersonJ , SmileyS , StamiloD . Magnesium sulfate neuroprotection and obesity: Is efficacy affected by obesity. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S218. McPhersonJA , RouseDJ , GrobmanWA , PalatnikA , StamilioDM . Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. Obstetrics and Gynecology2014;124(4):749-55. McPhersonJA , SmileyS , StamilioDM . Maternal obesity and neuroprotective magnesium sulfate. American Journal of Obstetrics and Gynecology2015;213(4):582.e1–6. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate &lt; 12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S252. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate for &gt;12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S104-5. Mendez-FigueroaH , ChauhanSP , PedrozaC , RefuerzoJS , DahlkeJD , RouseDJ . Preterm cesarean delivery for nonreassuring fetal heart rate: neonatal and neurologic morbidity. Obstetrics and Gynecology2015;125(3):636-42. Mendez-FigueroaH , DahlkeJD , ViteriOA , ChauhanSP , RouseDJ , SibaiBM , et al. Neonatal and infant outcomes in twin gestations with preterm premature rupture of membranes at 24-31 weeks of gestation. Obstetrics and Gynecology2014;124(2 Pt 1):323-31. MoussaH , Hosseini NasabS , FournieD , OntiverosA , AlkawasR , ChauhanS , et al. The impact of time of delivery on gestations complicated by preterm premature rupture of membranes: daytime versus nighttime. Journal of Maternal-Fetal &amp; Neonatal Medicine2019;32(20):3319-24. NCT00014989. Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) [Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)]. clinicaltrials.gov/show/NCT00014989 (first received 18 April 2001). NussEE , SpiegelmanJ , TuritzAL , Gyamfi-BannermanC . Childhood neurodevelopment after spontaneous versus indicated preterm birth. American Journal of Obstetrics and Gynecology MFM2020;2(2):100082. ObicanS , DrassinowerD , LevinH , Gyamfi-BannermanC . Mode of delivery at periviability and early childhood neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S124. OvertonE , BaptisteC , Gyamfi-BannermanC . 546: neurodevelopmental outcomes in late preterm and early term deliveries following antenatal corticosteroid exposure. American Journal of Obstetrics and Gynecology2019;220(1):S365-6. PalatnikA , RouseD , StamiloD , McPhersonJ , GrobmanW . The association between cerebral palsy or death and umbilical cord magnesium concentration. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S302. RobbinsLS , BlanchardCT , BiasiniFJ , PowellMF , CaseyBM , TitaAT , et al. General anesthesia for cesarean delivery and childhood neurodevelopmental and perinatal outcomes: a secondary analysis of a randomized controlled trial. International Journal of Obstetric Anesthesia2020;45:34-40. RobbinsLS , BlanchardCT , SinkeyRG , HarrisSL , TitaAT , HarperLM . Prenatal tobacco exposure and childhood neurodevelopment among infants born prematurely. American Journal of Perinatology2020;38(3):218-23. RobertsR , Ankumah N-A, ViteriO , Mendez-FigueroaH , ChauhanS , SibaiB . Significance of the absence of amniotic fluid from the cervical os with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S223. RouseD , HirtzD , ThomE , VarnerM , AlexanderJ , SpongC , et al. Magnesium sulfate for the prevention of cerebral palsy. New England Journal of Medicine2008;359:895-905. RouseD . A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. American Journal of Obstetrics and Gynecology2007;197(6):S2. RouseD . Magnesium sulfate (MGSO4) dose and timing, umbilical cord MG++ concentration: relationship to cerebral palsy. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S46. SagaramD , HaarEV , MillerR , Gyamfi-BannermanC . Birth order does not offer a neurologic advantage in twin pregnancy. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S427. SiegelAM , HeineRP , Dotters-KatzSK . The effect of non-penicillin antibiotic regimens on neonatal outcomes in preterm prelabor rupture of membranes. American Journal of Obstetrics and Gynecology2018;219(6):637. SonM , GrobmanWA , MillerES . Is mode of delivery associated with the risk of necrotizing enterocolitis?American Journal of Obstetrics and Gynecology2016;214(1 Suppl 1):S204-5. TuritzAL , TooGT , Gyamfi-BannermanC . Proximity of magnesium exposure to delivery and neonatal outcomes. American Journal of Obstetrics and Gynecology2016;215(4):508.e1-6. TwicklerD , McIntireD , AlexanderJ , LevenoK . Effects of magnesium sulfate on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S112. TwicklerDM , McIntireDD , AlexanderJM , LevenoKJ . Effects of magnesium sulfate on preterm fetal cerebral blood flow using Doppler analysis: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):21-5. Vander HaarE , GoldbergerA , Gyamfi-BannermanC . Mild intraventricular hemorrhage is not associated with low bayley scores at age 2. Reproductive Sciences2017;24(1 Suppl 1):83A. VilchezG , DaiJ , KumarK , MundyD , KontopoulosE , SokolRJ . Racial/ethnic disparities in magnesium sulfate neuroprotection: a subgroup analysis of a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(17):2304-11. VilchezG , DaiJ , LagosM , SokolRJ . Maternal side effects &amp; fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(2):178-83. WoodAM , PostAL , SwamyGK , GrotegutCA . Neonatal outcomes associated with noncephalic presentation at delivery in preterm birth. American Journal of Perinatology2018;35(12):1131-7. YadavaS , GarabedianM , SitA , El-SayedY . Use of magnesium sulfate and labor outcomes in PPROM at less than 37 weeks. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S203. YangM , VarnerMW , YoderB . Cord blood magnesium levels and nonneurologic outcomes in neonates less than 27 weeks gestational age. Journal of Investigative Medicine2019;67(1):86-7. ">Rouse 2008</a>; <a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a>), less than 33 weeks' (<a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a>), and less than 34 weeks' gestation (<a href="./references#CD004661-bbs2-0002" title="ACTRN12611000491965. MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: neuroprotection trial [Does antenatal magnesium sulphate given to women at risk of imminent preterm birth (defined as planned or definitely expected in the next 24 hours) between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children at 2 years corrected age? - a randomised controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000491965 (first received 11 May 2011). CrowtherCA , AshwoodP , MiddletonPF , McPheeA , TranT , HardineJE , et al. Prenatal intravenous magnesium at 30-34 weeks’ gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial. JAMA2023;330(7):603-14. CrowtherCA , MiddletonPF , WilkinsonD , AshwoodP , HaslamR . Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) - study protocol. BMC Pregnancy and Childbirth2013;13(1):91. PoppeT , ThompsonB , BoardmanJP , BastinME , AlsweilerJ , DeibG , et al. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: the MagNUM Study. EBioMedicine2022;78:103923. ">Crowther 2023</a>; <a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a>)). </p> <p>Four RCTs included singletons and twins (<a href="./references#CD004661-bbs2-0002" title="ACTRN12611000491965. MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: neuroprotection trial [Does antenatal magnesium sulphate given to women at risk of imminent preterm birth (defined as planned or definitely expected in the next 24 hours) between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children at 2 years corrected age? - a randomised controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000491965 (first received 11 May 2011). CrowtherCA , AshwoodP , MiddletonPF , McPheeA , TranT , HardineJE , et al. Prenatal intravenous magnesium at 30-34 weeks’ gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial. JAMA2023;330(7):603-14. CrowtherCA , MiddletonPF , WilkinsonD , AshwoodP , HaslamR . Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) - study protocol. BMC Pregnancy and Childbirth2013;13(1):91. PoppeT , ThompsonB , BoardmanJP , BastinME , AlsweilerJ , DeibG , et al. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: the MagNUM Study. EBioMedicine2022;78:103923. ">Crowther 2023</a>; <a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a>; <a href="./references#CD004661-bbs2-0005" title="BrookfieldKF , O'MalleyK , Yeaton-MasseyA , ButwickAJ . Does magnesium sulfate exposure attenuate the effect of steroids administered for fetal lung maturation? In: Society for Obstetric Anesthesia and Perinatology (SOAP) 48th Annual Meeting; 2016 May 18-22; Boston USA. 2016:SA-32. BuhimschiCS , JablonskiKA , RouseDJ , VarnerMW , ReddyUM , MercerBM , et al. Cord blood haptoglobin, cerebral palsy and death in infants of women at risk for preterm birth: a secondary analysis of a randomised controlled trial. Eclinicalmedicine2019;9:11-8. CostantineMM , WeinerSJ , RouseDJ , HirtzDG , VarnerMW , SpongCY , et al. Umbilical cord blood biomarkers of neurologic injury and the risk of cerebral palsy or infant death. International Journal of Developmental Neuroscience2011;29(8):917-22. CostantineMM . Cord blood biomarkers and the risk of cerebral palsy or death. Reproductive Sciences2010;17(3 Suppl 1):65A. DeihlTE , SimhanHN . Antenatal magnesium sulfate and ponderal index from birth to age 2 in preterm male and female infants. Reproductive Sciences2017;24(Suppl 1):130A. DeihlTE , SimhanHN . Antenatal magnesium sulfate exposure and ponderal index in preterm infants. American Journal of Perinatology2019;36(3):329-34. DenobleAE , WuJ , MitchellCJ , HughesBL , Dotters-KatzSK . Chorioamnionitis versus intraamniotic infection among preterm deliveries-is postpartum infectious morbidity different?American Journal of Obstetrics and Gynecology MFM2020;2(3):100176. DrassinowerD , FriedmanAM , LevinH , ObicanSG , Gyamfi-BannermanC . Does magnesium exposure affect neonatal resuscitation? Presented as a poster at the 35th annual meeting of the society for maternal-fetal medicine, San Diego, CA, Feb. 2-7, 2015. American Journal of Obstetrics and Gynecology2015;213(3):424e1-5. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm prelabour rupture of membranes and neurodevelopmental outcomes: a secondary analysis. BJOG: an international journal of obstetrics and gynaecology2016;123(10):1629-35. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of cerebral palsy. Journal of Maternal-Fetal &amp; Neonatal Medicine2016;29(17):2748-52. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of neonatal sepsis. American Journal of Obstetrics and Gynecology2016;214(6):743.e1-6. DrassinowerD , LevinH , ObicanS , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on cerebral palsy. American Journal of Obstetrics and Gynecology2015;212(1):S310-1. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . Immediate neonatal outcomes in infants exposed to magnesium sulfate at the time of delivery. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S90. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1):S161-2. EdwardsJ , EdwardsL , SwamyG , GrotegutC . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S215-6. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Effect of cord blood magnesium level at birth on non-neurologic neonatal outcomes. American Journal of Perinatology2019;36(1):3-7. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. Journal of Maternal-Fetal &amp; Neonatal Medicine2018;31(9):1156-60. FaucettAM , MetzTD , DeWittPE , GibbsRS . Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2016;214(2):287.e1-5. HaarEV , Gyamfi-BannermanC , Coletta-LucasJ . Sepsis but not chorioamnionitis is associated with cerebral palsy. Reproductive Sciences2015;22:372A. HaarEV , Gyamfi-BannermanC , RandisTM . Abnormal brain imaging in infants exposed to chorioamnionitis and sepsis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl. 1):S11-2. HaarEV , LucasJC , D'AltonM , Gyamfi-BannermanC . The effect of chorioamnionitis on neurocognitive development at age 2. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S139-40. HerreraC , SilverRM , MajorH , VarnerMW , ClarkEAS . Triple I criteria and adverse neonatal and childhood outcomes after early preterm birth. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S250. HirtzDG , WeinerSJ , BulasD , DiPietroM , SeibertJ , RouseDJ , et al. Antenatal magnesium and cerebral palsy in preterm infants. Journal of Pediatrics2015;167(4):834-9.e3. HirtzDG . Effect of prenatal MgSO4 on head ultrasound imaging in preterm infants. Annals of Neurology2011;70(Suppl 15):S110. HortonA . The effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S209. HortonL , YingleiL , RouseJ , SpongY , LevenoJ , VarnerW , et al. Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Perinatology2015;32(4):387-92. JohnsonLH , MappDC , RouseDJ , SpongCY , MercerBM , LevenoKJ , et al. Association of cord blood magnesium concentration and neonatal resuscitation. Journal of Pediatrics2012;160(4):573-7.e1. KachikisA , WalkerC , McAdamsR , WaldorfKA , Gyamfi-BannermanC . Influence of preterm premature rupture of membranes on neonatal respiratory complications. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S215. KachikisA , WalkerCL , McAdamsRM , Gyamfi-BannermanC , Adams WaldorfKM . Phenotypic overlap in neonatal respiratory morbidity following preterm premature rupture of membranes versus spontaneous preterm labor. Journal of Maternal-fetal &amp; Neonatal Medicine2021;34(12):1941-8. KamyarM , ClarkEA , YoderBA , VarnerMW , ManuckTA . Antenatal magnesium sulfate, necrotizing enterocolitis, and death among neonates &lt; 28 weeks gestation. AJP Reports2016;6(1):e148-54. KamyarM , ClarkEAS , VarnerMW , ManuckTA . Chorioamnionitis prevents protective effect of magnesium sulfate in the preterm infant. Reproductive Sciences2014;21(3 Suppl 1):78A. KamyarM , ManuckTA , StoddardGJ , VarnerMW , ClarkEAS . Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. BJOG: an international journal of obstetrics and gynaecology2016;123(7):1161-6. KamyarM , VarnerM , ClarkE . Magnesium sulfate neuroprophylaxis and the effect of infant sex. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S144. ManuckA , ShengX , YoderA , VarnerW . Correlation between initial neonatal and early childhood outcomes following preterm birth. American Journal of Obstetrics &amp; Gynecology2014;210(5):426.e1-9. ManuckT , ShengX , YoderB , VarnerM . Correlation between initial neonatal and early childhood outcomes among children delivered &lt;34 weeks gestation. American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S23. ManuckT , VarnerM . Is bigger better? Neonatal and childhood outcomes of large for gestational age (LGA) infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341-2. ManuckT , VarnerM . Neonatal and childhood outcomes following early vs later preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S340-1. ManuckT , VarnerM . Neonatal and childhood outcomes of small for gestational age infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341. ManuckTA , VarnerMW . Neonatal and early childhood outcomes following early vs later preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2014;211(3):308.e1-6. MarrsC , Mendez-FigueroaH , ChauhanS . Periventricular leukomalacia with PPROM: Obstetric antecedents and infants' outcomes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S85. MarrsCC , Mendez-FigueroaH , HammadIA , ChauhanSP . Differential morbidity in preterm small versus appropriate for gestational age: perhaps unverifiable. American Journal of Perinatology2015;32(13):1251-6. McPhersonJ , SmileyS , StamiloD . Magnesium sulfate neuroprotection and obesity: Is efficacy affected by obesity. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S218. McPhersonJA , RouseDJ , GrobmanWA , PalatnikA , StamilioDM . Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. Obstetrics and Gynecology2014;124(4):749-55. McPhersonJA , SmileyS , StamilioDM . Maternal obesity and neuroprotective magnesium sulfate. American Journal of Obstetrics and Gynecology2015;213(4):582.e1–6. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate &lt; 12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S252. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate for &gt;12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S104-5. Mendez-FigueroaH , ChauhanSP , PedrozaC , RefuerzoJS , DahlkeJD , RouseDJ . Preterm cesarean delivery for nonreassuring fetal heart rate: neonatal and neurologic morbidity. Obstetrics and Gynecology2015;125(3):636-42. Mendez-FigueroaH , DahlkeJD , ViteriOA , ChauhanSP , RouseDJ , SibaiBM , et al. Neonatal and infant outcomes in twin gestations with preterm premature rupture of membranes at 24-31 weeks of gestation. Obstetrics and Gynecology2014;124(2 Pt 1):323-31. MoussaH , Hosseini NasabS , FournieD , OntiverosA , AlkawasR , ChauhanS , et al. The impact of time of delivery on gestations complicated by preterm premature rupture of membranes: daytime versus nighttime. Journal of Maternal-Fetal &amp; Neonatal Medicine2019;32(20):3319-24. NCT00014989. Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) [Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)]. clinicaltrials.gov/show/NCT00014989 (first received 18 April 2001). NussEE , SpiegelmanJ , TuritzAL , Gyamfi-BannermanC . Childhood neurodevelopment after spontaneous versus indicated preterm birth. American Journal of Obstetrics and Gynecology MFM2020;2(2):100082. ObicanS , DrassinowerD , LevinH , Gyamfi-BannermanC . Mode of delivery at periviability and early childhood neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S124. OvertonE , BaptisteC , Gyamfi-BannermanC . 546: neurodevelopmental outcomes in late preterm and early term deliveries following antenatal corticosteroid exposure. American Journal of Obstetrics and Gynecology2019;220(1):S365-6. PalatnikA , RouseD , StamiloD , McPhersonJ , GrobmanW . The association between cerebral palsy or death and umbilical cord magnesium concentration. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S302. RobbinsLS , BlanchardCT , BiasiniFJ , PowellMF , CaseyBM , TitaAT , et al. General anesthesia for cesarean delivery and childhood neurodevelopmental and perinatal outcomes: a secondary analysis of a randomized controlled trial. International Journal of Obstetric Anesthesia2020;45:34-40. RobbinsLS , BlanchardCT , SinkeyRG , HarrisSL , TitaAT , HarperLM . Prenatal tobacco exposure and childhood neurodevelopment among infants born prematurely. American Journal of Perinatology2020;38(3):218-23. RobertsR , Ankumah N-A, ViteriO , Mendez-FigueroaH , ChauhanS , SibaiB . Significance of the absence of amniotic fluid from the cervical os with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S223. RouseD , HirtzD , ThomE , VarnerM , AlexanderJ , SpongC , et al. Magnesium sulfate for the prevention of cerebral palsy. New England Journal of Medicine2008;359:895-905. RouseD . A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. American Journal of Obstetrics and Gynecology2007;197(6):S2. RouseD . Magnesium sulfate (MGSO4) dose and timing, umbilical cord MG++ concentration: relationship to cerebral palsy. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S46. SagaramD , HaarEV , MillerR , Gyamfi-BannermanC . Birth order does not offer a neurologic advantage in twin pregnancy. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S427. SiegelAM , HeineRP , Dotters-KatzSK . The effect of non-penicillin antibiotic regimens on neonatal outcomes in preterm prelabor rupture of membranes. American Journal of Obstetrics and Gynecology2018;219(6):637. SonM , GrobmanWA , MillerES . Is mode of delivery associated with the risk of necrotizing enterocolitis?American Journal of Obstetrics and Gynecology2016;214(1 Suppl 1):S204-5. TuritzAL , TooGT , Gyamfi-BannermanC . Proximity of magnesium exposure to delivery and neonatal outcomes. American Journal of Obstetrics and Gynecology2016;215(4):508.e1-6. TwicklerD , McIntireD , AlexanderJ , LevenoK . Effects of magnesium sulfate on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S112. TwicklerDM , McIntireDD , AlexanderJM , LevenoKJ . Effects of magnesium sulfate on preterm fetal cerebral blood flow using Doppler analysis: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):21-5. Vander HaarE , GoldbergerA , Gyamfi-BannermanC . Mild intraventricular hemorrhage is not associated with low bayley scores at age 2. Reproductive Sciences2017;24(1 Suppl 1):83A. VilchezG , DaiJ , KumarK , MundyD , KontopoulosE , SokolRJ . Racial/ethnic disparities in magnesium sulfate neuroprotection: a subgroup analysis of a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(17):2304-11. VilchezG , DaiJ , LagosM , SokolRJ . Maternal side effects &amp; fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(2):178-83. WoodAM , PostAL , SwamyGK , GrotegutCA . Neonatal outcomes associated with noncephalic presentation at delivery in preterm birth. American Journal of Perinatology2018;35(12):1131-7. YadavaS , GarabedianM , SitA , El-SayedY . Use of magnesium sulfate and labor outcomes in PPROM at less than 37 weeks. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S203. YangM , VarnerMW , YoderB . Cord blood magnesium levels and nonneurologic outcomes in neonates less than 27 weeks gestational age. Journal of Investigative Medicine2019;67(1):86-7. ">Rouse 2008</a>; <a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a>), while two studies also included higher‐order multiple gestations (<a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a>; <a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a>). </p> <p>Additional inclusion and exclusion criteria varied (see <a href="./references#CD004661-sec-0213" title="">Characteristics of included studies</a> and <a href="#CD004661-tbl-0004">Table 1</a>). </p> <div class="table" id="CD004661-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Participant characteristics related to planned subgroup analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RCT</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Primary reason women were at high risk of preterm birth</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of babies in utero</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Gestational age at entry/randomisation</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a> </p> </td> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Inclusion criteria</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women if birth was planned or expected within 24 h; excluded women in the second stage of labour </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Singleton, twin, triplet, or quadruplet pregnancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 30 weeks’ gestation (no lower gestational age limit)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Population characteristics, magnesium sulphate vs placebo, N (%) unless stated</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reason for preterm birth</b> </p> <p>Preterm labour: 335 (62.6) vs 330 (62.6)</p> <p>Pre‐eclampsia/eclampsia: 86 (16.1) vs 75 (14.2)</p> <p>Chorioamnionitis: 73 (13.6) vs 72 (13.7)</p> <p>Antepartum haemorrhage: 70 (13.1) vs 81 (15.4)</p> <p>Severe IUGR: 50 (9.3) vs 42 (8.2)</p> <p>PROM: 43 (8.0) vs 54 (10.2)</p> <p>Fetal distress: 20 (3.7) vs 13 (2.5)</p> <p>Other: 29 (5.4) vs 30 (5.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiples: 88 (16.4) vs 89 (16.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (IQR) gestational age at entry: 27 weeks 3 days (25 weeks 5 days to 28 weeks 5 days) vs 27 weeks 2 days (25 weeks 5 days to 28 weeks 5 days) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD004661-bbs2-0002" title="ACTRN12611000491965. MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: neuroprotection trial [Does antenatal magnesium sulphate given to women at risk of imminent preterm birth (defined as planned or definitely expected in the next 24 hours) between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children at 2 years corrected age? - a randomised controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000491965 (first received 11 May 2011). CrowtherCA , AshwoodP , MiddletonPF , McPheeA , TranT , HardineJE , et al. Prenatal intravenous magnesium at 30-34 weeks’ gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial. JAMA2023;330(7):603-14. CrowtherCA , MiddletonPF , WilkinsonD , AshwoodP , HaslamR . Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) - study protocol. BMC Pregnancy and Childbirth2013;13(1):91. PoppeT , ThompsonB , BoardmanJP , BastinME , AlsweilerJ , DeibG , et al. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: the MagNUM Study. EBioMedicine2022;78:103923. ">Crowther 2023</a> </p> </td> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Inclusion criteria</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women if birth was planned or definitely expected within 24 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Singleton or twin pregnancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 to &lt; 34 weeks’ gestation</p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Population characteristics, magnesium sulphate vs placebo, N (%) unless stated</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reason at risk for preterm birth</b> </p> <p>Preterm labour: 207 (28.4) vs 182 (25.9)</p> <p>PPROM: 206 (28.3) vs 183 (26.0)</p> <p>Fetal compromise: 129 (17.7) vs 129 (18.3)</p> <p>Pre‐eclampsia: 65 (8.9) vs 81 (11.5)</p> <p>Antepartum haemorrhage: 72 (9.9) vs 67 (9.5)</p> <p>Unspecified: 50 (6.9) vs 62 (8.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Twin pregnancy: 130 (17.8) vs 120 (17.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) gestational age at entry: 32.1 (1.1) vs 32.1 (1.1)</p> <p>30 to &lt; 32 weeks: 323 (44.3) vs 308 (43.8)</p> <p>32 to &lt; 34 weeks: 406 (55.7) vs 396 (56.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a> </p> </td> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Inclusion criteria</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women if birth was expected or planned within 24 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Singleton, twin, or triplet pregnancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 33 weeks’ gestational age (no lower limit, except those established at individual participating centres concerning viability) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Population characteristics, magnesium sulphate vs placebo, N (%) unless stated</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reasons for preterm birth</b> </p> <p>Preterm labour: 236 (84.0) vs 242 (88.3)</p> <p>PPROM: 187 (53.9) vs 156 (46.6)</p> <p>Chorioamnionitis: 27 (9.5) vs 34 (12.6)</p> <p>Antepartum haemorrhage: 54 (19.0) vs 54 (20.0)</p> <p>Other: 33 (9.8) vs 43 (13.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Singleton pregnancy: 222 (77.6) vs 220 (79.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (range) gestational age at entry: 30 weeks (24 weeks to 32 weeks 6 days) vs 30 weeks (23 weeks 4 days to 32 weeks 6 days) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a> </p> </td> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Inclusion criteria</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women in preterm labour (subgroup of women in active labour with cervical dilatation &gt; 4 cm) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Triplet and higher‐order gestations were excluded.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 24 and &lt; 34 completed weeks' gestation</p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Population characteristics, magnesium sulphate vs placebo, N (%) unless stated</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Twin pregnancy: 1 (3.4) vs 1 (3.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 28 weeks' gestation: 6 (20.7) vs 5 (17.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD004661-bbs2-0005" title="BrookfieldKF , O'MalleyK , Yeaton-MasseyA , ButwickAJ . Does magnesium sulfate exposure attenuate the effect of steroids administered for fetal lung maturation? In: Society for Obstetric Anesthesia and Perinatology (SOAP) 48th Annual Meeting; 2016 May 18-22; Boston USA. 2016:SA-32. BuhimschiCS , JablonskiKA , RouseDJ , VarnerMW , ReddyUM , MercerBM , et al. Cord blood haptoglobin, cerebral palsy and death in infants of women at risk for preterm birth: a secondary analysis of a randomised controlled trial. Eclinicalmedicine2019;9:11-8. CostantineMM , WeinerSJ , RouseDJ , HirtzDG , VarnerMW , SpongCY , et al. Umbilical cord blood biomarkers of neurologic injury and the risk of cerebral palsy or infant death. International Journal of Developmental Neuroscience2011;29(8):917-22. CostantineMM . Cord blood biomarkers and the risk of cerebral palsy or death. Reproductive Sciences2010;17(3 Suppl 1):65A. DeihlTE , SimhanHN . Antenatal magnesium sulfate and ponderal index from birth to age 2 in preterm male and female infants. Reproductive Sciences2017;24(Suppl 1):130A. DeihlTE , SimhanHN . Antenatal magnesium sulfate exposure and ponderal index in preterm infants. American Journal of Perinatology2019;36(3):329-34. DenobleAE , WuJ , MitchellCJ , HughesBL , Dotters-KatzSK . Chorioamnionitis versus intraamniotic infection among preterm deliveries-is postpartum infectious morbidity different?American Journal of Obstetrics and Gynecology MFM2020;2(3):100176. DrassinowerD , FriedmanAM , LevinH , ObicanSG , Gyamfi-BannermanC . Does magnesium exposure affect neonatal resuscitation? Presented as a poster at the 35th annual meeting of the society for maternal-fetal medicine, San Diego, CA, Feb. 2-7, 2015. American Journal of Obstetrics and Gynecology2015;213(3):424e1-5. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm prelabour rupture of membranes and neurodevelopmental outcomes: a secondary analysis. BJOG: an international journal of obstetrics and gynaecology2016;123(10):1629-35. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of cerebral palsy. Journal of Maternal-Fetal &amp; Neonatal Medicine2016;29(17):2748-52. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of neonatal sepsis. American Journal of Obstetrics and Gynecology2016;214(6):743.e1-6. DrassinowerD , LevinH , ObicanS , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on cerebral palsy. American Journal of Obstetrics and Gynecology2015;212(1):S310-1. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . Immediate neonatal outcomes in infants exposed to magnesium sulfate at the time of delivery. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S90. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1):S161-2. EdwardsJ , EdwardsL , SwamyG , GrotegutC . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S215-6. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Effect of cord blood magnesium level at birth on non-neurologic neonatal outcomes. American Journal of Perinatology2019;36(1):3-7. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. Journal of Maternal-Fetal &amp; Neonatal Medicine2018;31(9):1156-60. FaucettAM , MetzTD , DeWittPE , GibbsRS . Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2016;214(2):287.e1-5. HaarEV , Gyamfi-BannermanC , Coletta-LucasJ . Sepsis but not chorioamnionitis is associated with cerebral palsy. Reproductive Sciences2015;22:372A. HaarEV , Gyamfi-BannermanC , RandisTM . Abnormal brain imaging in infants exposed to chorioamnionitis and sepsis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl. 1):S11-2. HaarEV , LucasJC , D'AltonM , Gyamfi-BannermanC . The effect of chorioamnionitis on neurocognitive development at age 2. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S139-40. HerreraC , SilverRM , MajorH , VarnerMW , ClarkEAS . Triple I criteria and adverse neonatal and childhood outcomes after early preterm birth. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S250. HirtzDG , WeinerSJ , BulasD , DiPietroM , SeibertJ , RouseDJ , et al. Antenatal magnesium and cerebral palsy in preterm infants. Journal of Pediatrics2015;167(4):834-9.e3. HirtzDG . Effect of prenatal MgSO4 on head ultrasound imaging in preterm infants. Annals of Neurology2011;70(Suppl 15):S110. HortonA . The effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S209. HortonL , YingleiL , RouseJ , SpongY , LevenoJ , VarnerW , et al. Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Perinatology2015;32(4):387-92. JohnsonLH , MappDC , RouseDJ , SpongCY , MercerBM , LevenoKJ , et al. Association of cord blood magnesium concentration and neonatal resuscitation. Journal of Pediatrics2012;160(4):573-7.e1. KachikisA , WalkerC , McAdamsR , WaldorfKA , Gyamfi-BannermanC . Influence of preterm premature rupture of membranes on neonatal respiratory complications. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S215. KachikisA , WalkerCL , McAdamsRM , Gyamfi-BannermanC , Adams WaldorfKM . Phenotypic overlap in neonatal respiratory morbidity following preterm premature rupture of membranes versus spontaneous preterm labor. Journal of Maternal-fetal &amp; Neonatal Medicine2021;34(12):1941-8. KamyarM , ClarkEA , YoderBA , VarnerMW , ManuckTA . Antenatal magnesium sulfate, necrotizing enterocolitis, and death among neonates &lt; 28 weeks gestation. AJP Reports2016;6(1):e148-54. KamyarM , ClarkEAS , VarnerMW , ManuckTA . Chorioamnionitis prevents protective effect of magnesium sulfate in the preterm infant. Reproductive Sciences2014;21(3 Suppl 1):78A. KamyarM , ManuckTA , StoddardGJ , VarnerMW , ClarkEAS . Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. BJOG: an international journal of obstetrics and gynaecology2016;123(7):1161-6. KamyarM , VarnerM , ClarkE . Magnesium sulfate neuroprophylaxis and the effect of infant sex. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S144. ManuckA , ShengX , YoderA , VarnerW . Correlation between initial neonatal and early childhood outcomes following preterm birth. American Journal of Obstetrics &amp; Gynecology2014;210(5):426.e1-9. ManuckT , ShengX , YoderB , VarnerM . Correlation between initial neonatal and early childhood outcomes among children delivered &lt;34 weeks gestation. American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S23. ManuckT , VarnerM . Is bigger better? Neonatal and childhood outcomes of large for gestational age (LGA) infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341-2. ManuckT , VarnerM . Neonatal and childhood outcomes following early vs later preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S340-1. ManuckT , VarnerM . Neonatal and childhood outcomes of small for gestational age infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341. ManuckTA , VarnerMW . Neonatal and early childhood outcomes following early vs later preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2014;211(3):308.e1-6. MarrsC , Mendez-FigueroaH , ChauhanS . Periventricular leukomalacia with PPROM: Obstetric antecedents and infants' outcomes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S85. MarrsCC , Mendez-FigueroaH , HammadIA , ChauhanSP . Differential morbidity in preterm small versus appropriate for gestational age: perhaps unverifiable. American Journal of Perinatology2015;32(13):1251-6. McPhersonJ , SmileyS , StamiloD . Magnesium sulfate neuroprotection and obesity: Is efficacy affected by obesity. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S218. McPhersonJA , RouseDJ , GrobmanWA , PalatnikA , StamilioDM . Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. Obstetrics and Gynecology2014;124(4):749-55. McPhersonJA , SmileyS , StamilioDM . Maternal obesity and neuroprotective magnesium sulfate. American Journal of Obstetrics and Gynecology2015;213(4):582.e1–6. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate &lt; 12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S252. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate for &gt;12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S104-5. Mendez-FigueroaH , ChauhanSP , PedrozaC , RefuerzoJS , DahlkeJD , RouseDJ . Preterm cesarean delivery for nonreassuring fetal heart rate: neonatal and neurologic morbidity. Obstetrics and Gynecology2015;125(3):636-42. Mendez-FigueroaH , DahlkeJD , ViteriOA , ChauhanSP , RouseDJ , SibaiBM , et al. Neonatal and infant outcomes in twin gestations with preterm premature rupture of membranes at 24-31 weeks of gestation. Obstetrics and Gynecology2014;124(2 Pt 1):323-31. MoussaH , Hosseini NasabS , FournieD , OntiverosA , AlkawasR , ChauhanS , et al. The impact of time of delivery on gestations complicated by preterm premature rupture of membranes: daytime versus nighttime. Journal of Maternal-Fetal &amp; Neonatal Medicine2019;32(20):3319-24. NCT00014989. Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) [Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)]. clinicaltrials.gov/show/NCT00014989 (first received 18 April 2001). NussEE , SpiegelmanJ , TuritzAL , Gyamfi-BannermanC . Childhood neurodevelopment after spontaneous versus indicated preterm birth. American Journal of Obstetrics and Gynecology MFM2020;2(2):100082. ObicanS , DrassinowerD , LevinH , Gyamfi-BannermanC . Mode of delivery at periviability and early childhood neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S124. OvertonE , BaptisteC , Gyamfi-BannermanC . 546: neurodevelopmental outcomes in late preterm and early term deliveries following antenatal corticosteroid exposure. American Journal of Obstetrics and Gynecology2019;220(1):S365-6. PalatnikA , RouseD , StamiloD , McPhersonJ , GrobmanW . The association between cerebral palsy or death and umbilical cord magnesium concentration. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S302. RobbinsLS , BlanchardCT , BiasiniFJ , PowellMF , CaseyBM , TitaAT , et al. General anesthesia for cesarean delivery and childhood neurodevelopmental and perinatal outcomes: a secondary analysis of a randomized controlled trial. International Journal of Obstetric Anesthesia2020;45:34-40. RobbinsLS , BlanchardCT , SinkeyRG , HarrisSL , TitaAT , HarperLM . Prenatal tobacco exposure and childhood neurodevelopment among infants born prematurely. American Journal of Perinatology2020;38(3):218-23. RobertsR , Ankumah N-A, ViteriO , Mendez-FigueroaH , ChauhanS , SibaiB . Significance of the absence of amniotic fluid from the cervical os with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S223. RouseD , HirtzD , ThomE , VarnerM , AlexanderJ , SpongC , et al. Magnesium sulfate for the prevention of cerebral palsy. New England Journal of Medicine2008;359:895-905. RouseD . A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. American Journal of Obstetrics and Gynecology2007;197(6):S2. RouseD . Magnesium sulfate (MGSO4) dose and timing, umbilical cord MG++ concentration: relationship to cerebral palsy. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S46. SagaramD , HaarEV , MillerR , Gyamfi-BannermanC . Birth order does not offer a neurologic advantage in twin pregnancy. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S427. SiegelAM , HeineRP , Dotters-KatzSK . The effect of non-penicillin antibiotic regimens on neonatal outcomes in preterm prelabor rupture of membranes. American Journal of Obstetrics and Gynecology2018;219(6):637. SonM , GrobmanWA , MillerES . Is mode of delivery associated with the risk of necrotizing enterocolitis?American Journal of Obstetrics and Gynecology2016;214(1 Suppl 1):S204-5. TuritzAL , TooGT , Gyamfi-BannermanC . Proximity of magnesium exposure to delivery and neonatal outcomes. American Journal of Obstetrics and Gynecology2016;215(4):508.e1-6. TwicklerD , McIntireD , AlexanderJ , LevenoK . Effects of magnesium sulfate on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S112. TwicklerDM , McIntireDD , AlexanderJM , LevenoKJ . Effects of magnesium sulfate on preterm fetal cerebral blood flow using Doppler analysis: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):21-5. Vander HaarE , GoldbergerA , Gyamfi-BannermanC . Mild intraventricular hemorrhage is not associated with low bayley scores at age 2. Reproductive Sciences2017;24(1 Suppl 1):83A. VilchezG , DaiJ , KumarK , MundyD , KontopoulosE , SokolRJ . Racial/ethnic disparities in magnesium sulfate neuroprotection: a subgroup analysis of a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(17):2304-11. VilchezG , DaiJ , LagosM , SokolRJ . Maternal side effects &amp; fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(2):178-83. WoodAM , PostAL , SwamyGK , GrotegutCA . Neonatal outcomes associated with noncephalic presentation at delivery in preterm birth. American Journal of Perinatology2018;35(12):1131-7. YadavaS , GarabedianM , SitA , El-SayedY . Use of magnesium sulfate and labor outcomes in PPROM at less than 37 weeks. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S203. YangM , VarnerMW , YoderB . Cord blood magnesium levels and nonneurologic outcomes in neonates less than 27 weeks gestational age. Journal of Investigative Medicine2019;67(1):86-7. ">Rouse 2008</a> </p> </td> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Inclusion criteria</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women at high risk of spontaneous birth because of ROM, or advanced preterm labour with cervical dilatation of 4 to 8 cm and intact membranes, or an indicated preterm birth anticipated within 2 to 24 h; birth &lt; 2 h or cervical dilatation &gt; 8 cm, and ROM &lt; 22 weeks' gestation excluded </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Singleton or twin pregnancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 to 31 completed weeks’ gestation (&lt; 32 weeks' gestation)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Population characteristics, magnesium sulphate vs placebo, N (%) unless stated</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Qualifying eligibility criterion</b> </p> <p>PROM: 947 (86.4) vs 995 (86.9)</p> <p>Advanced preterm labour: 116 (10.6) vs 114 (10.0)</p> <p>Indicated preterm delivery: 33 (3.0) vs 36 (3.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Twin pregnancy: 92 (8.4) vs 111 (9.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) gestational age at randomisation: 28.3 (2.5) vs 28.2 (2.4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a> </p> </td> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Inclusion criteria</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women expected to give birth preterm within 2 to 24 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Singleton or twin pregnancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 + 0 to 31 + 6 weeks’ gestation</p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Population characteristics, magnesium sulphate vs placebo, N (%) unless stated</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary reason for preterm birth</b> </p> <p>Advanced preterm labour: 183 (64.7) vs 174 (62.8)</p> <p>Antepartum haemorrhage: 19 (6.7) vs 22 (7.9)</p> <p>Chorioamnionitis: 11 (3.9) vs 7 (2.5)</p> <p>Fetal distress: 5 (1.8) vs 4 (1.4)</p> <p>Pre‐eclampsia, eclampsia, HELLP: 3 (1.1) vs 4 (1.4)</p> <p>PPROM: 42 (14.8) vs 37 (13.4)</p> <p>Severe IUGR: 20 (7.1) vs 29 (10.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Twin pregnancy: 60 (21.2) vs 60 (21.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) gestational age at randomisation: 28.6 (2.3) vs 28.7 (2.2)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Abbreviations:</b> HELLP: haemolysis, elevated liver enzymes, low platelet count; IQR: interquartile range; IUGR: intrauterine growth restriction; PPROM: preterm prelabour rupture of membranes; PROM: prelabour rupture of membranes; RCT: randomised controlled trial; ROM: rupture of membranes; SD: standard deviation </p> </div> </div> </section> <section id="CD004661-sec-0076"> <h5 class="title">Interventions and comparisons</h5> <section id="CD004661-sec-0077"> <h6 class="title">Intervention</h6> <p>A single loading dose of magnesium sulphate was reported in three RCTs:</p> <p> <ul id="CD004661-list-0022"> <li> <p>4 g intravenous (IV) over 30 minutes (<a href="./references#CD004661-bbs2-0002" title="ACTRN12611000491965. MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: neuroprotection trial [Does antenatal magnesium sulphate given to women at risk of imminent preterm birth (defined as planned or definitely expected in the next 24 hours) between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children at 2 years corrected age? - a randomised controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000491965 (first received 11 May 2011). CrowtherCA , AshwoodP , MiddletonPF , McPheeA , TranT , HardineJE , et al. Prenatal intravenous magnesium at 30-34 weeks’ gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial. JAMA2023;330(7):603-14. CrowtherCA , MiddletonPF , WilkinsonD , AshwoodP , HaslamR . Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) - study protocol. BMC Pregnancy and Childbirth2013;13(1):91. PoppeT , ThompsonB , BoardmanJP , BastinME , AlsweilerJ , DeibG , et al. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: the MagNUM Study. EBioMedicine2022;78:103923. ">Crowther 2023</a>; <a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a>); </p> </li> <li> <p>4 g IV bolus (<a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a>). </p> </li> </ul> </p> <p>A magnesium sulphate maintenance dose followed the loading dose in three RCTs:</p> <p> <ul id="CD004661-list-0023"> <li> <p>4 g IV loading dose over 20 minutes, followed by 1 g/hour IV until birth (if within 24 hours) or up to 24 hours (<a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a>); </p> </li> <li> <p>5 g IV loading dose over 20 to 30 minutes, followed by 1 g/hour IV maintenance dose until birth or for 24 hours if birth had not occurred. If at least six hours had passed since discontinuation of treatment, and birth had not occurred, the loading dose was repeated if birth was again imminent at less than 32 weeks' gestation (<a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a>); </p> </li> <li> <p>6 g IV loading dose over 20 to 30 minutes, followed by 2 g/hour IV maintenance dose. If birth had not occurred after 12 hours and was no longer considered imminent, the treatment was discontinued and resumed when birth was deemed imminent again; if at least six hours had passed since discontinuation, another loading dose was given (<a href="./references#CD004661-bbs2-0005" title="BrookfieldKF , O'MalleyK , Yeaton-MasseyA , ButwickAJ . Does magnesium sulfate exposure attenuate the effect of steroids administered for fetal lung maturation? In: Society for Obstetric Anesthesia and Perinatology (SOAP) 48th Annual Meeting; 2016 May 18-22; Boston USA. 2016:SA-32. BuhimschiCS , JablonskiKA , RouseDJ , VarnerMW , ReddyUM , MercerBM , et al. Cord blood haptoglobin, cerebral palsy and death in infants of women at risk for preterm birth: a secondary analysis of a randomised controlled trial. Eclinicalmedicine2019;9:11-8. CostantineMM , WeinerSJ , RouseDJ , HirtzDG , VarnerMW , SpongCY , et al. Umbilical cord blood biomarkers of neurologic injury and the risk of cerebral palsy or infant death. International Journal of Developmental Neuroscience2011;29(8):917-22. CostantineMM . Cord blood biomarkers and the risk of cerebral palsy or death. Reproductive Sciences2010;17(3 Suppl 1):65A. DeihlTE , SimhanHN . Antenatal magnesium sulfate and ponderal index from birth to age 2 in preterm male and female infants. Reproductive Sciences2017;24(Suppl 1):130A. DeihlTE , SimhanHN . Antenatal magnesium sulfate exposure and ponderal index in preterm infants. American Journal of Perinatology2019;36(3):329-34. DenobleAE , WuJ , MitchellCJ , HughesBL , Dotters-KatzSK . Chorioamnionitis versus intraamniotic infection among preterm deliveries-is postpartum infectious morbidity different?American Journal of Obstetrics and Gynecology MFM2020;2(3):100176. DrassinowerD , FriedmanAM , LevinH , ObicanSG , Gyamfi-BannermanC . Does magnesium exposure affect neonatal resuscitation? Presented as a poster at the 35th annual meeting of the society for maternal-fetal medicine, San Diego, CA, Feb. 2-7, 2015. American Journal of Obstetrics and Gynecology2015;213(3):424e1-5. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm prelabour rupture of membranes and neurodevelopmental outcomes: a secondary analysis. BJOG: an international journal of obstetrics and gynaecology2016;123(10):1629-35. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of cerebral palsy. Journal of Maternal-Fetal &amp; Neonatal Medicine2016;29(17):2748-52. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of neonatal sepsis. American Journal of Obstetrics and Gynecology2016;214(6):743.e1-6. DrassinowerD , LevinH , ObicanS , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on cerebral palsy. American Journal of Obstetrics and Gynecology2015;212(1):S310-1. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . Immediate neonatal outcomes in infants exposed to magnesium sulfate at the time of delivery. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S90. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1):S161-2. EdwardsJ , EdwardsL , SwamyG , GrotegutC . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S215-6. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Effect of cord blood magnesium level at birth on non-neurologic neonatal outcomes. American Journal of Perinatology2019;36(1):3-7. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. Journal of Maternal-Fetal &amp; Neonatal Medicine2018;31(9):1156-60. FaucettAM , MetzTD , DeWittPE , GibbsRS . Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2016;214(2):287.e1-5. HaarEV , Gyamfi-BannermanC , Coletta-LucasJ . Sepsis but not chorioamnionitis is associated with cerebral palsy. Reproductive Sciences2015;22:372A. HaarEV , Gyamfi-BannermanC , RandisTM . Abnormal brain imaging in infants exposed to chorioamnionitis and sepsis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl. 1):S11-2. HaarEV , LucasJC , D'AltonM , Gyamfi-BannermanC . The effect of chorioamnionitis on neurocognitive development at age 2. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S139-40. HerreraC , SilverRM , MajorH , VarnerMW , ClarkEAS . Triple I criteria and adverse neonatal and childhood outcomes after early preterm birth. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S250. HirtzDG , WeinerSJ , BulasD , DiPietroM , SeibertJ , RouseDJ , et al. Antenatal magnesium and cerebral palsy in preterm infants. Journal of Pediatrics2015;167(4):834-9.e3. HirtzDG . Effect of prenatal MgSO4 on head ultrasound imaging in preterm infants. Annals of Neurology2011;70(Suppl 15):S110. HortonA . The effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S209. HortonL , YingleiL , RouseJ , SpongY , LevenoJ , VarnerW , et al. Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Perinatology2015;32(4):387-92. JohnsonLH , MappDC , RouseDJ , SpongCY , MercerBM , LevenoKJ , et al. Association of cord blood magnesium concentration and neonatal resuscitation. Journal of Pediatrics2012;160(4):573-7.e1. KachikisA , WalkerC , McAdamsR , WaldorfKA , Gyamfi-BannermanC . Influence of preterm premature rupture of membranes on neonatal respiratory complications. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S215. KachikisA , WalkerCL , McAdamsRM , Gyamfi-BannermanC , Adams WaldorfKM . Phenotypic overlap in neonatal respiratory morbidity following preterm premature rupture of membranes versus spontaneous preterm labor. Journal of Maternal-fetal &amp; Neonatal Medicine2021;34(12):1941-8. KamyarM , ClarkEA , YoderBA , VarnerMW , ManuckTA . Antenatal magnesium sulfate, necrotizing enterocolitis, and death among neonates &lt; 28 weeks gestation. AJP Reports2016;6(1):e148-54. KamyarM , ClarkEAS , VarnerMW , ManuckTA . Chorioamnionitis prevents protective effect of magnesium sulfate in the preterm infant. Reproductive Sciences2014;21(3 Suppl 1):78A. KamyarM , ManuckTA , StoddardGJ , VarnerMW , ClarkEAS . Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. BJOG: an international journal of obstetrics and gynaecology2016;123(7):1161-6. KamyarM , VarnerM , ClarkE . Magnesium sulfate neuroprophylaxis and the effect of infant sex. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S144. ManuckA , ShengX , YoderA , VarnerW . Correlation between initial neonatal and early childhood outcomes following preterm birth. American Journal of Obstetrics &amp; Gynecology2014;210(5):426.e1-9. ManuckT , ShengX , YoderB , VarnerM . Correlation between initial neonatal and early childhood outcomes among children delivered &lt;34 weeks gestation. American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S23. ManuckT , VarnerM . Is bigger better? Neonatal and childhood outcomes of large for gestational age (LGA) infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341-2. ManuckT , VarnerM . Neonatal and childhood outcomes following early vs later preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S340-1. ManuckT , VarnerM . Neonatal and childhood outcomes of small for gestational age infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341. ManuckTA , VarnerMW . Neonatal and early childhood outcomes following early vs later preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2014;211(3):308.e1-6. MarrsC , Mendez-FigueroaH , ChauhanS . Periventricular leukomalacia with PPROM: Obstetric antecedents and infants' outcomes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S85. MarrsCC , Mendez-FigueroaH , HammadIA , ChauhanSP . Differential morbidity in preterm small versus appropriate for gestational age: perhaps unverifiable. American Journal of Perinatology2015;32(13):1251-6. McPhersonJ , SmileyS , StamiloD . Magnesium sulfate neuroprotection and obesity: Is efficacy affected by obesity. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S218. McPhersonJA , RouseDJ , GrobmanWA , PalatnikA , StamilioDM . Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. Obstetrics and Gynecology2014;124(4):749-55. McPhersonJA , SmileyS , StamilioDM . Maternal obesity and neuroprotective magnesium sulfate. American Journal of Obstetrics and Gynecology2015;213(4):582.e1–6. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate &lt; 12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S252. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate for &gt;12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S104-5. Mendez-FigueroaH , ChauhanSP , PedrozaC , RefuerzoJS , DahlkeJD , RouseDJ . Preterm cesarean delivery for nonreassuring fetal heart rate: neonatal and neurologic morbidity. Obstetrics and Gynecology2015;125(3):636-42. Mendez-FigueroaH , DahlkeJD , ViteriOA , ChauhanSP , RouseDJ , SibaiBM , et al. Neonatal and infant outcomes in twin gestations with preterm premature rupture of membranes at 24-31 weeks of gestation. Obstetrics and Gynecology2014;124(2 Pt 1):323-31. MoussaH , Hosseini NasabS , FournieD , OntiverosA , AlkawasR , ChauhanS , et al. The impact of time of delivery on gestations complicated by preterm premature rupture of membranes: daytime versus nighttime. Journal of Maternal-Fetal &amp; Neonatal Medicine2019;32(20):3319-24. NCT00014989. Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) [Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)]. clinicaltrials.gov/show/NCT00014989 (first received 18 April 2001). NussEE , SpiegelmanJ , TuritzAL , Gyamfi-BannermanC . Childhood neurodevelopment after spontaneous versus indicated preterm birth. American Journal of Obstetrics and Gynecology MFM2020;2(2):100082. ObicanS , DrassinowerD , LevinH , Gyamfi-BannermanC . Mode of delivery at periviability and early childhood neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S124. OvertonE , BaptisteC , Gyamfi-BannermanC . 546: neurodevelopmental outcomes in late preterm and early term deliveries following antenatal corticosteroid exposure. American Journal of Obstetrics and Gynecology2019;220(1):S365-6. PalatnikA , RouseD , StamiloD , McPhersonJ , GrobmanW . The association between cerebral palsy or death and umbilical cord magnesium concentration. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S302. RobbinsLS , BlanchardCT , BiasiniFJ , PowellMF , CaseyBM , TitaAT , et al. General anesthesia for cesarean delivery and childhood neurodevelopmental and perinatal outcomes: a secondary analysis of a randomized controlled trial. International Journal of Obstetric Anesthesia2020;45:34-40. RobbinsLS , BlanchardCT , SinkeyRG , HarrisSL , TitaAT , HarperLM . Prenatal tobacco exposure and childhood neurodevelopment among infants born prematurely. American Journal of Perinatology2020;38(3):218-23. RobertsR , Ankumah N-A, ViteriO , Mendez-FigueroaH , ChauhanS , SibaiB . Significance of the absence of amniotic fluid from the cervical os with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S223. RouseD , HirtzD , ThomE , VarnerM , AlexanderJ , SpongC , et al. Magnesium sulfate for the prevention of cerebral palsy. New England Journal of Medicine2008;359:895-905. RouseD . A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. American Journal of Obstetrics and Gynecology2007;197(6):S2. RouseD . Magnesium sulfate (MGSO4) dose and timing, umbilical cord MG++ concentration: relationship to cerebral palsy. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S46. SagaramD , HaarEV , MillerR , Gyamfi-BannermanC . Birth order does not offer a neurologic advantage in twin pregnancy. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S427. SiegelAM , HeineRP , Dotters-KatzSK . The effect of non-penicillin antibiotic regimens on neonatal outcomes in preterm prelabor rupture of membranes. American Journal of Obstetrics and Gynecology2018;219(6):637. SonM , GrobmanWA , MillerES . Is mode of delivery associated with the risk of necrotizing enterocolitis?American Journal of Obstetrics and Gynecology2016;214(1 Suppl 1):S204-5. TuritzAL , TooGT , Gyamfi-BannermanC . Proximity of magnesium exposure to delivery and neonatal outcomes. American Journal of Obstetrics and Gynecology2016;215(4):508.e1-6. TwicklerD , McIntireD , AlexanderJ , LevenoK . Effects of magnesium sulfate on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S112. TwicklerDM , McIntireDD , AlexanderJM , LevenoKJ . Effects of magnesium sulfate on preterm fetal cerebral blood flow using Doppler analysis: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):21-5. Vander HaarE , GoldbergerA , Gyamfi-BannermanC . Mild intraventricular hemorrhage is not associated with low bayley scores at age 2. Reproductive Sciences2017;24(1 Suppl 1):83A. VilchezG , DaiJ , KumarK , MundyD , KontopoulosE , SokolRJ . Racial/ethnic disparities in magnesium sulfate neuroprotection: a subgroup analysis of a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(17):2304-11. VilchezG , DaiJ , LagosM , SokolRJ . Maternal side effects &amp; fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(2):178-83. WoodAM , PostAL , SwamyGK , GrotegutCA . Neonatal outcomes associated with noncephalic presentation at delivery in preterm birth. American Journal of Perinatology2018;35(12):1131-7. YadavaS , GarabedianM , SitA , El-SayedY . Use of magnesium sulfate and labor outcomes in PPROM at less than 37 weeks. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S203. YangM , VarnerMW , YoderB . Cord blood magnesium levels and nonneurologic outcomes in neonates less than 27 weeks gestational age. Journal of Investigative Medicine2019;67(1):86-7. ">Rouse 2008</a>). </p> </li> </ul> </p> </section> <section id="CD004661-sec-0078"> <h6 class="title">Comparison</h6> <p>All six RCTs used a saline placebo.</p> <p>A single dose/infusion was reported in three RCTs:</p> <p> <ul id="CD004661-list-0024"> <li> <p>IV saline infusion over 30 minutes (<a href="./references#CD004661-bbs2-0002" title="ACTRN12611000491965. MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: neuroprotection trial [Does antenatal magnesium sulphate given to women at risk of imminent preterm birth (defined as planned or definitely expected in the next 24 hours) between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children at 2 years corrected age? - a randomised controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000491965 (first received 11 May 2011). CrowtherCA , AshwoodP , MiddletonPF , McPheeA , TranT , HardineJE , et al. Prenatal intravenous magnesium at 30-34 weeks’ gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial. JAMA2023;330(7):603-14. CrowtherCA , MiddletonPF , WilkinsonD , AshwoodP , HaslamR . Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) - study protocol. BMC Pregnancy and Childbirth2013;13(1):91. PoppeT , ThompsonB , BoardmanJP , BastinME , AlsweilerJ , DeibG , et al. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: the MagNUM Study. EBioMedicine2022;78:103923. ">Crowther 2023</a>; <a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a>); </p> </li> <li> <p>bolus saline solution (<a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a>). </p> </li> </ul> </p> <p>A loading and maintenance dose/infusion was reported in the other three RCTs, with regimens matching those used in the magnesium sulphate treatment group (<a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a>; <a href="./references#CD004661-bbs2-0005" title="BrookfieldKF , O'MalleyK , Yeaton-MasseyA , ButwickAJ . Does magnesium sulfate exposure attenuate the effect of steroids administered for fetal lung maturation? In: Society for Obstetric Anesthesia and Perinatology (SOAP) 48th Annual Meeting; 2016 May 18-22; Boston USA. 2016:SA-32. BuhimschiCS , JablonskiKA , RouseDJ , VarnerMW , ReddyUM , MercerBM , et al. Cord blood haptoglobin, cerebral palsy and death in infants of women at risk for preterm birth: a secondary analysis of a randomised controlled trial. Eclinicalmedicine2019;9:11-8. CostantineMM , WeinerSJ , RouseDJ , HirtzDG , VarnerMW , SpongCY , et al. Umbilical cord blood biomarkers of neurologic injury and the risk of cerebral palsy or infant death. International Journal of Developmental Neuroscience2011;29(8):917-22. CostantineMM . Cord blood biomarkers and the risk of cerebral palsy or death. Reproductive Sciences2010;17(3 Suppl 1):65A. DeihlTE , SimhanHN . Antenatal magnesium sulfate and ponderal index from birth to age 2 in preterm male and female infants. Reproductive Sciences2017;24(Suppl 1):130A. DeihlTE , SimhanHN . Antenatal magnesium sulfate exposure and ponderal index in preterm infants. American Journal of Perinatology2019;36(3):329-34. DenobleAE , WuJ , MitchellCJ , HughesBL , Dotters-KatzSK . Chorioamnionitis versus intraamniotic infection among preterm deliveries-is postpartum infectious morbidity different?American Journal of Obstetrics and Gynecology MFM2020;2(3):100176. DrassinowerD , FriedmanAM , LevinH , ObicanSG , Gyamfi-BannermanC . Does magnesium exposure affect neonatal resuscitation? Presented as a poster at the 35th annual meeting of the society for maternal-fetal medicine, San Diego, CA, Feb. 2-7, 2015. American Journal of Obstetrics and Gynecology2015;213(3):424e1-5. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm prelabour rupture of membranes and neurodevelopmental outcomes: a secondary analysis. BJOG: an international journal of obstetrics and gynaecology2016;123(10):1629-35. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of cerebral palsy. Journal of Maternal-Fetal &amp; Neonatal Medicine2016;29(17):2748-52. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of neonatal sepsis. American Journal of Obstetrics and Gynecology2016;214(6):743.e1-6. DrassinowerD , LevinH , ObicanS , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on cerebral palsy. American Journal of Obstetrics and Gynecology2015;212(1):S310-1. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . Immediate neonatal outcomes in infants exposed to magnesium sulfate at the time of delivery. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S90. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1):S161-2. EdwardsJ , EdwardsL , SwamyG , GrotegutC . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S215-6. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Effect of cord blood magnesium level at birth on non-neurologic neonatal outcomes. American Journal of Perinatology2019;36(1):3-7. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. Journal of Maternal-Fetal &amp; Neonatal Medicine2018;31(9):1156-60. FaucettAM , MetzTD , DeWittPE , GibbsRS . Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2016;214(2):287.e1-5. HaarEV , Gyamfi-BannermanC , Coletta-LucasJ . Sepsis but not chorioamnionitis is associated with cerebral palsy. Reproductive Sciences2015;22:372A. HaarEV , Gyamfi-BannermanC , RandisTM . Abnormal brain imaging in infants exposed to chorioamnionitis and sepsis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl. 1):S11-2. HaarEV , LucasJC , D'AltonM , Gyamfi-BannermanC . The effect of chorioamnionitis on neurocognitive development at age 2. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S139-40. HerreraC , SilverRM , MajorH , VarnerMW , ClarkEAS . Triple I criteria and adverse neonatal and childhood outcomes after early preterm birth. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S250. HirtzDG , WeinerSJ , BulasD , DiPietroM , SeibertJ , RouseDJ , et al. Antenatal magnesium and cerebral palsy in preterm infants. Journal of Pediatrics2015;167(4):834-9.e3. HirtzDG . Effect of prenatal MgSO4 on head ultrasound imaging in preterm infants. Annals of Neurology2011;70(Suppl 15):S110. HortonA . The effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S209. HortonL , YingleiL , RouseJ , SpongY , LevenoJ , VarnerW , et al. Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Perinatology2015;32(4):387-92. JohnsonLH , MappDC , RouseDJ , SpongCY , MercerBM , LevenoKJ , et al. Association of cord blood magnesium concentration and neonatal resuscitation. Journal of Pediatrics2012;160(4):573-7.e1. KachikisA , WalkerC , McAdamsR , WaldorfKA , Gyamfi-BannermanC . Influence of preterm premature rupture of membranes on neonatal respiratory complications. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S215. KachikisA , WalkerCL , McAdamsRM , Gyamfi-BannermanC , Adams WaldorfKM . Phenotypic overlap in neonatal respiratory morbidity following preterm premature rupture of membranes versus spontaneous preterm labor. Journal of Maternal-fetal &amp; Neonatal Medicine2021;34(12):1941-8. KamyarM , ClarkEA , YoderBA , VarnerMW , ManuckTA . Antenatal magnesium sulfate, necrotizing enterocolitis, and death among neonates &lt; 28 weeks gestation. AJP Reports2016;6(1):e148-54. KamyarM , ClarkEAS , VarnerMW , ManuckTA . Chorioamnionitis prevents protective effect of magnesium sulfate in the preterm infant. Reproductive Sciences2014;21(3 Suppl 1):78A. KamyarM , ManuckTA , StoddardGJ , VarnerMW , ClarkEAS . Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. BJOG: an international journal of obstetrics and gynaecology2016;123(7):1161-6. KamyarM , VarnerM , ClarkE . Magnesium sulfate neuroprophylaxis and the effect of infant sex. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S144. ManuckA , ShengX , YoderA , VarnerW . Correlation between initial neonatal and early childhood outcomes following preterm birth. American Journal of Obstetrics &amp; Gynecology2014;210(5):426.e1-9. ManuckT , ShengX , YoderB , VarnerM . Correlation between initial neonatal and early childhood outcomes among children delivered &lt;34 weeks gestation. American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S23. ManuckT , VarnerM . Is bigger better? Neonatal and childhood outcomes of large for gestational age (LGA) infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341-2. ManuckT , VarnerM . Neonatal and childhood outcomes following early vs later preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S340-1. ManuckT , VarnerM . Neonatal and childhood outcomes of small for gestational age infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341. ManuckTA , VarnerMW . Neonatal and early childhood outcomes following early vs later preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2014;211(3):308.e1-6. MarrsC , Mendez-FigueroaH , ChauhanS . Periventricular leukomalacia with PPROM: Obstetric antecedents and infants' outcomes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S85. MarrsCC , Mendez-FigueroaH , HammadIA , ChauhanSP . Differential morbidity in preterm small versus appropriate for gestational age: perhaps unverifiable. American Journal of Perinatology2015;32(13):1251-6. McPhersonJ , SmileyS , StamiloD . Magnesium sulfate neuroprotection and obesity: Is efficacy affected by obesity. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S218. McPhersonJA , RouseDJ , GrobmanWA , PalatnikA , StamilioDM . Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. Obstetrics and Gynecology2014;124(4):749-55. McPhersonJA , SmileyS , StamilioDM . Maternal obesity and neuroprotective magnesium sulfate. American Journal of Obstetrics and Gynecology2015;213(4):582.e1–6. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate &lt; 12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S252. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate for &gt;12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S104-5. Mendez-FigueroaH , ChauhanSP , PedrozaC , RefuerzoJS , DahlkeJD , RouseDJ . Preterm cesarean delivery for nonreassuring fetal heart rate: neonatal and neurologic morbidity. Obstetrics and Gynecology2015;125(3):636-42. Mendez-FigueroaH , DahlkeJD , ViteriOA , ChauhanSP , RouseDJ , SibaiBM , et al. Neonatal and infant outcomes in twin gestations with preterm premature rupture of membranes at 24-31 weeks of gestation. Obstetrics and Gynecology2014;124(2 Pt 1):323-31. MoussaH , Hosseini NasabS , FournieD , OntiverosA , AlkawasR , ChauhanS , et al. The impact of time of delivery on gestations complicated by preterm premature rupture of membranes: daytime versus nighttime. Journal of Maternal-Fetal &amp; Neonatal Medicine2019;32(20):3319-24. NCT00014989. Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) [Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)]. clinicaltrials.gov/show/NCT00014989 (first received 18 April 2001). NussEE , SpiegelmanJ , TuritzAL , Gyamfi-BannermanC . Childhood neurodevelopment after spontaneous versus indicated preterm birth. American Journal of Obstetrics and Gynecology MFM2020;2(2):100082. ObicanS , DrassinowerD , LevinH , Gyamfi-BannermanC . Mode of delivery at periviability and early childhood neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S124. OvertonE , BaptisteC , Gyamfi-BannermanC . 546: neurodevelopmental outcomes in late preterm and early term deliveries following antenatal corticosteroid exposure. American Journal of Obstetrics and Gynecology2019;220(1):S365-6. PalatnikA , RouseD , StamiloD , McPhersonJ , GrobmanW . The association between cerebral palsy or death and umbilical cord magnesium concentration. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S302. RobbinsLS , BlanchardCT , BiasiniFJ , PowellMF , CaseyBM , TitaAT , et al. General anesthesia for cesarean delivery and childhood neurodevelopmental and perinatal outcomes: a secondary analysis of a randomized controlled trial. International Journal of Obstetric Anesthesia2020;45:34-40. RobbinsLS , BlanchardCT , SinkeyRG , HarrisSL , TitaAT , HarperLM . Prenatal tobacco exposure and childhood neurodevelopment among infants born prematurely. American Journal of Perinatology2020;38(3):218-23. RobertsR , Ankumah N-A, ViteriO , Mendez-FigueroaH , ChauhanS , SibaiB . Significance of the absence of amniotic fluid from the cervical os with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S223. RouseD , HirtzD , ThomE , VarnerM , AlexanderJ , SpongC , et al. Magnesium sulfate for the prevention of cerebral palsy. New England Journal of Medicine2008;359:895-905. RouseD . A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. American Journal of Obstetrics and Gynecology2007;197(6):S2. RouseD . Magnesium sulfate (MGSO4) dose and timing, umbilical cord MG++ concentration: relationship to cerebral palsy. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S46. SagaramD , HaarEV , MillerR , Gyamfi-BannermanC . Birth order does not offer a neurologic advantage in twin pregnancy. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S427. SiegelAM , HeineRP , Dotters-KatzSK . The effect of non-penicillin antibiotic regimens on neonatal outcomes in preterm prelabor rupture of membranes. American Journal of Obstetrics and Gynecology2018;219(6):637. SonM , GrobmanWA , MillerES . Is mode of delivery associated with the risk of necrotizing enterocolitis?American Journal of Obstetrics and Gynecology2016;214(1 Suppl 1):S204-5. TuritzAL , TooGT , Gyamfi-BannermanC . Proximity of magnesium exposure to delivery and neonatal outcomes. American Journal of Obstetrics and Gynecology2016;215(4):508.e1-6. TwicklerD , McIntireD , AlexanderJ , LevenoK . Effects of magnesium sulfate on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S112. TwicklerDM , McIntireDD , AlexanderJM , LevenoKJ . Effects of magnesium sulfate on preterm fetal cerebral blood flow using Doppler analysis: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):21-5. Vander HaarE , GoldbergerA , Gyamfi-BannermanC . Mild intraventricular hemorrhage is not associated with low bayley scores at age 2. Reproductive Sciences2017;24(1 Suppl 1):83A. VilchezG , DaiJ , KumarK , MundyD , KontopoulosE , SokolRJ . Racial/ethnic disparities in magnesium sulfate neuroprotection: a subgroup analysis of a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(17):2304-11. VilchezG , DaiJ , LagosM , SokolRJ . Maternal side effects &amp; fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(2):178-83. WoodAM , PostAL , SwamyGK , GrotegutCA . Neonatal outcomes associated with noncephalic presentation at delivery in preterm birth. American Journal of Perinatology2018;35(12):1131-7. YadavaS , GarabedianM , SitA , El-SayedY . Use of magnesium sulfate and labor outcomes in PPROM at less than 37 weeks. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S203. YangM , VarnerMW , YoderB . Cord blood magnesium levels and nonneurologic outcomes in neonates less than 27 weeks gestational age. Journal of Investigative Medicine2019;67(1):86-7. ">Rouse 2008</a>; <a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a>). </p> <p>For further details on the intervention/comparison regimens, see <a href="#CD004661-tbl-0005">Table 2</a>. </p> <div class="table" id="CD004661-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Treatment characteristics related to planned subgroup analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RCT</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mode of administration</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Loading‐dose regimen</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Maintenance dose regimen</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Repeat treatment permitted</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Time of starting treatment prior to birth</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a> </p> </td> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Treatment intended</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 g over 20 min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 g/h until birth (if within 24 h) or up to 24 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women eligible if birth was planned or expected within 24 h</p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Treatment as received, magnesium sulphate vs placebo, N (%) unless stated</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Started: 522 (97.5) vs 509 (96.6)</p> <p>Completed: 484 (90.5) vs 495 (93.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Started:</p> <p>451 (84.2) vs 459 (87.1)</p> <p>Completed:</p> <p>70 (13.1) vs 77 (14.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD004661-bbs2-0002" title="ACTRN12611000491965. MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: neuroprotection trial [Does antenatal magnesium sulphate given to women at risk of imminent preterm birth (defined as planned or definitely expected in the next 24 hours) between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children at 2 years corrected age? - a randomised controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000491965 (first received 11 May 2011). CrowtherCA , AshwoodP , MiddletonPF , McPheeA , TranT , HardineJE , et al. Prenatal intravenous magnesium at 30-34 weeks’ gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial. JAMA2023;330(7):603-14. CrowtherCA , MiddletonPF , WilkinsonD , AshwoodP , HaslamR . Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) - study protocol. BMC Pregnancy and Childbirth2013;13(1):91. PoppeT , ThompsonB , BoardmanJP , BastinME , AlsweilerJ , DeibG , et al. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: the MagNUM Study. EBioMedicine2022;78:103923. ">Crowther 2023</a> </p> </td> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Treatment intended</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 g over 30 min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women eligible if birth was planned or definitely expected within 24 h</p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Treatment as received, magnesium sulphate vs placebo, N (%) unless stated</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Received: 690 (94.7) vs 667 (94.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a> </p> </td> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Treatment intended</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 g over 30 min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women eligible if birth was expected or planned within 24 h</p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Treatment as received, magnesium sulphate vs placebo, N (%) unless stated</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Started: 266 (93.0) vs 257 (92.4)</p> <p>Completed: 259 (90.6) vs 249 (89.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Interval from infusion to delivery, median (range): 1 h 38 min (5 min to 25 h 5 min) vs 1 h 30 min (8 min to 61 h 30 min) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a> </p> </td> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Treatment intended</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 g bolus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Treatment as received, magnesium sulphate vs placebo, N (%) unless stated</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD004661-bbs2-0005" title="BrookfieldKF , O'MalleyK , Yeaton-MasseyA , ButwickAJ . Does magnesium sulfate exposure attenuate the effect of steroids administered for fetal lung maturation? In: Society for Obstetric Anesthesia and Perinatology (SOAP) 48th Annual Meeting; 2016 May 18-22; Boston USA. 2016:SA-32. BuhimschiCS , JablonskiKA , RouseDJ , VarnerMW , ReddyUM , MercerBM , et al. Cord blood haptoglobin, cerebral palsy and death in infants of women at risk for preterm birth: a secondary analysis of a randomised controlled trial. Eclinicalmedicine2019;9:11-8. CostantineMM , WeinerSJ , RouseDJ , HirtzDG , VarnerMW , SpongCY , et al. Umbilical cord blood biomarkers of neurologic injury and the risk of cerebral palsy or infant death. International Journal of Developmental Neuroscience2011;29(8):917-22. CostantineMM . Cord blood biomarkers and the risk of cerebral palsy or death. Reproductive Sciences2010;17(3 Suppl 1):65A. DeihlTE , SimhanHN . Antenatal magnesium sulfate and ponderal index from birth to age 2 in preterm male and female infants. Reproductive Sciences2017;24(Suppl 1):130A. DeihlTE , SimhanHN . Antenatal magnesium sulfate exposure and ponderal index in preterm infants. American Journal of Perinatology2019;36(3):329-34. DenobleAE , WuJ , MitchellCJ , HughesBL , Dotters-KatzSK . Chorioamnionitis versus intraamniotic infection among preterm deliveries-is postpartum infectious morbidity different?American Journal of Obstetrics and Gynecology MFM2020;2(3):100176. DrassinowerD , FriedmanAM , LevinH , ObicanSG , Gyamfi-BannermanC . Does magnesium exposure affect neonatal resuscitation? Presented as a poster at the 35th annual meeting of the society for maternal-fetal medicine, San Diego, CA, Feb. 2-7, 2015. American Journal of Obstetrics and Gynecology2015;213(3):424e1-5. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm prelabour rupture of membranes and neurodevelopmental outcomes: a secondary analysis. BJOG: an international journal of obstetrics and gynaecology2016;123(10):1629-35. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of cerebral palsy. Journal of Maternal-Fetal &amp; Neonatal Medicine2016;29(17):2748-52. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of neonatal sepsis. American Journal of Obstetrics and Gynecology2016;214(6):743.e1-6. DrassinowerD , LevinH , ObicanS , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on cerebral palsy. American Journal of Obstetrics and Gynecology2015;212(1):S310-1. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . Immediate neonatal outcomes in infants exposed to magnesium sulfate at the time of delivery. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S90. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1):S161-2. EdwardsJ , EdwardsL , SwamyG , GrotegutC . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S215-6. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Effect of cord blood magnesium level at birth on non-neurologic neonatal outcomes. American Journal of Perinatology2019;36(1):3-7. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. Journal of Maternal-Fetal &amp; Neonatal Medicine2018;31(9):1156-60. FaucettAM , MetzTD , DeWittPE , GibbsRS . Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2016;214(2):287.e1-5. HaarEV , Gyamfi-BannermanC , Coletta-LucasJ . Sepsis but not chorioamnionitis is associated with cerebral palsy. Reproductive Sciences2015;22:372A. HaarEV , Gyamfi-BannermanC , RandisTM . Abnormal brain imaging in infants exposed to chorioamnionitis and sepsis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl. 1):S11-2. HaarEV , LucasJC , D'AltonM , Gyamfi-BannermanC . The effect of chorioamnionitis on neurocognitive development at age 2. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S139-40. HerreraC , SilverRM , MajorH , VarnerMW , ClarkEAS . Triple I criteria and adverse neonatal and childhood outcomes after early preterm birth. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S250. HirtzDG , WeinerSJ , BulasD , DiPietroM , SeibertJ , RouseDJ , et al. Antenatal magnesium and cerebral palsy in preterm infants. Journal of Pediatrics2015;167(4):834-9.e3. HirtzDG . Effect of prenatal MgSO4 on head ultrasound imaging in preterm infants. Annals of Neurology2011;70(Suppl 15):S110. HortonA . The effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S209. HortonL , YingleiL , RouseJ , SpongY , LevenoJ , VarnerW , et al. Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Perinatology2015;32(4):387-92. JohnsonLH , MappDC , RouseDJ , SpongCY , MercerBM , LevenoKJ , et al. Association of cord blood magnesium concentration and neonatal resuscitation. Journal of Pediatrics2012;160(4):573-7.e1. KachikisA , WalkerC , McAdamsR , WaldorfKA , Gyamfi-BannermanC . Influence of preterm premature rupture of membranes on neonatal respiratory complications. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S215. KachikisA , WalkerCL , McAdamsRM , Gyamfi-BannermanC , Adams WaldorfKM . Phenotypic overlap in neonatal respiratory morbidity following preterm premature rupture of membranes versus spontaneous preterm labor. Journal of Maternal-fetal &amp; Neonatal Medicine2021;34(12):1941-8. KamyarM , ClarkEA , YoderBA , VarnerMW , ManuckTA . Antenatal magnesium sulfate, necrotizing enterocolitis, and death among neonates &lt; 28 weeks gestation. AJP Reports2016;6(1):e148-54. KamyarM , ClarkEAS , VarnerMW , ManuckTA . Chorioamnionitis prevents protective effect of magnesium sulfate in the preterm infant. Reproductive Sciences2014;21(3 Suppl 1):78A. KamyarM , ManuckTA , StoddardGJ , VarnerMW , ClarkEAS . Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. BJOG: an international journal of obstetrics and gynaecology2016;123(7):1161-6. KamyarM , VarnerM , ClarkE . Magnesium sulfate neuroprophylaxis and the effect of infant sex. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S144. ManuckA , ShengX , YoderA , VarnerW . Correlation between initial neonatal and early childhood outcomes following preterm birth. American Journal of Obstetrics &amp; Gynecology2014;210(5):426.e1-9. ManuckT , ShengX , YoderB , VarnerM . Correlation between initial neonatal and early childhood outcomes among children delivered &lt;34 weeks gestation. American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S23. ManuckT , VarnerM . Is bigger better? Neonatal and childhood outcomes of large for gestational age (LGA) infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341-2. ManuckT , VarnerM . Neonatal and childhood outcomes following early vs later preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S340-1. ManuckT , VarnerM . Neonatal and childhood outcomes of small for gestational age infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341. ManuckTA , VarnerMW . Neonatal and early childhood outcomes following early vs later preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2014;211(3):308.e1-6. MarrsC , Mendez-FigueroaH , ChauhanS . Periventricular leukomalacia with PPROM: Obstetric antecedents and infants' outcomes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S85. MarrsCC , Mendez-FigueroaH , HammadIA , ChauhanSP . Differential morbidity in preterm small versus appropriate for gestational age: perhaps unverifiable. American Journal of Perinatology2015;32(13):1251-6. McPhersonJ , SmileyS , StamiloD . Magnesium sulfate neuroprotection and obesity: Is efficacy affected by obesity. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S218. McPhersonJA , RouseDJ , GrobmanWA , PalatnikA , StamilioDM . Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. Obstetrics and Gynecology2014;124(4):749-55. McPhersonJA , SmileyS , StamilioDM . Maternal obesity and neuroprotective magnesium sulfate. American Journal of Obstetrics and Gynecology2015;213(4):582.e1–6. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate &lt; 12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S252. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate for &gt;12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S104-5. Mendez-FigueroaH , ChauhanSP , PedrozaC , RefuerzoJS , DahlkeJD , RouseDJ . Preterm cesarean delivery for nonreassuring fetal heart rate: neonatal and neurologic morbidity. Obstetrics and Gynecology2015;125(3):636-42. Mendez-FigueroaH , DahlkeJD , ViteriOA , ChauhanSP , RouseDJ , SibaiBM , et al. Neonatal and infant outcomes in twin gestations with preterm premature rupture of membranes at 24-31 weeks of gestation. Obstetrics and Gynecology2014;124(2 Pt 1):323-31. MoussaH , Hosseini NasabS , FournieD , OntiverosA , AlkawasR , ChauhanS , et al. The impact of time of delivery on gestations complicated by preterm premature rupture of membranes: daytime versus nighttime. Journal of Maternal-Fetal &amp; Neonatal Medicine2019;32(20):3319-24. NCT00014989. Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) [Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)]. clinicaltrials.gov/show/NCT00014989 (first received 18 April 2001). NussEE , SpiegelmanJ , TuritzAL , Gyamfi-BannermanC . Childhood neurodevelopment after spontaneous versus indicated preterm birth. American Journal of Obstetrics and Gynecology MFM2020;2(2):100082. ObicanS , DrassinowerD , LevinH , Gyamfi-BannermanC . Mode of delivery at periviability and early childhood neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S124. OvertonE , BaptisteC , Gyamfi-BannermanC . 546: neurodevelopmental outcomes in late preterm and early term deliveries following antenatal corticosteroid exposure. American Journal of Obstetrics and Gynecology2019;220(1):S365-6. PalatnikA , RouseD , StamiloD , McPhersonJ , GrobmanW . The association between cerebral palsy or death and umbilical cord magnesium concentration. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S302. RobbinsLS , BlanchardCT , BiasiniFJ , PowellMF , CaseyBM , TitaAT , et al. General anesthesia for cesarean delivery and childhood neurodevelopmental and perinatal outcomes: a secondary analysis of a randomized controlled trial. International Journal of Obstetric Anesthesia2020;45:34-40. RobbinsLS , BlanchardCT , SinkeyRG , HarrisSL , TitaAT , HarperLM . Prenatal tobacco exposure and childhood neurodevelopment among infants born prematurely. American Journal of Perinatology2020;38(3):218-23. RobertsR , Ankumah N-A, ViteriO , Mendez-FigueroaH , ChauhanS , SibaiB . Significance of the absence of amniotic fluid from the cervical os with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S223. RouseD , HirtzD , ThomE , VarnerM , AlexanderJ , SpongC , et al. Magnesium sulfate for the prevention of cerebral palsy. New England Journal of Medicine2008;359:895-905. RouseD . A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. American Journal of Obstetrics and Gynecology2007;197(6):S2. RouseD . Magnesium sulfate (MGSO4) dose and timing, umbilical cord MG++ concentration: relationship to cerebral palsy. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S46. SagaramD , HaarEV , MillerR , Gyamfi-BannermanC . Birth order does not offer a neurologic advantage in twin pregnancy. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S427. SiegelAM , HeineRP , Dotters-KatzSK . The effect of non-penicillin antibiotic regimens on neonatal outcomes in preterm prelabor rupture of membranes. American Journal of Obstetrics and Gynecology2018;219(6):637. SonM , GrobmanWA , MillerES . Is mode of delivery associated with the risk of necrotizing enterocolitis?American Journal of Obstetrics and Gynecology2016;214(1 Suppl 1):S204-5. TuritzAL , TooGT , Gyamfi-BannermanC . Proximity of magnesium exposure to delivery and neonatal outcomes. American Journal of Obstetrics and Gynecology2016;215(4):508.e1-6. TwicklerD , McIntireD , AlexanderJ , LevenoK . Effects of magnesium sulfate on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S112. TwicklerDM , McIntireDD , AlexanderJM , LevenoKJ . Effects of magnesium sulfate on preterm fetal cerebral blood flow using Doppler analysis: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):21-5. Vander HaarE , GoldbergerA , Gyamfi-BannermanC . Mild intraventricular hemorrhage is not associated with low bayley scores at age 2. Reproductive Sciences2017;24(1 Suppl 1):83A. VilchezG , DaiJ , KumarK , MundyD , KontopoulosE , SokolRJ . Racial/ethnic disparities in magnesium sulfate neuroprotection: a subgroup analysis of a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(17):2304-11. VilchezG , DaiJ , LagosM , SokolRJ . Maternal side effects &amp; fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(2):178-83. WoodAM , PostAL , SwamyGK , GrotegutCA . Neonatal outcomes associated with noncephalic presentation at delivery in preterm birth. American Journal of Perinatology2018;35(12):1131-7. YadavaS , GarabedianM , SitA , El-SayedY . Use of magnesium sulfate and labor outcomes in PPROM at less than 37 weeks. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S203. YangM , VarnerMW , YoderB . Cord blood magnesium levels and nonneurologic outcomes in neonates less than 27 weeks gestational age. Journal of Investigative Medicine2019;67(1):86-7. ">Rouse 2008</a> </p> </td> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Treatment intended</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 g over 20 to 30 min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 g/h until birth or for up to 12 h (resumed if &lt; 6 h had passed and birth again appeared imminent) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If ≥ 6 h had passed since discontinuation, another loading dose was given.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clear, although women were not eligible if delivery was anticipated within less than 2 h; women with indicated preterm deliveries were eligible if birth was anticipated within 24 h </p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Treatment as received, magnesium sulphate vs placebo, N (%) unless stated</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Did not receive treatment:</p> <p>18 (1.6) vs 20 (1.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Received treatment for &lt; 3 h: 996 (90.9) vs 1024 (89.4)</p> <p>Received treatment for ≥ 3 h: 82 (7.5) vs 101 (8.8)</p> <p>Median (IQR) total dose: 31.5 g (29.0 to 44.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eligible for retreatment (total population): 1602 (71.5)</p> <p>Of eligible for retreatment, receiving drug at delivery (total population): 947 (59.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a> </p> </td> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Treatment intended</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 g over 10 to 30 min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 g/h until birth, or for 24 h if birth had not occurred</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loading dose repeated if ≥ 6 h had passed since discontinuation of treatment and birth was again imminent &lt; 32 weeks' gestation. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women eligible if expected to give birth within 2 to 24 h</p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Treatment as received, magnesium sulphate vs placebo, N (%) unless stated</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Started: 273 (96.5) vs 268 (96.7)</p> <p>Completed: 268 (94.7) vs 266 (96.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Started: 235 (83.0) vs 230 (83.0)</p> <p>Completed: 116 (41.0) vs 95 (34.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eligible for repeat loading dose (total population): 147 (26.3)</p> <p>Of those eligible for repeat loading dose, received it (total population):</p> <p>78 (53.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Abbreviations:</b> IQR: interquartile range; IV: intravenous; N/A: not applicable; RCT: randomised controlled trial </p> </div> </div> </section> </section> <section id="CD004661-sec-0079"> <h5 class="title">Outcomes</h5> <section id="CD004661-sec-0080"> <h6 class="title">Primary outcomes</h6> <p>The RCTs' primary outcomes focused on death and cerebral palsy. One RCT reported on neonatal mortality before hospital discharge (<a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a>), while two RCTs reported total paediatric mortality including fetal/stillbirths, neonatal and post‐neonatal mortality (<a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a>; <a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a>). </p> <p>Three RCTs reported on cerebral palsy as a primary outcome at age 18 months (<a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a>) or two years' corrected age (<a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a>), while one RCT reported on moderate to severe cerebral palsy (GMFCS level II‐V) at a minimum of 18 months' corrected age (<a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a>). </p> <p>Three RCTs reported a composite outcome of death or cerebral palsy (<a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a>; <a href="./references#CD004661-bbs2-0002" title="ACTRN12611000491965. MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: neuroprotection trial [Does antenatal magnesium sulphate given to women at risk of imminent preterm birth (defined as planned or definitely expected in the next 24 hours) between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children at 2 years corrected age? - a randomised controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000491965 (first received 11 May 2011). CrowtherCA , AshwoodP , MiddletonPF , McPheeA , TranT , HardineJE , et al. Prenatal intravenous magnesium at 30-34 weeks’ gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial. JAMA2023;330(7):603-14. CrowtherCA , MiddletonPF , WilkinsonD , AshwoodP , HaslamR . Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) - study protocol. BMC Pregnancy and Childbirth2013;13(1):91. PoppeT , ThompsonB , BoardmanJP , BastinME , AlsweilerJ , DeibG , et al. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: the MagNUM Study. EBioMedicine2022;78:103923. ">Crowther 2023</a>; <a href="./references#CD004661-bbs2-0005" title="BrookfieldKF , O'MalleyK , Yeaton-MasseyA , ButwickAJ . Does magnesium sulfate exposure attenuate the effect of steroids administered for fetal lung maturation? In: Society for Obstetric Anesthesia and Perinatology (SOAP) 48th Annual Meeting; 2016 May 18-22; Boston USA. 2016:SA-32. BuhimschiCS , JablonskiKA , RouseDJ , VarnerMW , ReddyUM , MercerBM , et al. Cord blood haptoglobin, cerebral palsy and death in infants of women at risk for preterm birth: a secondary analysis of a randomised controlled trial. Eclinicalmedicine2019;9:11-8. CostantineMM , WeinerSJ , RouseDJ , HirtzDG , VarnerMW , SpongCY , et al. Umbilical cord blood biomarkers of neurologic injury and the risk of cerebral palsy or infant death. International Journal of Developmental Neuroscience2011;29(8):917-22. CostantineMM . Cord blood biomarkers and the risk of cerebral palsy or death. Reproductive Sciences2010;17(3 Suppl 1):65A. DeihlTE , SimhanHN . Antenatal magnesium sulfate and ponderal index from birth to age 2 in preterm male and female infants. Reproductive Sciences2017;24(Suppl 1):130A. DeihlTE , SimhanHN . Antenatal magnesium sulfate exposure and ponderal index in preterm infants. American Journal of Perinatology2019;36(3):329-34. DenobleAE , WuJ , MitchellCJ , HughesBL , Dotters-KatzSK . Chorioamnionitis versus intraamniotic infection among preterm deliveries-is postpartum infectious morbidity different?American Journal of Obstetrics and Gynecology MFM2020;2(3):100176. DrassinowerD , FriedmanAM , LevinH , ObicanSG , Gyamfi-BannermanC . Does magnesium exposure affect neonatal resuscitation? Presented as a poster at the 35th annual meeting of the society for maternal-fetal medicine, San Diego, CA, Feb. 2-7, 2015. American Journal of Obstetrics and Gynecology2015;213(3):424e1-5. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm prelabour rupture of membranes and neurodevelopmental outcomes: a secondary analysis. BJOG: an international journal of obstetrics and gynaecology2016;123(10):1629-35. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of cerebral palsy. Journal of Maternal-Fetal &amp; Neonatal Medicine2016;29(17):2748-52. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of neonatal sepsis. American Journal of Obstetrics and Gynecology2016;214(6):743.e1-6. DrassinowerD , LevinH , ObicanS , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on cerebral palsy. American Journal of Obstetrics and Gynecology2015;212(1):S310-1. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . Immediate neonatal outcomes in infants exposed to magnesium sulfate at the time of delivery. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S90. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1):S161-2. EdwardsJ , EdwardsL , SwamyG , GrotegutC . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S215-6. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Effect of cord blood magnesium level at birth on non-neurologic neonatal outcomes. American Journal of Perinatology2019;36(1):3-7. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. Journal of Maternal-Fetal &amp; Neonatal Medicine2018;31(9):1156-60. FaucettAM , MetzTD , DeWittPE , GibbsRS . Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2016;214(2):287.e1-5. HaarEV , Gyamfi-BannermanC , Coletta-LucasJ . Sepsis but not chorioamnionitis is associated with cerebral palsy. Reproductive Sciences2015;22:372A. HaarEV , Gyamfi-BannermanC , RandisTM . Abnormal brain imaging in infants exposed to chorioamnionitis and sepsis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl. 1):S11-2. HaarEV , LucasJC , D'AltonM , Gyamfi-BannermanC . The effect of chorioamnionitis on neurocognitive development at age 2. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S139-40. HerreraC , SilverRM , MajorH , VarnerMW , ClarkEAS . Triple I criteria and adverse neonatal and childhood outcomes after early preterm birth. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S250. HirtzDG , WeinerSJ , BulasD , DiPietroM , SeibertJ , RouseDJ , et al. Antenatal magnesium and cerebral palsy in preterm infants. Journal of Pediatrics2015;167(4):834-9.e3. HirtzDG . Effect of prenatal MgSO4 on head ultrasound imaging in preterm infants. Annals of Neurology2011;70(Suppl 15):S110. HortonA . The effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S209. HortonL , YingleiL , RouseJ , SpongY , LevenoJ , VarnerW , et al. Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Perinatology2015;32(4):387-92. JohnsonLH , MappDC , RouseDJ , SpongCY , MercerBM , LevenoKJ , et al. Association of cord blood magnesium concentration and neonatal resuscitation. Journal of Pediatrics2012;160(4):573-7.e1. KachikisA , WalkerC , McAdamsR , WaldorfKA , Gyamfi-BannermanC . Influence of preterm premature rupture of membranes on neonatal respiratory complications. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S215. KachikisA , WalkerCL , McAdamsRM , Gyamfi-BannermanC , Adams WaldorfKM . Phenotypic overlap in neonatal respiratory morbidity following preterm premature rupture of membranes versus spontaneous preterm labor. Journal of Maternal-fetal &amp; Neonatal Medicine2021;34(12):1941-8. KamyarM , ClarkEA , YoderBA , VarnerMW , ManuckTA . Antenatal magnesium sulfate, necrotizing enterocolitis, and death among neonates &lt; 28 weeks gestation. AJP Reports2016;6(1):e148-54. KamyarM , ClarkEAS , VarnerMW , ManuckTA . Chorioamnionitis prevents protective effect of magnesium sulfate in the preterm infant. Reproductive Sciences2014;21(3 Suppl 1):78A. KamyarM , ManuckTA , StoddardGJ , VarnerMW , ClarkEAS . Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. BJOG: an international journal of obstetrics and gynaecology2016;123(7):1161-6. KamyarM , VarnerM , ClarkE . Magnesium sulfate neuroprophylaxis and the effect of infant sex. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S144. ManuckA , ShengX , YoderA , VarnerW . Correlation between initial neonatal and early childhood outcomes following preterm birth. American Journal of Obstetrics &amp; Gynecology2014;210(5):426.e1-9. ManuckT , ShengX , YoderB , VarnerM . Correlation between initial neonatal and early childhood outcomes among children delivered &lt;34 weeks gestation. American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S23. ManuckT , VarnerM . Is bigger better? Neonatal and childhood outcomes of large for gestational age (LGA) infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341-2. ManuckT , VarnerM . Neonatal and childhood outcomes following early vs later preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S340-1. ManuckT , VarnerM . Neonatal and childhood outcomes of small for gestational age infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341. ManuckTA , VarnerMW . Neonatal and early childhood outcomes following early vs later preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2014;211(3):308.e1-6. MarrsC , Mendez-FigueroaH , ChauhanS . Periventricular leukomalacia with PPROM: Obstetric antecedents and infants' outcomes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S85. MarrsCC , Mendez-FigueroaH , HammadIA , ChauhanSP . Differential morbidity in preterm small versus appropriate for gestational age: perhaps unverifiable. American Journal of Perinatology2015;32(13):1251-6. McPhersonJ , SmileyS , StamiloD . Magnesium sulfate neuroprotection and obesity: Is efficacy affected by obesity. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S218. McPhersonJA , RouseDJ , GrobmanWA , PalatnikA , StamilioDM . Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. Obstetrics and Gynecology2014;124(4):749-55. McPhersonJA , SmileyS , StamilioDM . Maternal obesity and neuroprotective magnesium sulfate. American Journal of Obstetrics and Gynecology2015;213(4):582.e1–6. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate &lt; 12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S252. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate for &gt;12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S104-5. Mendez-FigueroaH , ChauhanSP , PedrozaC , RefuerzoJS , DahlkeJD , RouseDJ . Preterm cesarean delivery for nonreassuring fetal heart rate: neonatal and neurologic morbidity. Obstetrics and Gynecology2015;125(3):636-42. Mendez-FigueroaH , DahlkeJD , ViteriOA , ChauhanSP , RouseDJ , SibaiBM , et al. Neonatal and infant outcomes in twin gestations with preterm premature rupture of membranes at 24-31 weeks of gestation. Obstetrics and Gynecology2014;124(2 Pt 1):323-31. MoussaH , Hosseini NasabS , FournieD , OntiverosA , AlkawasR , ChauhanS , et al. The impact of time of delivery on gestations complicated by preterm premature rupture of membranes: daytime versus nighttime. Journal of Maternal-Fetal &amp; Neonatal Medicine2019;32(20):3319-24. NCT00014989. Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) [Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)]. clinicaltrials.gov/show/NCT00014989 (first received 18 April 2001). NussEE , SpiegelmanJ , TuritzAL , Gyamfi-BannermanC . Childhood neurodevelopment after spontaneous versus indicated preterm birth. American Journal of Obstetrics and Gynecology MFM2020;2(2):100082. ObicanS , DrassinowerD , LevinH , Gyamfi-BannermanC . Mode of delivery at periviability and early childhood neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S124. OvertonE , BaptisteC , Gyamfi-BannermanC . 546: neurodevelopmental outcomes in late preterm and early term deliveries following antenatal corticosteroid exposure. American Journal of Obstetrics and Gynecology2019;220(1):S365-6. PalatnikA , RouseD , StamiloD , McPhersonJ , GrobmanW . The association between cerebral palsy or death and umbilical cord magnesium concentration. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S302. RobbinsLS , BlanchardCT , BiasiniFJ , PowellMF , CaseyBM , TitaAT , et al. General anesthesia for cesarean delivery and childhood neurodevelopmental and perinatal outcomes: a secondary analysis of a randomized controlled trial. International Journal of Obstetric Anesthesia2020;45:34-40. RobbinsLS , BlanchardCT , SinkeyRG , HarrisSL , TitaAT , HarperLM . Prenatal tobacco exposure and childhood neurodevelopment among infants born prematurely. American Journal of Perinatology2020;38(3):218-23. RobertsR , Ankumah N-A, ViteriO , Mendez-FigueroaH , ChauhanS , SibaiB . Significance of the absence of amniotic fluid from the cervical os with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S223. RouseD , HirtzD , ThomE , VarnerM , AlexanderJ , SpongC , et al. Magnesium sulfate for the prevention of cerebral palsy. New England Journal of Medicine2008;359:895-905. RouseD . A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. American Journal of Obstetrics and Gynecology2007;197(6):S2. RouseD . Magnesium sulfate (MGSO4) dose and timing, umbilical cord MG++ concentration: relationship to cerebral palsy. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S46. SagaramD , HaarEV , MillerR , Gyamfi-BannermanC . Birth order does not offer a neurologic advantage in twin pregnancy. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S427. SiegelAM , HeineRP , Dotters-KatzSK . The effect of non-penicillin antibiotic regimens on neonatal outcomes in preterm prelabor rupture of membranes. American Journal of Obstetrics and Gynecology2018;219(6):637. SonM , GrobmanWA , MillerES . Is mode of delivery associated with the risk of necrotizing enterocolitis?American Journal of Obstetrics and Gynecology2016;214(1 Suppl 1):S204-5. TuritzAL , TooGT , Gyamfi-BannermanC . Proximity of magnesium exposure to delivery and neonatal outcomes. American Journal of Obstetrics and Gynecology2016;215(4):508.e1-6. TwicklerD , McIntireD , AlexanderJ , LevenoK . Effects of magnesium sulfate on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S112. TwicklerDM , McIntireDD , AlexanderJM , LevenoKJ . Effects of magnesium sulfate on preterm fetal cerebral blood flow using Doppler analysis: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):21-5. Vander HaarE , GoldbergerA , Gyamfi-BannermanC . Mild intraventricular hemorrhage is not associated with low bayley scores at age 2. Reproductive Sciences2017;24(1 Suppl 1):83A. VilchezG , DaiJ , KumarK , MundyD , KontopoulosE , SokolRJ . Racial/ethnic disparities in magnesium sulfate neuroprotection: a subgroup analysis of a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(17):2304-11. VilchezG , DaiJ , LagosM , SokolRJ . Maternal side effects &amp; fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(2):178-83. WoodAM , PostAL , SwamyGK , GrotegutCA . Neonatal outcomes associated with noncephalic presentation at delivery in preterm birth. American Journal of Perinatology2018;35(12):1131-7. YadavaS , GarabedianM , SitA , El-SayedY . Use of magnesium sulfate and labor outcomes in PPROM at less than 37 weeks. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S203. YangM , VarnerMW , YoderB . Cord blood magnesium levels and nonneurologic outcomes in neonates less than 27 weeks gestational age. Journal of Investigative Medicine2019;67(1):86-7. ">Rouse 2008</a>). </p> <p>Finally, one RCT reported a primary outcome of neonatal cranial ultrasound abnormalities (severe white matter injury) and a combination of severe white matter injury and/or neonatal mortality (<a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a>). </p> <p>The RCTs reported on various secondary outcomes, many of which were relevant to this review. See <a href="./references#CD004661-sec-0213" title="">Characteristics of included studies</a>, where the review outcomes reported by each RCT are summarised. </p> </section> </section> <section id="CD004661-sec-0081"> <h5 class="title">Sources of funding</h5> <p>All RCTs reported funding sources. <a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a> reported funding from the National Health and Medical Research Council Australia (NHMRC) (main and school age follow‐up), the Channel 7 Research Foundation Australia, the Queen Victoria Hospital Research Foundation Australia, and support from the Department of Obstetrics and Gynaecology at the University of Adelaide, Australia, and the Victorian Government, Australia (school age follow‐up). <a href="./references#CD004661-bbs2-0002" title="ACTRN12611000491965. MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: neuroprotection trial [Does antenatal magnesium sulphate given to women at risk of imminent preterm birth (defined as planned or definitely expected in the next 24 hours) between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children at 2 years corrected age? - a randomised controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000491965 (first received 11 May 2011). CrowtherCA , AshwoodP , MiddletonPF , McPheeA , TranT , HardineJE , et al. Prenatal intravenous magnesium at 30-34 weeks’ gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial. JAMA2023;330(7):603-14. CrowtherCA , MiddletonPF , WilkinsonD , AshwoodP , HaslamR . Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) - study protocol. BMC Pregnancy and Childbirth2013;13(1):91. PoppeT , ThompsonB , BoardmanJP , BastinME , AlsweilerJ , DeibG , et al. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: the MagNUM Study. EBioMedicine2022;78:103923. ">Crowther 2023</a> reported funding from the NHMRC and the Cerebral Palsy Alliance Research Foundation Australia. <a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a> reported funding from the French Department of Health, Rouen University Hospital, and school age follow‐up funding from the European Regional Development Fund and the Upper‐Normandy region. <a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a> reported funding from the United Cerebral Palsy Research and Education Foundation USA, and <a href="./references#CD004661-bbs2-0005" title="BrookfieldKF , O'MalleyK , Yeaton-MasseyA , ButwickAJ . Does magnesium sulfate exposure attenuate the effect of steroids administered for fetal lung maturation? In: Society for Obstetric Anesthesia and Perinatology (SOAP) 48th Annual Meeting; 2016 May 18-22; Boston USA. 2016:SA-32. BuhimschiCS , JablonskiKA , RouseDJ , VarnerMW , ReddyUM , MercerBM , et al. Cord blood haptoglobin, cerebral palsy and death in infants of women at risk for preterm birth: a secondary analysis of a randomised controlled trial. Eclinicalmedicine2019;9:11-8. CostantineMM , WeinerSJ , RouseDJ , HirtzDG , VarnerMW , SpongCY , et al. Umbilical cord blood biomarkers of neurologic injury and the risk of cerebral palsy or infant death. International Journal of Developmental Neuroscience2011;29(8):917-22. CostantineMM . Cord blood biomarkers and the risk of cerebral palsy or death. Reproductive Sciences2010;17(3 Suppl 1):65A. DeihlTE , SimhanHN . Antenatal magnesium sulfate and ponderal index from birth to age 2 in preterm male and female infants. Reproductive Sciences2017;24(Suppl 1):130A. DeihlTE , SimhanHN . Antenatal magnesium sulfate exposure and ponderal index in preterm infants. American Journal of Perinatology2019;36(3):329-34. DenobleAE , WuJ , MitchellCJ , HughesBL , Dotters-KatzSK . Chorioamnionitis versus intraamniotic infection among preterm deliveries-is postpartum infectious morbidity different?American Journal of Obstetrics and Gynecology MFM2020;2(3):100176. DrassinowerD , FriedmanAM , LevinH , ObicanSG , Gyamfi-BannermanC . Does magnesium exposure affect neonatal resuscitation? Presented as a poster at the 35th annual meeting of the society for maternal-fetal medicine, San Diego, CA, Feb. 2-7, 2015. American Journal of Obstetrics and Gynecology2015;213(3):424e1-5. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm prelabour rupture of membranes and neurodevelopmental outcomes: a secondary analysis. BJOG: an international journal of obstetrics and gynaecology2016;123(10):1629-35. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of cerebral palsy. Journal of Maternal-Fetal &amp; Neonatal Medicine2016;29(17):2748-52. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of neonatal sepsis. American Journal of Obstetrics and Gynecology2016;214(6):743.e1-6. DrassinowerD , LevinH , ObicanS , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on cerebral palsy. American Journal of Obstetrics and Gynecology2015;212(1):S310-1. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . Immediate neonatal outcomes in infants exposed to magnesium sulfate at the time of delivery. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S90. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1):S161-2. EdwardsJ , EdwardsL , SwamyG , GrotegutC . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S215-6. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Effect of cord blood magnesium level at birth on non-neurologic neonatal outcomes. American Journal of Perinatology2019;36(1):3-7. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. Journal of Maternal-Fetal &amp; Neonatal Medicine2018;31(9):1156-60. FaucettAM , MetzTD , DeWittPE , GibbsRS . Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2016;214(2):287.e1-5. HaarEV , Gyamfi-BannermanC , Coletta-LucasJ . Sepsis but not chorioamnionitis is associated with cerebral palsy. Reproductive Sciences2015;22:372A. HaarEV , Gyamfi-BannermanC , RandisTM . Abnormal brain imaging in infants exposed to chorioamnionitis and sepsis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl. 1):S11-2. HaarEV , LucasJC , D'AltonM , Gyamfi-BannermanC . The effect of chorioamnionitis on neurocognitive development at age 2. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S139-40. HerreraC , SilverRM , MajorH , VarnerMW , ClarkEAS . Triple I criteria and adverse neonatal and childhood outcomes after early preterm birth. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S250. HirtzDG , WeinerSJ , BulasD , DiPietroM , SeibertJ , RouseDJ , et al. Antenatal magnesium and cerebral palsy in preterm infants. Journal of Pediatrics2015;167(4):834-9.e3. HirtzDG . Effect of prenatal MgSO4 on head ultrasound imaging in preterm infants. Annals of Neurology2011;70(Suppl 15):S110. HortonA . The effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S209. HortonL , YingleiL , RouseJ , SpongY , LevenoJ , VarnerW , et al. Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Perinatology2015;32(4):387-92. JohnsonLH , MappDC , RouseDJ , SpongCY , MercerBM , LevenoKJ , et al. Association of cord blood magnesium concentration and neonatal resuscitation. Journal of Pediatrics2012;160(4):573-7.e1. KachikisA , WalkerC , McAdamsR , WaldorfKA , Gyamfi-BannermanC . Influence of preterm premature rupture of membranes on neonatal respiratory complications. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S215. KachikisA , WalkerCL , McAdamsRM , Gyamfi-BannermanC , Adams WaldorfKM . Phenotypic overlap in neonatal respiratory morbidity following preterm premature rupture of membranes versus spontaneous preterm labor. Journal of Maternal-fetal &amp; Neonatal Medicine2021;34(12):1941-8. KamyarM , ClarkEA , YoderBA , VarnerMW , ManuckTA . Antenatal magnesium sulfate, necrotizing enterocolitis, and death among neonates &lt; 28 weeks gestation. AJP Reports2016;6(1):e148-54. KamyarM , ClarkEAS , VarnerMW , ManuckTA . Chorioamnionitis prevents protective effect of magnesium sulfate in the preterm infant. Reproductive Sciences2014;21(3 Suppl 1):78A. KamyarM , ManuckTA , StoddardGJ , VarnerMW , ClarkEAS . Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. BJOG: an international journal of obstetrics and gynaecology2016;123(7):1161-6. KamyarM , VarnerM , ClarkE . Magnesium sulfate neuroprophylaxis and the effect of infant sex. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S144. ManuckA , ShengX , YoderA , VarnerW . Correlation between initial neonatal and early childhood outcomes following preterm birth. American Journal of Obstetrics &amp; Gynecology2014;210(5):426.e1-9. ManuckT , ShengX , YoderB , VarnerM . Correlation between initial neonatal and early childhood outcomes among children delivered &lt;34 weeks gestation. American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S23. ManuckT , VarnerM . Is bigger better? Neonatal and childhood outcomes of large for gestational age (LGA) infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341-2. ManuckT , VarnerM . Neonatal and childhood outcomes following early vs later preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S340-1. ManuckT , VarnerM . Neonatal and childhood outcomes of small for gestational age infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341. ManuckTA , VarnerMW . Neonatal and early childhood outcomes following early vs later preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2014;211(3):308.e1-6. MarrsC , Mendez-FigueroaH , ChauhanS . Periventricular leukomalacia with PPROM: Obstetric antecedents and infants' outcomes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S85. MarrsCC , Mendez-FigueroaH , HammadIA , ChauhanSP . Differential morbidity in preterm small versus appropriate for gestational age: perhaps unverifiable. American Journal of Perinatology2015;32(13):1251-6. McPhersonJ , SmileyS , StamiloD . Magnesium sulfate neuroprotection and obesity: Is efficacy affected by obesity. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S218. McPhersonJA , RouseDJ , GrobmanWA , PalatnikA , StamilioDM . Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. Obstetrics and Gynecology2014;124(4):749-55. McPhersonJA , SmileyS , StamilioDM . Maternal obesity and neuroprotective magnesium sulfate. American Journal of Obstetrics and Gynecology2015;213(4):582.e1–6. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate &lt; 12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S252. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate for &gt;12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S104-5. Mendez-FigueroaH , ChauhanSP , PedrozaC , RefuerzoJS , DahlkeJD , RouseDJ . Preterm cesarean delivery for nonreassuring fetal heart rate: neonatal and neurologic morbidity. Obstetrics and Gynecology2015;125(3):636-42. Mendez-FigueroaH , DahlkeJD , ViteriOA , ChauhanSP , RouseDJ , SibaiBM , et al. Neonatal and infant outcomes in twin gestations with preterm premature rupture of membranes at 24-31 weeks of gestation. Obstetrics and Gynecology2014;124(2 Pt 1):323-31. MoussaH , Hosseini NasabS , FournieD , OntiverosA , AlkawasR , ChauhanS , et al. The impact of time of delivery on gestations complicated by preterm premature rupture of membranes: daytime versus nighttime. Journal of Maternal-Fetal &amp; Neonatal Medicine2019;32(20):3319-24. NCT00014989. Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) [Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)]. clinicaltrials.gov/show/NCT00014989 (first received 18 April 2001). NussEE , SpiegelmanJ , TuritzAL , Gyamfi-BannermanC . Childhood neurodevelopment after spontaneous versus indicated preterm birth. American Journal of Obstetrics and Gynecology MFM2020;2(2):100082. ObicanS , DrassinowerD , LevinH , Gyamfi-BannermanC . Mode of delivery at periviability and early childhood neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S124. OvertonE , BaptisteC , Gyamfi-BannermanC . 546: neurodevelopmental outcomes in late preterm and early term deliveries following antenatal corticosteroid exposure. American Journal of Obstetrics and Gynecology2019;220(1):S365-6. PalatnikA , RouseD , StamiloD , McPhersonJ , GrobmanW . The association between cerebral palsy or death and umbilical cord magnesium concentration. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S302. RobbinsLS , BlanchardCT , BiasiniFJ , PowellMF , CaseyBM , TitaAT , et al. General anesthesia for cesarean delivery and childhood neurodevelopmental and perinatal outcomes: a secondary analysis of a randomized controlled trial. International Journal of Obstetric Anesthesia2020;45:34-40. RobbinsLS , BlanchardCT , SinkeyRG , HarrisSL , TitaAT , HarperLM . Prenatal tobacco exposure and childhood neurodevelopment among infants born prematurely. American Journal of Perinatology2020;38(3):218-23. RobertsR , Ankumah N-A, ViteriO , Mendez-FigueroaH , ChauhanS , SibaiB . Significance of the absence of amniotic fluid from the cervical os with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S223. RouseD , HirtzD , ThomE , VarnerM , AlexanderJ , SpongC , et al. Magnesium sulfate for the prevention of cerebral palsy. New England Journal of Medicine2008;359:895-905. RouseD . A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. American Journal of Obstetrics and Gynecology2007;197(6):S2. RouseD . Magnesium sulfate (MGSO4) dose and timing, umbilical cord MG++ concentration: relationship to cerebral palsy. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S46. SagaramD , HaarEV , MillerR , Gyamfi-BannermanC . Birth order does not offer a neurologic advantage in twin pregnancy. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S427. SiegelAM , HeineRP , Dotters-KatzSK . The effect of non-penicillin antibiotic regimens on neonatal outcomes in preterm prelabor rupture of membranes. American Journal of Obstetrics and Gynecology2018;219(6):637. SonM , GrobmanWA , MillerES . Is mode of delivery associated with the risk of necrotizing enterocolitis?American Journal of Obstetrics and Gynecology2016;214(1 Suppl 1):S204-5. TuritzAL , TooGT , Gyamfi-BannermanC . Proximity of magnesium exposure to delivery and neonatal outcomes. American Journal of Obstetrics and Gynecology2016;215(4):508.e1-6. TwicklerD , McIntireD , AlexanderJ , LevenoK . Effects of magnesium sulfate on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S112. TwicklerDM , McIntireDD , AlexanderJM , LevenoKJ . Effects of magnesium sulfate on preterm fetal cerebral blood flow using Doppler analysis: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):21-5. Vander HaarE , GoldbergerA , Gyamfi-BannermanC . Mild intraventricular hemorrhage is not associated with low bayley scores at age 2. Reproductive Sciences2017;24(1 Suppl 1):83A. VilchezG , DaiJ , KumarK , MundyD , KontopoulosE , SokolRJ . Racial/ethnic disparities in magnesium sulfate neuroprotection: a subgroup analysis of a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(17):2304-11. VilchezG , DaiJ , LagosM , SokolRJ . Maternal side effects &amp; fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(2):178-83. WoodAM , PostAL , SwamyGK , GrotegutCA . Neonatal outcomes associated with noncephalic presentation at delivery in preterm birth. American Journal of Perinatology2018;35(12):1131-7. YadavaS , GarabedianM , SitA , El-SayedY . Use of magnesium sulfate and labor outcomes in PPROM at less than 37 weeks. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S203. YangM , VarnerMW , YoderB . Cord blood magnesium levels and nonneurologic outcomes in neonates less than 27 weeks gestational age. Journal of Investigative Medicine2019;67(1):86-7. ">Rouse 2008</a> reported funding from the National Institute of Child Health and Human Development and the National Institute of Neurological Disorders and Stroke USA. <a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a> reported funding from the Elsass Foundation, the Hospital Institutional Board at Hvidovre Hospital, the Department of Obstetrics and Gynaecology at Hvidovre Hospital, the Research Foundation at Hvidovre Hospital, Dagmar Marchall’s Foundation, Inge and Per Refshall’s Research Grant, NFOG Fund, Aase and Ejnar Danielsen’s Foundation, and Reprounion. </p> </section> <section id="CD004661-sec-0082"> <h5 class="title">Authors' declarations of interest</h5> <p><a href="./references#CD004661-bbs2-0002" title="ACTRN12611000491965. MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: neuroprotection trial [Does antenatal magnesium sulphate given to women at risk of imminent preterm birth (defined as planned or definitely expected in the next 24 hours) between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children at 2 years corrected age? - a randomised controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000491965 (first received 11 May 2011). CrowtherCA , AshwoodP , MiddletonPF , McPheeA , TranT , HardineJE , et al. Prenatal intravenous magnesium at 30-34 weeks’ gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial. JAMA2023;330(7):603-14. CrowtherCA , MiddletonPF , WilkinsonD , AshwoodP , HaslamR . Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) - study protocol. BMC Pregnancy and Childbirth2013;13(1):91. PoppeT , ThompsonB , BoardmanJP , BastinME , AlsweilerJ , DeibG , et al. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: the MagNUM Study. EBioMedicine2022;78:103923. ">Crowther 2023</a>, <a href="./references#CD004661-bbs2-0005" title="BrookfieldKF , O'MalleyK , Yeaton-MasseyA , ButwickAJ . Does magnesium sulfate exposure attenuate the effect of steroids administered for fetal lung maturation? In: Society for Obstetric Anesthesia and Perinatology (SOAP) 48th Annual Meeting; 2016 May 18-22; Boston USA. 2016:SA-32. BuhimschiCS , JablonskiKA , RouseDJ , VarnerMW , ReddyUM , MercerBM , et al. Cord blood haptoglobin, cerebral palsy and death in infants of women at risk for preterm birth: a secondary analysis of a randomised controlled trial. Eclinicalmedicine2019;9:11-8. CostantineMM , WeinerSJ , RouseDJ , HirtzDG , VarnerMW , SpongCY , et al. Umbilical cord blood biomarkers of neurologic injury and the risk of cerebral palsy or infant death. International Journal of Developmental Neuroscience2011;29(8):917-22. CostantineMM . Cord blood biomarkers and the risk of cerebral palsy or death. Reproductive Sciences2010;17(3 Suppl 1):65A. DeihlTE , SimhanHN . Antenatal magnesium sulfate and ponderal index from birth to age 2 in preterm male and female infants. Reproductive Sciences2017;24(Suppl 1):130A. DeihlTE , SimhanHN . Antenatal magnesium sulfate exposure and ponderal index in preterm infants. American Journal of Perinatology2019;36(3):329-34. DenobleAE , WuJ , MitchellCJ , HughesBL , Dotters-KatzSK . Chorioamnionitis versus intraamniotic infection among preterm deliveries-is postpartum infectious morbidity different?American Journal of Obstetrics and Gynecology MFM2020;2(3):100176. DrassinowerD , FriedmanAM , LevinH , ObicanSG , Gyamfi-BannermanC . Does magnesium exposure affect neonatal resuscitation? Presented as a poster at the 35th annual meeting of the society for maternal-fetal medicine, San Diego, CA, Feb. 2-7, 2015. American Journal of Obstetrics and Gynecology2015;213(3):424e1-5. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm prelabour rupture of membranes and neurodevelopmental outcomes: a secondary analysis. BJOG: an international journal of obstetrics and gynaecology2016;123(10):1629-35. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of cerebral palsy. Journal of Maternal-Fetal &amp; Neonatal Medicine2016;29(17):2748-52. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of neonatal sepsis. American Journal of Obstetrics and Gynecology2016;214(6):743.e1-6. DrassinowerD , LevinH , ObicanS , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on cerebral palsy. American Journal of Obstetrics and Gynecology2015;212(1):S310-1. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . Immediate neonatal outcomes in infants exposed to magnesium sulfate at the time of delivery. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S90. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1):S161-2. EdwardsJ , EdwardsL , SwamyG , GrotegutC . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S215-6. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Effect of cord blood magnesium level at birth on non-neurologic neonatal outcomes. American Journal of Perinatology2019;36(1):3-7. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. Journal of Maternal-Fetal &amp; Neonatal Medicine2018;31(9):1156-60. FaucettAM , MetzTD , DeWittPE , GibbsRS . Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2016;214(2):287.e1-5. HaarEV , Gyamfi-BannermanC , Coletta-LucasJ . Sepsis but not chorioamnionitis is associated with cerebral palsy. Reproductive Sciences2015;22:372A. HaarEV , Gyamfi-BannermanC , RandisTM . Abnormal brain imaging in infants exposed to chorioamnionitis and sepsis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl. 1):S11-2. HaarEV , LucasJC , D'AltonM , Gyamfi-BannermanC . The effect of chorioamnionitis on neurocognitive development at age 2. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S139-40. HerreraC , SilverRM , MajorH , VarnerMW , ClarkEAS . Triple I criteria and adverse neonatal and childhood outcomes after early preterm birth. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S250. HirtzDG , WeinerSJ , BulasD , DiPietroM , SeibertJ , RouseDJ , et al. Antenatal magnesium and cerebral palsy in preterm infants. Journal of Pediatrics2015;167(4):834-9.e3. HirtzDG . Effect of prenatal MgSO4 on head ultrasound imaging in preterm infants. Annals of Neurology2011;70(Suppl 15):S110. HortonA . The effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S209. HortonL , YingleiL , RouseJ , SpongY , LevenoJ , VarnerW , et al. Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Perinatology2015;32(4):387-92. JohnsonLH , MappDC , RouseDJ , SpongCY , MercerBM , LevenoKJ , et al. Association of cord blood magnesium concentration and neonatal resuscitation. Journal of Pediatrics2012;160(4):573-7.e1. KachikisA , WalkerC , McAdamsR , WaldorfKA , Gyamfi-BannermanC . Influence of preterm premature rupture of membranes on neonatal respiratory complications. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S215. KachikisA , WalkerCL , McAdamsRM , Gyamfi-BannermanC , Adams WaldorfKM . Phenotypic overlap in neonatal respiratory morbidity following preterm premature rupture of membranes versus spontaneous preterm labor. Journal of Maternal-fetal &amp; Neonatal Medicine2021;34(12):1941-8. KamyarM , ClarkEA , YoderBA , VarnerMW , ManuckTA . Antenatal magnesium sulfate, necrotizing enterocolitis, and death among neonates &lt; 28 weeks gestation. AJP Reports2016;6(1):e148-54. KamyarM , ClarkEAS , VarnerMW , ManuckTA . Chorioamnionitis prevents protective effect of magnesium sulfate in the preterm infant. Reproductive Sciences2014;21(3 Suppl 1):78A. KamyarM , ManuckTA , StoddardGJ , VarnerMW , ClarkEAS . Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. BJOG: an international journal of obstetrics and gynaecology2016;123(7):1161-6. KamyarM , VarnerM , ClarkE . Magnesium sulfate neuroprophylaxis and the effect of infant sex. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S144. ManuckA , ShengX , YoderA , VarnerW . Correlation between initial neonatal and early childhood outcomes following preterm birth. American Journal of Obstetrics &amp; Gynecology2014;210(5):426.e1-9. ManuckT , ShengX , YoderB , VarnerM . Correlation between initial neonatal and early childhood outcomes among children delivered &lt;34 weeks gestation. American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S23. ManuckT , VarnerM . Is bigger better? Neonatal and childhood outcomes of large for gestational age (LGA) infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341-2. ManuckT , VarnerM . Neonatal and childhood outcomes following early vs later preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S340-1. ManuckT , VarnerM . Neonatal and childhood outcomes of small for gestational age infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341. ManuckTA , VarnerMW . Neonatal and early childhood outcomes following early vs later preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2014;211(3):308.e1-6. MarrsC , Mendez-FigueroaH , ChauhanS . Periventricular leukomalacia with PPROM: Obstetric antecedents and infants' outcomes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S85. MarrsCC , Mendez-FigueroaH , HammadIA , ChauhanSP . Differential morbidity in preterm small versus appropriate for gestational age: perhaps unverifiable. American Journal of Perinatology2015;32(13):1251-6. McPhersonJ , SmileyS , StamiloD . Magnesium sulfate neuroprotection and obesity: Is efficacy affected by obesity. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S218. McPhersonJA , RouseDJ , GrobmanWA , PalatnikA , StamilioDM . Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. Obstetrics and Gynecology2014;124(4):749-55. McPhersonJA , SmileyS , StamilioDM . Maternal obesity and neuroprotective magnesium sulfate. American Journal of Obstetrics and Gynecology2015;213(4):582.e1–6. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate &lt; 12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S252. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate for &gt;12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S104-5. Mendez-FigueroaH , ChauhanSP , PedrozaC , RefuerzoJS , DahlkeJD , RouseDJ . Preterm cesarean delivery for nonreassuring fetal heart rate: neonatal and neurologic morbidity. Obstetrics and Gynecology2015;125(3):636-42. Mendez-FigueroaH , DahlkeJD , ViteriOA , ChauhanSP , RouseDJ , SibaiBM , et al. Neonatal and infant outcomes in twin gestations with preterm premature rupture of membranes at 24-31 weeks of gestation. Obstetrics and Gynecology2014;124(2 Pt 1):323-31. MoussaH , Hosseini NasabS , FournieD , OntiverosA , AlkawasR , ChauhanS , et al. The impact of time of delivery on gestations complicated by preterm premature rupture of membranes: daytime versus nighttime. Journal of Maternal-Fetal &amp; Neonatal Medicine2019;32(20):3319-24. NCT00014989. Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) [Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)]. clinicaltrials.gov/show/NCT00014989 (first received 18 April 2001). NussEE , SpiegelmanJ , TuritzAL , Gyamfi-BannermanC . Childhood neurodevelopment after spontaneous versus indicated preterm birth. American Journal of Obstetrics and Gynecology MFM2020;2(2):100082. ObicanS , DrassinowerD , LevinH , Gyamfi-BannermanC . Mode of delivery at periviability and early childhood neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S124. OvertonE , BaptisteC , Gyamfi-BannermanC . 546: neurodevelopmental outcomes in late preterm and early term deliveries following antenatal corticosteroid exposure. American Journal of Obstetrics and Gynecology2019;220(1):S365-6. PalatnikA , RouseD , StamiloD , McPhersonJ , GrobmanW . The association between cerebral palsy or death and umbilical cord magnesium concentration. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S302. RobbinsLS , BlanchardCT , BiasiniFJ , PowellMF , CaseyBM , TitaAT , et al. General anesthesia for cesarean delivery and childhood neurodevelopmental and perinatal outcomes: a secondary analysis of a randomized controlled trial. International Journal of Obstetric Anesthesia2020;45:34-40. RobbinsLS , BlanchardCT , SinkeyRG , HarrisSL , TitaAT , HarperLM . Prenatal tobacco exposure and childhood neurodevelopment among infants born prematurely. American Journal of Perinatology2020;38(3):218-23. RobertsR , Ankumah N-A, ViteriO , Mendez-FigueroaH , ChauhanS , SibaiB . Significance of the absence of amniotic fluid from the cervical os with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S223. RouseD , HirtzD , ThomE , VarnerM , AlexanderJ , SpongC , et al. Magnesium sulfate for the prevention of cerebral palsy. New England Journal of Medicine2008;359:895-905. RouseD . A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. American Journal of Obstetrics and Gynecology2007;197(6):S2. RouseD . Magnesium sulfate (MGSO4) dose and timing, umbilical cord MG++ concentration: relationship to cerebral palsy. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S46. SagaramD , HaarEV , MillerR , Gyamfi-BannermanC . Birth order does not offer a neurologic advantage in twin pregnancy. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S427. SiegelAM , HeineRP , Dotters-KatzSK . The effect of non-penicillin antibiotic regimens on neonatal outcomes in preterm prelabor rupture of membranes. American Journal of Obstetrics and Gynecology2018;219(6):637. SonM , GrobmanWA , MillerES . Is mode of delivery associated with the risk of necrotizing enterocolitis?American Journal of Obstetrics and Gynecology2016;214(1 Suppl 1):S204-5. TuritzAL , TooGT , Gyamfi-BannermanC . Proximity of magnesium exposure to delivery and neonatal outcomes. American Journal of Obstetrics and Gynecology2016;215(4):508.e1-6. TwicklerD , McIntireD , AlexanderJ , LevenoK . Effects of magnesium sulfate on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S112. TwicklerDM , McIntireDD , AlexanderJM , LevenoKJ . Effects of magnesium sulfate on preterm fetal cerebral blood flow using Doppler analysis: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):21-5. Vander HaarE , GoldbergerA , Gyamfi-BannermanC . Mild intraventricular hemorrhage is not associated with low bayley scores at age 2. Reproductive Sciences2017;24(1 Suppl 1):83A. VilchezG , DaiJ , KumarK , MundyD , KontopoulosE , SokolRJ . Racial/ethnic disparities in magnesium sulfate neuroprotection: a subgroup analysis of a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(17):2304-11. VilchezG , DaiJ , LagosM , SokolRJ . Maternal side effects &amp; fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(2):178-83. WoodAM , PostAL , SwamyGK , GrotegutCA . Neonatal outcomes associated with noncephalic presentation at delivery in preterm birth. American Journal of Perinatology2018;35(12):1131-7. YadavaS , GarabedianM , SitA , El-SayedY . Use of magnesium sulfate and labor outcomes in PPROM at less than 37 weeks. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S203. YangM , VarnerMW , YoderB . Cord blood magnesium levels and nonneurologic outcomes in neonates less than 27 weeks gestational age. Journal of Investigative Medicine2019;67(1):86-7. ">Rouse 2008</a>, and <a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a> reported no conflict of interests. <a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a> and <a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a> did not include a declaration of interest in the main RCT paper, but their school age follow‐up reported no conflicts of interest. <a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a> did not report whether they had any conflicting interests. </p> </section> </section> <section id="CD004661-sec-0083"> <h4 class="title">Ongoing studies</h4> <p>We identified four ongoing studies (<a href="./references#CD004661-bbs2-0021" title="CTRI/2018/06/014386. Role of magnesium suplhate to mother in protecting brain of preterm babies [Antenatal magnesium sulphate for neuroprotection in preterm infants: An open label randomized control trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2018/06/014386 (first received 4 June 2018). ">CTRI/2018/06/014386</a>; <a href="./references#CD004661-bbs2-0022" title="IRCT20120826010664N5. Magnesium sulfate neuroprotection in preterm infants [Evaluation of neuroprotective effects of magnesium sulfate on preterm infants with a gestational age of 32-36 weeks]. trialsearch.who.int/Trial2.aspx?TrialID=IRCT20120826010664N5 (first received 16 December 2019). ">IRCT20120826010664N5</a>; <a href="./references#CD004661-bbs2-0023" title="NCT02506894. Fetal middle cerebral artery doppler in preterm births receiving magnesium sulfate for neuroprotection. clinicaltrials.gov/show/NCT02506894 (first received 23 July 2015). ">NCT02506894</a>; <a href="./references#CD004661-bbs2-0024" title="NCT05674565. Magnesium sulphate neuroprotective strategies for preterm deliveries [The neuroprotective impact of magnesium sulphate therapy for preterm deliveries. Loading dose alone strategy versus loading plus maintenance dose strategy]. clinicaltrials.gov/show/NCT05674565 (first received 6 January 2023). ">NCT05674565</a>). For further details, see <a href="./references#CD004661-sec-0216" title="">Characteristics of ongoing studies</a>. </p> </section> <section id="CD004661-sec-0084"> <h4 class="title">Excluded studies</h4> <p>We excluded six studies (see <a href="./references#CD004661-sec-0214" title="">Characteristics of excluded studies</a>). </p> <p>One study was not randomised (<a href="./references#CD004661-bbs2-0009" title="GulczynskaEM , GadzinowskiJ , KesiakM , SobolewskaB , GrodzickaA , ZylinskaL . The influence of erythropoietin (EPO) effect of maternal magnesium sulfate on red cells membrane lipid peroxidation - is there a correlation with clinical outcome in VLBWN?European Journal of Pediatrics2006;165(Suppl 1):196-7. ">Gulczynska 2006</a>). In four studies, the indication for magnesium sulphate treatment was not fetal neuroprotection (<a href="./references#CD004661-bbs2-0007" title="CTRI/2010/091/000578. CTRI/2010/091/000578 [A prospective observational study on effect of predelivery maternal factors on route of delivery in post cesarean women with intrauterine fetal death beyond 34 weeksâ?? gestation]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/000578 (first received 4 June 2010). ">CTRI/2010/091/000578</a>; <a href="./references#CD004661-bbs2-0008" title="DasguptaS , GhoshD , SealSL , KamilyaG , KarmakarM , SahaD . Randomized controlled study comparing effect of magnesium sulfate with placebo on fetal umbilical artery and middle cerebral artery blood flow in mild preeclampsia at &gt;= 34 weeks gestational age. Journal of Obstetrics and Gynaecology Research2012;38(5):763-71. ">Dasgupta 2012</a>; <a href="./references#CD004661-bbs2-0010" title="DuleyL . The Magpie Trial follow up study: Outcome after discharge from hospital for women and children recruited to a trial comparing magnesium sulphate with placebo for pre-eclampsia [ISRCTN86938761]. BMC Pregnancy and Childbirth2004;4(1):5. Magpie Trial Follow Up Study Collaborative Group. The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months. BJOG: an international journal of obstetrics and gynaecology2007;114(3):289-99. ">Magpie 2006</a>; <a href="./references#CD004661-bbs2-0012" title="SayinNC , ArdaS , VarolFG , SutN . The effects of ritodrine and magnesium sulfate on maternal and fetal Doppler blood flow patterns in women with preterm labor. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2010;152(1):50-4. ">Sayin 2010</a>). Further, in one of the studies, the comparator was not placebo or no treatment (it was ritodrine) (<a href="./references#CD004661-bbs2-0012" title="SayinNC , ArdaS , VarolFG , SutN . The effects of ritodrine and magnesium sulfate on maternal and fetal Doppler blood flow patterns in women with preterm labor. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2010;152(1):50-4. ">Sayin 2010</a>). In one study, although magnesium sulphate was assessed for fetal neuroprotection, the comparator was not placebo or no treatment (it was nifedipine) (<a href="./references#CD004661-bbs2-0011" title="NCT02591004. Calcium channel blockers compared to magnesium sulfate in fetal cerebral blood flow [Comparing fetal cerebral blood flow between magnesium sulfate &amp; calcium channel blockers in patients with preterm labor; a randomized controlled trial]. clinicaltrials.gov/show/NCT02591004 (first received 19 October 2015). ">NCT02591004</a>). </p> </section> </section> <section id="CD004661-sec-0085"> <h3 class="title">Risk of bias in included studies</h3> <p>We judged the overall risk of bias for most domains across RCTs to be low. See <a href="#CD004661-fig-0003">Figure 3</a>; <a href="#CD004661-fig-0004">Figure 4</a>. </p> <div class="figure" id="CD004661-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD004661-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <div class="figure" id="CD004661-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD004661-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD004661-sec-0086"> <h4 class="title">Allocation</h4> <p>We judged all RCTs as at low risk of selection bias for random sequence generation, as all used a computer‐generated random sequence. </p> <p>We judged five RCTs as at low risk of selection bias for allocation concealment: in two studies, randomisation was conducted centrally (<a href="./references#CD004661-bbs2-0002" title="ACTRN12611000491965. MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: neuroprotection trial [Does antenatal magnesium sulphate given to women at risk of imminent preterm birth (defined as planned or definitely expected in the next 24 hours) between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children at 2 years corrected age? - a randomised controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000491965 (first received 11 May 2011). CrowtherCA , AshwoodP , MiddletonPF , McPheeA , TranT , HardineJE , et al. Prenatal intravenous magnesium at 30-34 weeks’ gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial. JAMA2023;330(7):603-14. CrowtherCA , MiddletonPF , WilkinsonD , AshwoodP , HaslamR . Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) - study protocol. BMC Pregnancy and Childbirth2013;13(1):91. PoppeT , ThompsonB , BoardmanJP , BastinME , AlsweilerJ , DeibG , et al. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: the MagNUM Study. EBioMedicine2022;78:103923. ">Crowther 2023</a>; <a href="./references#CD004661-bbs2-0005" title="BrookfieldKF , O'MalleyK , Yeaton-MasseyA , ButwickAJ . Does magnesium sulfate exposure attenuate the effect of steroids administered for fetal lung maturation? In: Society for Obstetric Anesthesia and Perinatology (SOAP) 48th Annual Meeting; 2016 May 18-22; Boston USA. 2016:SA-32. BuhimschiCS , JablonskiKA , RouseDJ , VarnerMW , ReddyUM , MercerBM , et al. Cord blood haptoglobin, cerebral palsy and death in infants of women at risk for preterm birth: a secondary analysis of a randomised controlled trial. Eclinicalmedicine2019;9:11-8. CostantineMM , WeinerSJ , RouseDJ , HirtzDG , VarnerMW , SpongCY , et al. Umbilical cord blood biomarkers of neurologic injury and the risk of cerebral palsy or infant death. International Journal of Developmental Neuroscience2011;29(8):917-22. CostantineMM . Cord blood biomarkers and the risk of cerebral palsy or death. Reproductive Sciences2010;17(3 Suppl 1):65A. DeihlTE , SimhanHN . Antenatal magnesium sulfate and ponderal index from birth to age 2 in preterm male and female infants. Reproductive Sciences2017;24(Suppl 1):130A. DeihlTE , SimhanHN . Antenatal magnesium sulfate exposure and ponderal index in preterm infants. American Journal of Perinatology2019;36(3):329-34. DenobleAE , WuJ , MitchellCJ , HughesBL , Dotters-KatzSK . Chorioamnionitis versus intraamniotic infection among preterm deliveries-is postpartum infectious morbidity different?American Journal of Obstetrics and Gynecology MFM2020;2(3):100176. DrassinowerD , FriedmanAM , LevinH , ObicanSG , Gyamfi-BannermanC . Does magnesium exposure affect neonatal resuscitation? Presented as a poster at the 35th annual meeting of the society for maternal-fetal medicine, San Diego, CA, Feb. 2-7, 2015. American Journal of Obstetrics and Gynecology2015;213(3):424e1-5. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm prelabour rupture of membranes and neurodevelopmental outcomes: a secondary analysis. BJOG: an international journal of obstetrics and gynaecology2016;123(10):1629-35. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of cerebral palsy. Journal of Maternal-Fetal &amp; Neonatal Medicine2016;29(17):2748-52. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of neonatal sepsis. American Journal of Obstetrics and Gynecology2016;214(6):743.e1-6. DrassinowerD , LevinH , ObicanS , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on cerebral palsy. American Journal of Obstetrics and Gynecology2015;212(1):S310-1. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . Immediate neonatal outcomes in infants exposed to magnesium sulfate at the time of delivery. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S90. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1):S161-2. EdwardsJ , EdwardsL , SwamyG , GrotegutC . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S215-6. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Effect of cord blood magnesium level at birth on non-neurologic neonatal outcomes. American Journal of Perinatology2019;36(1):3-7. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. Journal of Maternal-Fetal &amp; Neonatal Medicine2018;31(9):1156-60. FaucettAM , MetzTD , DeWittPE , GibbsRS . Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2016;214(2):287.e1-5. HaarEV , Gyamfi-BannermanC , Coletta-LucasJ . Sepsis but not chorioamnionitis is associated with cerebral palsy. Reproductive Sciences2015;22:372A. HaarEV , Gyamfi-BannermanC , RandisTM . Abnormal brain imaging in infants exposed to chorioamnionitis and sepsis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl. 1):S11-2. HaarEV , LucasJC , D'AltonM , Gyamfi-BannermanC . The effect of chorioamnionitis on neurocognitive development at age 2. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S139-40. HerreraC , SilverRM , MajorH , VarnerMW , ClarkEAS . Triple I criteria and adverse neonatal and childhood outcomes after early preterm birth. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S250. HirtzDG , WeinerSJ , BulasD , DiPietroM , SeibertJ , RouseDJ , et al. Antenatal magnesium and cerebral palsy in preterm infants. Journal of Pediatrics2015;167(4):834-9.e3. HirtzDG . Effect of prenatal MgSO4 on head ultrasound imaging in preterm infants. Annals of Neurology2011;70(Suppl 15):S110. HortonA . The effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S209. HortonL , YingleiL , RouseJ , SpongY , LevenoJ , VarnerW , et al. Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Perinatology2015;32(4):387-92. JohnsonLH , MappDC , RouseDJ , SpongCY , MercerBM , LevenoKJ , et al. Association of cord blood magnesium concentration and neonatal resuscitation. Journal of Pediatrics2012;160(4):573-7.e1. KachikisA , WalkerC , McAdamsR , WaldorfKA , Gyamfi-BannermanC . Influence of preterm premature rupture of membranes on neonatal respiratory complications. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S215. KachikisA , WalkerCL , McAdamsRM , Gyamfi-BannermanC , Adams WaldorfKM . Phenotypic overlap in neonatal respiratory morbidity following preterm premature rupture of membranes versus spontaneous preterm labor. Journal of Maternal-fetal &amp; Neonatal Medicine2021;34(12):1941-8. KamyarM , ClarkEA , YoderBA , VarnerMW , ManuckTA . Antenatal magnesium sulfate, necrotizing enterocolitis, and death among neonates &lt; 28 weeks gestation. AJP Reports2016;6(1):e148-54. KamyarM , ClarkEAS , VarnerMW , ManuckTA . Chorioamnionitis prevents protective effect of magnesium sulfate in the preterm infant. Reproductive Sciences2014;21(3 Suppl 1):78A. KamyarM , ManuckTA , StoddardGJ , VarnerMW , ClarkEAS . Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. BJOG: an international journal of obstetrics and gynaecology2016;123(7):1161-6. KamyarM , VarnerM , ClarkE . Magnesium sulfate neuroprophylaxis and the effect of infant sex. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S144. ManuckA , ShengX , YoderA , VarnerW . Correlation between initial neonatal and early childhood outcomes following preterm birth. American Journal of Obstetrics &amp; Gynecology2014;210(5):426.e1-9. ManuckT , ShengX , YoderB , VarnerM . Correlation between initial neonatal and early childhood outcomes among children delivered &lt;34 weeks gestation. American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S23. ManuckT , VarnerM . Is bigger better? Neonatal and childhood outcomes of large for gestational age (LGA) infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341-2. ManuckT , VarnerM . Neonatal and childhood outcomes following early vs later preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S340-1. ManuckT , VarnerM . Neonatal and childhood outcomes of small for gestational age infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341. ManuckTA , VarnerMW . Neonatal and early childhood outcomes following early vs later preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2014;211(3):308.e1-6. MarrsC , Mendez-FigueroaH , ChauhanS . Periventricular leukomalacia with PPROM: Obstetric antecedents and infants' outcomes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S85. MarrsCC , Mendez-FigueroaH , HammadIA , ChauhanSP . Differential morbidity in preterm small versus appropriate for gestational age: perhaps unverifiable. American Journal of Perinatology2015;32(13):1251-6. McPhersonJ , SmileyS , StamiloD . Magnesium sulfate neuroprotection and obesity: Is efficacy affected by obesity. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S218. McPhersonJA , RouseDJ , GrobmanWA , PalatnikA , StamilioDM . Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. Obstetrics and Gynecology2014;124(4):749-55. McPhersonJA , SmileyS , StamilioDM . Maternal obesity and neuroprotective magnesium sulfate. American Journal of Obstetrics and Gynecology2015;213(4):582.e1–6. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate &lt; 12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S252. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate for &gt;12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S104-5. Mendez-FigueroaH , ChauhanSP , PedrozaC , RefuerzoJS , DahlkeJD , RouseDJ . Preterm cesarean delivery for nonreassuring fetal heart rate: neonatal and neurologic morbidity. Obstetrics and Gynecology2015;125(3):636-42. Mendez-FigueroaH , DahlkeJD , ViteriOA , ChauhanSP , RouseDJ , SibaiBM , et al. Neonatal and infant outcomes in twin gestations with preterm premature rupture of membranes at 24-31 weeks of gestation. Obstetrics and Gynecology2014;124(2 Pt 1):323-31. MoussaH , Hosseini NasabS , FournieD , OntiverosA , AlkawasR , ChauhanS , et al. The impact of time of delivery on gestations complicated by preterm premature rupture of membranes: daytime versus nighttime. Journal of Maternal-Fetal &amp; Neonatal Medicine2019;32(20):3319-24. NCT00014989. Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) [Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)]. clinicaltrials.gov/show/NCT00014989 (first received 18 April 2001). NussEE , SpiegelmanJ , TuritzAL , Gyamfi-BannermanC . Childhood neurodevelopment after spontaneous versus indicated preterm birth. American Journal of Obstetrics and Gynecology MFM2020;2(2):100082. ObicanS , DrassinowerD , LevinH , Gyamfi-BannermanC . Mode of delivery at periviability and early childhood neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S124. OvertonE , BaptisteC , Gyamfi-BannermanC . 546: neurodevelopmental outcomes in late preterm and early term deliveries following antenatal corticosteroid exposure. American Journal of Obstetrics and Gynecology2019;220(1):S365-6. PalatnikA , RouseD , StamiloD , McPhersonJ , GrobmanW . The association between cerebral palsy or death and umbilical cord magnesium concentration. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S302. RobbinsLS , BlanchardCT , BiasiniFJ , PowellMF , CaseyBM , TitaAT , et al. General anesthesia for cesarean delivery and childhood neurodevelopmental and perinatal outcomes: a secondary analysis of a randomized controlled trial. International Journal of Obstetric Anesthesia2020;45:34-40. RobbinsLS , BlanchardCT , SinkeyRG , HarrisSL , TitaAT , HarperLM . Prenatal tobacco exposure and childhood neurodevelopment among infants born prematurely. American Journal of Perinatology2020;38(3):218-23. RobertsR , Ankumah N-A, ViteriO , Mendez-FigueroaH , ChauhanS , SibaiB . Significance of the absence of amniotic fluid from the cervical os with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S223. RouseD , HirtzD , ThomE , VarnerM , AlexanderJ , SpongC , et al. Magnesium sulfate for the prevention of cerebral palsy. New England Journal of Medicine2008;359:895-905. RouseD . A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. American Journal of Obstetrics and Gynecology2007;197(6):S2. RouseD . Magnesium sulfate (MGSO4) dose and timing, umbilical cord MG++ concentration: relationship to cerebral palsy. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S46. SagaramD , HaarEV , MillerR , Gyamfi-BannermanC . Birth order does not offer a neurologic advantage in twin pregnancy. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S427. SiegelAM , HeineRP , Dotters-KatzSK . The effect of non-penicillin antibiotic regimens on neonatal outcomes in preterm prelabor rupture of membranes. American Journal of Obstetrics and Gynecology2018;219(6):637. SonM , GrobmanWA , MillerES . Is mode of delivery associated with the risk of necrotizing enterocolitis?American Journal of Obstetrics and Gynecology2016;214(1 Suppl 1):S204-5. TuritzAL , TooGT , Gyamfi-BannermanC . Proximity of magnesium exposure to delivery and neonatal outcomes. American Journal of Obstetrics and Gynecology2016;215(4):508.e1-6. TwicklerD , McIntireD , AlexanderJ , LevenoK . Effects of magnesium sulfate on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S112. TwicklerDM , McIntireDD , AlexanderJM , LevenoKJ . Effects of magnesium sulfate on preterm fetal cerebral blood flow using Doppler analysis: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):21-5. Vander HaarE , GoldbergerA , Gyamfi-BannermanC . Mild intraventricular hemorrhage is not associated with low bayley scores at age 2. Reproductive Sciences2017;24(1 Suppl 1):83A. VilchezG , DaiJ , KumarK , MundyD , KontopoulosE , SokolRJ . Racial/ethnic disparities in magnesium sulfate neuroprotection: a subgroup analysis of a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(17):2304-11. VilchezG , DaiJ , LagosM , SokolRJ . Maternal side effects &amp; fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(2):178-83. WoodAM , PostAL , SwamyGK , GrotegutCA . Neonatal outcomes associated with noncephalic presentation at delivery in preterm birth. American Journal of Perinatology2018;35(12):1131-7. YadavaS , GarabedianM , SitA , El-SayedY . Use of magnesium sulfate and labor outcomes in PPROM at less than 37 weeks. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S203. YangM , VarnerMW , YoderB . Cord blood magnesium levels and nonneurologic outcomes in neonates less than 27 weeks gestational age. Journal of Investigative Medicine2019;67(1):86-7. ">Rouse 2008</a>), and in three studies treatment packs were prepared by central/independent staff (<a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a>; <a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a>; <a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a>). We assessed one RCT as at unclear risk of bias as the method of allocation concealment was not stated (<a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a>). </p> </section> <section id="CD004661-sec-0087"> <h4 class="title">Blinding</h4> <p>We judged all RCTs as at low risk of performance bias due to blinding of participants and personnel. Treatment packs looked identical, ensuring blinding of participants, and clinicians were reported to be blinded to treatment group allocation (<a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a>; <a href="./references#CD004661-bbs2-0002" title="ACTRN12611000491965. MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: neuroprotection trial [Does antenatal magnesium sulphate given to women at risk of imminent preterm birth (defined as planned or definitely expected in the next 24 hours) between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children at 2 years corrected age? - a randomised controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000491965 (first received 11 May 2011). CrowtherCA , AshwoodP , MiddletonPF , McPheeA , TranT , HardineJE , et al. Prenatal intravenous magnesium at 30-34 weeks’ gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial. JAMA2023;330(7):603-14. CrowtherCA , MiddletonPF , WilkinsonD , AshwoodP , HaslamR . Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) - study protocol. BMC Pregnancy and Childbirth2013;13(1):91. PoppeT , ThompsonB , BoardmanJP , BastinME , AlsweilerJ , DeibG , et al. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: the MagNUM Study. EBioMedicine2022;78:103923. ">Crowther 2023</a>; <a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a>). While <a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a> reported unblinding of two women due to serious side effects, we judged that this was unlikely to introduce significant risk of bias. <a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a> and <a href="./references#CD004661-bbs2-0005" title="BrookfieldKF , O'MalleyK , Yeaton-MasseyA , ButwickAJ . Does magnesium sulfate exposure attenuate the effect of steroids administered for fetal lung maturation? In: Society for Obstetric Anesthesia and Perinatology (SOAP) 48th Annual Meeting; 2016 May 18-22; Boston USA. 2016:SA-32. BuhimschiCS , JablonskiKA , RouseDJ , VarnerMW , ReddyUM , MercerBM , et al. Cord blood haptoglobin, cerebral palsy and death in infants of women at risk for preterm birth: a secondary analysis of a randomised controlled trial. Eclinicalmedicine2019;9:11-8. CostantineMM , WeinerSJ , RouseDJ , HirtzDG , VarnerMW , SpongCY , et al. Umbilical cord blood biomarkers of neurologic injury and the risk of cerebral palsy or infant death. International Journal of Developmental Neuroscience2011;29(8):917-22. CostantineMM . Cord blood biomarkers and the risk of cerebral palsy or death. Reproductive Sciences2010;17(3 Suppl 1):65A. DeihlTE , SimhanHN . Antenatal magnesium sulfate and ponderal index from birth to age 2 in preterm male and female infants. Reproductive Sciences2017;24(Suppl 1):130A. DeihlTE , SimhanHN . Antenatal magnesium sulfate exposure and ponderal index in preterm infants. American Journal of Perinatology2019;36(3):329-34. DenobleAE , WuJ , MitchellCJ , HughesBL , Dotters-KatzSK . Chorioamnionitis versus intraamniotic infection among preterm deliveries-is postpartum infectious morbidity different?American Journal of Obstetrics and Gynecology MFM2020;2(3):100176. DrassinowerD , FriedmanAM , LevinH , ObicanSG , Gyamfi-BannermanC . Does magnesium exposure affect neonatal resuscitation? Presented as a poster at the 35th annual meeting of the society for maternal-fetal medicine, San Diego, CA, Feb. 2-7, 2015. American Journal of Obstetrics and Gynecology2015;213(3):424e1-5. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm prelabour rupture of membranes and neurodevelopmental outcomes: a secondary analysis. BJOG: an international journal of obstetrics and gynaecology2016;123(10):1629-35. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of cerebral palsy. Journal of Maternal-Fetal &amp; Neonatal Medicine2016;29(17):2748-52. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of neonatal sepsis. American Journal of Obstetrics and Gynecology2016;214(6):743.e1-6. DrassinowerD , LevinH , ObicanS , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on cerebral palsy. American Journal of Obstetrics and Gynecology2015;212(1):S310-1. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . Immediate neonatal outcomes in infants exposed to magnesium sulfate at the time of delivery. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S90. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1):S161-2. EdwardsJ , EdwardsL , SwamyG , GrotegutC . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S215-6. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Effect of cord blood magnesium level at birth on non-neurologic neonatal outcomes. American Journal of Perinatology2019;36(1):3-7. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. Journal of Maternal-Fetal &amp; Neonatal Medicine2018;31(9):1156-60. FaucettAM , MetzTD , DeWittPE , GibbsRS . Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2016;214(2):287.e1-5. HaarEV , Gyamfi-BannermanC , Coletta-LucasJ . Sepsis but not chorioamnionitis is associated with cerebral palsy. Reproductive Sciences2015;22:372A. HaarEV , Gyamfi-BannermanC , RandisTM . Abnormal brain imaging in infants exposed to chorioamnionitis and sepsis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl. 1):S11-2. HaarEV , LucasJC , D'AltonM , Gyamfi-BannermanC . The effect of chorioamnionitis on neurocognitive development at age 2. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S139-40. HerreraC , SilverRM , MajorH , VarnerMW , ClarkEAS . Triple I criteria and adverse neonatal and childhood outcomes after early preterm birth. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S250. HirtzDG , WeinerSJ , BulasD , DiPietroM , SeibertJ , RouseDJ , et al. Antenatal magnesium and cerebral palsy in preterm infants. Journal of Pediatrics2015;167(4):834-9.e3. HirtzDG . Effect of prenatal MgSO4 on head ultrasound imaging in preterm infants. Annals of Neurology2011;70(Suppl 15):S110. HortonA . The effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S209. HortonL , YingleiL , RouseJ , SpongY , LevenoJ , VarnerW , et al. Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Perinatology2015;32(4):387-92. JohnsonLH , MappDC , RouseDJ , SpongCY , MercerBM , LevenoKJ , et al. Association of cord blood magnesium concentration and neonatal resuscitation. Journal of Pediatrics2012;160(4):573-7.e1. KachikisA , WalkerC , McAdamsR , WaldorfKA , Gyamfi-BannermanC . Influence of preterm premature rupture of membranes on neonatal respiratory complications. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S215. KachikisA , WalkerCL , McAdamsRM , Gyamfi-BannermanC , Adams WaldorfKM . Phenotypic overlap in neonatal respiratory morbidity following preterm premature rupture of membranes versus spontaneous preterm labor. Journal of Maternal-fetal &amp; Neonatal Medicine2021;34(12):1941-8. KamyarM , ClarkEA , YoderBA , VarnerMW , ManuckTA . Antenatal magnesium sulfate, necrotizing enterocolitis, and death among neonates &lt; 28 weeks gestation. AJP Reports2016;6(1):e148-54. KamyarM , ClarkEAS , VarnerMW , ManuckTA . Chorioamnionitis prevents protective effect of magnesium sulfate in the preterm infant. Reproductive Sciences2014;21(3 Suppl 1):78A. KamyarM , ManuckTA , StoddardGJ , VarnerMW , ClarkEAS . Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. BJOG: an international journal of obstetrics and gynaecology2016;123(7):1161-6. KamyarM , VarnerM , ClarkE . Magnesium sulfate neuroprophylaxis and the effect of infant sex. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S144. ManuckA , ShengX , YoderA , VarnerW . Correlation between initial neonatal and early childhood outcomes following preterm birth. American Journal of Obstetrics &amp; Gynecology2014;210(5):426.e1-9. ManuckT , ShengX , YoderB , VarnerM . Correlation between initial neonatal and early childhood outcomes among children delivered &lt;34 weeks gestation. American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S23. ManuckT , VarnerM . Is bigger better? Neonatal and childhood outcomes of large for gestational age (LGA) infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341-2. ManuckT , VarnerM . Neonatal and childhood outcomes following early vs later preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S340-1. ManuckT , VarnerM . Neonatal and childhood outcomes of small for gestational age infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341. ManuckTA , VarnerMW . Neonatal and early childhood outcomes following early vs later preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2014;211(3):308.e1-6. MarrsC , Mendez-FigueroaH , ChauhanS . Periventricular leukomalacia with PPROM: Obstetric antecedents and infants' outcomes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S85. MarrsCC , Mendez-FigueroaH , HammadIA , ChauhanSP . Differential morbidity in preterm small versus appropriate for gestational age: perhaps unverifiable. American Journal of Perinatology2015;32(13):1251-6. McPhersonJ , SmileyS , StamiloD . Magnesium sulfate neuroprotection and obesity: Is efficacy affected by obesity. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S218. McPhersonJA , RouseDJ , GrobmanWA , PalatnikA , StamilioDM . Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. Obstetrics and Gynecology2014;124(4):749-55. McPhersonJA , SmileyS , StamilioDM . Maternal obesity and neuroprotective magnesium sulfate. American Journal of Obstetrics and Gynecology2015;213(4):582.e1–6. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate &lt; 12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S252. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate for &gt;12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S104-5. Mendez-FigueroaH , ChauhanSP , PedrozaC , RefuerzoJS , DahlkeJD , RouseDJ . Preterm cesarean delivery for nonreassuring fetal heart rate: neonatal and neurologic morbidity. Obstetrics and Gynecology2015;125(3):636-42. Mendez-FigueroaH , DahlkeJD , ViteriOA , ChauhanSP , RouseDJ , SibaiBM , et al. Neonatal and infant outcomes in twin gestations with preterm premature rupture of membranes at 24-31 weeks of gestation. Obstetrics and Gynecology2014;124(2 Pt 1):323-31. MoussaH , Hosseini NasabS , FournieD , OntiverosA , AlkawasR , ChauhanS , et al. The impact of time of delivery on gestations complicated by preterm premature rupture of membranes: daytime versus nighttime. Journal of Maternal-Fetal &amp; Neonatal Medicine2019;32(20):3319-24. NCT00014989. Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) [Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)]. clinicaltrials.gov/show/NCT00014989 (first received 18 April 2001). NussEE , SpiegelmanJ , TuritzAL , Gyamfi-BannermanC . Childhood neurodevelopment after spontaneous versus indicated preterm birth. American Journal of Obstetrics and Gynecology MFM2020;2(2):100082. ObicanS , DrassinowerD , LevinH , Gyamfi-BannermanC . Mode of delivery at periviability and early childhood neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S124. OvertonE , BaptisteC , Gyamfi-BannermanC . 546: neurodevelopmental outcomes in late preterm and early term deliveries following antenatal corticosteroid exposure. American Journal of Obstetrics and Gynecology2019;220(1):S365-6. PalatnikA , RouseD , StamiloD , McPhersonJ , GrobmanW . The association between cerebral palsy or death and umbilical cord magnesium concentration. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S302. RobbinsLS , BlanchardCT , BiasiniFJ , PowellMF , CaseyBM , TitaAT , et al. General anesthesia for cesarean delivery and childhood neurodevelopmental and perinatal outcomes: a secondary analysis of a randomized controlled trial. International Journal of Obstetric Anesthesia2020;45:34-40. RobbinsLS , BlanchardCT , SinkeyRG , HarrisSL , TitaAT , HarperLM . Prenatal tobacco exposure and childhood neurodevelopment among infants born prematurely. American Journal of Perinatology2020;38(3):218-23. RobertsR , Ankumah N-A, ViteriO , Mendez-FigueroaH , ChauhanS , SibaiB . Significance of the absence of amniotic fluid from the cervical os with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S223. RouseD , HirtzD , ThomE , VarnerM , AlexanderJ , SpongC , et al. Magnesium sulfate for the prevention of cerebral palsy. New England Journal of Medicine2008;359:895-905. RouseD . A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. American Journal of Obstetrics and Gynecology2007;197(6):S2. RouseD . Magnesium sulfate (MGSO4) dose and timing, umbilical cord MG++ concentration: relationship to cerebral palsy. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S46. SagaramD , HaarEV , MillerR , Gyamfi-BannermanC . Birth order does not offer a neurologic advantage in twin pregnancy. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S427. SiegelAM , HeineRP , Dotters-KatzSK . The effect of non-penicillin antibiotic regimens on neonatal outcomes in preterm prelabor rupture of membranes. American Journal of Obstetrics and Gynecology2018;219(6):637. SonM , GrobmanWA , MillerES . Is mode of delivery associated with the risk of necrotizing enterocolitis?American Journal of Obstetrics and Gynecology2016;214(1 Suppl 1):S204-5. TuritzAL , TooGT , Gyamfi-BannermanC . Proximity of magnesium exposure to delivery and neonatal outcomes. American Journal of Obstetrics and Gynecology2016;215(4):508.e1-6. TwicklerD , McIntireD , AlexanderJ , LevenoK . Effects of magnesium sulfate on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S112. TwicklerDM , McIntireDD , AlexanderJM , LevenoKJ . Effects of magnesium sulfate on preterm fetal cerebral blood flow using Doppler analysis: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):21-5. Vander HaarE , GoldbergerA , Gyamfi-BannermanC . Mild intraventricular hemorrhage is not associated with low bayley scores at age 2. Reproductive Sciences2017;24(1 Suppl 1):83A. VilchezG , DaiJ , KumarK , MundyD , KontopoulosE , SokolRJ . Racial/ethnic disparities in magnesium sulfate neuroprotection: a subgroup analysis of a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(17):2304-11. VilchezG , DaiJ , LagosM , SokolRJ . Maternal side effects &amp; fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(2):178-83. WoodAM , PostAL , SwamyGK , GrotegutCA . Neonatal outcomes associated with noncephalic presentation at delivery in preterm birth. American Journal of Perinatology2018;35(12):1131-7. YadavaS , GarabedianM , SitA , El-SayedY . Use of magnesium sulfate and labor outcomes in PPROM at less than 37 weeks. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S203. YangM , VarnerMW , YoderB . Cord blood magnesium levels and nonneurologic outcomes in neonates less than 27 weeks gestational age. Journal of Investigative Medicine2019;67(1):86-7. ">Rouse 2008</a> were reported to be double‐blind, with <a href="./references#CD004661-bbs2-0005" title="BrookfieldKF , O'MalleyK , Yeaton-MasseyA , ButwickAJ . Does magnesium sulfate exposure attenuate the effect of steroids administered for fetal lung maturation? In: Society for Obstetric Anesthesia and Perinatology (SOAP) 48th Annual Meeting; 2016 May 18-22; Boston USA. 2016:SA-32. BuhimschiCS , JablonskiKA , RouseDJ , VarnerMW , ReddyUM , MercerBM , et al. Cord blood haptoglobin, cerebral palsy and death in infants of women at risk for preterm birth: a secondary analysis of a randomised controlled trial. Eclinicalmedicine2019;9:11-8. CostantineMM , WeinerSJ , RouseDJ , HirtzDG , VarnerMW , SpongCY , et al. Umbilical cord blood biomarkers of neurologic injury and the risk of cerebral palsy or infant death. International Journal of Developmental Neuroscience2011;29(8):917-22. CostantineMM . Cord blood biomarkers and the risk of cerebral palsy or death. Reproductive Sciences2010;17(3 Suppl 1):65A. DeihlTE , SimhanHN . Antenatal magnesium sulfate and ponderal index from birth to age 2 in preterm male and female infants. Reproductive Sciences2017;24(Suppl 1):130A. DeihlTE , SimhanHN . Antenatal magnesium sulfate exposure and ponderal index in preterm infants. American Journal of Perinatology2019;36(3):329-34. DenobleAE , WuJ , MitchellCJ , HughesBL , Dotters-KatzSK . Chorioamnionitis versus intraamniotic infection among preterm deliveries-is postpartum infectious morbidity different?American Journal of Obstetrics and Gynecology MFM2020;2(3):100176. DrassinowerD , FriedmanAM , LevinH , ObicanSG , Gyamfi-BannermanC . Does magnesium exposure affect neonatal resuscitation? Presented as a poster at the 35th annual meeting of the society for maternal-fetal medicine, San Diego, CA, Feb. 2-7, 2015. American Journal of Obstetrics and Gynecology2015;213(3):424e1-5. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm prelabour rupture of membranes and neurodevelopmental outcomes: a secondary analysis. BJOG: an international journal of obstetrics and gynaecology2016;123(10):1629-35. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of cerebral palsy. Journal of Maternal-Fetal &amp; Neonatal Medicine2016;29(17):2748-52. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of neonatal sepsis. American Journal of Obstetrics and Gynecology2016;214(6):743.e1-6. DrassinowerD , LevinH , ObicanS , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on cerebral palsy. American Journal of Obstetrics and Gynecology2015;212(1):S310-1. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . Immediate neonatal outcomes in infants exposed to magnesium sulfate at the time of delivery. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S90. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1):S161-2. EdwardsJ , EdwardsL , SwamyG , GrotegutC . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S215-6. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Effect of cord blood magnesium level at birth on non-neurologic neonatal outcomes. American Journal of Perinatology2019;36(1):3-7. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. Journal of Maternal-Fetal &amp; Neonatal Medicine2018;31(9):1156-60. FaucettAM , MetzTD , DeWittPE , GibbsRS . Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2016;214(2):287.e1-5. HaarEV , Gyamfi-BannermanC , Coletta-LucasJ . Sepsis but not chorioamnionitis is associated with cerebral palsy. Reproductive Sciences2015;22:372A. HaarEV , Gyamfi-BannermanC , RandisTM . Abnormal brain imaging in infants exposed to chorioamnionitis and sepsis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl. 1):S11-2. HaarEV , LucasJC , D'AltonM , Gyamfi-BannermanC . The effect of chorioamnionitis on neurocognitive development at age 2. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S139-40. HerreraC , SilverRM , MajorH , VarnerMW , ClarkEAS . Triple I criteria and adverse neonatal and childhood outcomes after early preterm birth. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S250. HirtzDG , WeinerSJ , BulasD , DiPietroM , SeibertJ , RouseDJ , et al. Antenatal magnesium and cerebral palsy in preterm infants. Journal of Pediatrics2015;167(4):834-9.e3. HirtzDG . Effect of prenatal MgSO4 on head ultrasound imaging in preterm infants. Annals of Neurology2011;70(Suppl 15):S110. HortonA . The effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S209. HortonL , YingleiL , RouseJ , SpongY , LevenoJ , VarnerW , et al. Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Perinatology2015;32(4):387-92. JohnsonLH , MappDC , RouseDJ , SpongCY , MercerBM , LevenoKJ , et al. Association of cord blood magnesium concentration and neonatal resuscitation. Journal of Pediatrics2012;160(4):573-7.e1. KachikisA , WalkerC , McAdamsR , WaldorfKA , Gyamfi-BannermanC . Influence of preterm premature rupture of membranes on neonatal respiratory complications. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S215. KachikisA , WalkerCL , McAdamsRM , Gyamfi-BannermanC , Adams WaldorfKM . Phenotypic overlap in neonatal respiratory morbidity following preterm premature rupture of membranes versus spontaneous preterm labor. Journal of Maternal-fetal &amp; Neonatal Medicine2021;34(12):1941-8. KamyarM , ClarkEA , YoderBA , VarnerMW , ManuckTA . Antenatal magnesium sulfate, necrotizing enterocolitis, and death among neonates &lt; 28 weeks gestation. AJP Reports2016;6(1):e148-54. KamyarM , ClarkEAS , VarnerMW , ManuckTA . Chorioamnionitis prevents protective effect of magnesium sulfate in the preterm infant. Reproductive Sciences2014;21(3 Suppl 1):78A. KamyarM , ManuckTA , StoddardGJ , VarnerMW , ClarkEAS . Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. BJOG: an international journal of obstetrics and gynaecology2016;123(7):1161-6. KamyarM , VarnerM , ClarkE . Magnesium sulfate neuroprophylaxis and the effect of infant sex. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S144. ManuckA , ShengX , YoderA , VarnerW . Correlation between initial neonatal and early childhood outcomes following preterm birth. American Journal of Obstetrics &amp; Gynecology2014;210(5):426.e1-9. ManuckT , ShengX , YoderB , VarnerM . Correlation between initial neonatal and early childhood outcomes among children delivered &lt;34 weeks gestation. American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S23. ManuckT , VarnerM . Is bigger better? Neonatal and childhood outcomes of large for gestational age (LGA) infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341-2. ManuckT , VarnerM . Neonatal and childhood outcomes following early vs later preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S340-1. ManuckT , VarnerM . Neonatal and childhood outcomes of small for gestational age infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341. ManuckTA , VarnerMW . Neonatal and early childhood outcomes following early vs later preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2014;211(3):308.e1-6. MarrsC , Mendez-FigueroaH , ChauhanS . Periventricular leukomalacia with PPROM: Obstetric antecedents and infants' outcomes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S85. MarrsCC , Mendez-FigueroaH , HammadIA , ChauhanSP . Differential morbidity in preterm small versus appropriate for gestational age: perhaps unverifiable. American Journal of Perinatology2015;32(13):1251-6. McPhersonJ , SmileyS , StamiloD . Magnesium sulfate neuroprotection and obesity: Is efficacy affected by obesity. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S218. McPhersonJA , RouseDJ , GrobmanWA , PalatnikA , StamilioDM . Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. Obstetrics and Gynecology2014;124(4):749-55. McPhersonJA , SmileyS , StamilioDM . Maternal obesity and neuroprotective magnesium sulfate. American Journal of Obstetrics and Gynecology2015;213(4):582.e1–6. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate &lt; 12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S252. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate for &gt;12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S104-5. Mendez-FigueroaH , ChauhanSP , PedrozaC , RefuerzoJS , DahlkeJD , RouseDJ . Preterm cesarean delivery for nonreassuring fetal heart rate: neonatal and neurologic morbidity. Obstetrics and Gynecology2015;125(3):636-42. Mendez-FigueroaH , DahlkeJD , ViteriOA , ChauhanSP , RouseDJ , SibaiBM , et al. Neonatal and infant outcomes in twin gestations with preterm premature rupture of membranes at 24-31 weeks of gestation. Obstetrics and Gynecology2014;124(2 Pt 1):323-31. MoussaH , Hosseini NasabS , FournieD , OntiverosA , AlkawasR , ChauhanS , et al. The impact of time of delivery on gestations complicated by preterm premature rupture of membranes: daytime versus nighttime. Journal of Maternal-Fetal &amp; Neonatal Medicine2019;32(20):3319-24. NCT00014989. Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) [Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)]. clinicaltrials.gov/show/NCT00014989 (first received 18 April 2001). NussEE , SpiegelmanJ , TuritzAL , Gyamfi-BannermanC . Childhood neurodevelopment after spontaneous versus indicated preterm birth. American Journal of Obstetrics and Gynecology MFM2020;2(2):100082. ObicanS , DrassinowerD , LevinH , Gyamfi-BannermanC . Mode of delivery at periviability and early childhood neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S124. OvertonE , BaptisteC , Gyamfi-BannermanC . 546: neurodevelopmental outcomes in late preterm and early term deliveries following antenatal corticosteroid exposure. American Journal of Obstetrics and Gynecology2019;220(1):S365-6. PalatnikA , RouseD , StamiloD , McPhersonJ , GrobmanW . The association between cerebral palsy or death and umbilical cord magnesium concentration. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S302. RobbinsLS , BlanchardCT , BiasiniFJ , PowellMF , CaseyBM , TitaAT , et al. General anesthesia for cesarean delivery and childhood neurodevelopmental and perinatal outcomes: a secondary analysis of a randomized controlled trial. International Journal of Obstetric Anesthesia2020;45:34-40. RobbinsLS , BlanchardCT , SinkeyRG , HarrisSL , TitaAT , HarperLM . Prenatal tobacco exposure and childhood neurodevelopment among infants born prematurely. American Journal of Perinatology2020;38(3):218-23. RobertsR , Ankumah N-A, ViteriO , Mendez-FigueroaH , ChauhanS , SibaiB . Significance of the absence of amniotic fluid from the cervical os with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S223. RouseD , HirtzD , ThomE , VarnerM , AlexanderJ , SpongC , et al. Magnesium sulfate for the prevention of cerebral palsy. New England Journal of Medicine2008;359:895-905. RouseD . A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. American Journal of Obstetrics and Gynecology2007;197(6):S2. RouseD . Magnesium sulfate (MGSO4) dose and timing, umbilical cord MG++ concentration: relationship to cerebral palsy. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S46. SagaramD , HaarEV , MillerR , Gyamfi-BannermanC . Birth order does not offer a neurologic advantage in twin pregnancy. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S427. SiegelAM , HeineRP , Dotters-KatzSK . The effect of non-penicillin antibiotic regimens on neonatal outcomes in preterm prelabor rupture of membranes. American Journal of Obstetrics and Gynecology2018;219(6):637. SonM , GrobmanWA , MillerES . Is mode of delivery associated with the risk of necrotizing enterocolitis?American Journal of Obstetrics and Gynecology2016;214(1 Suppl 1):S204-5. TuritzAL , TooGT , Gyamfi-BannermanC . Proximity of magnesium exposure to delivery and neonatal outcomes. American Journal of Obstetrics and Gynecology2016;215(4):508.e1-6. TwicklerD , McIntireD , AlexanderJ , LevenoK . Effects of magnesium sulfate on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S112. TwicklerDM , McIntireDD , AlexanderJM , LevenoKJ . Effects of magnesium sulfate on preterm fetal cerebral blood flow using Doppler analysis: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):21-5. Vander HaarE , GoldbergerA , Gyamfi-BannermanC . Mild intraventricular hemorrhage is not associated with low bayley scores at age 2. Reproductive Sciences2017;24(1 Suppl 1):83A. VilchezG , DaiJ , KumarK , MundyD , KontopoulosE , SokolRJ . Racial/ethnic disparities in magnesium sulfate neuroprotection: a subgroup analysis of a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(17):2304-11. VilchezG , DaiJ , LagosM , SokolRJ . Maternal side effects &amp; fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(2):178-83. WoodAM , PostAL , SwamyGK , GrotegutCA . Neonatal outcomes associated with noncephalic presentation at delivery in preterm birth. American Journal of Perinatology2018;35(12):1131-7. YadavaS , GarabedianM , SitA , El-SayedY . Use of magnesium sulfate and labor outcomes in PPROM at less than 37 weeks. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S203. YangM , VarnerMW , YoderB . Cord blood magnesium levels and nonneurologic outcomes in neonates less than 27 weeks gestational age. Journal of Investigative Medicine2019;67(1):86-7. ">Rouse 2008</a> specifying use of an identical‐appearing placebo. One RCT described incomplete blinding, as there was no attempt to blind anaesthetists/obstetricians to enable immediate treatment of side effects if necessary, and given characteristic maternal flushing from magnesium sulphate (<a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a>). We considered that the review outcomes were not likely to be influenced by this lack of blinding. </p> <p>We judged all RCTs to be at low risk of detection bias due to blinding of outcome assessment. Outcome assessors/investigators were reported to be blinded to treatment group allocation (<a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a>; <a href="./references#CD004661-bbs2-0002" title="ACTRN12611000491965. MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: neuroprotection trial [Does antenatal magnesium sulphate given to women at risk of imminent preterm birth (defined as planned or definitely expected in the next 24 hours) between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children at 2 years corrected age? - a randomised controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000491965 (first received 11 May 2011). CrowtherCA , AshwoodP , MiddletonPF , McPheeA , TranT , HardineJE , et al. Prenatal intravenous magnesium at 30-34 weeks’ gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial. JAMA2023;330(7):603-14. CrowtherCA , MiddletonPF , WilkinsonD , AshwoodP , HaslamR . Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) - study protocol. BMC Pregnancy and Childbirth2013;13(1):91. PoppeT , ThompsonB , BoardmanJP , BastinME , AlsweilerJ , DeibG , et al. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: the MagNUM Study. EBioMedicine2022;78:103923. ">Crowther 2023</a>; <a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a>; <a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a>; <a href="./references#CD004661-bbs2-0005" title="BrookfieldKF , O'MalleyK , Yeaton-MasseyA , ButwickAJ . Does magnesium sulfate exposure attenuate the effect of steroids administered for fetal lung maturation? In: Society for Obstetric Anesthesia and Perinatology (SOAP) 48th Annual Meeting; 2016 May 18-22; Boston USA. 2016:SA-32. BuhimschiCS , JablonskiKA , RouseDJ , VarnerMW , ReddyUM , MercerBM , et al. Cord blood haptoglobin, cerebral palsy and death in infants of women at risk for preterm birth: a secondary analysis of a randomised controlled trial. Eclinicalmedicine2019;9:11-8. CostantineMM , WeinerSJ , RouseDJ , HirtzDG , VarnerMW , SpongCY , et al. Umbilical cord blood biomarkers of neurologic injury and the risk of cerebral palsy or infant death. International Journal of Developmental Neuroscience2011;29(8):917-22. CostantineMM . Cord blood biomarkers and the risk of cerebral palsy or death. Reproductive Sciences2010;17(3 Suppl 1):65A. DeihlTE , SimhanHN . Antenatal magnesium sulfate and ponderal index from birth to age 2 in preterm male and female infants. Reproductive Sciences2017;24(Suppl 1):130A. DeihlTE , SimhanHN . Antenatal magnesium sulfate exposure and ponderal index in preterm infants. American Journal of Perinatology2019;36(3):329-34. DenobleAE , WuJ , MitchellCJ , HughesBL , Dotters-KatzSK . Chorioamnionitis versus intraamniotic infection among preterm deliveries-is postpartum infectious morbidity different?American Journal of Obstetrics and Gynecology MFM2020;2(3):100176. DrassinowerD , FriedmanAM , LevinH , ObicanSG , Gyamfi-BannermanC . Does magnesium exposure affect neonatal resuscitation? Presented as a poster at the 35th annual meeting of the society for maternal-fetal medicine, San Diego, CA, Feb. 2-7, 2015. American Journal of Obstetrics and Gynecology2015;213(3):424e1-5. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm prelabour rupture of membranes and neurodevelopmental outcomes: a secondary analysis. BJOG: an international journal of obstetrics and gynaecology2016;123(10):1629-35. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of cerebral palsy. Journal of Maternal-Fetal &amp; Neonatal Medicine2016;29(17):2748-52. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of neonatal sepsis. American Journal of Obstetrics and Gynecology2016;214(6):743.e1-6. DrassinowerD , LevinH , ObicanS , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on cerebral palsy. American Journal of Obstetrics and Gynecology2015;212(1):S310-1. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . Immediate neonatal outcomes in infants exposed to magnesium sulfate at the time of delivery. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S90. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1):S161-2. EdwardsJ , EdwardsL , SwamyG , GrotegutC . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S215-6. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Effect of cord blood magnesium level at birth on non-neurologic neonatal outcomes. American Journal of Perinatology2019;36(1):3-7. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. Journal of Maternal-Fetal &amp; Neonatal Medicine2018;31(9):1156-60. FaucettAM , MetzTD , DeWittPE , GibbsRS . Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2016;214(2):287.e1-5. HaarEV , Gyamfi-BannermanC , Coletta-LucasJ . Sepsis but not chorioamnionitis is associated with cerebral palsy. Reproductive Sciences2015;22:372A. HaarEV , Gyamfi-BannermanC , RandisTM . Abnormal brain imaging in infants exposed to chorioamnionitis and sepsis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl. 1):S11-2. HaarEV , LucasJC , D'AltonM , Gyamfi-BannermanC . The effect of chorioamnionitis on neurocognitive development at age 2. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S139-40. HerreraC , SilverRM , MajorH , VarnerMW , ClarkEAS . Triple I criteria and adverse neonatal and childhood outcomes after early preterm birth. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S250. HirtzDG , WeinerSJ , BulasD , DiPietroM , SeibertJ , RouseDJ , et al. Antenatal magnesium and cerebral palsy in preterm infants. Journal of Pediatrics2015;167(4):834-9.e3. HirtzDG . Effect of prenatal MgSO4 on head ultrasound imaging in preterm infants. Annals of Neurology2011;70(Suppl 15):S110. HortonA . The effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S209. HortonL , YingleiL , RouseJ , SpongY , LevenoJ , VarnerW , et al. Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Perinatology2015;32(4):387-92. JohnsonLH , MappDC , RouseDJ , SpongCY , MercerBM , LevenoKJ , et al. Association of cord blood magnesium concentration and neonatal resuscitation. Journal of Pediatrics2012;160(4):573-7.e1. KachikisA , WalkerC , McAdamsR , WaldorfKA , Gyamfi-BannermanC . Influence of preterm premature rupture of membranes on neonatal respiratory complications. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S215. KachikisA , WalkerCL , McAdamsRM , Gyamfi-BannermanC , Adams WaldorfKM . Phenotypic overlap in neonatal respiratory morbidity following preterm premature rupture of membranes versus spontaneous preterm labor. Journal of Maternal-fetal &amp; Neonatal Medicine2021;34(12):1941-8. KamyarM , ClarkEA , YoderBA , VarnerMW , ManuckTA . Antenatal magnesium sulfate, necrotizing enterocolitis, and death among neonates &lt; 28 weeks gestation. AJP Reports2016;6(1):e148-54. KamyarM , ClarkEAS , VarnerMW , ManuckTA . Chorioamnionitis prevents protective effect of magnesium sulfate in the preterm infant. Reproductive Sciences2014;21(3 Suppl 1):78A. KamyarM , ManuckTA , StoddardGJ , VarnerMW , ClarkEAS . Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. BJOG: an international journal of obstetrics and gynaecology2016;123(7):1161-6. KamyarM , VarnerM , ClarkE . Magnesium sulfate neuroprophylaxis and the effect of infant sex. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S144. ManuckA , ShengX , YoderA , VarnerW . Correlation between initial neonatal and early childhood outcomes following preterm birth. American Journal of Obstetrics &amp; Gynecology2014;210(5):426.e1-9. ManuckT , ShengX , YoderB , VarnerM . Correlation between initial neonatal and early childhood outcomes among children delivered &lt;34 weeks gestation. American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S23. ManuckT , VarnerM . Is bigger better? Neonatal and childhood outcomes of large for gestational age (LGA) infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341-2. ManuckT , VarnerM . Neonatal and childhood outcomes following early vs later preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S340-1. ManuckT , VarnerM . Neonatal and childhood outcomes of small for gestational age infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341. ManuckTA , VarnerMW . Neonatal and early childhood outcomes following early vs later preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2014;211(3):308.e1-6. MarrsC , Mendez-FigueroaH , ChauhanS . Periventricular leukomalacia with PPROM: Obstetric antecedents and infants' outcomes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S85. MarrsCC , Mendez-FigueroaH , HammadIA , ChauhanSP . Differential morbidity in preterm small versus appropriate for gestational age: perhaps unverifiable. American Journal of Perinatology2015;32(13):1251-6. McPhersonJ , SmileyS , StamiloD . Magnesium sulfate neuroprotection and obesity: Is efficacy affected by obesity. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S218. McPhersonJA , RouseDJ , GrobmanWA , PalatnikA , StamilioDM . Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. Obstetrics and Gynecology2014;124(4):749-55. McPhersonJA , SmileyS , StamilioDM . Maternal obesity and neuroprotective magnesium sulfate. American Journal of Obstetrics and Gynecology2015;213(4):582.e1–6. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate &lt; 12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S252. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate for &gt;12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S104-5. Mendez-FigueroaH , ChauhanSP , PedrozaC , RefuerzoJS , DahlkeJD , RouseDJ . Preterm cesarean delivery for nonreassuring fetal heart rate: neonatal and neurologic morbidity. Obstetrics and Gynecology2015;125(3):636-42. Mendez-FigueroaH , DahlkeJD , ViteriOA , ChauhanSP , RouseDJ , SibaiBM , et al. Neonatal and infant outcomes in twin gestations with preterm premature rupture of membranes at 24-31 weeks of gestation. Obstetrics and Gynecology2014;124(2 Pt 1):323-31. MoussaH , Hosseini NasabS , FournieD , OntiverosA , AlkawasR , ChauhanS , et al. The impact of time of delivery on gestations complicated by preterm premature rupture of membranes: daytime versus nighttime. Journal of Maternal-Fetal &amp; Neonatal Medicine2019;32(20):3319-24. NCT00014989. Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) [Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)]. clinicaltrials.gov/show/NCT00014989 (first received 18 April 2001). NussEE , SpiegelmanJ , TuritzAL , Gyamfi-BannermanC . Childhood neurodevelopment after spontaneous versus indicated preterm birth. American Journal of Obstetrics and Gynecology MFM2020;2(2):100082. ObicanS , DrassinowerD , LevinH , Gyamfi-BannermanC . Mode of delivery at periviability and early childhood neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S124. OvertonE , BaptisteC , Gyamfi-BannermanC . 546: neurodevelopmental outcomes in late preterm and early term deliveries following antenatal corticosteroid exposure. American Journal of Obstetrics and Gynecology2019;220(1):S365-6. PalatnikA , RouseD , StamiloD , McPhersonJ , GrobmanW . The association between cerebral palsy or death and umbilical cord magnesium concentration. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S302. RobbinsLS , BlanchardCT , BiasiniFJ , PowellMF , CaseyBM , TitaAT , et al. General anesthesia for cesarean delivery and childhood neurodevelopmental and perinatal outcomes: a secondary analysis of a randomized controlled trial. International Journal of Obstetric Anesthesia2020;45:34-40. RobbinsLS , BlanchardCT , SinkeyRG , HarrisSL , TitaAT , HarperLM . Prenatal tobacco exposure and childhood neurodevelopment among infants born prematurely. American Journal of Perinatology2020;38(3):218-23. RobertsR , Ankumah N-A, ViteriO , Mendez-FigueroaH , ChauhanS , SibaiB . Significance of the absence of amniotic fluid from the cervical os with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S223. RouseD , HirtzD , ThomE , VarnerM , AlexanderJ , SpongC , et al. Magnesium sulfate for the prevention of cerebral palsy. New England Journal of Medicine2008;359:895-905. RouseD . A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. American Journal of Obstetrics and Gynecology2007;197(6):S2. RouseD . Magnesium sulfate (MGSO4) dose and timing, umbilical cord MG++ concentration: relationship to cerebral palsy. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S46. SagaramD , HaarEV , MillerR , Gyamfi-BannermanC . Birth order does not offer a neurologic advantage in twin pregnancy. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S427. SiegelAM , HeineRP , Dotters-KatzSK . The effect of non-penicillin antibiotic regimens on neonatal outcomes in preterm prelabor rupture of membranes. American Journal of Obstetrics and Gynecology2018;219(6):637. SonM , GrobmanWA , MillerES . Is mode of delivery associated with the risk of necrotizing enterocolitis?American Journal of Obstetrics and Gynecology2016;214(1 Suppl 1):S204-5. TuritzAL , TooGT , Gyamfi-BannermanC . Proximity of magnesium exposure to delivery and neonatal outcomes. American Journal of Obstetrics and Gynecology2016;215(4):508.e1-6. TwicklerD , McIntireD , AlexanderJ , LevenoK . Effects of magnesium sulfate on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S112. TwicklerDM , McIntireDD , AlexanderJM , LevenoKJ . Effects of magnesium sulfate on preterm fetal cerebral blood flow using Doppler analysis: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):21-5. Vander HaarE , GoldbergerA , Gyamfi-BannermanC . Mild intraventricular hemorrhage is not associated with low bayley scores at age 2. Reproductive Sciences2017;24(1 Suppl 1):83A. VilchezG , DaiJ , KumarK , MundyD , KontopoulosE , SokolRJ . Racial/ethnic disparities in magnesium sulfate neuroprotection: a subgroup analysis of a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(17):2304-11. VilchezG , DaiJ , LagosM , SokolRJ . Maternal side effects &amp; fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(2):178-83. WoodAM , PostAL , SwamyGK , GrotegutCA . Neonatal outcomes associated with noncephalic presentation at delivery in preterm birth. American Journal of Perinatology2018;35(12):1131-7. YadavaS , GarabedianM , SitA , El-SayedY . Use of magnesium sulfate and labor outcomes in PPROM at less than 37 weeks. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S203. YangM , VarnerMW , YoderB . Cord blood magnesium levels and nonneurologic outcomes in neonates less than 27 weeks gestational age. Journal of Investigative Medicine2019;67(1):86-7. ">Rouse 2008</a>; <a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a>). <a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a> specified blinding of technicians and researchers processing biologic specimens, and the developmentalist; while they did not specify blinding of paediatric radiologists conducting cranial ultrasounds, we deemed that blinding was likely. The school age follow‐up of <a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a> did not specify blinding of outcome assessors; however, we judged the risk of bias to be low. </p> </section> <section id="CD004661-sec-0088"> <h4 class="title">Incomplete outcome data</h4> <p>We judged four RCTs as at low risk of attrition bias as there was minimal loss to follow‐up in the main RCT and initial follow‐up (and/or the loss to follow‐up was considered unlikely to impact the findings) (<a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a>; <a href="./references#CD004661-bbs2-0002" title="ACTRN12611000491965. MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: neuroprotection trial [Does antenatal magnesium sulphate given to women at risk of imminent preterm birth (defined as planned or definitely expected in the next 24 hours) between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children at 2 years corrected age? - a randomised controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000491965 (first received 11 May 2011). CrowtherCA , AshwoodP , MiddletonPF , McPheeA , TranT , HardineJE , et al. Prenatal intravenous magnesium at 30-34 weeks’ gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial. JAMA2023;330(7):603-14. CrowtherCA , MiddletonPF , WilkinsonD , AshwoodP , HaslamR . Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) - study protocol. BMC Pregnancy and Childbirth2013;13(1):91. PoppeT , ThompsonB , BoardmanJP , BastinME , AlsweilerJ , DeibG , et al. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: the MagNUM Study. EBioMedicine2022;78:103923. ">Crowther 2023</a>; <a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a>; <a href="./references#CD004661-bbs2-0005" title="BrookfieldKF , O'MalleyK , Yeaton-MasseyA , ButwickAJ . Does magnesium sulfate exposure attenuate the effect of steroids administered for fetal lung maturation? In: Society for Obstetric Anesthesia and Perinatology (SOAP) 48th Annual Meeting; 2016 May 18-22; Boston USA. 2016:SA-32. BuhimschiCS , JablonskiKA , RouseDJ , VarnerMW , ReddyUM , MercerBM , et al. Cord blood haptoglobin, cerebral palsy and death in infants of women at risk for preterm birth: a secondary analysis of a randomised controlled trial. Eclinicalmedicine2019;9:11-8. CostantineMM , WeinerSJ , RouseDJ , HirtzDG , VarnerMW , SpongCY , et al. Umbilical cord blood biomarkers of neurologic injury and the risk of cerebral palsy or infant death. International Journal of Developmental Neuroscience2011;29(8):917-22. CostantineMM . Cord blood biomarkers and the risk of cerebral palsy or death. Reproductive Sciences2010;17(3 Suppl 1):65A. DeihlTE , SimhanHN . Antenatal magnesium sulfate and ponderal index from birth to age 2 in preterm male and female infants. Reproductive Sciences2017;24(Suppl 1):130A. DeihlTE , SimhanHN . Antenatal magnesium sulfate exposure and ponderal index in preterm infants. American Journal of Perinatology2019;36(3):329-34. DenobleAE , WuJ , MitchellCJ , HughesBL , Dotters-KatzSK . Chorioamnionitis versus intraamniotic infection among preterm deliveries-is postpartum infectious morbidity different?American Journal of Obstetrics and Gynecology MFM2020;2(3):100176. DrassinowerD , FriedmanAM , LevinH , ObicanSG , Gyamfi-BannermanC . Does magnesium exposure affect neonatal resuscitation? Presented as a poster at the 35th annual meeting of the society for maternal-fetal medicine, San Diego, CA, Feb. 2-7, 2015. American Journal of Obstetrics and Gynecology2015;213(3):424e1-5. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm prelabour rupture of membranes and neurodevelopmental outcomes: a secondary analysis. BJOG: an international journal of obstetrics and gynaecology2016;123(10):1629-35. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of cerebral palsy. Journal of Maternal-Fetal &amp; Neonatal Medicine2016;29(17):2748-52. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of neonatal sepsis. American Journal of Obstetrics and Gynecology2016;214(6):743.e1-6. DrassinowerD , LevinH , ObicanS , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on cerebral palsy. American Journal of Obstetrics and Gynecology2015;212(1):S310-1. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . Immediate neonatal outcomes in infants exposed to magnesium sulfate at the time of delivery. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S90. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1):S161-2. EdwardsJ , EdwardsL , SwamyG , GrotegutC . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S215-6. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Effect of cord blood magnesium level at birth on non-neurologic neonatal outcomes. American Journal of Perinatology2019;36(1):3-7. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. Journal of Maternal-Fetal &amp; Neonatal Medicine2018;31(9):1156-60. FaucettAM , MetzTD , DeWittPE , GibbsRS . Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2016;214(2):287.e1-5. HaarEV , Gyamfi-BannermanC , Coletta-LucasJ . Sepsis but not chorioamnionitis is associated with cerebral palsy. Reproductive Sciences2015;22:372A. HaarEV , Gyamfi-BannermanC , RandisTM . Abnormal brain imaging in infants exposed to chorioamnionitis and sepsis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl. 1):S11-2. HaarEV , LucasJC , D'AltonM , Gyamfi-BannermanC . The effect of chorioamnionitis on neurocognitive development at age 2. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S139-40. HerreraC , SilverRM , MajorH , VarnerMW , ClarkEAS . Triple I criteria and adverse neonatal and childhood outcomes after early preterm birth. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S250. HirtzDG , WeinerSJ , BulasD , DiPietroM , SeibertJ , RouseDJ , et al. Antenatal magnesium and cerebral palsy in preterm infants. Journal of Pediatrics2015;167(4):834-9.e3. HirtzDG . Effect of prenatal MgSO4 on head ultrasound imaging in preterm infants. Annals of Neurology2011;70(Suppl 15):S110. HortonA . The effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S209. HortonL , YingleiL , RouseJ , SpongY , LevenoJ , VarnerW , et al. Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Perinatology2015;32(4):387-92. JohnsonLH , MappDC , RouseDJ , SpongCY , MercerBM , LevenoKJ , et al. Association of cord blood magnesium concentration and neonatal resuscitation. Journal of Pediatrics2012;160(4):573-7.e1. KachikisA , WalkerC , McAdamsR , WaldorfKA , Gyamfi-BannermanC . Influence of preterm premature rupture of membranes on neonatal respiratory complications. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S215. KachikisA , WalkerCL , McAdamsRM , Gyamfi-BannermanC , Adams WaldorfKM . Phenotypic overlap in neonatal respiratory morbidity following preterm premature rupture of membranes versus spontaneous preterm labor. Journal of Maternal-fetal &amp; Neonatal Medicine2021;34(12):1941-8. KamyarM , ClarkEA , YoderBA , VarnerMW , ManuckTA . Antenatal magnesium sulfate, necrotizing enterocolitis, and death among neonates &lt; 28 weeks gestation. AJP Reports2016;6(1):e148-54. KamyarM , ClarkEAS , VarnerMW , ManuckTA . Chorioamnionitis prevents protective effect of magnesium sulfate in the preterm infant. Reproductive Sciences2014;21(3 Suppl 1):78A. KamyarM , ManuckTA , StoddardGJ , VarnerMW , ClarkEAS . Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. BJOG: an international journal of obstetrics and gynaecology2016;123(7):1161-6. KamyarM , VarnerM , ClarkE . Magnesium sulfate neuroprophylaxis and the effect of infant sex. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S144. ManuckA , ShengX , YoderA , VarnerW . Correlation between initial neonatal and early childhood outcomes following preterm birth. American Journal of Obstetrics &amp; Gynecology2014;210(5):426.e1-9. ManuckT , ShengX , YoderB , VarnerM . Correlation between initial neonatal and early childhood outcomes among children delivered &lt;34 weeks gestation. American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S23. ManuckT , VarnerM . Is bigger better? Neonatal and childhood outcomes of large for gestational age (LGA) infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341-2. ManuckT , VarnerM . Neonatal and childhood outcomes following early vs later preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S340-1. ManuckT , VarnerM . Neonatal and childhood outcomes of small for gestational age infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341. ManuckTA , VarnerMW . Neonatal and early childhood outcomes following early vs later preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2014;211(3):308.e1-6. MarrsC , Mendez-FigueroaH , ChauhanS . Periventricular leukomalacia with PPROM: Obstetric antecedents and infants' outcomes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S85. MarrsCC , Mendez-FigueroaH , HammadIA , ChauhanSP . Differential morbidity in preterm small versus appropriate for gestational age: perhaps unverifiable. American Journal of Perinatology2015;32(13):1251-6. McPhersonJ , SmileyS , StamiloD . Magnesium sulfate neuroprotection and obesity: Is efficacy affected by obesity. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S218. McPhersonJA , RouseDJ , GrobmanWA , PalatnikA , StamilioDM . Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. Obstetrics and Gynecology2014;124(4):749-55. McPhersonJA , SmileyS , StamilioDM . Maternal obesity and neuroprotective magnesium sulfate. American Journal of Obstetrics and Gynecology2015;213(4):582.e1–6. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate &lt; 12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S252. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate for &gt;12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S104-5. Mendez-FigueroaH , ChauhanSP , PedrozaC , RefuerzoJS , DahlkeJD , RouseDJ . Preterm cesarean delivery for nonreassuring fetal heart rate: neonatal and neurologic morbidity. Obstetrics and Gynecology2015;125(3):636-42. Mendez-FigueroaH , DahlkeJD , ViteriOA , ChauhanSP , RouseDJ , SibaiBM , et al. Neonatal and infant outcomes in twin gestations with preterm premature rupture of membranes at 24-31 weeks of gestation. Obstetrics and Gynecology2014;124(2 Pt 1):323-31. MoussaH , Hosseini NasabS , FournieD , OntiverosA , AlkawasR , ChauhanS , et al. The impact of time of delivery on gestations complicated by preterm premature rupture of membranes: daytime versus nighttime. Journal of Maternal-Fetal &amp; Neonatal Medicine2019;32(20):3319-24. NCT00014989. Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) [Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)]. clinicaltrials.gov/show/NCT00014989 (first received 18 April 2001). NussEE , SpiegelmanJ , TuritzAL , Gyamfi-BannermanC . Childhood neurodevelopment after spontaneous versus indicated preterm birth. American Journal of Obstetrics and Gynecology MFM2020;2(2):100082. ObicanS , DrassinowerD , LevinH , Gyamfi-BannermanC . Mode of delivery at periviability and early childhood neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S124. OvertonE , BaptisteC , Gyamfi-BannermanC . 546: neurodevelopmental outcomes in late preterm and early term deliveries following antenatal corticosteroid exposure. American Journal of Obstetrics and Gynecology2019;220(1):S365-6. PalatnikA , RouseD , StamiloD , McPhersonJ , GrobmanW . The association between cerebral palsy or death and umbilical cord magnesium concentration. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S302. RobbinsLS , BlanchardCT , BiasiniFJ , PowellMF , CaseyBM , TitaAT , et al. General anesthesia for cesarean delivery and childhood neurodevelopmental and perinatal outcomes: a secondary analysis of a randomized controlled trial. International Journal of Obstetric Anesthesia2020;45:34-40. RobbinsLS , BlanchardCT , SinkeyRG , HarrisSL , TitaAT , HarperLM . Prenatal tobacco exposure and childhood neurodevelopment among infants born prematurely. American Journal of Perinatology2020;38(3):218-23. RobertsR , Ankumah N-A, ViteriO , Mendez-FigueroaH , ChauhanS , SibaiB . Significance of the absence of amniotic fluid from the cervical os with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S223. RouseD , HirtzD , ThomE , VarnerM , AlexanderJ , SpongC , et al. Magnesium sulfate for the prevention of cerebral palsy. New England Journal of Medicine2008;359:895-905. RouseD . A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. American Journal of Obstetrics and Gynecology2007;197(6):S2. RouseD . Magnesium sulfate (MGSO4) dose and timing, umbilical cord MG++ concentration: relationship to cerebral palsy. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S46. SagaramD , HaarEV , MillerR , Gyamfi-BannermanC . Birth order does not offer a neurologic advantage in twin pregnancy. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S427. SiegelAM , HeineRP , Dotters-KatzSK . The effect of non-penicillin antibiotic regimens on neonatal outcomes in preterm prelabor rupture of membranes. American Journal of Obstetrics and Gynecology2018;219(6):637. SonM , GrobmanWA , MillerES . Is mode of delivery associated with the risk of necrotizing enterocolitis?American Journal of Obstetrics and Gynecology2016;214(1 Suppl 1):S204-5. TuritzAL , TooGT , Gyamfi-BannermanC . Proximity of magnesium exposure to delivery and neonatal outcomes. American Journal of Obstetrics and Gynecology2016;215(4):508.e1-6. TwicklerD , McIntireD , AlexanderJ , LevenoK . Effects of magnesium sulfate on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S112. TwicklerDM , McIntireDD , AlexanderJM , LevenoKJ . Effects of magnesium sulfate on preterm fetal cerebral blood flow using Doppler analysis: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):21-5. Vander HaarE , GoldbergerA , Gyamfi-BannermanC . Mild intraventricular hemorrhage is not associated with low bayley scores at age 2. Reproductive Sciences2017;24(1 Suppl 1):83A. VilchezG , DaiJ , KumarK , MundyD , KontopoulosE , SokolRJ . Racial/ethnic disparities in magnesium sulfate neuroprotection: a subgroup analysis of a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(17):2304-11. VilchezG , DaiJ , LagosM , SokolRJ . Maternal side effects &amp; fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(2):178-83. WoodAM , PostAL , SwamyGK , GrotegutCA . Neonatal outcomes associated with noncephalic presentation at delivery in preterm birth. American Journal of Perinatology2018;35(12):1131-7. YadavaS , GarabedianM , SitA , El-SayedY . Use of magnesium sulfate and labor outcomes in PPROM at less than 37 weeks. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S203. YangM , VarnerMW , YoderB . Cord blood magnesium levels and nonneurologic outcomes in neonates less than 27 weeks gestational age. Journal of Investigative Medicine2019;67(1):86-7. ">Rouse 2008</a>; <a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a>). However, we judged the risk of bias to be unclear in the associated school age follow‐up of two of these RCTs (<a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a>; <a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a>). In the school age follow‐up of <a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a>, two of the original sites did not participate, leaving 867 of 1060 known survivors available, of which school age outcomes were determined for 669 (77%). <a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a> reported that 185 children (27%) of the original 688 randomised were lost to school age follow‐up (72 children were known to have died before two years). </p> <p>We judged one RCT to be at unclear risk of attrition bias (<a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a>), as there was insufficient reporting of attrition/exclusions to permit a judgement. </p> </section> <section id="CD004661-sec-0089"> <h4 class="title">Selective reporting</h4> <p>We judged four RCTs as at low risk of reporting bias as there was no clear indication of selective reporting (<a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a>; <a href="./references#CD004661-bbs2-0002" title="ACTRN12611000491965. MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: neuroprotection trial [Does antenatal magnesium sulphate given to women at risk of imminent preterm birth (defined as planned or definitely expected in the next 24 hours) between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children at 2 years corrected age? - a randomised controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000491965 (first received 11 May 2011). CrowtherCA , AshwoodP , MiddletonPF , McPheeA , TranT , HardineJE , et al. Prenatal intravenous magnesium at 30-34 weeks’ gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial. JAMA2023;330(7):603-14. CrowtherCA , MiddletonPF , WilkinsonD , AshwoodP , HaslamR . Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) - study protocol. BMC Pregnancy and Childbirth2013;13(1):91. PoppeT , ThompsonB , BoardmanJP , BastinME , AlsweilerJ , DeibG , et al. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: the MagNUM Study. EBioMedicine2022;78:103923. ">Crowther 2023</a>; <a href="./references#CD004661-bbs2-0005" title="BrookfieldKF , O'MalleyK , Yeaton-MasseyA , ButwickAJ . Does magnesium sulfate exposure attenuate the effect of steroids administered for fetal lung maturation? In: Society for Obstetric Anesthesia and Perinatology (SOAP) 48th Annual Meeting; 2016 May 18-22; Boston USA. 2016:SA-32. BuhimschiCS , JablonskiKA , RouseDJ , VarnerMW , ReddyUM , MercerBM , et al. Cord blood haptoglobin, cerebral palsy and death in infants of women at risk for preterm birth: a secondary analysis of a randomised controlled trial. Eclinicalmedicine2019;9:11-8. CostantineMM , WeinerSJ , RouseDJ , HirtzDG , VarnerMW , SpongCY , et al. Umbilical cord blood biomarkers of neurologic injury and the risk of cerebral palsy or infant death. International Journal of Developmental Neuroscience2011;29(8):917-22. CostantineMM . Cord blood biomarkers and the risk of cerebral palsy or death. Reproductive Sciences2010;17(3 Suppl 1):65A. DeihlTE , SimhanHN . Antenatal magnesium sulfate and ponderal index from birth to age 2 in preterm male and female infants. Reproductive Sciences2017;24(Suppl 1):130A. DeihlTE , SimhanHN . Antenatal magnesium sulfate exposure and ponderal index in preterm infants. American Journal of Perinatology2019;36(3):329-34. DenobleAE , WuJ , MitchellCJ , HughesBL , Dotters-KatzSK . Chorioamnionitis versus intraamniotic infection among preterm deliveries-is postpartum infectious morbidity different?American Journal of Obstetrics and Gynecology MFM2020;2(3):100176. DrassinowerD , FriedmanAM , LevinH , ObicanSG , Gyamfi-BannermanC . Does magnesium exposure affect neonatal resuscitation? Presented as a poster at the 35th annual meeting of the society for maternal-fetal medicine, San Diego, CA, Feb. 2-7, 2015. American Journal of Obstetrics and Gynecology2015;213(3):424e1-5. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm prelabour rupture of membranes and neurodevelopmental outcomes: a secondary analysis. BJOG: an international journal of obstetrics and gynaecology2016;123(10):1629-35. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of cerebral palsy. Journal of Maternal-Fetal &amp; Neonatal Medicine2016;29(17):2748-52. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of neonatal sepsis. American Journal of Obstetrics and Gynecology2016;214(6):743.e1-6. DrassinowerD , LevinH , ObicanS , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on cerebral palsy. American Journal of Obstetrics and Gynecology2015;212(1):S310-1. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . Immediate neonatal outcomes in infants exposed to magnesium sulfate at the time of delivery. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S90. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1):S161-2. EdwardsJ , EdwardsL , SwamyG , GrotegutC . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S215-6. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Effect of cord blood magnesium level at birth on non-neurologic neonatal outcomes. American Journal of Perinatology2019;36(1):3-7. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. Journal of Maternal-Fetal &amp; Neonatal Medicine2018;31(9):1156-60. FaucettAM , MetzTD , DeWittPE , GibbsRS . Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2016;214(2):287.e1-5. HaarEV , Gyamfi-BannermanC , Coletta-LucasJ . Sepsis but not chorioamnionitis is associated with cerebral palsy. Reproductive Sciences2015;22:372A. HaarEV , Gyamfi-BannermanC , RandisTM . Abnormal brain imaging in infants exposed to chorioamnionitis and sepsis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl. 1):S11-2. HaarEV , LucasJC , D'AltonM , Gyamfi-BannermanC . The effect of chorioamnionitis on neurocognitive development at age 2. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S139-40. HerreraC , SilverRM , MajorH , VarnerMW , ClarkEAS . Triple I criteria and adverse neonatal and childhood outcomes after early preterm birth. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S250. HirtzDG , WeinerSJ , BulasD , DiPietroM , SeibertJ , RouseDJ , et al. Antenatal magnesium and cerebral palsy in preterm infants. Journal of Pediatrics2015;167(4):834-9.e3. HirtzDG . Effect of prenatal MgSO4 on head ultrasound imaging in preterm infants. Annals of Neurology2011;70(Suppl 15):S110. HortonA . The effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S209. HortonL , YingleiL , RouseJ , SpongY , LevenoJ , VarnerW , et al. Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Perinatology2015;32(4):387-92. JohnsonLH , MappDC , RouseDJ , SpongCY , MercerBM , LevenoKJ , et al. Association of cord blood magnesium concentration and neonatal resuscitation. Journal of Pediatrics2012;160(4):573-7.e1. KachikisA , WalkerC , McAdamsR , WaldorfKA , Gyamfi-BannermanC . Influence of preterm premature rupture of membranes on neonatal respiratory complications. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S215. KachikisA , WalkerCL , McAdamsRM , Gyamfi-BannermanC , Adams WaldorfKM . Phenotypic overlap in neonatal respiratory morbidity following preterm premature rupture of membranes versus spontaneous preterm labor. Journal of Maternal-fetal &amp; Neonatal Medicine2021;34(12):1941-8. KamyarM , ClarkEA , YoderBA , VarnerMW , ManuckTA . Antenatal magnesium sulfate, necrotizing enterocolitis, and death among neonates &lt; 28 weeks gestation. AJP Reports2016;6(1):e148-54. KamyarM , ClarkEAS , VarnerMW , ManuckTA . Chorioamnionitis prevents protective effect of magnesium sulfate in the preterm infant. Reproductive Sciences2014;21(3 Suppl 1):78A. KamyarM , ManuckTA , StoddardGJ , VarnerMW , ClarkEAS . Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. BJOG: an international journal of obstetrics and gynaecology2016;123(7):1161-6. KamyarM , VarnerM , ClarkE . Magnesium sulfate neuroprophylaxis and the effect of infant sex. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S144. ManuckA , ShengX , YoderA , VarnerW . Correlation between initial neonatal and early childhood outcomes following preterm birth. American Journal of Obstetrics &amp; Gynecology2014;210(5):426.e1-9. ManuckT , ShengX , YoderB , VarnerM . Correlation between initial neonatal and early childhood outcomes among children delivered &lt;34 weeks gestation. American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S23. ManuckT , VarnerM . Is bigger better? Neonatal and childhood outcomes of large for gestational age (LGA) infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341-2. ManuckT , VarnerM . Neonatal and childhood outcomes following early vs later preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S340-1. ManuckT , VarnerM . Neonatal and childhood outcomes of small for gestational age infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341. ManuckTA , VarnerMW . Neonatal and early childhood outcomes following early vs later preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2014;211(3):308.e1-6. MarrsC , Mendez-FigueroaH , ChauhanS . Periventricular leukomalacia with PPROM: Obstetric antecedents and infants' outcomes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S85. MarrsCC , Mendez-FigueroaH , HammadIA , ChauhanSP . Differential morbidity in preterm small versus appropriate for gestational age: perhaps unverifiable. American Journal of Perinatology2015;32(13):1251-6. McPhersonJ , SmileyS , StamiloD . Magnesium sulfate neuroprotection and obesity: Is efficacy affected by obesity. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S218. McPhersonJA , RouseDJ , GrobmanWA , PalatnikA , StamilioDM . Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. Obstetrics and Gynecology2014;124(4):749-55. McPhersonJA , SmileyS , StamilioDM . Maternal obesity and neuroprotective magnesium sulfate. American Journal of Obstetrics and Gynecology2015;213(4):582.e1–6. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate &lt; 12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S252. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate for &gt;12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S104-5. Mendez-FigueroaH , ChauhanSP , PedrozaC , RefuerzoJS , DahlkeJD , RouseDJ . Preterm cesarean delivery for nonreassuring fetal heart rate: neonatal and neurologic morbidity. Obstetrics and Gynecology2015;125(3):636-42. Mendez-FigueroaH , DahlkeJD , ViteriOA , ChauhanSP , RouseDJ , SibaiBM , et al. Neonatal and infant outcomes in twin gestations with preterm premature rupture of membranes at 24-31 weeks of gestation. Obstetrics and Gynecology2014;124(2 Pt 1):323-31. MoussaH , Hosseini NasabS , FournieD , OntiverosA , AlkawasR , ChauhanS , et al. The impact of time of delivery on gestations complicated by preterm premature rupture of membranes: daytime versus nighttime. Journal of Maternal-Fetal &amp; Neonatal Medicine2019;32(20):3319-24. NCT00014989. Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) [Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)]. clinicaltrials.gov/show/NCT00014989 (first received 18 April 2001). NussEE , SpiegelmanJ , TuritzAL , Gyamfi-BannermanC . Childhood neurodevelopment after spontaneous versus indicated preterm birth. American Journal of Obstetrics and Gynecology MFM2020;2(2):100082. ObicanS , DrassinowerD , LevinH , Gyamfi-BannermanC . Mode of delivery at periviability and early childhood neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S124. OvertonE , BaptisteC , Gyamfi-BannermanC . 546: neurodevelopmental outcomes in late preterm and early term deliveries following antenatal corticosteroid exposure. American Journal of Obstetrics and Gynecology2019;220(1):S365-6. PalatnikA , RouseD , StamiloD , McPhersonJ , GrobmanW . The association between cerebral palsy or death and umbilical cord magnesium concentration. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S302. RobbinsLS , BlanchardCT , BiasiniFJ , PowellMF , CaseyBM , TitaAT , et al. General anesthesia for cesarean delivery and childhood neurodevelopmental and perinatal outcomes: a secondary analysis of a randomized controlled trial. International Journal of Obstetric Anesthesia2020;45:34-40. RobbinsLS , BlanchardCT , SinkeyRG , HarrisSL , TitaAT , HarperLM . Prenatal tobacco exposure and childhood neurodevelopment among infants born prematurely. American Journal of Perinatology2020;38(3):218-23. RobertsR , Ankumah N-A, ViteriO , Mendez-FigueroaH , ChauhanS , SibaiB . Significance of the absence of amniotic fluid from the cervical os with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S223. RouseD , HirtzD , ThomE , VarnerM , AlexanderJ , SpongC , et al. Magnesium sulfate for the prevention of cerebral palsy. New England Journal of Medicine2008;359:895-905. RouseD . A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. American Journal of Obstetrics and Gynecology2007;197(6):S2. RouseD . Magnesium sulfate (MGSO4) dose and timing, umbilical cord MG++ concentration: relationship to cerebral palsy. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S46. SagaramD , HaarEV , MillerR , Gyamfi-BannermanC . Birth order does not offer a neurologic advantage in twin pregnancy. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S427. SiegelAM , HeineRP , Dotters-KatzSK . The effect of non-penicillin antibiotic regimens on neonatal outcomes in preterm prelabor rupture of membranes. American Journal of Obstetrics and Gynecology2018;219(6):637. SonM , GrobmanWA , MillerES . Is mode of delivery associated with the risk of necrotizing enterocolitis?American Journal of Obstetrics and Gynecology2016;214(1 Suppl 1):S204-5. TuritzAL , TooGT , Gyamfi-BannermanC . Proximity of magnesium exposure to delivery and neonatal outcomes. American Journal of Obstetrics and Gynecology2016;215(4):508.e1-6. TwicklerD , McIntireD , AlexanderJ , LevenoK . Effects of magnesium sulfate on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S112. TwicklerDM , McIntireDD , AlexanderJM , LevenoKJ . Effects of magnesium sulfate on preterm fetal cerebral blood flow using Doppler analysis: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):21-5. Vander HaarE , GoldbergerA , Gyamfi-BannermanC . Mild intraventricular hemorrhage is not associated with low bayley scores at age 2. Reproductive Sciences2017;24(1 Suppl 1):83A. VilchezG , DaiJ , KumarK , MundyD , KontopoulosE , SokolRJ . Racial/ethnic disparities in magnesium sulfate neuroprotection: a subgroup analysis of a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(17):2304-11. VilchezG , DaiJ , LagosM , SokolRJ . Maternal side effects &amp; fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(2):178-83. WoodAM , PostAL , SwamyGK , GrotegutCA . Neonatal outcomes associated with noncephalic presentation at delivery in preterm birth. American Journal of Perinatology2018;35(12):1131-7. YadavaS , GarabedianM , SitA , El-SayedY . Use of magnesium sulfate and labor outcomes in PPROM at less than 37 weeks. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S203. YangM , VarnerMW , YoderB . Cord blood magnesium levels and nonneurologic outcomes in neonates less than 27 weeks gestational age. Journal of Investigative Medicine2019;67(1):86-7. ">Rouse 2008</a>; <a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a>). Detailed study protocols/registrations were not available for two RCTs (<a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a>; <a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a>), preventing a judgement of risk of bias due to selective reporting. </p> </section> <section id="CD004661-sec-0090"> <h4 class="title">Other potential sources of bias</h4> <p>There was no indication of other sources of bias in five RCTs (<a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a>; <a href="./references#CD004661-bbs2-0002" title="ACTRN12611000491965. MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: neuroprotection trial [Does antenatal magnesium sulphate given to women at risk of imminent preterm birth (defined as planned or definitely expected in the next 24 hours) between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children at 2 years corrected age? - a randomised controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000491965 (first received 11 May 2011). CrowtherCA , AshwoodP , MiddletonPF , McPheeA , TranT , HardineJE , et al. Prenatal intravenous magnesium at 30-34 weeks’ gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial. JAMA2023;330(7):603-14. CrowtherCA , MiddletonPF , WilkinsonD , AshwoodP , HaslamR . Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) - study protocol. BMC Pregnancy and Childbirth2013;13(1):91. PoppeT , ThompsonB , BoardmanJP , BastinME , AlsweilerJ , DeibG , et al. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: the MagNUM Study. EBioMedicine2022;78:103923. ">Crowther 2023</a>; <a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a>; <a href="./references#CD004661-bbs2-0005" title="BrookfieldKF , O'MalleyK , Yeaton-MasseyA , ButwickAJ . Does magnesium sulfate exposure attenuate the effect of steroids administered for fetal lung maturation? In: Society for Obstetric Anesthesia and Perinatology (SOAP) 48th Annual Meeting; 2016 May 18-22; Boston USA. 2016:SA-32. BuhimschiCS , JablonskiKA , RouseDJ , VarnerMW , ReddyUM , MercerBM , et al. Cord blood haptoglobin, cerebral palsy and death in infants of women at risk for preterm birth: a secondary analysis of a randomised controlled trial. Eclinicalmedicine2019;9:11-8. CostantineMM , WeinerSJ , RouseDJ , HirtzDG , VarnerMW , SpongCY , et al. Umbilical cord blood biomarkers of neurologic injury and the risk of cerebral palsy or infant death. International Journal of Developmental Neuroscience2011;29(8):917-22. CostantineMM . Cord blood biomarkers and the risk of cerebral palsy or death. Reproductive Sciences2010;17(3 Suppl 1):65A. DeihlTE , SimhanHN . Antenatal magnesium sulfate and ponderal index from birth to age 2 in preterm male and female infants. Reproductive Sciences2017;24(Suppl 1):130A. DeihlTE , SimhanHN . Antenatal magnesium sulfate exposure and ponderal index in preterm infants. American Journal of Perinatology2019;36(3):329-34. DenobleAE , WuJ , MitchellCJ , HughesBL , Dotters-KatzSK . Chorioamnionitis versus intraamniotic infection among preterm deliveries-is postpartum infectious morbidity different?American Journal of Obstetrics and Gynecology MFM2020;2(3):100176. DrassinowerD , FriedmanAM , LevinH , ObicanSG , Gyamfi-BannermanC . Does magnesium exposure affect neonatal resuscitation? Presented as a poster at the 35th annual meeting of the society for maternal-fetal medicine, San Diego, CA, Feb. 2-7, 2015. American Journal of Obstetrics and Gynecology2015;213(3):424e1-5. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm prelabour rupture of membranes and neurodevelopmental outcomes: a secondary analysis. BJOG: an international journal of obstetrics and gynaecology2016;123(10):1629-35. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of cerebral palsy. Journal of Maternal-Fetal &amp; Neonatal Medicine2016;29(17):2748-52. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of neonatal sepsis. American Journal of Obstetrics and Gynecology2016;214(6):743.e1-6. DrassinowerD , LevinH , ObicanS , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on cerebral palsy. American Journal of Obstetrics and Gynecology2015;212(1):S310-1. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . Immediate neonatal outcomes in infants exposed to magnesium sulfate at the time of delivery. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S90. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1):S161-2. EdwardsJ , EdwardsL , SwamyG , GrotegutC . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S215-6. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Effect of cord blood magnesium level at birth on non-neurologic neonatal outcomes. American Journal of Perinatology2019;36(1):3-7. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. Journal of Maternal-Fetal &amp; Neonatal Medicine2018;31(9):1156-60. FaucettAM , MetzTD , DeWittPE , GibbsRS . Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2016;214(2):287.e1-5. HaarEV , Gyamfi-BannermanC , Coletta-LucasJ . Sepsis but not chorioamnionitis is associated with cerebral palsy. Reproductive Sciences2015;22:372A. HaarEV , Gyamfi-BannermanC , RandisTM . Abnormal brain imaging in infants exposed to chorioamnionitis and sepsis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl. 1):S11-2. HaarEV , LucasJC , D'AltonM , Gyamfi-BannermanC . The effect of chorioamnionitis on neurocognitive development at age 2. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S139-40. HerreraC , SilverRM , MajorH , VarnerMW , ClarkEAS . Triple I criteria and adverse neonatal and childhood outcomes after early preterm birth. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S250. HirtzDG , WeinerSJ , BulasD , DiPietroM , SeibertJ , RouseDJ , et al. Antenatal magnesium and cerebral palsy in preterm infants. Journal of Pediatrics2015;167(4):834-9.e3. HirtzDG . Effect of prenatal MgSO4 on head ultrasound imaging in preterm infants. Annals of Neurology2011;70(Suppl 15):S110. HortonA . The effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S209. HortonL , YingleiL , RouseJ , SpongY , LevenoJ , VarnerW , et al. Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Perinatology2015;32(4):387-92. JohnsonLH , MappDC , RouseDJ , SpongCY , MercerBM , LevenoKJ , et al. Association of cord blood magnesium concentration and neonatal resuscitation. Journal of Pediatrics2012;160(4):573-7.e1. KachikisA , WalkerC , McAdamsR , WaldorfKA , Gyamfi-BannermanC . Influence of preterm premature rupture of membranes on neonatal respiratory complications. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S215. KachikisA , WalkerCL , McAdamsRM , Gyamfi-BannermanC , Adams WaldorfKM . Phenotypic overlap in neonatal respiratory morbidity following preterm premature rupture of membranes versus spontaneous preterm labor. Journal of Maternal-fetal &amp; Neonatal Medicine2021;34(12):1941-8. KamyarM , ClarkEA , YoderBA , VarnerMW , ManuckTA . Antenatal magnesium sulfate, necrotizing enterocolitis, and death among neonates &lt; 28 weeks gestation. AJP Reports2016;6(1):e148-54. KamyarM , ClarkEAS , VarnerMW , ManuckTA . Chorioamnionitis prevents protective effect of magnesium sulfate in the preterm infant. Reproductive Sciences2014;21(3 Suppl 1):78A. KamyarM , ManuckTA , StoddardGJ , VarnerMW , ClarkEAS . Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. BJOG: an international journal of obstetrics and gynaecology2016;123(7):1161-6. KamyarM , VarnerM , ClarkE . Magnesium sulfate neuroprophylaxis and the effect of infant sex. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S144. ManuckA , ShengX , YoderA , VarnerW . Correlation between initial neonatal and early childhood outcomes following preterm birth. American Journal of Obstetrics &amp; Gynecology2014;210(5):426.e1-9. ManuckT , ShengX , YoderB , VarnerM . Correlation between initial neonatal and early childhood outcomes among children delivered &lt;34 weeks gestation. American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S23. ManuckT , VarnerM . Is bigger better? Neonatal and childhood outcomes of large for gestational age (LGA) infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341-2. ManuckT , VarnerM . Neonatal and childhood outcomes following early vs later preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S340-1. ManuckT , VarnerM . Neonatal and childhood outcomes of small for gestational age infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341. ManuckTA , VarnerMW . Neonatal and early childhood outcomes following early vs later preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2014;211(3):308.e1-6. MarrsC , Mendez-FigueroaH , ChauhanS . Periventricular leukomalacia with PPROM: Obstetric antecedents and infants' outcomes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S85. MarrsCC , Mendez-FigueroaH , HammadIA , ChauhanSP . Differential morbidity in preterm small versus appropriate for gestational age: perhaps unverifiable. American Journal of Perinatology2015;32(13):1251-6. McPhersonJ , SmileyS , StamiloD . Magnesium sulfate neuroprotection and obesity: Is efficacy affected by obesity. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S218. McPhersonJA , RouseDJ , GrobmanWA , PalatnikA , StamilioDM . Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. Obstetrics and Gynecology2014;124(4):749-55. McPhersonJA , SmileyS , StamilioDM . Maternal obesity and neuroprotective magnesium sulfate. American Journal of Obstetrics and Gynecology2015;213(4):582.e1–6. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate &lt; 12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S252. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate for &gt;12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S104-5. Mendez-FigueroaH , ChauhanSP , PedrozaC , RefuerzoJS , DahlkeJD , RouseDJ . Preterm cesarean delivery for nonreassuring fetal heart rate: neonatal and neurologic morbidity. Obstetrics and Gynecology2015;125(3):636-42. Mendez-FigueroaH , DahlkeJD , ViteriOA , ChauhanSP , RouseDJ , SibaiBM , et al. Neonatal and infant outcomes in twin gestations with preterm premature rupture of membranes at 24-31 weeks of gestation. Obstetrics and Gynecology2014;124(2 Pt 1):323-31. MoussaH , Hosseini NasabS , FournieD , OntiverosA , AlkawasR , ChauhanS , et al. The impact of time of delivery on gestations complicated by preterm premature rupture of membranes: daytime versus nighttime. Journal of Maternal-Fetal &amp; Neonatal Medicine2019;32(20):3319-24. NCT00014989. Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) [Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)]. clinicaltrials.gov/show/NCT00014989 (first received 18 April 2001). NussEE , SpiegelmanJ , TuritzAL , Gyamfi-BannermanC . Childhood neurodevelopment after spontaneous versus indicated preterm birth. American Journal of Obstetrics and Gynecology MFM2020;2(2):100082. ObicanS , DrassinowerD , LevinH , Gyamfi-BannermanC . Mode of delivery at periviability and early childhood neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S124. OvertonE , BaptisteC , Gyamfi-BannermanC . 546: neurodevelopmental outcomes in late preterm and early term deliveries following antenatal corticosteroid exposure. American Journal of Obstetrics and Gynecology2019;220(1):S365-6. PalatnikA , RouseD , StamiloD , McPhersonJ , GrobmanW . The association between cerebral palsy or death and umbilical cord magnesium concentration. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S302. RobbinsLS , BlanchardCT , BiasiniFJ , PowellMF , CaseyBM , TitaAT , et al. General anesthesia for cesarean delivery and childhood neurodevelopmental and perinatal outcomes: a secondary analysis of a randomized controlled trial. International Journal of Obstetric Anesthesia2020;45:34-40. RobbinsLS , BlanchardCT , SinkeyRG , HarrisSL , TitaAT , HarperLM . Prenatal tobacco exposure and childhood neurodevelopment among infants born prematurely. American Journal of Perinatology2020;38(3):218-23. RobertsR , Ankumah N-A, ViteriO , Mendez-FigueroaH , ChauhanS , SibaiB . Significance of the absence of amniotic fluid from the cervical os with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S223. RouseD , HirtzD , ThomE , VarnerM , AlexanderJ , SpongC , et al. Magnesium sulfate for the prevention of cerebral palsy. New England Journal of Medicine2008;359:895-905. RouseD . A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. American Journal of Obstetrics and Gynecology2007;197(6):S2. RouseD . Magnesium sulfate (MGSO4) dose and timing, umbilical cord MG++ concentration: relationship to cerebral palsy. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S46. SagaramD , HaarEV , MillerR , Gyamfi-BannermanC . Birth order does not offer a neurologic advantage in twin pregnancy. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S427. SiegelAM , HeineRP , Dotters-KatzSK . The effect of non-penicillin antibiotic regimens on neonatal outcomes in preterm prelabor rupture of membranes. American Journal of Obstetrics and Gynecology2018;219(6):637. SonM , GrobmanWA , MillerES . Is mode of delivery associated with the risk of necrotizing enterocolitis?American Journal of Obstetrics and Gynecology2016;214(1 Suppl 1):S204-5. TuritzAL , TooGT , Gyamfi-BannermanC . Proximity of magnesium exposure to delivery and neonatal outcomes. American Journal of Obstetrics and Gynecology2016;215(4):508.e1-6. TwicklerD , McIntireD , AlexanderJ , LevenoK . Effects of magnesium sulfate on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S112. TwicklerDM , McIntireDD , AlexanderJM , LevenoKJ . Effects of magnesium sulfate on preterm fetal cerebral blood flow using Doppler analysis: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):21-5. Vander HaarE , GoldbergerA , Gyamfi-BannermanC . Mild intraventricular hemorrhage is not associated with low bayley scores at age 2. Reproductive Sciences2017;24(1 Suppl 1):83A. VilchezG , DaiJ , KumarK , MundyD , KontopoulosE , SokolRJ . Racial/ethnic disparities in magnesium sulfate neuroprotection: a subgroup analysis of a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(17):2304-11. VilchezG , DaiJ , LagosM , SokolRJ . Maternal side effects &amp; fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(2):178-83. WoodAM , PostAL , SwamyGK , GrotegutCA . Neonatal outcomes associated with noncephalic presentation at delivery in preterm birth. American Journal of Perinatology2018;35(12):1131-7. YadavaS , GarabedianM , SitA , El-SayedY . Use of magnesium sulfate and labor outcomes in PPROM at less than 37 weeks. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S203. YangM , VarnerMW , YoderB . Cord blood magnesium levels and nonneurologic outcomes in neonates less than 27 weeks gestational age. Journal of Investigative Medicine2019;67(1):86-7. ">Rouse 2008</a>; <a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a>). We judged <a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a> to be at unclear risk of bias due to insufficient methodological detail to permit an assessment. </p> </section> </section> <section id="CD004661-sec-0091"> <h3 class="title" id="CD004661-sec-0091">Effects of interventions</h3> <p>See: <a href="./full#CD004661-tbl-0001"><b>Summary of findings 1</b> Magnesium sulphate versus placebo (outcomes for infants/children, up to 2 years' corrected age)</a>; <a href="./full#CD004661-tbl-0002"><b>Summary of findings 2</b> Magnesium sulphate versus placebo (outcomes for infants/children, up to school age)</a>; <a href="./full#CD004661-tbl-0003"><b>Summary of findings 3</b> Magnesium sulphate versus placebo (outcomes for women)</a> </p> <p>See <a href="./full#CD004661-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD004661-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD004661-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD004661-sec-0092"> <h4 class="title">Magnesium sulphate versus placebo</h4> <section id="CD004661-sec-0093"> <h5 class="title">Primary outcomes</h5> <section id="CD004661-sec-0094"> <h6 class="title">For infants/children</h6> <section id="CD004661-sec-0095"> <p><b>Death (fetal, neonatal, or later (up to two years' corrected age))</b></p> <p>Magnesium sulphate compared with placebo probably resulted in little to no difference in death (fetal, neonatal, or later (up to two years' corrected age)) (risk ratio (RR) 0.96, 95% confidence interval (CI) 0.82 to 1.13; 6 RCTs, 6759 children; moderate‐certainty evidence; <a href="./references#CD004661-fig-0005" title="">Analysis 1.1</a>). </p> <p>Interaction tests demonstrated no evidence of a difference between subgroups with the available data (gestational age at randomisation: <a href="./references#CD004661-fig-0100" title="">Analysis 7.1</a>; loading‐dose regimen: <a href="./references#CD004661-fig-0109" title="">Analysis 8.1</a>; maintenance dose regimen: <a href="./references#CD004661-fig-0115" title="">Analysis 9.1</a>; repeat treatment permitted: <a href="./references#CD004661-fig-0124" title="">Analysis 10.1</a>). In a sensitivity analysis based on RCT quality, we removed one RCT due to unclear risk of selection bias (<a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a>), and the result remained similar to the overall analysis (RR 0.96, 95% CI 0.82 to 1.12; 5 RCTs, 6700 children). In a post hoc sensitivity analysis pooling adjusted effects sizes, where reported, the result also remained similar to the overall analysis (RR 0.96, 95% CI 0.81 to 1.13; 6 RCTs, 6759 children; <a href="./references#CD004661-fig-0130" title="">Analysis 11.1</a>). </p> </section> <section id="CD004661-sec-0096"> <p><b>Cerebral palsy (up to two years' corrected age)</b></p> <p>Magnesium sulphate compared with placebo reduced the risk of cerebral palsy up to two years' corrected age (RR 0.71, 95% CI 0.57 to 0.89; 6 RCTs, 6107 children; number needed to treat for additional beneficial outcome (NNTB) 60, 95% CI 41 to 158; high‐certainty evidence; <a href="./references#CD004661-fig-0006" title="">Analysis 1.2</a>). </p> <p>Interaction tests demonstrated no evidence of a difference between subgroups with the available data (gestational age at randomisation: <a href="./references#CD004661-fig-0101" title="">Analysis 7.2</a>; loading‐dose regimen: <a href="./references#CD004661-fig-0110" title="">Analysis 8.2</a>; maintenance dose regimen: <a href="./references#CD004661-fig-0116" title="">Analysis 9.2</a>; repeat treatment permitted: <a href="./references#CD004661-fig-0125" title="">Analysis 10.2</a>). In a sensitivity analysis on RCT quality, we removed one RCT due to unclear risk of selection bias (<a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a>), and the result remained similar to the overall analysis (RR 0.69, 95% CI 0.55 to 0.86; 5 RCTs, 6051 children). In a post hoc sensitivity analysis pooling adjusted effect sizes, where reported, the result also remained similar to the overall analysis (RR 0.70, 95% CI 0.55 to 0.88; 6 RCTs, 6107 children; <a href="./references#CD004661-fig-0131" title="">Analysis 11.2</a>). </p> </section> <section id="CD004661-sec-0097"> <p><b>Death or cerebral palsy (up to two years' corrected age)</b></p> <p>Magnesium sulphate compared with placebo reduced the risk of death or cerebral palsy up to two years' corrected age (RR 0.87, 95% CI 0.77 to 0.98; 6 RCTs, 6481 children; NNTB 56, 95% CI 32 to 363; high‐certainty evidence; <a href="./references#CD004661-fig-0007" title="">Analysis 1.3</a>). </p> <p>Interaction tests demonstrated no evidence of a difference between subgroups with the available data (gestational age at randomisation: <a href="./references#CD004661-fig-0102" title="">Analysis 7.3</a>; loading‐dose regimen: <a href="./references#CD004661-fig-0111" title="">Analysis 8.3</a>; maintenance dose regimen: <a href="./references#CD004661-fig-0117" title="">Analysis 9.3</a>; repeat treatment permitted: <a href="./references#CD004661-fig-0126" title="">Analysis 10.3</a>). In a sensitivity analysis on RCT quality, we removed one RCT due to unclear risk of selection bias (<a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a>), and the result remained similar to the overall analysis (RR 0.86, 95% CI 0.76 to 0.97; 5 RCTs, 6422 children). In a post hoc sensitivity analysis pooling adjusted effects sizes, where reported, the result also remained similar to the overall analysis (RR 0.85, 95% CI 0.74 to 0.97; 6 RCTs, 6481 children; <a href="./references#CD004661-fig-0132" title="">Analysis 11.3</a>). </p> </section> <section id="CD004661-sec-0098"> <p><b>Major neurodevelopmental disability (up to two years' corrected age)</b></p> <p>Magnesium sulphate compared with placebo probably resulted in little to no difference in major neurodevelopmental disability up to two years' corrected age (RR 1.09, 95% CI 0.83 to 1.44; 1 RCT, 987 children; moderate‐certainty evidence; <a href="./references#CD004661-fig-0008" title="">Analysis 1.4</a>). Subgroup and sensitivity analyses were not applicable (no adjusted effect; single RCT). </p> </section> <section id="CD004661-sec-0099"> <p><b>Death or major neurodevelopmental disability (up to two years' corrected age)</b></p> <p>Magnesium sulphate compared with placebo probably resulted in little to no difference in death or major neurodevelopmental disability up to two years' corrected age (RR 0.95, 95% CI 0.85 to 1.07; 3 RCTs, 4279 children; moderate‐certainty evidence; <a href="./references#CD004661-fig-0009" title="">Analysis 1.5</a>). </p> <p>Interaction tests demonstrated no evidence of a difference between subgroups with the available data (gestational age at randomisation: <a href="./references#CD004661-fig-0103" title="">Analysis 7.4</a>; loading‐dose regimen: <a href="./references#CD004661-fig-0112" title="">Analysis 8.4</a> maintenance dose regimen: <a href="./references#CD004661-fig-0118" title="">Analysis 9.4</a>; repeat treatment permitted: <a href="./references#CD004661-fig-0127" title="">Analysis 10.4</a>). In a post hoc sensitivity analysis pooling adjusted effects sizes, where reported, the result remained similar to the overall analysis (RR 0.94, 95% CI 0.84 to 1.05; 3 RCTs, 4279 children; <a href="./references#CD004661-fig-0133" title="">Analysis 11.4</a>). </p> </section> <section id="CD004661-sec-0100"> <p><b>Death (fetal, neonatal, or later (up to school age))</b></p> <p>Magnesium sulphate compared with placebo may have resulted in little to no difference in death (fetal, neonatal, or later (up to school age)) (RR 0.82, 95% CI 0.66 to 1.02; 2 RCTs, 1758 children; low‐certainty evidence; <a href="./references#CD004661-fig-0010" title="">Analysis 1.6</a>). </p> <p>Interaction tests demonstrated no evidence of a difference between subgroups with the available data (gestational age at randomisation: <a href="./references#CD004661-fig-0104" title="">Analysis 7.5</a>; maintenance dose regimen: <a href="./references#CD004661-fig-0119" title="">Analysis 9.5</a>). Sensitivity analyses were not applicable (no adjusted effects reported). </p> </section> <section id="CD004661-sec-0101"> <p><b>Cerebral palsy (school age)</b></p> <p>Magnesium sulphate compared with placebo may have resulted in little to no difference in cerebral palsy at school age (RR 0.99, 95% CI 0.69 to 1.41; 2 RCTs, 1038 children; low‐certainty evidence; <a href="./references#CD004661-fig-0011" title="">Analysis 1.7</a>). </p> <p>Interaction tests demonstrated no evidence of a difference between subgroups with the available data (gestational age at randomisation: <a href="./references#CD004661-fig-0105" title="">Analysis 7.6</a>; maintenance dose regimen: <a href="./references#CD004661-fig-0120" title="">Analysis 9.6</a>). In a post hoc sensitivity analysis pooling adjusted effects sizes, where reported, the result remained similar to the overall analysis (RR 1.09, 95% CI 0.79 to 1.52; 2 RCTs, 1038 children; <a href="./references#CD004661-fig-0134" title="">Analysis 11.5</a>). </p> </section> <section id="CD004661-sec-0102"> <p><b>Death or cerebral palsy (up to school age)</b></p> <p>Magnesium sulphate compared with placebo may have resulted in little to no difference in death or cerebral palsy at school age (RR 0.90, 95% CI 0.67 to 1.20; 1 RCT, 503 children; low‐certainty evidence; <a href="./references#CD004661-fig-0012" title="">Analysis 1.8</a>). Subgroup and sensitivity analyses were not applicable (no adjusted effect; single RCT). </p> </section> <section id="CD004661-sec-0103"> <p><b>Major neurodevelopmental disability (school age)</b></p> <p>Magnesium sulphate compared with placebo may have resulted in little or no effect on major neurodevelopmental disability at school age, but the evidence is very uncertain (average RR 0.92, 95% CI 0.53 to 1.62; Tau<sup>2</sup> = 0.09; I<sup>2</sup> =57%; 2 RCTs, 940 children; very low‐certainty evidence; <a href="./references#CD004661-fig-0013" title="">Analysis 1.9</a>). </p> <p>Interaction tests demonstrated no evidence of a difference between subgroups with the available data (gestational age at randomisation: <a href="./references#CD004661-fig-0106" title="">Analysis 7.7</a>; maintenance dose regimen: <a href="./references#CD004661-fig-0121" title="">Analysis 9.7</a>). Sensitivity analyses were not applicable (no adjusted effects reported). </p> </section> <section id="CD004661-sec-0104"> <p><b>Death or major neurodevelopmental disability (school age)</b></p> <p>Magnesium sulphate compared with placebo may have resulted in little to no difference in death or major neurodevelopmental disability at school age (RR 0.81, 95% CI 0.59 to 1.12; 1 RCT, 503 children; low‐certainty evidence; <a href="./references#CD004661-fig-0014" title="">Analysis 1.10</a>). Subgroup and sensitivity analyses were not applicable (no adjusted effect; single RCT). </p> </section> </section> <section id="CD004661-sec-0105"> <h6 class="title">For women</h6> <section id="CD004661-sec-0106"> <p><b>Severe maternal outcome potentially related to treatment</b></p> <p>Magnesium sulphate compared with placebo may have resulted in little to no difference in severe maternal outcomes (death, cardiac arrest, respiratory arrest) potentially related to treatment, in part because there was only one such adverse event (maternal death) overall (RR 0.32, 95% CI 0.01 to 7.92; 4 RCTs, 5300 women; low‐certainty evidence; <a href="./references#CD004661-fig-0015" title="">Analysis 1.11</a>). </p> <p>Interaction tests demonstrated no evidence of a difference between subgroups with the available data (gestational age at randomisation: <a href="./references#CD004661-fig-0107" title="">Analysis 7.8</a>; loading‐dose regimen: <a href="./references#CD004661-fig-0113" title="">Analysis 8.5</a>; maintenance dose regimen: <a href="./references#CD004661-fig-0122" title="">Analysis 9.8</a>; repeat treatment permitted: <a href="./references#CD004661-fig-0128" title="">Analysis 10.5</a>). Sensitivity analysis based on RCT quality was not applicable (<a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a> did not report this outcome). </p> </section> <section id="CD004661-sec-0107"> <p><b>Adverse effects severe enough to stop treatment</b></p> <p>Magnesium sulphate compared with placebo probably increased adverse effects severe enough to stop treatment (average RR 3.21, 95% CI 1.88 to 5.48; Tau<sup>2</sup> = 0.10; I<sup>2</sup> = 46%; 3 RCTs, 4736 women; moderate‐certainty evidence; <a href="./references#CD004661-fig-0016" title="">Analysis 1.12</a>). </p> <p>Interaction tests demonstrated no evidence of a difference between subgroups with the available data (gestational age at randomisation: <a href="./references#CD004661-fig-0108" title="">Analysis 7.9</a>; loading‐dose regimen: <a href="./references#CD004661-fig-0114" title="">Analysis 8.6</a>; maintenance dose regimen: <a href="./references#CD004661-fig-0123" title="">Analysis 9.9</a>; repeat treatment permitted: <a href="./references#CD004661-fig-0129" title="">Analysis 10.6</a>). </p> </section> </section> </section> <section id="CD004661-sec-0108"> <h5 class="title">Secondary outcomes</h5> <section id="CD004661-sec-0109"> <h6 class="title">For fetuses/neonates/infants</h6> <section id="CD004661-sec-0110"> <p><b>Fetal death</b></p> <p>There was no evidence of a difference in fetal death between the magnesium sulphate and placebo groups (RR 0.83, 95% CI 0.46 to 1.52; 6 RCTs, 6805 fetuses; <a href="./references#CD004661-fig-0017" title="">Analysis 2.1</a>). </p> </section> <section id="CD004661-sec-0111"> <p><b>Neonatal death</b></p> <p>There may be little to no difference in neonatal death between the magnesium sulphate and placebo groups (variously defined: RR 0.97, 95% CI 0.80 to 1.17; 6 RCTs, 6751 infants; defined, where possible, as up to hospital discharge: RR 0.96, 95% C 0.80 to 1.15; 6 RCTs, 6751 infants; <a href="./references#CD004661-fig-0018" title="">Analysis 2.2</a>). </p> </section> <section id="CD004661-sec-0112"> <p><b>Body size at birth (weight, length, head circumference z‐scores)</b></p> <p>There were no evidence of a difference in birthweight, length, and head circumference at birth between the magnesium sulphate and placebo groups. Birthweight: mean difference (MD) 5.6 g, 95% CI −18.8 to 30.1; 4 RCTs, 6009 infants; z‐score, MD 0.03, 95% CI −0.08 to 0.14; 1 RCT, 1679 infants (<a href="./references#CD004661-fig-0019" title="">Analysis 2.3</a>); length at birth: MD 0.30 cm, 95% CI −0.04 to 0.64; z‐score MD 0.06, 95% CI −0.05 to 0.17; both 1 RCT, 1559 infants (<a href="./references#CD004661-fig-0020" title="">Analysis 2.4</a>); head circumference at birth: MD 0.10, 95% CI −0.10 to 0.30; z‐score MD −0.01, 95% CI −0.12 to 0.10; both 1 RCT, 1642 infants (<a href="./references#CD004661-fig-0021" title="">Analysis 2.5</a>). </p> <p>One RCT reported no evidence of a difference in median (interquartile range (IQR)) birthweight (magnesium sulphate group: 1350 g (1080 to 1670 g) (N = 352); placebo group: 1415 g (1120 to 1680 g) (N = 336)); length at birth (both groups, 40 cm (38 to 42 cm) (N = 352 and N = 336)); and head circumference at birth (both groups 28 cm (26 to 29 cm) (N = 352 and N = 336)) (<a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a>). </p> </section> <section id="CD004661-sec-0113"> <p><b>Gestational age at birth</b></p> <p>There was no evidence of a difference in gestational age at birth between the magnesium sulphate and placebo groups (MD 0.10 weeks, 95% CI −0.02 to 0.22; 2 RCTs, 4123 infants; <a href="./references#CD004661-fig-0022" title="">Analysis 2.6</a>). </p> <p>Two RCTs reported no evidence of a difference in median (IQR) gestational age at birth (<a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a>: magnesium sulphate group: 27 weeks, 5 days (26 to 29 weeks) (N = 629); placebo group: 27 weeks, 3 days (25 weeks, 6 days to 29 weeks) (N = 626); <a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a>: magnesium sulphate group: 30 weeks, 1 day (24 weeks, 1 day to 32 weeks, 6 days (N = 352); placebo group: 30 weeks, 1 day (23 weeks, 4 days to 32 weeks, 6 days) (N = 336)). One RCT reported that gestational age was "similar in the two groups" (mean 30 weeks; SD 4 days) (N = 343 and N = 337) (<a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a>). </p> </section> <section id="CD004661-sec-0114"> <p><b>Apgar score less than seven at five minutes</b></p> <p>There may be little to no difference in Apgar score less than seven at five minutes between the magnesium sulphate and placebo groups (RR 1.02, 95% CI 0.89 to 1.16; 4 RCTs, 5006 infants; <a href="./references#CD004661-fig-0023" title="">Analysis 2.7</a>). </p> </section> <section id="CD004661-sec-0115"> <p><b>Use of active resuscitation at birth</b></p> <p>Regarding resuscitation at birth, there may be little to no differences between the magnesium sulphate and placebo groups in: any resuscitation (RR 0.99, 95% CI 0.96 to 1.03; 3 RCTs, 3776 infants); use of supplementary oxygen (RR 1.03, 95% CI 0.96 to 1.10; 2 RCTs, 3093 infants); and use of chest compressions (RR 1.17, 95% CI 0.78 to 1.75; 2 RCTs, 3093 infants). Fewer infants required intubation for resuscitation in the magnesium sulphate group compared with the placebo group (RR 0.88, 95% CI 0.80 to 0.98; 2 RCTs, 3093 infants) (all <a href="./references#CD004661-fig-0024" title="">Analysis 2.8</a>). </p> </section> <section id="CD004661-sec-0116"> <p><b>Intraventricular haemorrhage</b></p> <p>There was no evidence of a difference in intraventricular haemorrhage between the magnesium sulphate and placebo groups (RR 0.94, 95% CI 0.85 to 1.04; 6 RCTs, 6550 infants; <a href="./references#CD004661-fig-0025" title="">Analysis 2.9</a>). </p> </section> <section id="CD004661-sec-0117"> <p><b>Severe intraventricular haemorrhage (grade 3 or 4)</b></p> <p>Magnesium sulphate compared with placebo probably reduced severe intraventricular haemorrhage (grade 3 or 4) (RR 0.76, 95% CI 0.60 to 0.98; 5 RCTs, 5885 infants; NNTB 92, 95% CI 55 to 1102; moderate‐certainty evidence; <a href="./references#CD004661-fig-0026" title="">Analysis 2.10</a>). </p> </section> <section id="CD004661-sec-0118"> <p><b>Cystic periventricular leukomalacia</b></p> <p>There was no evidence of a difference in cystic periventricular leukomalacia between the magnesium sulphate and placebo groups (RR 0.88, 95% CI 0.65 to 1.17; 6 RCTs, 6550 infants; <a href="./references#CD004661-fig-0027" title="">Analysis 2.11</a>). </p> </section> <section id="CD004661-sec-0119"> <p><b>Post‐haemorrhagic hydrocephalus or ventriculomegaly</b></p> <p>There was no evidence of a difference in ventriculomegaly between the magnesium sulphate and placebo groups (RR 0.88, 95% CI 0.53 to 1.46; 1 RCT, 1776 infants; <a href="./references#CD004661-fig-0028" title="">Analysis 2.12</a>). </p> </section> <section id="CD004661-sec-0120"> <p><b>Neonatal encephalopathy</b></p> <p>There was evidence of a difference in neonatal encephalopathy between the magnesium sulphate and placebo groups (RR 0.96, 95% CI 0.06 to 15.27; 1 RCT, 1679 infants; <a href="./references#CD004661-fig-0029" title="">Analysis 2.13</a>). </p> </section> <section id="CD004661-sec-0121"> <p><b>Neonatal convulsions</b></p> <p>There was no evidence of a difference in neonatal convulsions between the magnesium sulphate and placebo groups (RR 0.87, 95% CI 0.63 to 1.20; 5 RCTs, 6689 infants; <a href="./references#CD004661-fig-0030" title="">Analysis 2.14</a>). </p> </section> <section id="CD004661-sec-0122"> <p><b>Neonatal hypoglycaemia</b></p> <p>Not reported.</p> </section> <section id="CD004661-sec-0123"> <p><b>Neonatal hypotonia</b></p> <p>There was no evidence of a difference in neonatal hypotonia between the magnesium sulphate and placebo groups (RR 1.03, 95% CI 0.77 to 1.37; 1 RCT, 2415 infants; <a href="./references#CD004661-fig-0031" title="">Analysis 2.15</a>). </p> </section> <section id="CD004661-sec-0124"> <p><b>Necrotising enterocolitis</b></p> <p>There was no evidence of a difference in necrotising enterocolitis between the magnesium sulphate and placebo groups (RR 1.22, 95% CI 0.98 to 1.50; 5 RCTs, 6689 infants; <a href="./references#CD004661-fig-0032" title="">Analysis 2.16</a>). </p> </section> <section id="CD004661-sec-0125"> <p><b>Intestinal perforation</b></p> <p>Not reported.</p> </section> <section id="CD004661-sec-0126"> <p><b>Retinopathy of prematurity</b></p> <p>There was no evidence of a difference in retinopathy of prematurity between the magnesium sulphate and placebo groups (RR 0.99, 95% CI 0.86 to 1.13; 3 RCTs, 3639 infants; <a href="./references#CD004661-fig-0033" title="">Analysis 2.17</a>). </p> </section> <section id="CD004661-sec-0127"> <p><b>Patent ductus arteriosus</b></p> <p>There was no evidence of a difference in patent ductus arteriosus between the magnesium sulphate and placebo groups (RR 0.88, 95% CI 0.73 to 1.06; 3 RCTs, 4771 infants; <a href="./references#CD004661-fig-0034" title="">Analysis 2.18</a>). </p> </section> <section id="CD004661-sec-0128"> <p><b>Respiratory distress syndrome</b></p> <p>There was no evidence of a difference in respiratory distress syndrome between the magnesium sulphate and placebo groups (average RR 0.95, 95% CI 0.83 to 1.08; Tau<sup>2</sup> = 0.01; I<sup>2</sup> = 69%; 3 RCTs, 4777 infants; <a href="./references#CD004661-fig-0035" title="">Analysis 2.19</a>). </p> </section> <section id="CD004661-sec-0129"> <p><b>Chronic lung disease/bronchopulmonary dysplasia</b></p> <p>Magnesium sulphate compared with placebo may have resulted in little to no difference in chronic lung disease/bronchopulmonary dysplasia (average RR 0.92, 95% CI 0.77 to 1.10; Tau<sup>2</sup> = 0.02; I<sup>2</sup> = 55%; 5 RCTs, 6689 infants; low‐certainty evidence; <a href="./references#CD004661-fig-0036" title="">Analysis 2.20</a>). </p> </section> <section id="CD004661-sec-0130"> <p><b>Use of respiratory support</b></p> <p>There was no evidence of a difference in endotracheal intubation (average RR 0.86, 95% CI 0.58 to 1.28; Tau<sup>2</sup> = 0.07; I<sup>2</sup> = 89%; 2 RCTs, 1360 infants; <a href="./references#CD004661-fig-0037" title="">Analysis 2.21</a>) or in mechanical ventilation or continuous positive airway pressure (average RR 0.98, 95% CI 0.91 to 1.05; Tau<sup>2</sup> = 0.00; I<sup>2</sup> = 77%; 4 RCTs, 6012 infants; <a href="./references#CD004661-fig-0038" title="">Analysis 2.22</a>) between the magnesium sulphate and placebo groups. </p> </section> <section id="CD004661-sec-0131"> <p><b>Use of postnatal corticosteroids to prevent or treat chronic lung disease/bronchopulmonary dysplasia</b></p> <p>Not reported.</p> </section> <section id="CD004661-sec-0132"> <p><b>Use of inotropic support</b></p> <p>There was no evidence of a difference in use of inotropic support between the magnesium sulphate and placebo groups (average RR 0.81, 95% CI 0.50 to 1.29; Tau<sup>2</sup> = 0.10; I<sup>2</sup> = 82%; 2 RCTs, 3092 infants; <a href="./references#CD004661-fig-0039" title="">Analysis 2.23</a>). </p> </section> <section id="CD004661-sec-0133"> <p><b>Air leak syndrome</b></p> <p>There was no evidence of a difference in air leak syndrome between the magnesium sulphate and placebo groups (RR 0.55, 95% CI 0.23 to 1.30; 1 RCT, 1679 infants; <a href="./references#CD004661-fig-0040" title="">Analysis 2.24</a>). </p> </section> <section id="CD004661-sec-0134"> <p><b>Early‐ and late‐onset sepsis</b></p> <p>There was no evidence of a difference between the magnesium sulphate and placebo groups in culture‐proven sepsis (RR 0.97, 95% CI 0.81 to 1.15; 1 RCT, 2415 infants); early‐onset sepsis (RR 1.28, 95% CI 0.29 to 5.68; 1 RCT, 1679 infants); or late‐onset sepsis (RR 1.03, 95% CI 0.49 to 2.18; 1 RCT, 1679 infants); however, there were more neonates with reported maternal‐fetal infection in the magnesium sulphate versus placebo group (RR 1.53, 95% CI 1.09 to 2.14; 1 RCT, 683 infants) (all <a href="./references#CD004661-fig-0041" title="">Analysis 2.25</a>). </p> </section> <section id="CD004661-sec-0135"> <p><b>Severe adverse neonatal outcome composite</b></p> <p>There was no evidence of a difference in severe adverse neonatal outcome composite between the magnesium sulphate and placebo groups (RR 0.93, 95% CI 0.72 to 1.19; 2 RCTs, 863 infants; <a href="./references#CD004661-fig-0042" title="">Analysis 2.26</a>). </p> </section> </section> <section id="CD004661-sec-0136"> <h6 class="title">For infants/children/adults</h6> <section id="CD004661-sec-0137"> <p><b>Later death</b></p> <p>There was no evidence of a difference in later death (up to two years' corrected age) between the magnesium sulphate and placebo groups (RR 1.09, 95% CI 0.66 to 1.78; 5 RCTs, 6646 children; <a href="./references#CD004661-fig-0043" title="">Analysis 3.1</a>). </p> <p>There was no evidence of a difference in later death (school age) between the magnesium sulphate and placebo groups (RR 0.50, 95% CI 0.12 to 1.97; 2 RCTs, 1738 children; <a href="./references#CD004661-fig-0058" title="">Analysis 4.1</a>). </p> </section> <section id="CD004661-sec-0138"> <p><b>Cerebral palsy severity</b></p> <p>There were fewer children with mild cerebral palsy (up to two years' corrected age) (RR 0.73, 95% CI 0.53 to 1.00; 6 RCTs, 6108 children) and moderate or severe cerebral palsy (up to two years' corrected age) in the magnesium sulphate group compared with the placebo group (RR 0.69, 95% CI 0.50 to 0.95; 6 RCTs, 6108 children; <a href="./references#CD004661-fig-0044" title="">Analysis 3.2</a>). </p> <p>There was no evidence of a difference in mild to moderate cerebral palsy (school age) (RR 1.07, 95% CI 0.72 to 1.60; 2 RCTs, 1065 children) or severe cerebral palsy (school age) (RR 0.81, 95% CI 0.34 to 1.92; 2 RCTs, 1038 children) between the magnesium sulphate and placebo groups (<a href="./references#CD004661-fig-0059" title="">Analysis 4.2</a>). </p> </section> <section id="CD004661-sec-0139"> <p><b>Any neurodevelopmental disability</b></p> <p>There was no evidence of a difference in any neurodevelopmental disability (up to two years' corrected age) between the magnesium sulphate and placebo groups (RR 0.99, 95% CI 0.84 to 1.16; 1 RCT, 987 children; <a href="./references#CD004661-fig-0045" title="">Analysis 3.3</a>). </p> <p>There were no evidence of a difference in any (RR 0.95, 95% CI 0.85 to 1.05; 2 RCTs, 940 children), mild (RR 0.88, 95% CI 0.63 to 1.24; 1 RCT, 511 children), moderate (RR 1.00, 95% CI 0.87 to 1.14; 2 RCTs, 940 children), or severe (RR 0.80, 95% CI 0.50 to 1.29; 2 RCTs, 940 children) neurodevelopmental disability (all at school age) between the magnesium sulphate and placebo groups (<a href="./references#CD004661-fig-0060" title="">Analysis 4.3</a>). </p> </section> <section id="CD004661-sec-0140"> <p><b>Death or any neurodevelopmental disability</b></p> <p>Fewer children died or had any neurodevelopmental disability (up to two years' corrected age) in the magnesium sulphate compared with the placebo group (RR 0.91, 95% CI 0.83 to 1.00; 3 RCTs, 3194 children; <a href="./references#CD004661-fig-0046" title="">Analysis 3.4</a>). </p> <p>There was no evidence of a difference in death or any neurodevelopmental disability (at school age) between the magnesium sulphate and placebo groups (RR 0.94, 95% CI 0.86 to 1.02; 1 RCT, 501 children; <a href="./references#CD004661-fig-0061" title="">Analysis 4.4</a>). </p> </section> <section id="CD004661-sec-0141"> <p><b>Blindness</b></p> <p>There was no evidence of a difference in blindness between the magnesium sulphate and placebo groups (up to two years' corrected age: RR 1.61, 95% CI 0.39 to 6.69; 4 RCTs, 3633 children; <a href="./references#CD004661-fig-0047" title="">Analysis 3.5</a>; at school age: RR 1.05, 95% CI 0.86 to 1.28; 2 RCTs, 983 children; <a href="./references#CD004661-fig-0062" title="">Analysis 4.5</a>). </p> </section> <section id="CD004661-sec-0142"> <p><b>Deafness</b></p> <p>There was no evidence of a difference in deafness between the magnesium sulphate and placebo groups (up to two years' corrected age: RR 0.67, 95% CI 0.32 to 1.42; 4 RCTs, 3633 children; <a href="./references#CD004661-fig-0048" title="">Analysis 3.6</a>; at school age: RR 0.72, 95% CI 0.38 to 1.38; 2 RCTs, 1013 children; <a href="./references#CD004661-fig-0063" title="">Analysis 4.6</a>). </p> </section> <section id="CD004661-sec-0143"> <p><b>Developmental delay/intellectual impairment</b></p> <p>There was no evidence of a difference in developmental delay/intellectual impairment (up to two years' corrected age) between the magnesium sulphate and placebo groups: any (RR 0.98, 95% CI 0.90 to 1.06; 4 RCTs, 5245 children); mild (RR 0.94, 95% CI 0.84 to 1.06; 3 RCTs, 4639 children); moderate or severe (RR 1.06, 95% CI 0.91 to 1.24; 3 RCTs, 4639 children) (all <a href="./references#CD004661-fig-0049" title="">Analysis 3.7</a>). </p> <p>There was no evidence of a difference in developmental delay/intellectual impairment (school age) between the magnesium sulphate and placebo groups: moderate (RR 1.04, 95% CI 0.88 to 1.24; 1 RCT, 429 children); severe (RR 0.66, 95% CI 0.35 to 1.24; 1 RCT, 429 children) (both <a href="./references#CD004661-fig-0064" title="">Analysis 4.7</a>). </p> </section> <section id="CD004661-sec-0144"> <p><b>Gross motor dysfunction</b></p> <p>There was no evidence of a difference in any gross motor dysfunction (up to two years' corrected age) between the magnesium sulphate and placebo groups (RR 0.88, 95% CI 0.72 to 1.07; 2 RCTs, 1648 children). There were fewer children with substantial gross motor dysfunction (up to two years' corrected age) in the magnesium sulphate group compared with the placebo group (RR 0.61, 95% CI 0.41 to 0.92; 2 RCTs, 1648 children) (both <a href="./references#CD004661-fig-0050" title="">Analysis 3.8</a>). </p> <p>There were no evidence of a difference in various measures of gross motor dysfunction (at school age) between the magnesium sulphate and placebo groups: motor dysfunction/deficits (RR 0.96, 95% CI 0.82 to 1.12; 2 RCTs, 1026 children); no cerebral palsy, other motor disorder (RR 0.94, 95% CI 0.73 to 1.22; 1 RCT, 429 children); GMFCS levels I‐V (RR 1.12, 95% CI 0.73 to 1.70; 1 RCT, 618 children); Movement Assessment Battery for Children (MABC) suspect/abnormal (RR 1.01, 95% CI 0.82 to 1.25; 1 RCT, 598 children) (all <a href="./references#CD004661-fig-0065" title="">Analysis 4.8</a>). </p> </section> <section id="CD004661-sec-0145"> <p><b>Psychomotor dysfunction</b></p> <p>There was no evidence of a difference in any psychomotor dysfunction (up to two years' corrected age) (average RR 0.92, 95% CI 0.72 to 1.18; Tau<sup>2</sup> = 0.02; I<sup>2</sup> = 52%; 2 RCTs, 3696 children) or moderate or severe psychomotor dysfunction (up to two years' corrected age) (RR 1.02, 95% CI 0.82 to 1.25; 2 RCTs, 3696 children) between the magnesium sulphate and placebo groups (both <a href="./references#CD004661-fig-0051" title="">Analysis 3.9</a>). </p> </section> <section id="CD004661-sec-0146"> <p><b>Death or substantial gross motor dysfunction</b></p> <p>Fewer children died or had substantial gross motor dysfunction (up to two years' corrected age) in the magnesium sulphate group compared with the placebo group (RR 0.86, 95% CI 0.74 to 0.98; 6 RCTs, 5097 children; <a href="./references#CD004661-fig-0052" title="">Analysis 3.10</a>). </p> <p>There was no evidence of a difference in death or substantial gross motor dysfunction (at school age) between the magnesium sulphate and placebo groups (RR 0.93, 95% CI 0.80 to 1.08; 1 RCT, 501 children; <a href="./references#CD004661-fig-0066" title="">Analysis 4.9</a>). </p> </section> <section id="CD004661-sec-0147"> <p><b>Growth</b></p> <p>There was no evidence of a difference in weight, height, and head circumference (all up to two years' corrected age) between the magnesium sulphate and placebo groups: weight (MD 0.00 kg, 95% CI −0.22 to 0.22; z‐score MD 0.03, 95% CI −0.09 to 0.15; both 1 RCT, 1330 children); height (MD −0.20 cm, 95% CI −0.75 to 0.35; z‐score MD 0.05, 95% CI −0.08 to 0.18; both 1 RCT, 1305 children); head circumference (MD 0.00 cm, 95% CI −0.21 to 0.21; z‐score MD 0.01, 95% CI −0.13 to 0.15; both 1 RCT, 1265 children) (all <a href="./references#CD004661-fig-0053" title="">Analysis 3.11</a>). </p> <p>There was no evidence of a difference in weight, head circumference, height, and body mass index (BMI) (all SD scores) (at school age) between the magnesium sulphate and placebo groups: weight (MD −0.23, 95% CI −0.45 to −0.01;* 1 RCT, 614 children); head circumference (MD −0.21, 95% CI −0.40 to −0.02;* 1 RCT, 609 children); height (MD −0.16, 95% CI −0.35 to 0.03; 1 RCT, 618 children); and BMI (MD −0.19, 95% CI −0.41 to 0.03; 1 RCT, 612 children) (all in <a href="./references#CD004661-fig-0067" title="">Analysis 4.10</a>). </p> <p><i>*Effect size reported by RCT (adjusting for clustering within mother and study centre, and using multiple imputation to handle missing data) indicated no difference for these outcomes.</i> </p> </section> <section id="CD004661-sec-0148"> <p><b>Respiratory function</b></p> <p>There was no evidence of a difference in childhood respiratory morbidity (up to two years' corrected age) (RR 0.93, 95% CI 0.80 to 1.08; 1 RCT, 1365 children) or asthma or wheezing (up to two years' corrected age) (RR 0.95, 95% CI 0.78 to 1.15; 1 RCT, 1365 children) between the magnesium sulphate and placebo groups (both <a href="./references#CD004661-fig-0054" title="">Analysis 3.12</a>). </p> <p>There was no evidence of a difference in asthma (at school age) between the magnesium sulphate and placebo groups (RR 0.72, 95% CI 0.51 to 1.03; 1 RCT, 424 children; <a href="./references#CD004661-fig-0068" title="">Analysis 4.11</a>). </p> </section> <section id="CD004661-sec-0149"> <p><b>Blood pressure</b></p> <p>There was no evidence of differences in systolic or diastolic blood pressure or hypertension (all up to two years' corrected age) between the magnesium sulphate and placebo groups (systolic hypertension: RR 1.01, 95% CI 0.76 to 1.34; systolic blood pressure: MD 0.06 mmHg, 95% CI −1.52 to 1.64; z‐score MD 0.00, 95% CI −0.15 to 0.15; all 1 RCT, 679 children) (diastolic hypertension: RR 0.99, 95% CI 0.81 to 1.20; diastolic blood pressure: MD −0.93 mmHg, 95% CI −2.46 to 0.60; MD −0.08, 95% CI −0.22 to 0.06; all 1 RCT, 674 children) (<a href="./references#CD004661-fig-0055" title="">Analysis 3.13</a>; <a href="./references#CD004661-fig-0056" title="">Analysis 3.14</a>). </p> </section> <section id="CD004661-sec-0150"> <p><b>Behaviour</b></p> <p>There were more children (up to two years' corrected age) with behavioural scores (assessed by the Child Behaviour Checklist) within the clinical problem range overall (RR 1.62, 95% CI 1.00 to 2.64; 1 RCT, 768 children) and for the following scales: anxiety (RR 2.14, 95% CI 1.18 to 3.88; 1 RCT, 793 children); withdrawal (RR 1.47, 95% CI 1.06 to 2.04; 1 RCT, 791 children); sleeping problems (RR 2.54, 95% CI 1.14 to 5.67; 1 RCT, 795 children); and other (RR 7.92, 95% CI 1.00 to 63.00; 1 RCT, 774 children) in the magnesium sulphate group compared with the placebo group. There was no evidence of a difference between magnesium sulphate and placebo groups for the scales: somatic problem (RR 1.01, 95% CI 0.59 to 1.74; 1 RCT, 785 children); aggressive behaviour (RR 4.34, 95% CI 0.94 to 19.97; 1 RCT, 786 children); and destructive behaviour (RR 0.96, 95% CI 0.06 to 15.30; 1 RCT, 796 children) (all <a href="./references#CD004661-fig-0057" title="">Analysis 3.15</a>). </p> <p>There was no evidence of a difference (at school age) between the magnesium sulphate and placebo groups for behavioural and psychiatric disorder (moderate) (RR 0.87, 95% CI 0.67 to 1.12) or borderline and abnormal scores for: Strengths and Difficulties Questionnaire (SDQ) total difficulties score (RR 0.74, 95% CI 0.55 to 1.00); emotional symptom scale (RR 0.95, 95% CI 0.76 to 1.20); conduct problem scale (RR 1.05, 95% CI 0.76 to 1.46); hyperactivity scale (RR 0.85, 95% CI 0.61 to 1.19); peer problem scale (RR 0.91, 95% CI 0.67 to 1.24); or prosocial scale (RR 1.06, 95% CI 0.49 to 2.27) (all in 1 RCT, 431 children <a href="./references#CD004661-fig-0069" title="">Analysis 4.12</a>). In <a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a>, there was no evidence of a difference (at school age) between the magnesium sulphate and placebo groups for SDQ total difficulties scores (median, range): parent scores: magnesium sulphate group: 11 (6 to 17) (N = 304) versus placebo group: 10 (6 to 15) (N = 318); teacher scores: magnesium sulphate group: 8 (4 to 14) (N = 269) versus placebo group: 8 (4 to 13) (N = 279). </p> <p>There was no evidence of a difference (at school age) for Conners ADHS/DSM‐IV Scales (CADS) parent T scores (all in 1 RCT, 623 children): ADHD index (MD 1.00, 95% CI −0.75 to 2.75); DSM‐IV inattentive (MD 0.70, 95% CI −1.05 to 2.45); DSM‐IV hyperactive‐impulsive (MD 0.20, 95% CI −1.71 to 2.11); DSM‐IV (MD 0.60, 95% CI −1.20 to 2.40); or CADS teacher T scores (all in 1 RCT, 552 children): ADHD index (MD 0.50, 95% CI −1.32 to 2.32); DSM‐IV inattentive (MD 0.60, 95% CI −0.82 to 2.02); DSM‐IV hyperactive‐impulsive (MD 0.70, 95% CI −0.96 to 2.36); DSM‐IV (MD 0.80, 95% CI −0.81 to 2.41); Behavior Rating Inventory of Executive Function (BRIEF) teacher T scores: global executive composite (MD 0.90, 95% CI −1.14 to 2.94; 1 RCT, 507 children); metacognition index (MD 0.50, 95% CI −1.59 to 2.59; 1 RCT, 495 children); or Behavioral Regulation Index (MD 0.50, 95% CI −1.42 to 2.42; 1 RCT, 537 children) (all in <a href="./references#CD004661-fig-0070" title="">Analysis 4.13</a>). </p> </section> <section id="CD004661-sec-0151"> <p><b>Educational achievement</b></p> <p>There was no evidence of a difference in measures of educational achievement (at school age) between the magnesium sulphate and placebo groups: specialised classroom (RR 0.87, 95% CI 0.32 to 2.35); specialised institution (RR 0.99, 95% CI 0.25 to 3.91); repeated grades (RR 0.52, 95% CI 0.24 to 1.15); specific education assistance (RR 0.75, 95% CI 0.40 to 1.39); home education services (RR 0.39, 95% CI 0.17 to 0.91*); and language disorder (RR 0.90, 95% CI 0.53 to 1.52) (all in 1 RCT, 422 children; <a href="./references#CD004661-fig-0071" title="">Analysis 4.14</a>). </p> <p><i>*Effect size reported by RCT (gestational age, singleton/multiple pregnancy, socioeconomic variables, sex, and birthweight) indicated no difference for this outcome.</i> </p> <p>There was no evidence of a difference in other measures of educational achievement (at school age) between the magnesium sulphate and placebo groups: Wide Range Achievement Test (WRAT3) academic skills scales for: reading (MD 0.50, 95% CI −2.24 to 3.24; 1 RCT, 588 children); spelling (MD 1.20, 95% CI −1.31 to 3.71; 1 RCT, 584 children); and arithmetic (MD 0.30, 95% CI −2.35 to 2.95; 1 RCT, 587 children) (all <a href="./references#CD004661-fig-0072" title="">Analysis 4.15</a>). </p> <p>Regarding general cognitive function/intelligence quotient (IQ), there was no evidence of a difference in full scale IQ (Wechsler Intelligence Scale for Children ‐ Fourth Edition: WISC‐IV) (MD −1.10, 95% CI −3.60 to 1.40; 1 RCT, 583 children); or for the WISC‐IV: verbal comprehension index (MD −0.70, 95% CI −3.00 to 1.60; 1 RCT, 601 children); perceptual reasoning index (MD −1.50, 95% CI −3.95 to 0.95; 1 RCT, 601 children); working memory index (MD −1.30, 95% CI −3.68 to 1.08; 1 RCT, 592 children); or processing speed index (MD 0.40, 95% CI −1.97 to 2.77; 1 RCT, 585 children) (all <a href="./references#CD004661-fig-0072" title="">Analysis 4.15</a>). </p> </section> </section> <section id="CD004661-sec-0152"> <h6 class="title">For women</h6> <section id="CD004661-sec-0153"> <p><b>Individual components of severe maternal outcome potentially related to treatment</b></p> <p>There was no evidence of a difference in maternal death between the magnesium sulphate and placebo groups (only one event in placebo group) (RR 0.32, 95% CI 0.01 to 7.92; 4 RCTs, 5300 women; <a href="./references#CD004661-fig-0073" title="">Analysis 5.1</a>). There were no maternal cardiac arrests (4 RCTs, 5300 women; <a href="./references#CD004661-fig-0074" title="">Analysis 5.2</a>) or respiratory arrests in the RCTs included in the meta‐analyses (4 RCTs, 5300 women; <a href="./references#CD004661-fig-0075" title="">Analysis 5.3</a>). One RCT described "For two women, unblinding was performed due to serious side effects (respiratory arrest and hypotension)"; however, as reporting was unclear (group/s not reported), these data were not incorporated in the meta‐analysis (<a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a>). </p> </section> <section id="CD004661-sec-0154"> <p><b>Maternal side effects of treatment</b></p> <p>More women experienced any side effects of treatment in the magnesium sulphate group compared with the placebo group (average RR 4.49, 95% CI 2.53 to 7.97; Tau<sup>2</sup> = 0.29; I<sup>2</sup> = 97%; 4 RCTs, 5300 women; <a href="./references#CD004661-fig-0076" title="">Analysis 5.4</a>), along with the following side effects: hypotension (RR 1.70, 95% CI 1.29 to 2.25; 3 RCTs, 3059 women; <a href="./references#CD004661-fig-0078" title="">Analysis 5.6</a>); tachycardia (RR 1.53, 95% CI 1.03 to 2.29; 1 RCT, 1062 women; <a href="./references#CD004661-fig-0079" title="">Analysis 5.7</a>); warmth over body/flushing (average RR 7.13, 95% CI 4.28 to 11.86; Tau<sup>2</sup> = 0.19; I<sup>2</sup> = 91%; 4 RCTs, 5300 women; <a href="./references#CD004661-fig-0080" title="">Analysis 5.8</a>); arm discomfort with infusion (RR 9.64, 95% CI 7.85 to 11.83; 3 RCTs, 4736 women; <a href="./references#CD004661-fig-0081" title="">Analysis 5.9</a>); mouth dryness (average RR 3.26, 95% CI 1.31 to 8.15; Tau<sup>2</sup> = 0.41; I<sup>2</sup> = 93%; 2 RCTs, 2495 women; <a href="./references#CD004661-fig-0082" title="">Analysis 5.10</a>); nausea or vomiting (average RR 3.99, 95% CI 2.05 to 7.74; Tau<sup>2</sup> = 0.35; I<sup>2</sup> = 88%; 4 RCTs, 5300 women; <a href="./references#CD004661-fig-0083" title="">Analysis 5.11</a>); sleepiness (RR 2.49, 95% CI 1.82 to 3.42; 1 RCT, 1062 women; <a href="./references#CD004661-fig-0084" title="">Analysis 5.12</a>); sweating (average RR 6.12, 95% CI 2.86 to 13.10; Tau<sup>2</sup> = 0.40; I<sup>2</sup> = 89%; 3 RCTs, 4736 women; <a href="./references#CD004661-fig-0085" title="">Analysis 5.13</a>); dizziness (average RR 3.16, 95% CI 1.50 to 6.68; Tau<sup>2</sup> = 0.24; I<sup>2</sup> = 82%; 2 RCTs, 2495 women; <a href="./references#CD004661-fig-0086" title="">Analysis 5.14</a>); blurred vision (average RR 4.33, 95% CI 1.05 to 17.88; Tau<sup>2</sup> = 0.84; I<sup>2</sup> = 79%; 2 RCTs, 2495 women; <a href="./references#CD004661-fig-0087" title="">Analysis 5.15</a>). </p> <p>There was no evidence of a difference between the magnesium sulphate and placebo groups in the following side effects: respiratory depression (variously defined) (RR 1.14, 95% CI 0.82 to 1.61; 3 RCTs, 4736 women; RR 1.31, 95% CI 0.83 to 2.07; 2 RCTs, 3303 women; <a href="./references#CD004661-fig-0077" title="">Analysis 5.5</a>); tendon reflex abolition (RR 1.94, 95% CI 0.18 to 21.32; 1 RCT, 564 women; <a href="./references#CD004661-fig-0088" title="">Analysis 5.16</a>); "curarisation" (RR 2.92, 95% CI 0.12 to 71.29; 1 RCT, 564 women; <a href="./references#CD004661-fig-0089" title="">Analysis 5.17</a>); and headache (RR 3.89, 95% CI 0.44 to 34.57; 1 RCT, 564 women; <a href="./references#CD004661-fig-0090" title="">Analysis 5.18</a>). </p> </section> <section id="CD004661-sec-0155"> <p><b>Time between randomisation and birth</b></p> <p>Two RCTs reported no evidence of a difference in time between randomisation and birth (<a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a> (median, IQR): magnesium sulphate group: 3.7 hours (1.4 to 13.8 hours) (N = 535); placebo group: 3.1 hours (1.3 to 12.9 hours) (N = 527); <a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a> (median, range ‐ from infusion to birth): magnesium sulphate group: 1 hour, 38 minutes (5 minutes to 25 hours, 5 minutes) (N = 286); placebo group: 1 hour, 30 minutes (8 minutes to 61 hours, 30 minutes) (N = 278)). In one RCT, the time between randomisation and birth was longer in the magnesium sulphate group compared with the placebo group (<a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a>: (median, IQR): magnesium sulphate group: 24 hours (3 to 195 hours) (N = 283); placebo group: 7 hours (2 to 81 hours) (N = 277)). </p> </section> <section id="CD004661-sec-0156"> <p><b>Mode of birth (caesarean section)</b></p> <p>There was probably little to no difference in caesarean section between the magnesium sulphate and placebo groups (RR 0.96, 95% CI 0.91 to 1.02; 5 RCTs, 5861 women; moderate‐certainty evidence; <a href="./references#CD004661-fig-0091" title="">Analysis 5.19</a>). </p> </section> <section id="CD004661-sec-0157"> <p><b>Chorioamnionitis</b></p> <p>There was no evidence of a difference in chorioamnionitis between the magnesium sulphate and placebo groups (RR 1.01, 95% CI 0.81 to 1.27; 1 RCT, 2241 women; <a href="./references#CD004661-fig-0092" title="">Analysis 5.20</a>). </p> </section> <section id="CD004661-sec-0158"> <p><b>Postpartum haemorrhage</b></p> <p>There was probably little to no difference in postpartum haemorrhage between the magnesium sulphate and placebo groups (RR 0.94, 95% CI 0.80 to 1.09; 2 RCTs, 2495 women; moderate‐certainty evidence). There was no evidence of a difference in severe postpartum haemorrhage between the magnesium sulphate and placebo groups (RR 1.36, 95% CI 0.90 to 2.05; 3 RCTs, 3059 women) (both <a href="./references#CD004661-fig-0093" title="">Analysis 5.21</a>). </p> </section> <section id="CD004661-sec-0159"> <p><b>Breastfeeding at hospital discharge</b></p> <p>Not reported.</p> </section> <section id="CD004661-sec-0160"> <p><b>Women's views of treatment</b></p> <p>Not reported.</p> </section> </section> <section id="CD004661-sec-0161"> <h6 class="title">Use of health services</h6> <section id="CD004661-sec-0162"> <p><b>Maternal admission to the intensive care unit</b></p> <p>There were no maternal admissions to the intensive care unit (1 RCT, 1062 women; <a href="./references#CD004661-fig-0094" title="">Analysis 6.1</a>). </p> </section> <section id="CD004661-sec-0163"> <p><b>Length of postnatal hospitalisation for women</b></p> <p>There was no evidence of a difference in length of maternal hospitalisation for women between groups (MD 0.20 days, 95% CI −0.18 to 0.58; 1 RCT, 1062 women; <a href="./references#CD004661-fig-0095" title="">Analysis 6.2</a>). </p> </section> <section id="CD004661-sec-0164"> <p><b>Admission to the neonatal intensive care unit</b></p> <p>Not reported.</p> </section> <section id="CD004661-sec-0165"> <p><b>Length of stay in neonatal intensive care unit</b></p> <p>Not reported.</p> </section> <section id="CD004661-sec-0166"> <p><b>Length of neonatal/infant hospitalisation</b></p> <p>There was no evidence of a difference in length of neonatal/infant hospitalisation between groups (MD 1.80 days, 95% CI −2.62 to 6.22; 1 RCT, 1235 infants; <a href="./references#CD004661-fig-0096" title="">Analysis 6.3</a>). </p> <p>Two RCTs also reported no evidence of a difference in length of neonatal/infant hospitalisation between groups (<a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a> (median, IQR): magnesium sulphate group: 76 days (61 to 94 days) (N = 620); placebo group: 74 days (59 to 95 days) (N = 615); <a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a> (median, range): magnesium sulphate group: 45 days (26 to 67 days) (N = 343); placebo group: 47 days (29 to 70 days) (N = 337)). </p> </section> <section id="CD004661-sec-0167"> <p><b>Costs of maternal care</b></p> <p>Not reported.</p> </section> <section id="CD004661-sec-0168"> <p><b>Costs of neonatal care</b></p> <p>Not reported.</p> </section> <section id="CD004661-sec-0169"> <p><b>Use of care for infant/child/adult</b></p> <p>There may be little to no differences between the magnesium sulphate and placebo groups in hospital admissions (up to two years' corrected age) (RR 0.91, 95% CI 0.79 to 1.03; 1 RCT, 1365 children; <a href="./references#CD004661-fig-0097" title="">Analysis 6.4</a>); postdischarge service (up to two years' corrected age) (RR 0.95, 95% CI 0.83 to 1.10; 1 RCT, 1352 children; <a href="./references#CD004661-fig-0098" title="">Analysis 6.5</a>); and hospital admissions (school age) (RR 0.83, 95% CI 0.69 to 1.00; 1 RCT, 420 children; <a href="./references#CD004661-fig-0099" title="">Analysis 6.6</a>). </p> </section> <section id="CD004661-sec-0170"> <p><b>Costs of care for infant/child/adult</b></p> <p>Not reported.</p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004661-sec-0171" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004661-sec-0171"></div> <section id="CD004661-sec-0172"> <h3 class="title" id="CD004661-sec-0172">Summary of main results</h3> <p>We included six RCTs (enrolling 5917 women at less than 34 weeks' gestation and their 6759 fetuses alive at randomisation) that compared magnesium sulphate with placebo for women at risk of preterm birth for neuroprotection of the fetus in this review. </p> <p>Regarding our <b>primary outcomes</b><i>for infants/children</i>, up to two years' corrected age, magnesium sulphate compared with placebo reduced cerebral palsy (6 RCTs, 6107 children) and reduced death or cerebral palsy (6 RCTs, 6481 children) (both high‐certainty evidence). At up to two years' corrected age, magnesium sulphate probably resulted in little to no difference in death (fetal, neonatal, or later) (6 RCTs, 6759 children), major neurodevelopmental disability (1 RCT, 987 children), and death or major neurodevelopmental disability (3 RCTs, 4279 children) (all moderate‐certainty evidence). At early school age, magnesium sulphate may have resulted in little to no difference in death (fetal, neonatal, or later) (2 RCTs, 1758 children), cerebral palsy (2 RCTs, 1038 children), death or cerebral palsy (1 RCT, 503 children) and death or major neurodevelopmental disability (1 RCT, 503 children) (all low‐certainty evidence). Magnesium sulphate may have resulted in little to no effect on major neurodevelopmental disability, but the evidence was very uncertain (2 RCTs, 940 children; very low‐certainty evidence). </p> <p><i>For women</i>, magnesium sulphate may have resulted in little to no difference in severe maternal outcomes potentially related to treatment (death, cardiac arrest, respiratory arrest) (4 RCTs, 5300 women; low‐certainty evidence). However, magnesium sulphate probably increased adverse effects severe enough to stop treatment (3 RCTs, 4736 women; moderate‐certainty evidence). </p> <p>Subgroup analyses for our primary outcomes (based on gestational age at randomisation, loading‐dose regimen, maintenance dose regimen, and whether repeat treatment was permitted) revealed no clear differential treatment effects according to the characteristics assessed. Insufficient information precluded an assessment of the impact of the primary reason women were considered at high risk of preterm birth, number of babies in utero, mode of magnesium sulphate administration, and time treatment was intended to be started prior to preterm birth. Sensitivity analyses (restricting to the RCTs at low risk of selection bias, and including adjusted effect sizes where reported) supported the findings observed in the main analyses. </p> <p>Considering <b>secondary outcomes assessed using GRADE</b><i>for infants/children</i> , magnesium sulphate probably reduced severe intraventricular haemorrhage (grade 3 or 4) (5 RCTs, 5885 infants; moderate‐certainty evidence) and may have resulted in little to no difference in chronic lung disease/bronchopulmonary dysplasia (5 RCTs, 6689 infants) (low‐certainty evidence). <i>For women</i>, magnesium sulphate probably resulted in little or no difference in caesarean section (5 RCTs, 5861 women) and postpartum haemorrhage (2 RCTs, 2495 women) (both moderate‐certainty evidence). No data were reported for breastfeeding at discharge and women's views of treatment. </p> <p>For the majority of other <b>secondary outcomes not assessed using GRADE</b><i>for infants/children</i> , no evidence of differences was observed. However, we did observe a number of possible benefits in the magnesium sulphate versus placebo group: fewer infants required intubation for resuscitation (2 RCTs, 3093 infants); and up to two years' corrected age, fewer children had moderate or severe cerebral palsy (6 RCTs, 6108 children); died or had any neurodevelopmental disability (3 RCTs, 3194 children); had substantial gross motor dysfunction (2 RCTs, 1648 children); and died or had substantial gross motor dysfunction (6 RCTs, 5097 children). No harms for infants/children were observed with magnesium sulphate versus placebo, except for possibly more children up to two years' corrected age with behavioural scores (assessed by the Child Behaviour Checklist) within the clinical problem range overall, and on the following scales: anxiety, withdrawal, sleeping problems, other (all in 1 RCT, up to 795 children). <i>For women</i>, in large part, no evidence of differences in outcomes, including no benefits, was observed. However, we did observe some possible harms in the magnesium sulphate versus placebo group: more women experienced any side effects of treatment (4 RCTs, 5300 women) and the following side effects: hypotension (3 RCTs, 3059 women), tachycardia (1 RCT, 1062 women), warmth over body/flushing (4 RCTs, 5300 women), arm discomfort with infusion (3 RCTs, 4736 women), mouth dryness (2 RCTs, 2495 women), nausea or vomiting (4 RCTs, 5300 women), sleepiness (RCT, 1062 women), sweating (3 RCTs, 4736 women), dizziness (2 RCTs, 2495 women), and blurred vision (2 RCTs, 2495 women). </p> </section> <section id="CD004661-sec-0173"> <h3 class="title" id="CD004661-sec-0173">Overall completeness and applicability of evidence</h3> <p>The evidence assessing the effects of magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus is incomplete. </p> <p>While for our primary outcomes of death, cerebral palsy, and death or cerebral palsy up to two years' corrected age, we were able to include data from all six RCTs, for many outcomes, only one to five RCTs contributed data. Only two of the six RCTs reported data up to early school age, and none reported on follow‐up beyond this into adolescence or adulthood. </p> <p>For a variety of prespecified review outcomes (neonatal hypoglycaemia, intestinal perforation, use of postnatal corticosteroids to prevent or treat chronic lung disease/bronchopulmonary dysplasia, breastfeeding at hospital discharge, women's views of treatment, maternal admission to the intensive care unit, length of postnatal hospitalisation for women, admission to the neonatal intensive care unit, length of stay in neonatal intensive care unit, costs of maternal care, costs of neonatal care, costs of care for infant/child/adult), no data were reported by the included RCTs. This review thus presents an incomplete picture of the benefits and harms of magnesium sulphate for women and their infants/children. </p> <p>The review's findings are limited by notable variations in the characteristics of the enrolled women, and the magnesium sulphate regimens used in the included RCTs (as summarised in <a href="#CD004661-tbl-0004">Table 1</a> and <a href="#CD004661-tbl-0005">Table 2</a>). While we chose to combine RCTs in one comparison, and attempted to explore variation through subgroup analyses, this was limited by the difficulty in meaningfully grouping RCTs according to important characteristics (as the inclusion criteria did not enable allocation to one or the other subgroup, or stratified results were not presented, or both). </p> <p>All included RCTs were conducted in high‐income countries (Australia, Denmark, France, New Zealand, the USA). The studies commenced the enrolment/randomisation of women between 1995 and 2018. Thus, although there are nearly 6000 women and their children in the included RCTs, it is important to consider the potential limitations of the review's findings in terms of applicability (to low‐ and middle‐income countries) and generalisability (to present‐day clinical context/practice). </p> <p>For example, the RCTs used specific and varied approaches to childhood follow‐up, including different definitions/diagnostic criteria for important outcomes, including cerebral palsy. Today, a cerebral palsy diagnosis (including the interim use of a 'high risk of cerebral palsy' diagnosis) may be made according to 2017 international clinical practice guideline recommendations (<a href="./references#CD004661-bbs2-0052" title="NovakI , MorganC , AddeL , BlackmanJ , BoydRN , Brunstrom-HernandezJ , et al. Early, accurate diagnosis and early intervention in cerebral palsy: advances in diagnosis and treatment. JAMA Pediatrics2017;171:897-907.">Novak 2017</a>). These guidelines suggest that to make the most accurate, earliest (possible under the age of six months) diagnosis, a combination of clinical history, neuroimaging, standardised neurological assessments, and standardised motor assessments are used (<a href="./references#CD004661-bbs2-0052" title="NovakI , MorganC , AddeL , BlackmanJ , BoydRN , Brunstrom-HernandezJ , et al. Early, accurate diagnosis and early intervention in cerebral palsy: advances in diagnosis and treatment. JAMA Pediatrics2017;171:897-907.">Novak 2017</a>). Within the RCTs included in this review, the diagnosis of cerebral palsy was commonly made following a clinical (e.g. paediatric) examination, and/or parent interview/questionnaire at up to two years' corrected age. While a clinical examination at up to two years' corrected age was previously regarded as the most accurate available approach, it has recognised limitations. The diagnosis of cerebral palsy continues to present challenges. Indeed, despite early diagnosis being highlighted as important ‐ particularly to facilitate early intervention (<a href="./references#CD004661-bbs2-0060" title="SpittleAJ , MorganC , OlsenJE , NovakI , CheongJLY . Early diagnosis and treatment of cerebral palsy in children with a history of preterm birth. Clinics in Perinatology2018;45:409-20.">Spittle 2018</a>) ‐ the value of time, including to rule out other diagnoses, is still recognised. For example, certain national cerebral palsy registries do not consider a child's record as 'complete' until it is 'confirmed' at five years of age, recognising the potential for new information to potentially change a previous diagnosis of cerebral palsy (<a href="./references#CD004661-bbs2-0025" title="ACPR Group. Australian Cerebral Palsy Register Report 2023. cpregister.com/wp-content/uploads/2023/01/2023-ACPR-Report.pdf (accessed 18 October 2023).">ACPR 2023</a>). </p> <p>Following screening of potentially eligible studies for trustworthiness, a total of eight studies were classified as <a href="./references#CD004661-bbs1-0003" title="">Studies awaiting classification</a>. These studies were conducted in various low‐ or middle‐income countries (Moldova, India, Indonesia, Iran, and Iraq; see <a href="./references#CD004661-sec-0215" title="">Characteristics of studies awaiting classification</a>). Their future potential inclusion (along with potential inclusion of <a href="./references#CD004661-bbs1-0004" title="">Ongoing studies</a>) may extend the applicability and generalisability of the review's findings. We await further information from the study authors. Direct evidence from such settings would be beneficial, given the inherent advantages of magnesium sulphate treatment, which are particularly relevant to low‐ and middle‐income countries, such as its relative low cost, widespread availability (<a href="./references#CD004661-bbs2-0048" title="LingamI , RobertsonNJ . Magnesium as a neuroprotective agent: A review of its use in the fetus, term infant with neonatal encephalopathy, and the adult stroke patient. Developmental Neuroscience2018;40:1-12.">Lingam 2018</a>), favourable safety profile (<a href="./references#CD004661-bbs2-0026" title="BainES , MiddletonPF , CrowtherCA . Maternal adverse effects of different antenatal magnesium sulphate regimens for improving maternal and infant outcomes: a systematic review. BMC Pregnancy and Childbirth2013;13:195.">Bain 2013</a>; <a href="./references#CD004661-bbs2-0058" title="ShepherdE , SalamRA , ManhasD , SynnesA , MiddletonP , Makrides et al. Antenatal magnesium sulphate and adverse neonatal outcomes: A systematic review and meta-analysis. PLOS Medicine2019;16(12):e1002988.">Shepherd 2019</a>), and long history of use in perinatal care globally, particularly for preventing and treating eclampsia and treating pre‐eclampsia (<a href="./references#CD004661-bbs2-0034" title="DuleyL , GülmezogluAM , Henderson-SmartDJ , ChouD . Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database of Systematic Reviews2010, Issue 11. Art. No: CD000025. [DOI: 10.1002/14651858.CD000025.pub2]">Duley 2010</a>; <a href="./references#CD004661-bbs2-0039" title="Fishel BartalM , SibaiBM . Eclampsia in the 21st century. American Journal of Obstetrics and Gynecology2022;226(2s):S1237-53.">Fishel 2022</a>). </p> </section> <section id="CD004661-sec-0174"> <h3 class="title" id="CD004661-sec-0174">Quality of the evidence</h3> <p>We judged the overall risk of bias of the six RCTs to be low. Sensitivity analyses restricted to the five RCTs at low risk of selection bias supported the findings from the main analyses (<a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a>; <a href="./references#CD004661-bbs2-0002" title="ACTRN12611000491965. MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: neuroprotection trial [Does antenatal magnesium sulphate given to women at risk of imminent preterm birth (defined as planned or definitely expected in the next 24 hours) between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children at 2 years corrected age? - a randomised controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000491965 (first received 11 May 2011). CrowtherCA , AshwoodP , MiddletonPF , McPheeA , TranT , HardineJE , et al. Prenatal intravenous magnesium at 30-34 weeks’ gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial. JAMA2023;330(7):603-14. CrowtherCA , MiddletonPF , WilkinsonD , AshwoodP , HaslamR . Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) - study protocol. BMC Pregnancy and Childbirth2013;13(1):91. PoppeT , ThompsonB , BoardmanJP , BastinME , AlsweilerJ , DeibG , et al. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: the MagNUM Study. EBioMedicine2022;78:103923. ">Crowther 2023</a>; <a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a>; <a href="./references#CD004661-bbs2-0005" title="BrookfieldKF , O'MalleyK , Yeaton-MasseyA , ButwickAJ . Does magnesium sulfate exposure attenuate the effect of steroids administered for fetal lung maturation? In: Society for Obstetric Anesthesia and Perinatology (SOAP) 48th Annual Meeting; 2016 May 18-22; Boston USA. 2016:SA-32. BuhimschiCS , JablonskiKA , RouseDJ , VarnerMW , ReddyUM , MercerBM , et al. Cord blood haptoglobin, cerebral palsy and death in infants of women at risk for preterm birth: a secondary analysis of a randomised controlled trial. Eclinicalmedicine2019;9:11-8. CostantineMM , WeinerSJ , RouseDJ , HirtzDG , VarnerMW , SpongCY , et al. Umbilical cord blood biomarkers of neurologic injury and the risk of cerebral palsy or infant death. International Journal of Developmental Neuroscience2011;29(8):917-22. CostantineMM . Cord blood biomarkers and the risk of cerebral palsy or death. Reproductive Sciences2010;17(3 Suppl 1):65A. DeihlTE , SimhanHN . Antenatal magnesium sulfate and ponderal index from birth to age 2 in preterm male and female infants. Reproductive Sciences2017;24(Suppl 1):130A. DeihlTE , SimhanHN . Antenatal magnesium sulfate exposure and ponderal index in preterm infants. American Journal of Perinatology2019;36(3):329-34. DenobleAE , WuJ , MitchellCJ , HughesBL , Dotters-KatzSK . Chorioamnionitis versus intraamniotic infection among preterm deliveries-is postpartum infectious morbidity different?American Journal of Obstetrics and Gynecology MFM2020;2(3):100176. DrassinowerD , FriedmanAM , LevinH , ObicanSG , Gyamfi-BannermanC . Does magnesium exposure affect neonatal resuscitation? Presented as a poster at the 35th annual meeting of the society for maternal-fetal medicine, San Diego, CA, Feb. 2-7, 2015. American Journal of Obstetrics and Gynecology2015;213(3):424e1-5. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm prelabour rupture of membranes and neurodevelopmental outcomes: a secondary analysis. BJOG: an international journal of obstetrics and gynaecology2016;123(10):1629-35. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of cerebral palsy. Journal of Maternal-Fetal &amp; Neonatal Medicine2016;29(17):2748-52. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of neonatal sepsis. American Journal of Obstetrics and Gynecology2016;214(6):743.e1-6. DrassinowerD , LevinH , ObicanS , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on cerebral palsy. American Journal of Obstetrics and Gynecology2015;212(1):S310-1. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . Immediate neonatal outcomes in infants exposed to magnesium sulfate at the time of delivery. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S90. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1):S161-2. EdwardsJ , EdwardsL , SwamyG , GrotegutC . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S215-6. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Effect of cord blood magnesium level at birth on non-neurologic neonatal outcomes. American Journal of Perinatology2019;36(1):3-7. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. Journal of Maternal-Fetal &amp; Neonatal Medicine2018;31(9):1156-60. FaucettAM , MetzTD , DeWittPE , GibbsRS . Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2016;214(2):287.e1-5. HaarEV , Gyamfi-BannermanC , Coletta-LucasJ . Sepsis but not chorioamnionitis is associated with cerebral palsy. Reproductive Sciences2015;22:372A. HaarEV , Gyamfi-BannermanC , RandisTM . Abnormal brain imaging in infants exposed to chorioamnionitis and sepsis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl. 1):S11-2. HaarEV , LucasJC , D'AltonM , Gyamfi-BannermanC . The effect of chorioamnionitis on neurocognitive development at age 2. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S139-40. HerreraC , SilverRM , MajorH , VarnerMW , ClarkEAS . Triple I criteria and adverse neonatal and childhood outcomes after early preterm birth. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S250. HirtzDG , WeinerSJ , BulasD , DiPietroM , SeibertJ , RouseDJ , et al. Antenatal magnesium and cerebral palsy in preterm infants. Journal of Pediatrics2015;167(4):834-9.e3. HirtzDG . Effect of prenatal MgSO4 on head ultrasound imaging in preterm infants. Annals of Neurology2011;70(Suppl 15):S110. HortonA . The effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S209. HortonL , YingleiL , RouseJ , SpongY , LevenoJ , VarnerW , et al. Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Perinatology2015;32(4):387-92. JohnsonLH , MappDC , RouseDJ , SpongCY , MercerBM , LevenoKJ , et al. Association of cord blood magnesium concentration and neonatal resuscitation. Journal of Pediatrics2012;160(4):573-7.e1. KachikisA , WalkerC , McAdamsR , WaldorfKA , Gyamfi-BannermanC . Influence of preterm premature rupture of membranes on neonatal respiratory complications. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S215. KachikisA , WalkerCL , McAdamsRM , Gyamfi-BannermanC , Adams WaldorfKM . Phenotypic overlap in neonatal respiratory morbidity following preterm premature rupture of membranes versus spontaneous preterm labor. Journal of Maternal-fetal &amp; Neonatal Medicine2021;34(12):1941-8. KamyarM , ClarkEA , YoderBA , VarnerMW , ManuckTA . Antenatal magnesium sulfate, necrotizing enterocolitis, and death among neonates &lt; 28 weeks gestation. AJP Reports2016;6(1):e148-54. KamyarM , ClarkEAS , VarnerMW , ManuckTA . Chorioamnionitis prevents protective effect of magnesium sulfate in the preterm infant. Reproductive Sciences2014;21(3 Suppl 1):78A. KamyarM , ManuckTA , StoddardGJ , VarnerMW , ClarkEAS . Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. BJOG: an international journal of obstetrics and gynaecology2016;123(7):1161-6. KamyarM , VarnerM , ClarkE . Magnesium sulfate neuroprophylaxis and the effect of infant sex. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S144. ManuckA , ShengX , YoderA , VarnerW . Correlation between initial neonatal and early childhood outcomes following preterm birth. American Journal of Obstetrics &amp; Gynecology2014;210(5):426.e1-9. ManuckT , ShengX , YoderB , VarnerM . Correlation between initial neonatal and early childhood outcomes among children delivered &lt;34 weeks gestation. American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S23. ManuckT , VarnerM . Is bigger better? Neonatal and childhood outcomes of large for gestational age (LGA) infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341-2. ManuckT , VarnerM . Neonatal and childhood outcomes following early vs later preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S340-1. ManuckT , VarnerM . Neonatal and childhood outcomes of small for gestational age infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341. ManuckTA , VarnerMW . Neonatal and early childhood outcomes following early vs later preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2014;211(3):308.e1-6. MarrsC , Mendez-FigueroaH , ChauhanS . Periventricular leukomalacia with PPROM: Obstetric antecedents and infants' outcomes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S85. MarrsCC , Mendez-FigueroaH , HammadIA , ChauhanSP . Differential morbidity in preterm small versus appropriate for gestational age: perhaps unverifiable. American Journal of Perinatology2015;32(13):1251-6. McPhersonJ , SmileyS , StamiloD . Magnesium sulfate neuroprotection and obesity: Is efficacy affected by obesity. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S218. McPhersonJA , RouseDJ , GrobmanWA , PalatnikA , StamilioDM . Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. Obstetrics and Gynecology2014;124(4):749-55. McPhersonJA , SmileyS , StamilioDM . Maternal obesity and neuroprotective magnesium sulfate. American Journal of Obstetrics and Gynecology2015;213(4):582.e1–6. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate &lt; 12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S252. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate for &gt;12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S104-5. Mendez-FigueroaH , ChauhanSP , PedrozaC , RefuerzoJS , DahlkeJD , RouseDJ . Preterm cesarean delivery for nonreassuring fetal heart rate: neonatal and neurologic morbidity. Obstetrics and Gynecology2015;125(3):636-42. Mendez-FigueroaH , DahlkeJD , ViteriOA , ChauhanSP , RouseDJ , SibaiBM , et al. Neonatal and infant outcomes in twin gestations with preterm premature rupture of membranes at 24-31 weeks of gestation. Obstetrics and Gynecology2014;124(2 Pt 1):323-31. MoussaH , Hosseini NasabS , FournieD , OntiverosA , AlkawasR , ChauhanS , et al. The impact of time of delivery on gestations complicated by preterm premature rupture of membranes: daytime versus nighttime. Journal of Maternal-Fetal &amp; Neonatal Medicine2019;32(20):3319-24. NCT00014989. Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) [Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)]. clinicaltrials.gov/show/NCT00014989 (first received 18 April 2001). NussEE , SpiegelmanJ , TuritzAL , Gyamfi-BannermanC . Childhood neurodevelopment after spontaneous versus indicated preterm birth. American Journal of Obstetrics and Gynecology MFM2020;2(2):100082. ObicanS , DrassinowerD , LevinH , Gyamfi-BannermanC . Mode of delivery at periviability and early childhood neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S124. OvertonE , BaptisteC , Gyamfi-BannermanC . 546: neurodevelopmental outcomes in late preterm and early term deliveries following antenatal corticosteroid exposure. American Journal of Obstetrics and Gynecology2019;220(1):S365-6. PalatnikA , RouseD , StamiloD , McPhersonJ , GrobmanW . The association between cerebral palsy or death and umbilical cord magnesium concentration. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S302. RobbinsLS , BlanchardCT , BiasiniFJ , PowellMF , CaseyBM , TitaAT , et al. General anesthesia for cesarean delivery and childhood neurodevelopmental and perinatal outcomes: a secondary analysis of a randomized controlled trial. International Journal of Obstetric Anesthesia2020;45:34-40. RobbinsLS , BlanchardCT , SinkeyRG , HarrisSL , TitaAT , HarperLM . Prenatal tobacco exposure and childhood neurodevelopment among infants born prematurely. American Journal of Perinatology2020;38(3):218-23. RobertsR , Ankumah N-A, ViteriO , Mendez-FigueroaH , ChauhanS , SibaiB . Significance of the absence of amniotic fluid from the cervical os with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S223. RouseD , HirtzD , ThomE , VarnerM , AlexanderJ , SpongC , et al. Magnesium sulfate for the prevention of cerebral palsy. New England Journal of Medicine2008;359:895-905. RouseD . A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. American Journal of Obstetrics and Gynecology2007;197(6):S2. RouseD . Magnesium sulfate (MGSO4) dose and timing, umbilical cord MG++ concentration: relationship to cerebral palsy. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S46. SagaramD , HaarEV , MillerR , Gyamfi-BannermanC . Birth order does not offer a neurologic advantage in twin pregnancy. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S427. SiegelAM , HeineRP , Dotters-KatzSK . The effect of non-penicillin antibiotic regimens on neonatal outcomes in preterm prelabor rupture of membranes. American Journal of Obstetrics and Gynecology2018;219(6):637. SonM , GrobmanWA , MillerES . Is mode of delivery associated with the risk of necrotizing enterocolitis?American Journal of Obstetrics and Gynecology2016;214(1 Suppl 1):S204-5. TuritzAL , TooGT , Gyamfi-BannermanC . Proximity of magnesium exposure to delivery and neonatal outcomes. American Journal of Obstetrics and Gynecology2016;215(4):508.e1-6. TwicklerD , McIntireD , AlexanderJ , LevenoK . Effects of magnesium sulfate on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S112. TwicklerDM , McIntireDD , AlexanderJM , LevenoKJ . Effects of magnesium sulfate on preterm fetal cerebral blood flow using Doppler analysis: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):21-5. Vander HaarE , GoldbergerA , Gyamfi-BannermanC . Mild intraventricular hemorrhage is not associated with low bayley scores at age 2. Reproductive Sciences2017;24(1 Suppl 1):83A. VilchezG , DaiJ , KumarK , MundyD , KontopoulosE , SokolRJ . Racial/ethnic disparities in magnesium sulfate neuroprotection: a subgroup analysis of a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(17):2304-11. VilchezG , DaiJ , LagosM , SokolRJ . Maternal side effects &amp; fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(2):178-83. WoodAM , PostAL , SwamyGK , GrotegutCA . Neonatal outcomes associated with noncephalic presentation at delivery in preterm birth. American Journal of Perinatology2018;35(12):1131-7. YadavaS , GarabedianM , SitA , El-SayedY . Use of magnesium sulfate and labor outcomes in PPROM at less than 37 weeks. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S203. YangM , VarnerMW , YoderB . Cord blood magnesium levels and nonneurologic outcomes in neonates less than 27 weeks gestational age. Journal of Investigative Medicine2019;67(1):86-7. ">Rouse 2008</a>; <a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a>). To date, only two RCTs have reported on school age follow‐up (<a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a>; <a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a>); the risk of attrition bias due to the proportion of participants lost was judged to be unclear for relevant outcomes. </p> <p>For the outcomes assessed using GRADE, we judged the evidence to be of high certainty (cerebral palsy (up to two years' corrected age); death or cerebral palsy (up to two years' corrected age)); moderate certainty (maternal adverse effects severe enough to stop treatment; mode of birth (caesarean section); postpartum haemorrhage; death (fetal, neonatal, or later (up to two years' corrected age)); major neurodevelopmental disability (up to two years' corrected age); death or major neurodevelopmental disability (up to two years' corrected age); any severe intraventricular haemorrhage (grade 3 or 4)); low certainty (severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest); chronic lung disease/bronchopulmonary dysplasia; death (fetal, neonatal, or later (up to school age)); cerebral palsy (school age); death or cerebral palsy (school age); death or major neurodevelopmental disability (school age)); or very low certainty (major neurodevelopmental disability (school age)). We downgraded the certainty of the evidence predominantly due to imprecision (uncertain effect estimates, with 95% CIs including both benefit and harm), design limitations (risk of bias, considering attrition for school age outcomes), and/or inconsistency (statistical heterogeneity). We did not downgrade outcomes for indirectness; however, we have noted potential concerns regarding our review's findings concerning applicability/generalisability above. See <a href="./full#CD004661-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD004661-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD004661-tbl-0003">summary of findings Table 3</a>. </p> <p>We recognise that with our many review outcomes, there is a risk of statistical type 1 error (a 'false‐positive' result). Results where there are very few RCTs included, or with moderate or substantial heterogeneity, and/or 'borderline statistical significance', should be interpreted with caution. </p> </section> <section id="CD004661-sec-0175"> <h3 class="title" id="CD004661-sec-0175">Potential biases in the review process</h3> <p>We took steps to minimise bias throughout the review process. The Cochrane Pregnancy and Childbirth Information Specialist conducted a detailed and systematic search, without language, date, or publication status restrictions. It is possible that additional RCTs assessing magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus have been published but not identified, and that further RCTs have been conducted but are not yet published, or both. Should we identify such RCTs in the future, we will assess them for inclusion in an update to this review. As there were a maximum of six RCTs included in our meta‐analyses, we were not able to formally investigate reporting biases (such as publication bias) using funnel plots. </p> <p>At least two review authors independently assessed RCTs for inclusion (including trustworthiness assessment), performed data extraction including risk of bias assessment, and assessed the certainty of the evidence (using GRADE), with any disagreements discussed until consensus was reached. Despite independent assessments, these processes, particularly assessing risk of bias and the certainty of the evidence, are inherently subjective and require a degree of interpretation. In all cases, we sought to be consistent and transparent, documenting our decisions and rationale. </p> <p>Seven of the nine review authors are also trialists/authors for one or more of the included RCTs (<a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a>: Caroline A Crowther, Lex W Doyle; <a href="./references#CD004661-bbs2-0002" title="ACTRN12611000491965. MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: neuroprotection trial [Does antenatal magnesium sulphate given to women at risk of imminent preterm birth (defined as planned or definitely expected in the next 24 hours) between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children at 2 years corrected age? - a randomised controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000491965 (first received 11 May 2011). CrowtherCA , AshwoodP , MiddletonPF , McPheeA , TranT , HardineJE , et al. Prenatal intravenous magnesium at 30-34 weeks’ gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial. JAMA2023;330(7):603-14. CrowtherCA , MiddletonPF , WilkinsonD , AshwoodP , HaslamR . Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) - study protocol. BMC Pregnancy and Childbirth2013;13(1):91. PoppeT , ThompsonB , BoardmanJP , BastinME , AlsweilerJ , DeibG , et al. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: the MagNUM Study. EBioMedicine2022;78:103923. ">Crowther 2023</a>: Caroline A Crowther, Philippa Middleton; <a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a>: Stéphane Marret; <a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a>: Peter Pryde; <a href="./references#CD004661-bbs2-0005" title="BrookfieldKF , O'MalleyK , Yeaton-MasseyA , ButwickAJ . Does magnesium sulfate exposure attenuate the effect of steroids administered for fetal lung maturation? In: Society for Obstetric Anesthesia and Perinatology (SOAP) 48th Annual Meeting; 2016 May 18-22; Boston USA. 2016:SA-32. BuhimschiCS , JablonskiKA , RouseDJ , VarnerMW , ReddyUM , MercerBM , et al. Cord blood haptoglobin, cerebral palsy and death in infants of women at risk for preterm birth: a secondary analysis of a randomised controlled trial. Eclinicalmedicine2019;9:11-8. CostantineMM , WeinerSJ , RouseDJ , HirtzDG , VarnerMW , SpongCY , et al. Umbilical cord blood biomarkers of neurologic injury and the risk of cerebral palsy or infant death. International Journal of Developmental Neuroscience2011;29(8):917-22. CostantineMM . Cord blood biomarkers and the risk of cerebral palsy or death. Reproductive Sciences2010;17(3 Suppl 1):65A. DeihlTE , SimhanHN . Antenatal magnesium sulfate and ponderal index from birth to age 2 in preterm male and female infants. Reproductive Sciences2017;24(Suppl 1):130A. DeihlTE , SimhanHN . Antenatal magnesium sulfate exposure and ponderal index in preterm infants. American Journal of Perinatology2019;36(3):329-34. DenobleAE , WuJ , MitchellCJ , HughesBL , Dotters-KatzSK . Chorioamnionitis versus intraamniotic infection among preterm deliveries-is postpartum infectious morbidity different?American Journal of Obstetrics and Gynecology MFM2020;2(3):100176. DrassinowerD , FriedmanAM , LevinH , ObicanSG , Gyamfi-BannermanC . Does magnesium exposure affect neonatal resuscitation? Presented as a poster at the 35th annual meeting of the society for maternal-fetal medicine, San Diego, CA, Feb. 2-7, 2015. American Journal of Obstetrics and Gynecology2015;213(3):424e1-5. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm prelabour rupture of membranes and neurodevelopmental outcomes: a secondary analysis. BJOG: an international journal of obstetrics and gynaecology2016;123(10):1629-35. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of cerebral palsy. Journal of Maternal-Fetal &amp; Neonatal Medicine2016;29(17):2748-52. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of neonatal sepsis. American Journal of Obstetrics and Gynecology2016;214(6):743.e1-6. DrassinowerD , LevinH , ObicanS , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on cerebral palsy. American Journal of Obstetrics and Gynecology2015;212(1):S310-1. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . Immediate neonatal outcomes in infants exposed to magnesium sulfate at the time of delivery. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S90. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1):S161-2. EdwardsJ , EdwardsL , SwamyG , GrotegutC . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S215-6. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Effect of cord blood magnesium level at birth on non-neurologic neonatal outcomes. American Journal of Perinatology2019;36(1):3-7. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. Journal of Maternal-Fetal &amp; Neonatal Medicine2018;31(9):1156-60. FaucettAM , MetzTD , DeWittPE , GibbsRS . Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2016;214(2):287.e1-5. HaarEV , Gyamfi-BannermanC , Coletta-LucasJ . Sepsis but not chorioamnionitis is associated with cerebral palsy. Reproductive Sciences2015;22:372A. HaarEV , Gyamfi-BannermanC , RandisTM . Abnormal brain imaging in infants exposed to chorioamnionitis and sepsis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl. 1):S11-2. HaarEV , LucasJC , D'AltonM , Gyamfi-BannermanC . The effect of chorioamnionitis on neurocognitive development at age 2. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S139-40. HerreraC , SilverRM , MajorH , VarnerMW , ClarkEAS . Triple I criteria and adverse neonatal and childhood outcomes after early preterm birth. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S250. HirtzDG , WeinerSJ , BulasD , DiPietroM , SeibertJ , RouseDJ , et al. Antenatal magnesium and cerebral palsy in preterm infants. Journal of Pediatrics2015;167(4):834-9.e3. HirtzDG . Effect of prenatal MgSO4 on head ultrasound imaging in preterm infants. Annals of Neurology2011;70(Suppl 15):S110. HortonA . The effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S209. HortonL , YingleiL , RouseJ , SpongY , LevenoJ , VarnerW , et al. Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Perinatology2015;32(4):387-92. JohnsonLH , MappDC , RouseDJ , SpongCY , MercerBM , LevenoKJ , et al. Association of cord blood magnesium concentration and neonatal resuscitation. Journal of Pediatrics2012;160(4):573-7.e1. KachikisA , WalkerC , McAdamsR , WaldorfKA , Gyamfi-BannermanC . Influence of preterm premature rupture of membranes on neonatal respiratory complications. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S215. KachikisA , WalkerCL , McAdamsRM , Gyamfi-BannermanC , Adams WaldorfKM . Phenotypic overlap in neonatal respiratory morbidity following preterm premature rupture of membranes versus spontaneous preterm labor. Journal of Maternal-fetal &amp; Neonatal Medicine2021;34(12):1941-8. KamyarM , ClarkEA , YoderBA , VarnerMW , ManuckTA . Antenatal magnesium sulfate, necrotizing enterocolitis, and death among neonates &lt; 28 weeks gestation. AJP Reports2016;6(1):e148-54. KamyarM , ClarkEAS , VarnerMW , ManuckTA . Chorioamnionitis prevents protective effect of magnesium sulfate in the preterm infant. Reproductive Sciences2014;21(3 Suppl 1):78A. KamyarM , ManuckTA , StoddardGJ , VarnerMW , ClarkEAS . Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. BJOG: an international journal of obstetrics and gynaecology2016;123(7):1161-6. KamyarM , VarnerM , ClarkE . Magnesium sulfate neuroprophylaxis and the effect of infant sex. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S144. ManuckA , ShengX , YoderA , VarnerW . Correlation between initial neonatal and early childhood outcomes following preterm birth. American Journal of Obstetrics &amp; Gynecology2014;210(5):426.e1-9. ManuckT , ShengX , YoderB , VarnerM . Correlation between initial neonatal and early childhood outcomes among children delivered &lt;34 weeks gestation. American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S23. ManuckT , VarnerM . Is bigger better? Neonatal and childhood outcomes of large for gestational age (LGA) infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341-2. ManuckT , VarnerM . Neonatal and childhood outcomes following early vs later preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S340-1. ManuckT , VarnerM . Neonatal and childhood outcomes of small for gestational age infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341. ManuckTA , VarnerMW . Neonatal and early childhood outcomes following early vs later preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2014;211(3):308.e1-6. MarrsC , Mendez-FigueroaH , ChauhanS . Periventricular leukomalacia with PPROM: Obstetric antecedents and infants' outcomes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S85. MarrsCC , Mendez-FigueroaH , HammadIA , ChauhanSP . Differential morbidity in preterm small versus appropriate for gestational age: perhaps unverifiable. American Journal of Perinatology2015;32(13):1251-6. McPhersonJ , SmileyS , StamiloD . Magnesium sulfate neuroprotection and obesity: Is efficacy affected by obesity. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S218. McPhersonJA , RouseDJ , GrobmanWA , PalatnikA , StamilioDM . Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. Obstetrics and Gynecology2014;124(4):749-55. McPhersonJA , SmileyS , StamilioDM . Maternal obesity and neuroprotective magnesium sulfate. American Journal of Obstetrics and Gynecology2015;213(4):582.e1–6. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate &lt; 12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S252. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate for &gt;12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S104-5. Mendez-FigueroaH , ChauhanSP , PedrozaC , RefuerzoJS , DahlkeJD , RouseDJ . Preterm cesarean delivery for nonreassuring fetal heart rate: neonatal and neurologic morbidity. Obstetrics and Gynecology2015;125(3):636-42. Mendez-FigueroaH , DahlkeJD , ViteriOA , ChauhanSP , RouseDJ , SibaiBM , et al. Neonatal and infant outcomes in twin gestations with preterm premature rupture of membranes at 24-31 weeks of gestation. Obstetrics and Gynecology2014;124(2 Pt 1):323-31. MoussaH , Hosseini NasabS , FournieD , OntiverosA , AlkawasR , ChauhanS , et al. The impact of time of delivery on gestations complicated by preterm premature rupture of membranes: daytime versus nighttime. Journal of Maternal-Fetal &amp; Neonatal Medicine2019;32(20):3319-24. NCT00014989. Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) [Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)]. clinicaltrials.gov/show/NCT00014989 (first received 18 April 2001). NussEE , SpiegelmanJ , TuritzAL , Gyamfi-BannermanC . Childhood neurodevelopment after spontaneous versus indicated preterm birth. American Journal of Obstetrics and Gynecology MFM2020;2(2):100082. ObicanS , DrassinowerD , LevinH , Gyamfi-BannermanC . Mode of delivery at periviability and early childhood neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S124. OvertonE , BaptisteC , Gyamfi-BannermanC . 546: neurodevelopmental outcomes in late preterm and early term deliveries following antenatal corticosteroid exposure. American Journal of Obstetrics and Gynecology2019;220(1):S365-6. PalatnikA , RouseD , StamiloD , McPhersonJ , GrobmanW . The association between cerebral palsy or death and umbilical cord magnesium concentration. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S302. RobbinsLS , BlanchardCT , BiasiniFJ , PowellMF , CaseyBM , TitaAT , et al. General anesthesia for cesarean delivery and childhood neurodevelopmental and perinatal outcomes: a secondary analysis of a randomized controlled trial. International Journal of Obstetric Anesthesia2020;45:34-40. RobbinsLS , BlanchardCT , SinkeyRG , HarrisSL , TitaAT , HarperLM . Prenatal tobacco exposure and childhood neurodevelopment among infants born prematurely. American Journal of Perinatology2020;38(3):218-23. RobertsR , Ankumah N-A, ViteriO , Mendez-FigueroaH , ChauhanS , SibaiB . Significance of the absence of amniotic fluid from the cervical os with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S223. RouseD , HirtzD , ThomE , VarnerM , AlexanderJ , SpongC , et al. Magnesium sulfate for the prevention of cerebral palsy. New England Journal of Medicine2008;359:895-905. RouseD . A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. American Journal of Obstetrics and Gynecology2007;197(6):S2. RouseD . Magnesium sulfate (MGSO4) dose and timing, umbilical cord MG++ concentration: relationship to cerebral palsy. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S46. SagaramD , HaarEV , MillerR , Gyamfi-BannermanC . Birth order does not offer a neurologic advantage in twin pregnancy. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S427. SiegelAM , HeineRP , Dotters-KatzSK . The effect of non-penicillin antibiotic regimens on neonatal outcomes in preterm prelabor rupture of membranes. American Journal of Obstetrics and Gynecology2018;219(6):637. SonM , GrobmanWA , MillerES . Is mode of delivery associated with the risk of necrotizing enterocolitis?American Journal of Obstetrics and Gynecology2016;214(1 Suppl 1):S204-5. TuritzAL , TooGT , Gyamfi-BannermanC . Proximity of magnesium exposure to delivery and neonatal outcomes. American Journal of Obstetrics and Gynecology2016;215(4):508.e1-6. TwicklerD , McIntireD , AlexanderJ , LevenoK . Effects of magnesium sulfate on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S112. TwicklerDM , McIntireDD , AlexanderJM , LevenoKJ . Effects of magnesium sulfate on preterm fetal cerebral blood flow using Doppler analysis: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):21-5. Vander HaarE , GoldbergerA , Gyamfi-BannermanC . Mild intraventricular hemorrhage is not associated with low bayley scores at age 2. Reproductive Sciences2017;24(1 Suppl 1):83A. VilchezG , DaiJ , KumarK , MundyD , KontopoulosE , SokolRJ . Racial/ethnic disparities in magnesium sulfate neuroprotection: a subgroup analysis of a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(17):2304-11. VilchezG , DaiJ , LagosM , SokolRJ . Maternal side effects &amp; fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(2):178-83. WoodAM , PostAL , SwamyGK , GrotegutCA . Neonatal outcomes associated with noncephalic presentation at delivery in preterm birth. American Journal of Perinatology2018;35(12):1131-7. YadavaS , GarabedianM , SitA , El-SayedY . Use of magnesium sulfate and labor outcomes in PPROM at less than 37 weeks. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S203. YangM , VarnerMW , YoderB . Cord blood magnesium levels and nonneurologic outcomes in neonates less than 27 weeks gestational age. Journal of Investigative Medicine2019;67(1):86-7. ">Rouse 2008</a>: Dwight J Rouse; <a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a>: Hanne Trap Wolf). For these RCTs, Emily Shepherd and a second review author not involved in the RCT assessed it for eligibility. Emily Shepherd and Shona Goldsmith conducted data extraction including risk of bias assessment for all RCTs. </p> </section> <section id="CD004661-sec-0176"> <h3 class="title" id="CD004661-sec-0176">Agreements and disagreements with other studies or reviews</h3> <p>Our review provides the most up‐to‐date and comprehensive assessment of trustworthy evidence. </p> <p>The results and conclusions of our review are broadly consistent with those of prior systematic reviews (<a href="./references#CD004661-bbs2-0030" title="Conde-AgudeloA , RomeroR . Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis. American Journal of Obstetrics and Gynecology2009;200(6):595-609.">Conde‐Agudelo 2009</a>; <a href="./references#CD004661-bbs2-0031" title="CostantineMM , WeinerSJ . Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis. Obstetrics &amp; Gynecology2009;114(2 Pt 1):354-64.">Costantine 2009</a>; <a href="./references#CD004661-bbs2-0063" title="WolfHT , HuusomLD , HenriksenTB , HeggardHK , BrokJ , PinborgA . Magnesium sulphate for fetal neuroprotection at imminent risk for preterm delivery: a systematic review with meta-analysis and trial sequential analysis. BJOG: an international journal of obstetrics &amp; gynaecology2020;127(10):1180-8.">Wolf 2020</a>; <a href="./references#CD004661-bbs2-0064" title="ZengX , XueY , TianQ , SunR , AnR . Effects and safety of magnesium sulfate on neuroprotection: A meta-analysis based on PRISMA guidelines. Medicine (Baltimore)2016;95(1):e2451.">Zeng 2016</a>). These reviews have previously confirmed the neuroprotective role of magnesium sulphate in women at risk of preterm birth, demonstrating reductions in outcomes for children up to two years' corrected age, including cerebral palsy, moderate or severe cerebral palsy, substantial gross motor dysfunction, and death or cerebral palsy, without an increase in death. Our review is also broadly consistent with previous comprehensive reviews of adverse maternal and neonatal outcomes associated with magnesium sulphate (when used for the prevention or treatment of eclampsia, for preventing preterm labour and birth (tocolysis), and fetal neuroprotection) (<a href="./references#CD004661-bbs2-0026" title="BainES , MiddletonPF , CrowtherCA . Maternal adverse effects of different antenatal magnesium sulphate regimens for improving maternal and infant outcomes: a systematic review. BMC Pregnancy and Childbirth2013;13:195.">Bain 2013</a>; <a href="./references#CD004661-bbs2-0058" title="ShepherdE , SalamRA , ManhasD , SynnesA , MiddletonP , Makrides et al. Antenatal magnesium sulphate and adverse neonatal outcomes: A systematic review and meta-analysis. PLOS Medicine2019;16(12):e1002988.">Shepherd 2019</a>). Magnesium sulphate has not been shown to increase serious maternal adverse effects (death, cardiac arrest, respiratory arrest), though an increase in comparatively 'minor' adverse effects and treatment cessation has been shown (<a href="./references#CD004661-bbs2-0026" title="BainES , MiddletonPF , CrowtherCA . Maternal adverse effects of different antenatal magnesium sulphate regimens for improving maternal and infant outcomes: a systematic review. BMC Pregnancy and Childbirth2013;13:195.">Bain 2013</a>). Magnesium sulphate has also not been shown to increase neonatal adverse outcomes, including death (<a href="./references#CD004661-bbs2-0058" title="ShepherdE , SalamRA , ManhasD , SynnesA , MiddletonP , Makrides et al. Antenatal magnesium sulphate and adverse neonatal outcomes: A systematic review and meta-analysis. PLOS Medicine2019;16(12):e1002988.">Shepherd 2019</a>). </p> <p>The most recent systematic review on this topic (<a href="./references#CD004661-bbs2-0063" title="WolfHT , HuusomLD , HenriksenTB , HeggardHK , BrokJ , PinborgA . Magnesium sulphate for fetal neuroprotection at imminent risk for preterm delivery: a systematic review with meta-analysis and trial sequential analysis. BJOG: an international journal of obstetrics &amp; gynaecology2020;127(10):1180-8.">Wolf 2020</a>) was the first to include data from the <a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a> RCT. While it also included the <a href="./references#CD004661-bbs2-0010" title="DuleyL . The Magpie Trial follow up study: Outcome after discharge from hospital for women and children recruited to a trial comparing magnesium sulphate with placebo for pre-eclampsia [ISRCTN86938761]. BMC Pregnancy and Childbirth2004;4(1):5. Magpie Trial Follow Up Study Collaborative Group. The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months. BJOG: an international journal of obstetrics and gynaecology2007;114(3):289-99. ">Magpie 2006</a> RCT (now excluded from this review; see <a href="#CD004661-sec-0198">Differences between protocol and review</a>), its overall findings/conclusions are consistent with ours. Our review is the first to include data from the <a href="./references#CD004661-bbs2-0002" title="ACTRN12611000491965. MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: neuroprotection trial [Does antenatal magnesium sulphate given to women at risk of imminent preterm birth (defined as planned or definitely expected in the next 24 hours) between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children at 2 years corrected age? - a randomised controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000491965 (first received 11 May 2011). CrowtherCA , AshwoodP , MiddletonPF , McPheeA , TranT , HardineJE , et al. Prenatal intravenous magnesium at 30-34 weeks’ gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial. JAMA2023;330(7):603-14. CrowtherCA , MiddletonPF , WilkinsonD , AshwoodP , HaslamR . Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) - study protocol. BMC Pregnancy and Childbirth2013;13(1):91. PoppeT , ThompsonB , BoardmanJP , BastinME , AlsweilerJ , DeibG , et al. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: the MagNUM Study. EBioMedicine2022;78:103923. ">Crowther 2023</a> RCT. This RCT was designed to assess the effect of magnesium sulphate at 30 to 34 weeks' gestation (beyond the gestational age currently recommended in some countries based on the previous version of this review (<a href="./references#CD004661-bbs2-0067" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. Art. No: CD004661. [DOI: 10.1002/14651858.CD004661.pub3]">Doyle 2009</a>)) (<a href="./references#CD004661-bbs2-0044" title="JayaramPM , MohanMK , FaridI , LindowS . Antenatal magnesium sulfate for fetal neuroprotection: a critical appraisal and systematic review of clinical practice guidelines. Journal of Perinatal Medicine2019;47(3):262-9.">Jayaram 2019</a>). While a reduction in the RCT's composite primary outcome (death or cerebral palsy for children at two years' corrected age; or the separate components) was not shown, the authors recognised the limited power to detect small between‐group differences due to the lower event rates for death and cerebral palsy than predicted and the RCT's sample size (<a href="./references#CD004661-bbs2-0002" title="ACTRN12611000491965. MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: neuroprotection trial [Does antenatal magnesium sulphate given to women at risk of imminent preterm birth (defined as planned or definitely expected in the next 24 hours) between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children at 2 years corrected age? - a randomised controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000491965 (first received 11 May 2011). CrowtherCA , AshwoodP , MiddletonPF , McPheeA , TranT , HardineJE , et al. Prenatal intravenous magnesium at 30-34 weeks’ gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial. JAMA2023;330(7):603-14. CrowtherCA , MiddletonPF , WilkinsonD , AshwoodP , HaslamR . Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) - study protocol. BMC Pregnancy and Childbirth2013;13(1):91. PoppeT , ThompsonB , BoardmanJP , BastinME , AlsweilerJ , DeibG , et al. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: the MagNUM Study. EBioMedicine2022;78:103923. ">Crowther 2023</a>). Despite the absence of benefit observed in <a href="./references#CD004661-bbs2-0002" title="ACTRN12611000491965. MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: neuroprotection trial [Does antenatal magnesium sulphate given to women at risk of imminent preterm birth (defined as planned or definitely expected in the next 24 hours) between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children at 2 years corrected age? - a randomised controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000491965 (first received 11 May 2011). CrowtherCA , AshwoodP , MiddletonPF , McPheeA , TranT , HardineJE , et al. Prenatal intravenous magnesium at 30-34 weeks’ gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial. JAMA2023;330(7):603-14. CrowtherCA , MiddletonPF , WilkinsonD , AshwoodP , HaslamR . Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) - study protocol. BMC Pregnancy and Childbirth2013;13(1):91. PoppeT , ThompsonB , BoardmanJP , BastinME , AlsweilerJ , DeibG , et al. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: the MagNUM Study. EBioMedicine2022;78:103923. ">Crowther 2023</a>, the addition of its data to our review's meta‐analysis did not negate the overall neuroprotective benefits observed with this treatment. </p> <p>To date, only one other systematic review has reported on school age outcomes of antenatal magnesium sulphate for fetal neuroprotection (<a href="./references#CD004661-bbs2-0045" title="KobayashiA , ItoM , OtaE , NambaF . School-age outcomes of antenatal magnesium sulphate in preterm infants. Children2023;10(8):1324.">Kobayashi 2023</a>). Its findings supported ours, that is an absence of clear benefits or harms, and the need for additional follow‐up data to determine effects with greater certainty. </p> <p>The findings of our review's limited subgroup analyses are consistent with those from a previous individual participant data meta‐analysis (<a href="./references#CD004661-bbs2-0033" title="CrowtherCA , MiddletonPF , VoyseyM , AskieL , DuleyL , PrydePG , MarretS , DoyleLW . Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: An individual participant data meta-analysis. PLoS Medicine2017;14(10):e1002398.">Crowther 2017</a>), which similarly demonstrated reductions for children up to two years' corrected age in cerebral palsy, and death or cerebral palsy, with benefit not clearly affected by characteristics including preterm gestational age, and treatment regimen. With the availability of individual participant data, the meta‐analyses were able to assess the impacts of characteristics (such as the reason women were at risk of preterm birth; and total dose received by women) that we were not able to explore in our review, due to limitations of the aggregate data available from the included RCTs. There is now an important opportunity and need to extend/update the previous individual participant data meta‐analysis to include the more recent RCTs (<a href="./references#CD004661-bbs2-0002" title="ACTRN12611000491965. MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: neuroprotection trial [Does antenatal magnesium sulphate given to women at risk of imminent preterm birth (defined as planned or definitely expected in the next 24 hours) between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children at 2 years corrected age? - a randomised controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000491965 (first received 11 May 2011). CrowtherCA , AshwoodP , MiddletonPF , McPheeA , TranT , HardineJE , et al. Prenatal intravenous magnesium at 30-34 weeks’ gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial. JAMA2023;330(7):603-14. CrowtherCA , MiddletonPF , WilkinsonD , AshwoodP , HaslamR . Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) - study protocol. BMC Pregnancy and Childbirth2013;13(1):91. PoppeT , ThompsonB , BoardmanJP , BastinME , AlsweilerJ , DeibG , et al. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: the MagNUM Study. EBioMedicine2022;78:103923. ">Crowther 2023</a>; <a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a>), and longer‐term (school age) follow‐up data (from <a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a>; <a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a>). </p> <p>The current international guideline from the World Health Organization on interventions to improve preterm birth outcomes used the previous version of this Cochrane review, <a href="./references#CD004661-bbs2-0067" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. Art. No: CD004661. [DOI: 10.1002/14651858.CD004661.pub3]">Doyle 2009</a>, on which to base their recommendation (<a href="./references#CD004661-bbs2-0061" title="World Health Organization. WHO recommendations on interventions to improve preterm birth outcomes. www.who.int/publications/i/item/9789241508988;(accessed 18 October 2023).">WHO 2015</a>). Similarly, the clinical practice guideline recommendations provided by professional bodies in many high‐income countries (summarised in the systematic review <a href="./references#CD004661-bbs2-0044" title="JayaramPM , MohanMK , FaridI , LindowS . Antenatal magnesium sulfate for fetal neuroprotection: a critical appraisal and systematic review of clinical practice guidelines. Journal of Perinatal Medicine2019;47(3):262-9.">Jayaram 2019</a>) are based on the previous version of this review (<a href="./references#CD004661-bbs2-0067" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. Art. No: CD004661. [DOI: 10.1002/14651858.CD004661.pub3]">Doyle 2009</a>). While available guidelines all support the use of this treatment for preterm cerebral palsy prevention, as systematic reviews and meta‐analysis have not supported a particular upper gestational age or dosing regimen, recommendations vary (e.g. recommending use in women at less than 30 weeks' gestation, or up to 34 weeks' gestation) (<a href="./references#CD004661-bbs2-0044" title="JayaramPM , MohanMK , FaridI , LindowS . Antenatal magnesium sulfate for fetal neuroprotection: a critical appraisal and systematic review of clinical practice guidelines. Journal of Perinatal Medicine2019;47(3):262-9.">Jayaram 2019</a>). As noted above, the opportunity to further investigate which women to treat (i.e. considering the primary reason women are at risk of preterm birth, the number of babies in utero, and gestational age); when to treat (i.e. considering how long prior to anticipated or planned preterm birth); and how to treat (i.e. considering both loading‐dose and maintenance dose regimens) through an updated individual participant data meta‐analysis should be explored. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004661-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Process for screening eligible studies for scientific integrity/trustworthiness. Figure produced with permission from Cochrane Pregnancy and Childbirth." data-id="CD004661-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Process for screening eligible studies for scientific integrity/trustworthiness.<br/>Figure produced with permission from Cochrane Pregnancy and Childbirth. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/full#CD004661-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD004661-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/full#CD004661-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD004661-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/full#CD004661-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD004661-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/full#CD004661-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Magnesium sulphate versus placebo: primary outcomes, Outcome 1: Death (fetal, neonatal, or later (up to 2 years' corrected age))" data-id="CD004661-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Magnesium sulphate versus placebo: primary outcomes, Outcome 1: Death (fetal, neonatal, or later (up to 2 years' corrected age)) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Magnesium sulphate versus placebo: primary outcomes, Outcome 2: Cerebral palsy (up to 2 years' corrected age)" data-id="CD004661-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Magnesium sulphate versus placebo: primary outcomes, Outcome 2: Cerebral palsy (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Magnesium sulphate versus placebo: primary outcomes, Outcome 3: Death or cerebral palsy (up to 2 years' corrected age)" data-id="CD004661-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Magnesium sulphate versus placebo: primary outcomes, Outcome 3: Death or cerebral palsy (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Magnesium sulphate versus placebo: primary outcomes, Outcome 4: Major neurodevelopmental disability (up to 2 years' corrected age)" data-id="CD004661-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Magnesium sulphate versus placebo: primary outcomes, Outcome 4: Major neurodevelopmental disability (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Magnesium sulphate versus placebo: primary outcomes, Outcome 5: Death or major neurodevelopmental disability (up to 2 years' corrected age)" data-id="CD004661-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Magnesium sulphate versus placebo: primary outcomes, Outcome 5: Death or major neurodevelopmental disability (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Magnesium sulphate versus placebo: primary outcomes, Outcome 6: Death (fetal, neonatal, or later (up to school age))" data-id="CD004661-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Magnesium sulphate versus placebo: primary outcomes, Outcome 6: Death (fetal, neonatal, or later (up to school age)) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Magnesium sulphate versus placebo: primary outcomes, Outcome 7: Cerebral palsy (school age)" data-id="CD004661-fig-0011" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Magnesium sulphate versus placebo: primary outcomes, Outcome 7: Cerebral palsy (school age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Magnesium sulphate versus placebo: primary outcomes, Outcome 8: Death or cerebral palsy (up to school age)" data-id="CD004661-fig-0012" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Magnesium sulphate versus placebo: primary outcomes, Outcome 8: Death or cerebral palsy (up to school age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Magnesium sulphate versus placebo: primary outcomes, Outcome 9: Major neurodevelopmental disability (school age)" data-id="CD004661-fig-0013" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Magnesium sulphate versus placebo: primary outcomes, Outcome 9: Major neurodevelopmental disability (school age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Magnesium sulphate versus placebo: primary outcomes, Outcome 10: Death or major neurodevelopmental disability (up to school age)" data-id="CD004661-fig-0014" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Magnesium sulphate versus placebo: primary outcomes, Outcome 10: Death or major neurodevelopmental disability (up to school age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Magnesium sulphate versus placebo: primary outcomes, Outcome 11: Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest)" data-id="CD004661-fig-0015" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Magnesium sulphate versus placebo: primary outcomes, Outcome 11: Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Magnesium sulphate versus placebo: primary outcomes, Outcome 12: Adverse effects severe enough to stop treatment" data-id="CD004661-fig-0016" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Magnesium sulphate versus placebo: primary outcomes, Outcome 12: Adverse effects severe enough to stop treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 1: Fetal death" data-id="CD004661-fig-0017" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 1: Fetal death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 2: Neonatal death" data-id="CD004661-fig-0018" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 2: Neonatal death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 3: Birthweight" data-id="CD004661-fig-0019" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 3: Birthweight </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 4: Length at birth" data-id="CD004661-fig-0020" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 4: Length at birth </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 5: Head circumference at birth" data-id="CD004661-fig-0021" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 5: Head circumference at birth </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 6: Gestational age at birth (weeks)" data-id="CD004661-fig-0022" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 6: Gestational age at birth (weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 7: Apgar score less than 7 at 5 minutes" data-id="CD004661-fig-0023" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 7: Apgar score less than 7 at 5 minutes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 8: Use of active resuscitation at birth" data-id="CD004661-fig-0024" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 8: Use of active resuscitation at birth </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 9: Intraventricular haemorrhage" data-id="CD004661-fig-0025" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 9: Intraventricular haemorrhage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 10: Severe intraventricular haemorrhage (grade 3 or 4)" data-id="CD004661-fig-0026" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 10: Severe intraventricular haemorrhage (grade 3 or 4) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 11: Cystic periventricular leukomalacia" data-id="CD004661-fig-0027" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 11: Cystic periventricular leukomalacia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-002.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 12: Ventriculomegaly" data-id="CD004661-fig-0028" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-002.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 12: Ventriculomegaly </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-002.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 13: Neonatal encephalopathy" data-id="CD004661-fig-0029" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-002.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 13: Neonatal encephalopathy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-002.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 14: Neonatal convulsions" data-id="CD004661-fig-0030" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-002.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 14: Neonatal convulsions </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-002.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 15: Neonatal hypotonia" data-id="CD004661-fig-0031" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-002.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 15: Neonatal hypotonia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-002.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 16: Necrotising enterocolitis" data-id="CD004661-fig-0032" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-002.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 16: Necrotising enterocolitis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-002.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 17: Retinopathy of prematurity" data-id="CD004661-fig-0033" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-002.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 17: Retinopathy of prematurity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-002.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 18: Patent ductus arteriosus" data-id="CD004661-fig-0034" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-002.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 18: Patent ductus arteriosus </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-002.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 19: Respiratory distress syndrome" data-id="CD004661-fig-0035" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-002.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 19: Respiratory distress syndrome </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-002.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 20: Chronic lung disease/bronchopulmonary dysplasia" data-id="CD004661-fig-0036" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-002.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 20: Chronic lung disease/bronchopulmonary dysplasia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-002.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 21: Use of respiratory support (endotracheal intubation)" data-id="CD004661-fig-0037" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-002.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 21: Use of respiratory support (endotracheal intubation) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-002.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 22: Use of respiratory support (mechanical ventilation or continuous positive airway pressure)" data-id="CD004661-fig-0038" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-002.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 22: Use of respiratory support (mechanical ventilation or continuous positive airway pressure) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-002.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 23: Use of inotropic support" data-id="CD004661-fig-0039" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-002.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.23</div> <div class="figure-caption"> <p>Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 23: Use of inotropic support </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-002.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 24: Air leak syndrome" data-id="CD004661-fig-0040" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-002.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.24</div> <div class="figure-caption"> <p>Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 24: Air leak syndrome </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-002.25" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 25: Early‐ or late‐onset sepsis" data-id="CD004661-fig-0041" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.25.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-002.25.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.25</div> <div class="figure-caption"> <p>Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 25: Early‐ or late‐onset sepsis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.25.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-002.26" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 26: Severe adverse neonatal outcome composite" data-id="CD004661-fig-0042" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.26.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-002.26.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.26</div> <div class="figure-caption"> <p>Comparison 2: Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants, Outcome 26: Severe adverse neonatal outcome composite </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-002.26.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age), Outcome 1: Later death (up to 2 years' corrected age)" data-id="CD004661-fig-0043" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age), Outcome 1: Later death (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age), Outcome 2: Cerebral palsy severity (up to 2 years' corrected age)" data-id="CD004661-fig-0044" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age), Outcome 2: Cerebral palsy severity (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age), Outcome 3: Any neurodevelopmental disability (up to 2 years' corrected age)" data-id="CD004661-fig-0045" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age), Outcome 3: Any neurodevelopmental disability (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age), Outcome 4: Death or any neurodevelopmental disability (up to 2 years' corrected age)" data-id="CD004661-fig-0046" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age), Outcome 4: Death or any neurodevelopmental disability (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age), Outcome 5: Blindness (up to 2 years' corrected age)" data-id="CD004661-fig-0047" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age), Outcome 5: Blindness (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age), Outcome 6: Deafness (up to 2 years' corrected age)" data-id="CD004661-fig-0048" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age), Outcome 6: Deafness (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age), Outcome 7: Developmental delay/intellectual impairment (up to 2 years' corrected age)" data-id="CD004661-fig-0049" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age), Outcome 7: Developmental delay/intellectual impairment (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age), Outcome 8: Gross motor dysfunction (up to 2 years' corrected age)" data-id="CD004661-fig-0050" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age), Outcome 8: Gross motor dysfunction (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age), Outcome 9: Psychomotor dysfunction (up to 2 years' corrected age)" data-id="CD004661-fig-0051" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age), Outcome 9: Psychomotor dysfunction (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-003.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age), Outcome 10: Death or substantial gross motor dysfunction (up to 2 years' corrected age)" data-id="CD004661-fig-0052" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-003.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-003.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3: Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age), Outcome 10: Death or substantial gross motor dysfunction (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-003.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-003.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age), Outcome 11: Growth (up to 2 years' corrected age)" data-id="CD004661-fig-0053" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-003.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-003.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3: Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age), Outcome 11: Growth (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-003.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-003.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age), Outcome 12: Respiratory function (up to 2 years' corrected age)" data-id="CD004661-fig-0054" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-003.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-003.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3: Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age), Outcome 12: Respiratory function (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-003.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-003.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age), Outcome 13: Blood pressure (up to 2 years' corrected age)" data-id="CD004661-fig-0055" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-003.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-003.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3: Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age), Outcome 13: Blood pressure (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-003.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-003.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age), Outcome 14: Blood pressure (up to 2 years' corrected age)" data-id="CD004661-fig-0056" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-003.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-003.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3: Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age), Outcome 14: Blood pressure (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-003.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-003.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age), Outcome 15: Behaviour (up to 2 years' corrected age)" data-id="CD004661-fig-0057" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-003.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-003.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3: Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age), Outcome 15: Behaviour (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-003.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Magnesium sulphate versus placebo: secondary outcomes for children (school age), Outcome 1: Later death (school age)" data-id="CD004661-fig-0058" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Magnesium sulphate versus placebo: secondary outcomes for children (school age), Outcome 1: Later death (school age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Magnesium sulphate versus placebo: secondary outcomes for children (school age), Outcome 2: Cerebral palsy severity (school age)" data-id="CD004661-fig-0059" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Magnesium sulphate versus placebo: secondary outcomes for children (school age), Outcome 2: Cerebral palsy severity (school age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Magnesium sulphate versus placebo: secondary outcomes for children (school age), Outcome 3: Any neurodevelopmental disability (school age)" data-id="CD004661-fig-0060" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Magnesium sulphate versus placebo: secondary outcomes for children (school age), Outcome 3: Any neurodevelopmental disability (school age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Magnesium sulphate versus placebo: secondary outcomes for children (school age), Outcome 4: Death or any neurodevelopmental disability (school age)" data-id="CD004661-fig-0061" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Magnesium sulphate versus placebo: secondary outcomes for children (school age), Outcome 4: Death or any neurodevelopmental disability (school age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Magnesium sulphate versus placebo: secondary outcomes for children (school age), Outcome 5: Blindness (school age)" data-id="CD004661-fig-0062" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Magnesium sulphate versus placebo: secondary outcomes for children (school age), Outcome 5: Blindness (school age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Magnesium sulphate versus placebo: secondary outcomes for children (school age), Outcome 6: Deafness (school age)" data-id="CD004661-fig-0063" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Magnesium sulphate versus placebo: secondary outcomes for children (school age), Outcome 6: Deafness (school age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Magnesium sulphate versus placebo: secondary outcomes for children (school age), Outcome 7: Developmental delay/intellectual impairment (school age)" data-id="CD004661-fig-0064" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Magnesium sulphate versus placebo: secondary outcomes for children (school age), Outcome 7: Developmental delay/intellectual impairment (school age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Magnesium sulphate versus placebo: secondary outcomes for children (school age), Outcome 8: Gross motor dysfunction (school age)" data-id="CD004661-fig-0065" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: Magnesium sulphate versus placebo: secondary outcomes for children (school age), Outcome 8: Gross motor dysfunction (school age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-004.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Magnesium sulphate versus placebo: secondary outcomes for children (school age), Outcome 9: Death or substantial gross motor dysfunction (school age)" data-id="CD004661-fig-0066" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-004.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-004.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4: Magnesium sulphate versus placebo: secondary outcomes for children (school age), Outcome 9: Death or substantial gross motor dysfunction (school age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-004.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-004.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Magnesium sulphate versus placebo: secondary outcomes for children (school age), Outcome 10: Growth (school age)" data-id="CD004661-fig-0067" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-004.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-004.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4: Magnesium sulphate versus placebo: secondary outcomes for children (school age), Outcome 10: Growth (school age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-004.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-004.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Magnesium sulphate versus placebo: secondary outcomes for children (school age), Outcome 11: Respiratory function (school age)" data-id="CD004661-fig-0068" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-004.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-004.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4: Magnesium sulphate versus placebo: secondary outcomes for children (school age), Outcome 11: Respiratory function (school age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-004.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-004.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Magnesium sulphate versus placebo: secondary outcomes for children (school age), Outcome 12: Behaviour (school age)" data-id="CD004661-fig-0069" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-004.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-004.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4: Magnesium sulphate versus placebo: secondary outcomes for children (school age), Outcome 12: Behaviour (school age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-004.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-004.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Magnesium sulphate versus placebo: secondary outcomes for children (school age), Outcome 13: Behaviour (school age)" data-id="CD004661-fig-0070" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-004.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-004.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.13</div> <div class="figure-caption"> <p>Comparison 4: Magnesium sulphate versus placebo: secondary outcomes for children (school age), Outcome 13: Behaviour (school age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-004.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-004.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Magnesium sulphate versus placebo: secondary outcomes for children (school age), Outcome 14: Educational achievement (school age)" data-id="CD004661-fig-0071" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-004.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-004.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.14</div> <div class="figure-caption"> <p>Comparison 4: Magnesium sulphate versus placebo: secondary outcomes for children (school age), Outcome 14: Educational achievement (school age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-004.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-004.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Magnesium sulphate versus placebo: secondary outcomes for children (school age), Outcome 15: Educational achievement (school age)" data-id="CD004661-fig-0072" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-004.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-004.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.15</div> <div class="figure-caption"> <p>Comparison 4: Magnesium sulphate versus placebo: secondary outcomes for children (school age), Outcome 15: Educational achievement (school age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-004.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 1: Death" data-id="CD004661-fig-0073" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 1: Death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 2: Cardiac arrest" data-id="CD004661-fig-0074" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 2: Cardiac arrest </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 3: Respiratory arrest" data-id="CD004661-fig-0075" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 3: Respiratory arrest </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 4: Side effects of treatment" data-id="CD004661-fig-0076" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 4: Side effects of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 5: Side effect: respiratory depression" data-id="CD004661-fig-0077" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 5: Side effect: respiratory depression </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 6: Side effect: hypotension" data-id="CD004661-fig-0078" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 6: Side effect: hypotension </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 7: Side effect: tachycardia" data-id="CD004661-fig-0079" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 7: Side effect: tachycardia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-005.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 8: Side effect: warmth over body/flushing" data-id="CD004661-fig-0080" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-005.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 8: Side effect: warmth over body/flushing </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-005.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 9: Side effect: arm discomfort with infusion" data-id="CD004661-fig-0081" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-005.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 9: Side effect: arm discomfort with infusion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-005.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 10: Side effect: mouth dryness" data-id="CD004661-fig-0082" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-005.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 10: Side effect: mouth dryness </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-005.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 11: Side effect: nausea or vomiting" data-id="CD004661-fig-0083" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-005.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.11</div> <div class="figure-caption"> <p>Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 11: Side effect: nausea or vomiting </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-005.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 12: Side effect: sleepiness" data-id="CD004661-fig-0084" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-005.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.12</div> <div class="figure-caption"> <p>Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 12: Side effect: sleepiness </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-005.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 13: Side effect: sweating" data-id="CD004661-fig-0085" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-005.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.13</div> <div class="figure-caption"> <p>Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 13: Side effect: sweating </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-005.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 14: Side effect: dizziness" data-id="CD004661-fig-0086" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-005.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.14</div> <div class="figure-caption"> <p>Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 14: Side effect: dizziness </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-005.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 15: Side effect: blurred vision" data-id="CD004661-fig-0087" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-005.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.15</div> <div class="figure-caption"> <p>Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 15: Side effect: blurred vision </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-005.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 16: Side effect: tendon reflex abolition" data-id="CD004661-fig-0088" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-005.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.16</div> <div class="figure-caption"> <p>Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 16: Side effect: tendon reflex abolition </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-005.17" target="_blank"><b></b></a></p> </div><img alt='Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 17: Side effect: "curarisation"' data-id="CD004661-fig-0089" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-005.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.17</div> <div class="figure-caption"> <p>Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 17: Side effect: "curarisation" </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-005.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 18: Side effect: headache" data-id="CD004661-fig-0090" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-005.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.18</div> <div class="figure-caption"> <p>Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 18: Side effect: headache </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-005.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 19: Mode of birth: caesarean birth" data-id="CD004661-fig-0091" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-005.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.19</div> <div class="figure-caption"> <p>Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 19: Mode of birth: caesarean birth </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-005.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 20: Chorioamnionitis" data-id="CD004661-fig-0092" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-005.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.20</div> <div class="figure-caption"> <p>Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 20: Chorioamnionitis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-005.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 21: Postpartum haemorrhage" data-id="CD004661-fig-0093" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-005.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.21</div> <div class="figure-caption"> <p>Comparison 5: Magnesium sulphate versus placebo: secondary outcomes for women, Outcome 21: Postpartum haemorrhage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-005.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Magnesium sulphate versus placebo: secondary outcomes for health services, Outcome 1: Maternal admission to the intensive care unit" data-id="CD004661-fig-0094" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Magnesium sulphate versus placebo: secondary outcomes for health services, Outcome 1: Maternal admission to the intensive care unit </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Magnesium sulphate versus placebo: secondary outcomes for health services, Outcome 2: Length of postnatal hospitalisation for women (days)" data-id="CD004661-fig-0095" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Magnesium sulphate versus placebo: secondary outcomes for health services, Outcome 2: Length of postnatal hospitalisation for women (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Magnesium sulphate versus placebo: secondary outcomes for health services, Outcome 3: Length of neonatal/infant hospitalisation (days)" data-id="CD004661-fig-0096" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Magnesium sulphate versus placebo: secondary outcomes for health services, Outcome 3: Length of neonatal/infant hospitalisation (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Magnesium sulphate versus placebo: secondary outcomes for health services, Outcome 4: Hospital admissions (up to 2 years' corrected age)" data-id="CD004661-fig-0097" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Magnesium sulphate versus placebo: secondary outcomes for health services, Outcome 4: Hospital admissions (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Magnesium sulphate versus placebo: secondary outcomes for health services, Outcome 5: Postdischarge service (up to 2 years' corrected age)" data-id="CD004661-fig-0098" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: Magnesium sulphate versus placebo: secondary outcomes for health services, Outcome 5: Postdischarge service (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-006.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Magnesium sulphate versus placebo: secondary outcomes for health services, Outcome 6: Hospital admissions (school age)" data-id="CD004661-fig-0099" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-006.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-006.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6: Magnesium sulphate versus placebo: secondary outcomes for health services, Outcome 6: Hospital admissions (school age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-006.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Subgroup analysis: gestational age at randomisation, Outcome 1: Death (fetal, neonatal, or later (up to 2 years' corrected age))" data-id="CD004661-fig-0100" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Subgroup analysis: gestational age at randomisation, Outcome 1: Death (fetal, neonatal, or later (up to 2 years' corrected age)) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Subgroup analysis: gestational age at randomisation, Outcome 2: Cerebral palsy (up to 2 years' corrected age)" data-id="CD004661-fig-0101" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Subgroup analysis: gestational age at randomisation, Outcome 2: Cerebral palsy (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Subgroup analysis: gestational age at randomisation, Outcome 3: Death or cerebral palsy (up to 2 years' corrected age)" data-id="CD004661-fig-0102" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Subgroup analysis: gestational age at randomisation, Outcome 3: Death or cerebral palsy (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Subgroup analysis: gestational age at randomisation, Outcome 4: Death or major neurodevelopmental disability (up to 2 years' corrected age)" data-id="CD004661-fig-0103" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Subgroup analysis: gestational age at randomisation, Outcome 4: Death or major neurodevelopmental disability (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-007.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Subgroup analysis: gestational age at randomisation, Outcome 5: Death (fetal, neonatal, or later (up to school age))" data-id="CD004661-fig-0104" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-007.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-007.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7: Subgroup analysis: gestational age at randomisation, Outcome 5: Death (fetal, neonatal, or later (up to school age)) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-007.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-007.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Subgroup analysis: gestational age at randomisation, Outcome 6: Cerebral palsy (school age)" data-id="CD004661-fig-0105" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-007.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-007.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7: Subgroup analysis: gestational age at randomisation, Outcome 6: Cerebral palsy (school age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-007.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-007.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Subgroup analysis: gestational age at randomisation, Outcome 7: Major neurodevelopmental disability (school age)" data-id="CD004661-fig-0106" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-007.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-007.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7: Subgroup analysis: gestational age at randomisation, Outcome 7: Major neurodevelopmental disability (school age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-007.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-007.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Subgroup analysis: gestational age at randomisation, Outcome 8: Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest)" data-id="CD004661-fig-0107" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-007.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-007.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7: Subgroup analysis: gestational age at randomisation, Outcome 8: Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-007.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-007.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Subgroup analysis: gestational age at randomisation, Outcome 9: Adverse effects severe enough to stop treatment" data-id="CD004661-fig-0108" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-007.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-007.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.9</div> <div class="figure-caption"> <p>Comparison 7: Subgroup analysis: gestational age at randomisation, Outcome 9: Adverse effects severe enough to stop treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-007.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Subgroup analysis: loading‐dose regimen, Outcome 1: Death (fetal, neonatal, or later (up to 2 years' corrected age))" data-id="CD004661-fig-0109" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Subgroup analysis: loading‐dose regimen, Outcome 1: Death (fetal, neonatal, or later (up to 2 years' corrected age)) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Subgroup analysis: loading‐dose regimen, Outcome 2: Cerebral palsy (up to 2 years' corrected age)" data-id="CD004661-fig-0110" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Subgroup analysis: loading‐dose regimen, Outcome 2: Cerebral palsy (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Subgroup analysis: loading‐dose regimen, Outcome 3: Death or cerebral palsy (up to 2 years' corrected age)" data-id="CD004661-fig-0111" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Subgroup analysis: loading‐dose regimen, Outcome 3: Death or cerebral palsy (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-008.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Subgroup analysis: loading‐dose regimen, Outcome 4: Death or major neurodevelopmental disability (up to 2 years' corrected age)" data-id="CD004661-fig-0112" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-008.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-008.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8: Subgroup analysis: loading‐dose regimen, Outcome 4: Death or major neurodevelopmental disability (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-008.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-008.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Subgroup analysis: loading‐dose regimen, Outcome 5: Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest)" data-id="CD004661-fig-0113" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-008.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-008.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8: Subgroup analysis: loading‐dose regimen, Outcome 5: Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-008.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-008.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Subgroup analysis: loading‐dose regimen, Outcome 6: Adverse effects severe enough to stop treatment" data-id="CD004661-fig-0114" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-008.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-008.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8: Subgroup analysis: loading‐dose regimen, Outcome 6: Adverse effects severe enough to stop treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-008.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Subgroup analysis: maintenance dose regimen, Outcome 1: Death (fetal, neonatal, or later (up to 2 years' corrected age))" data-id="CD004661-fig-0115" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Subgroup analysis: maintenance dose regimen, Outcome 1: Death (fetal, neonatal, or later (up to 2 years' corrected age)) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Subgroup analysis: maintenance dose regimen, Outcome 2: Cerebral palsy (up to 2 years' corrected age)" data-id="CD004661-fig-0116" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Subgroup analysis: maintenance dose regimen, Outcome 2: Cerebral palsy (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Subgroup analysis: maintenance dose regimen, Outcome 3: Death or cerebral palsy (up to 2 years' corrected age)" data-id="CD004661-fig-0117" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: Subgroup analysis: maintenance dose regimen, Outcome 3: Death or cerebral palsy (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0118"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-009.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Subgroup analysis: maintenance dose regimen, Outcome 4: Death or major neurodevelopmental disability (up to 2 years' corrected age)" data-id="CD004661-fig-0118" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-009.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-009.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9: Subgroup analysis: maintenance dose regimen, Outcome 4: Death or major neurodevelopmental disability (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0118">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-009.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0119"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-009.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Subgroup analysis: maintenance dose regimen, Outcome 5: Death (fetal, neonatal, or later (up to school age))" data-id="CD004661-fig-0119" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-009.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-009.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9: Subgroup analysis: maintenance dose regimen, Outcome 5: Death (fetal, neonatal, or later (up to school age)) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0119">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-009.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0120"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-009.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Subgroup analysis: maintenance dose regimen, Outcome 6: Cerebral palsy (school age)" data-id="CD004661-fig-0120" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-009.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-009.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.6</div> <div class="figure-caption"> <p>Comparison 9: Subgroup analysis: maintenance dose regimen, Outcome 6: Cerebral palsy (school age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0120">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-009.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0121"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-009.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Subgroup analysis: maintenance dose regimen, Outcome 7: Major neurodevelopmental disability (school age)" data-id="CD004661-fig-0121" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-009.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-009.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.7</div> <div class="figure-caption"> <p>Comparison 9: Subgroup analysis: maintenance dose regimen, Outcome 7: Major neurodevelopmental disability (school age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0121">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-009.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0122"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-009.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Subgroup analysis: maintenance dose regimen, Outcome 8: Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest)" data-id="CD004661-fig-0122" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-009.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-009.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.8</div> <div class="figure-caption"> <p>Comparison 9: Subgroup analysis: maintenance dose regimen, Outcome 8: Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0122">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-009.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0123"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-009.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Subgroup analysis: maintenance dose regimen, Outcome 9: Adverse effects severe enough to stop treatment" data-id="CD004661-fig-0123" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-009.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-009.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.9</div> <div class="figure-caption"> <p>Comparison 9: Subgroup analysis: maintenance dose regimen, Outcome 9: Adverse effects severe enough to stop treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0123">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-009.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0124"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Subgroup analysis: repeat treatment permitted, Outcome 1: Death (fetal, neonatal, or later (up to 2 years' corrected age))" data-id="CD004661-fig-0124" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Subgroup analysis: repeat treatment permitted, Outcome 1: Death (fetal, neonatal, or later (up to 2 years' corrected age)) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0124">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0125"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Subgroup analysis: repeat treatment permitted, Outcome 2: Cerebral palsy (up to 2 years' corrected age)" data-id="CD004661-fig-0125" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Subgroup analysis: repeat treatment permitted, Outcome 2: Cerebral palsy (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0125">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0126"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-010.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Subgroup analysis: repeat treatment permitted, Outcome 3: Death or cerebral palsy (up to 2 years' corrected age)" data-id="CD004661-fig-0126" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-010.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-010.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10: Subgroup analysis: repeat treatment permitted, Outcome 3: Death or cerebral palsy (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0126">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-010.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0127"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-010.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Subgroup analysis: repeat treatment permitted, Outcome 4: Death or major neurodevelopmental disability (up to 2 years' corrected age)" data-id="CD004661-fig-0127" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-010.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-010.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10: Subgroup analysis: repeat treatment permitted, Outcome 4: Death or major neurodevelopmental disability (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0127">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-010.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0128"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-010.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Subgroup analysis: repeat treatment permitted, Outcome 5: Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest)" data-id="CD004661-fig-0128" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-010.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-010.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10: Subgroup analysis: repeat treatment permitted, Outcome 5: Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0128">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-010.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0129"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-010.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Subgroup analysis: repeat treatment permitted, Outcome 6: Adverse effects severe enough to stop treatment" data-id="CD004661-fig-0129" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-010.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-010.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.6</div> <div class="figure-caption"> <p>Comparison 10: Subgroup analysis: repeat treatment permitted, Outcome 6: Adverse effects severe enough to stop treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0129">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-010.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0130"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Sensitivity analysis, Outcome 1: Death (fetal, neonatal, or later (up to 2 years' corrected age))" data-id="CD004661-fig-0130" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: Sensitivity analysis, Outcome 1: Death (fetal, neonatal, or later (up to 2 years' corrected age)) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0130">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0131"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Sensitivity analysis, Outcome 2: Cerebral palsy (up to 2 years' corrected age)" data-id="CD004661-fig-0131" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: Sensitivity analysis, Outcome 2: Cerebral palsy (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0131">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0132"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-011.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Sensitivity analysis, Outcome 3: Death or cerebral palsy (up to 2 years' corrected age)" data-id="CD004661-fig-0132" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-011.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-011.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11: Sensitivity analysis, Outcome 3: Death or cerebral palsy (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0132">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-011.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0133"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-011.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Sensitivity analysis, Outcome 4: Death or major neurodevelopmental disability (up to 2 years' corrected age)" data-id="CD004661-fig-0133" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-011.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-011.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11: Sensitivity analysis, Outcome 4: Death or major neurodevelopmental disability (up to 2 years' corrected age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0133">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-011.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004661-fig-0134"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/urn:x-wiley:14651858:media:CD004661:CD004661-CMP-011.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Sensitivity analysis, Outcome 5: Cerebral palsy (school age)" data-id="CD004661-fig-0134" src="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-011.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_t/tCD004661-CMP-011.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.5</div> <div class="figure-caption"> <p>Comparison 11: Sensitivity analysis, Outcome 5: Cerebral palsy (school age)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-fig-0134">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/media/CDSR/CD004661/image_n/nCD004661-CMP-011.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD004661-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Magnesium sulphate versus placebo (outcomes for infants/children, up to 2 years' corrected age)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Magnesium sulphate versus placebo (outcomes for infants/children, up to 2 years' corrected age)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> women at risk of preterm birth (&lt; 34 weeks' gestation)<br/><b>Setting:</b> hospitals in high‐income countries<br/><b>Intervention:</b> magnesium sulphate<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with magnesium sulphate</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death (fetal, neonatal, or later (up to 2 years' corrected age))**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>78 per 1000 (66 to 92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.96</b> (0.82 to 1.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6759 (6 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy (up to 2 years' corrected age)**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000 (33 to 52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.71</b> (0.57 to 0.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6107 (6 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death or cerebral palsy (up to 2 years' corrected age)**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>138 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 per 1000 (106 to 135)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.87</b> (0.77 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6481 (6 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major neurodevelopmental disability (up to 2 years' corrected age)**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>162 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>177 per 1000 (135 to 233)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.09</b> (0.83 to 1.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>987 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death or major neurodevelopmental disability (up to 2 years' corrected age)**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>223 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>212 per 1000 (190 to 239)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b> (0.85 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4279 (3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe intraventricular haemorrhage (grade 3 or 4) (newborn/infant)**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000 (27 to 44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.76</b> (0.60 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5885 (5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic lung disease/bronchopulmonary dysplasia (newborn/infant)**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>183 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>168 per 1000 (141 to 201)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.92</b> (0.77 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6689 (5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>**Outcomes as defined by RCT authors.<br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded 1 level due to imprecision, as the 95% CI includes both benefit and harm.<br/><sup>b</sup>Not downgraded for risk of bias; however, data from 1 RCT from secondary analysis (result remained similar when this RCT was excluded from meta‐analysis).<br/><sup>c</sup>Downgraded 1 level due to risk of bias, as when data from 1 RCT with potential methodological concerns were excluded from the meta‐analysis the 95% CI includes the null value. <br/><sup>d</sup>Downgraded 1 level due to inconsistency as evidenced by statistical heterogeneity that could be due to variations in outcome definitions. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Magnesium sulphate versus placebo (outcomes for infants/children, up to 2 years' corrected age)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/full#CD004661-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004661-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Magnesium sulphate versus placebo (outcomes for infants/children, up to school age)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Magnesium sulphate versus placebo (outcomes for infants/children, up to school age)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> women at risk of preterm birth (&lt; 34 weeks' gestation)<br/><b>Setting:</b> hospitals in high‐income countries<br/><b>Intervention:</b> magnesium sulphate<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with magnesium sulphate</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death (fetal, neonatal, or later (up to school age))**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>169 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>139 per 1000 (112 to 172)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.82</b> (0.66 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1758 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy (school age)**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>103 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>102 per 1000 (71 to 145)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b> (0.69 to 1.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1038 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death or cerebral palsy (up to school age)**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>283 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>255 per 1000 (190 to 340)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.90</b> (0.67 to 1.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>503 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major neurodevelopmental disability (school age)**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>116 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>107 per 1000 (62 to 188)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.92</b> (0.53 to 1.62) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>940 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death or major neurodevelopmental disability (up to school age)**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>259 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>210 per 1000 (153 to 290)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.81</b> (0.59 to 1.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>503 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>**Outcomes as defined by RCT authors.<br/><b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded 1 level due to risk of bias, as the included RCTs were judged to have some limitations due to missing outcome data at school age follow‐up.<br/><sup>b</sup>Downgraded 1 level due to imprecision, as the 95% CI includes both benefit and harm.<br/><sup>c</sup>Downgraded 1 level due to inconsistency as evidenced by statistical heterogeneity that could be due to variations in outcome definitions. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Magnesium sulphate versus placebo (outcomes for infants/children, up to school age)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/full#CD004661-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004661-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Magnesium sulphate versus placebo (outcomes for women)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Magnesium sulphate versus placebo (outcomes for women)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> women at risk of preterm birth (&lt; 34 weeks' gestation)<br/><b>Setting:</b> hospitals in high‐income countries<br/><b>Intervention:</b> magnesium sulphate<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with magnesium sulphate</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest)** </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/>(0 to 8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.32</b> (0.01 to 7.92) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5300 (4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects severe enough to stop treatment**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1000 (36 to 104)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.21</b> (1.88 to 5.48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4736 (3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mode of birth (caesarean section)**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>476 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>457 per 1000 (433 to 486)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.96</b> (0.91 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5861 (5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Postpartum haemorrhage**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>216 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>203 per 1000 (173 to 235)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b> (0.80 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2495 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Breastfeeding at hospital discharge**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No RCTs reported data for this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women’s views of treatment**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No RCTs reported data for this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>**Outcomes as defined by RCT authors.<br/><b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded 2 levels due to imprecision, as there was only 1 event and a wide 95% CI includes both benefit and harm.<br/><sup>b</sup>Downgraded 1 level due to inconsistency as evidenced by statistical heterogeneity that could be due to differences in protocols for stopping treatment.<br/><sup>c</sup>Downgraded 1 level due to inconsistency as evidenced by statistical heterogeneity that could be due to differences in birth intervention practices.<br/><sup>d</sup>Downgraded 1 level due to imprecision, as the 95% CI includes both benefit and harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Magnesium sulphate versus placebo (outcomes for women)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/full#CD004661-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004661-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Participant characteristics related to planned subgroup analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RCT</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Primary reason women were at high risk of preterm birth</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of babies in utero</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Gestational age at entry/randomisation</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a> </p> </td> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Inclusion criteria</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women if birth was planned or expected within 24 h; excluded women in the second stage of labour </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Singleton, twin, triplet, or quadruplet pregnancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 30 weeks’ gestation (no lower gestational age limit)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Population characteristics, magnesium sulphate vs placebo, N (%) unless stated</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reason for preterm birth</b> </p> <p>Preterm labour: 335 (62.6) vs 330 (62.6)</p> <p>Pre‐eclampsia/eclampsia: 86 (16.1) vs 75 (14.2)</p> <p>Chorioamnionitis: 73 (13.6) vs 72 (13.7)</p> <p>Antepartum haemorrhage: 70 (13.1) vs 81 (15.4)</p> <p>Severe IUGR: 50 (9.3) vs 42 (8.2)</p> <p>PROM: 43 (8.0) vs 54 (10.2)</p> <p>Fetal distress: 20 (3.7) vs 13 (2.5)</p> <p>Other: 29 (5.4) vs 30 (5.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiples: 88 (16.4) vs 89 (16.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (IQR) gestational age at entry: 27 weeks 3 days (25 weeks 5 days to 28 weeks 5 days) vs 27 weeks 2 days (25 weeks 5 days to 28 weeks 5 days) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD004661-bbs2-0002" title="ACTRN12611000491965. MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: neuroprotection trial [Does antenatal magnesium sulphate given to women at risk of imminent preterm birth (defined as planned or definitely expected in the next 24 hours) between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children at 2 years corrected age? - a randomised controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000491965 (first received 11 May 2011). CrowtherCA , AshwoodP , MiddletonPF , McPheeA , TranT , HardineJE , et al. Prenatal intravenous magnesium at 30-34 weeks’ gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial. JAMA2023;330(7):603-14. CrowtherCA , MiddletonPF , WilkinsonD , AshwoodP , HaslamR . Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) - study protocol. BMC Pregnancy and Childbirth2013;13(1):91. PoppeT , ThompsonB , BoardmanJP , BastinME , AlsweilerJ , DeibG , et al. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: the MagNUM Study. EBioMedicine2022;78:103923. ">Crowther 2023</a> </p> </td> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Inclusion criteria</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women if birth was planned or definitely expected within 24 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Singleton or twin pregnancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 to &lt; 34 weeks’ gestation</p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Population characteristics, magnesium sulphate vs placebo, N (%) unless stated</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reason at risk for preterm birth</b> </p> <p>Preterm labour: 207 (28.4) vs 182 (25.9)</p> <p>PPROM: 206 (28.3) vs 183 (26.0)</p> <p>Fetal compromise: 129 (17.7) vs 129 (18.3)</p> <p>Pre‐eclampsia: 65 (8.9) vs 81 (11.5)</p> <p>Antepartum haemorrhage: 72 (9.9) vs 67 (9.5)</p> <p>Unspecified: 50 (6.9) vs 62 (8.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Twin pregnancy: 130 (17.8) vs 120 (17.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) gestational age at entry: 32.1 (1.1) vs 32.1 (1.1)</p> <p>30 to &lt; 32 weeks: 323 (44.3) vs 308 (43.8)</p> <p>32 to &lt; 34 weeks: 406 (55.7) vs 396 (56.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a> </p> </td> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Inclusion criteria</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women if birth was expected or planned within 24 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Singleton, twin, or triplet pregnancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 33 weeks’ gestational age (no lower limit, except those established at individual participating centres concerning viability) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Population characteristics, magnesium sulphate vs placebo, N (%) unless stated</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reasons for preterm birth</b> </p> <p>Preterm labour: 236 (84.0) vs 242 (88.3)</p> <p>PPROM: 187 (53.9) vs 156 (46.6)</p> <p>Chorioamnionitis: 27 (9.5) vs 34 (12.6)</p> <p>Antepartum haemorrhage: 54 (19.0) vs 54 (20.0)</p> <p>Other: 33 (9.8) vs 43 (13.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Singleton pregnancy: 222 (77.6) vs 220 (79.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (range) gestational age at entry: 30 weeks (24 weeks to 32 weeks 6 days) vs 30 weeks (23 weeks 4 days to 32 weeks 6 days) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a> </p> </td> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Inclusion criteria</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women in preterm labour (subgroup of women in active labour with cervical dilatation &gt; 4 cm) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Triplet and higher‐order gestations were excluded.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 24 and &lt; 34 completed weeks' gestation</p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Population characteristics, magnesium sulphate vs placebo, N (%) unless stated</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Twin pregnancy: 1 (3.4) vs 1 (3.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 28 weeks' gestation: 6 (20.7) vs 5 (17.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD004661-bbs2-0005" title="BrookfieldKF , O'MalleyK , Yeaton-MasseyA , ButwickAJ . Does magnesium sulfate exposure attenuate the effect of steroids administered for fetal lung maturation? In: Society for Obstetric Anesthesia and Perinatology (SOAP) 48th Annual Meeting; 2016 May 18-22; Boston USA. 2016:SA-32. BuhimschiCS , JablonskiKA , RouseDJ , VarnerMW , ReddyUM , MercerBM , et al. Cord blood haptoglobin, cerebral palsy and death in infants of women at risk for preterm birth: a secondary analysis of a randomised controlled trial. Eclinicalmedicine2019;9:11-8. CostantineMM , WeinerSJ , RouseDJ , HirtzDG , VarnerMW , SpongCY , et al. Umbilical cord blood biomarkers of neurologic injury and the risk of cerebral palsy or infant death. International Journal of Developmental Neuroscience2011;29(8):917-22. CostantineMM . Cord blood biomarkers and the risk of cerebral palsy or death. Reproductive Sciences2010;17(3 Suppl 1):65A. DeihlTE , SimhanHN . Antenatal magnesium sulfate and ponderal index from birth to age 2 in preterm male and female infants. Reproductive Sciences2017;24(Suppl 1):130A. DeihlTE , SimhanHN . Antenatal magnesium sulfate exposure and ponderal index in preterm infants. American Journal of Perinatology2019;36(3):329-34. DenobleAE , WuJ , MitchellCJ , HughesBL , Dotters-KatzSK . Chorioamnionitis versus intraamniotic infection among preterm deliveries-is postpartum infectious morbidity different?American Journal of Obstetrics and Gynecology MFM2020;2(3):100176. DrassinowerD , FriedmanAM , LevinH , ObicanSG , Gyamfi-BannermanC . Does magnesium exposure affect neonatal resuscitation? Presented as a poster at the 35th annual meeting of the society for maternal-fetal medicine, San Diego, CA, Feb. 2-7, 2015. American Journal of Obstetrics and Gynecology2015;213(3):424e1-5. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm prelabour rupture of membranes and neurodevelopmental outcomes: a secondary analysis. BJOG: an international journal of obstetrics and gynaecology2016;123(10):1629-35. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of cerebral palsy. Journal of Maternal-Fetal &amp; Neonatal Medicine2016;29(17):2748-52. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of neonatal sepsis. American Journal of Obstetrics and Gynecology2016;214(6):743.e1-6. DrassinowerD , LevinH , ObicanS , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on cerebral palsy. American Journal of Obstetrics and Gynecology2015;212(1):S310-1. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . Immediate neonatal outcomes in infants exposed to magnesium sulfate at the time of delivery. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S90. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1):S161-2. EdwardsJ , EdwardsL , SwamyG , GrotegutC . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S215-6. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Effect of cord blood magnesium level at birth on non-neurologic neonatal outcomes. American Journal of Perinatology2019;36(1):3-7. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. Journal of Maternal-Fetal &amp; Neonatal Medicine2018;31(9):1156-60. FaucettAM , MetzTD , DeWittPE , GibbsRS . Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2016;214(2):287.e1-5. HaarEV , Gyamfi-BannermanC , Coletta-LucasJ . Sepsis but not chorioamnionitis is associated with cerebral palsy. Reproductive Sciences2015;22:372A. HaarEV , Gyamfi-BannermanC , RandisTM . Abnormal brain imaging in infants exposed to chorioamnionitis and sepsis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl. 1):S11-2. HaarEV , LucasJC , D'AltonM , Gyamfi-BannermanC . The effect of chorioamnionitis on neurocognitive development at age 2. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S139-40. HerreraC , SilverRM , MajorH , VarnerMW , ClarkEAS . Triple I criteria and adverse neonatal and childhood outcomes after early preterm birth. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S250. HirtzDG , WeinerSJ , BulasD , DiPietroM , SeibertJ , RouseDJ , et al. Antenatal magnesium and cerebral palsy in preterm infants. Journal of Pediatrics2015;167(4):834-9.e3. HirtzDG . Effect of prenatal MgSO4 on head ultrasound imaging in preterm infants. Annals of Neurology2011;70(Suppl 15):S110. HortonA . The effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S209. HortonL , YingleiL , RouseJ , SpongY , LevenoJ , VarnerW , et al. Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Perinatology2015;32(4):387-92. JohnsonLH , MappDC , RouseDJ , SpongCY , MercerBM , LevenoKJ , et al. Association of cord blood magnesium concentration and neonatal resuscitation. Journal of Pediatrics2012;160(4):573-7.e1. KachikisA , WalkerC , McAdamsR , WaldorfKA , Gyamfi-BannermanC . Influence of preterm premature rupture of membranes on neonatal respiratory complications. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S215. KachikisA , WalkerCL , McAdamsRM , Gyamfi-BannermanC , Adams WaldorfKM . Phenotypic overlap in neonatal respiratory morbidity following preterm premature rupture of membranes versus spontaneous preterm labor. Journal of Maternal-fetal &amp; Neonatal Medicine2021;34(12):1941-8. KamyarM , ClarkEA , YoderBA , VarnerMW , ManuckTA . Antenatal magnesium sulfate, necrotizing enterocolitis, and death among neonates &lt; 28 weeks gestation. AJP Reports2016;6(1):e148-54. KamyarM , ClarkEAS , VarnerMW , ManuckTA . Chorioamnionitis prevents protective effect of magnesium sulfate in the preterm infant. Reproductive Sciences2014;21(3 Suppl 1):78A. KamyarM , ManuckTA , StoddardGJ , VarnerMW , ClarkEAS . Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. BJOG: an international journal of obstetrics and gynaecology2016;123(7):1161-6. KamyarM , VarnerM , ClarkE . Magnesium sulfate neuroprophylaxis and the effect of infant sex. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S144. ManuckA , ShengX , YoderA , VarnerW . Correlation between initial neonatal and early childhood outcomes following preterm birth. American Journal of Obstetrics &amp; Gynecology2014;210(5):426.e1-9. ManuckT , ShengX , YoderB , VarnerM . Correlation between initial neonatal and early childhood outcomes among children delivered &lt;34 weeks gestation. American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S23. ManuckT , VarnerM . Is bigger better? Neonatal and childhood outcomes of large for gestational age (LGA) infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341-2. ManuckT , VarnerM . Neonatal and childhood outcomes following early vs later preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S340-1. ManuckT , VarnerM . Neonatal and childhood outcomes of small for gestational age infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341. ManuckTA , VarnerMW . Neonatal and early childhood outcomes following early vs later preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2014;211(3):308.e1-6. MarrsC , Mendez-FigueroaH , ChauhanS . Periventricular leukomalacia with PPROM: Obstetric antecedents and infants' outcomes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S85. MarrsCC , Mendez-FigueroaH , HammadIA , ChauhanSP . Differential morbidity in preterm small versus appropriate for gestational age: perhaps unverifiable. American Journal of Perinatology2015;32(13):1251-6. McPhersonJ , SmileyS , StamiloD . Magnesium sulfate neuroprotection and obesity: Is efficacy affected by obesity. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S218. McPhersonJA , RouseDJ , GrobmanWA , PalatnikA , StamilioDM . Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. Obstetrics and Gynecology2014;124(4):749-55. McPhersonJA , SmileyS , StamilioDM . Maternal obesity and neuroprotective magnesium sulfate. American Journal of Obstetrics and Gynecology2015;213(4):582.e1–6. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate &lt; 12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S252. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate for &gt;12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S104-5. Mendez-FigueroaH , ChauhanSP , PedrozaC , RefuerzoJS , DahlkeJD , RouseDJ . Preterm cesarean delivery for nonreassuring fetal heart rate: neonatal and neurologic morbidity. Obstetrics and Gynecology2015;125(3):636-42. Mendez-FigueroaH , DahlkeJD , ViteriOA , ChauhanSP , RouseDJ , SibaiBM , et al. Neonatal and infant outcomes in twin gestations with preterm premature rupture of membranes at 24-31 weeks of gestation. Obstetrics and Gynecology2014;124(2 Pt 1):323-31. MoussaH , Hosseini NasabS , FournieD , OntiverosA , AlkawasR , ChauhanS , et al. The impact of time of delivery on gestations complicated by preterm premature rupture of membranes: daytime versus nighttime. Journal of Maternal-Fetal &amp; Neonatal Medicine2019;32(20):3319-24. NCT00014989. Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) [Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)]. clinicaltrials.gov/show/NCT00014989 (first received 18 April 2001). NussEE , SpiegelmanJ , TuritzAL , Gyamfi-BannermanC . Childhood neurodevelopment after spontaneous versus indicated preterm birth. American Journal of Obstetrics and Gynecology MFM2020;2(2):100082. ObicanS , DrassinowerD , LevinH , Gyamfi-BannermanC . Mode of delivery at periviability and early childhood neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S124. OvertonE , BaptisteC , Gyamfi-BannermanC . 546: neurodevelopmental outcomes in late preterm and early term deliveries following antenatal corticosteroid exposure. American Journal of Obstetrics and Gynecology2019;220(1):S365-6. PalatnikA , RouseD , StamiloD , McPhersonJ , GrobmanW . The association between cerebral palsy or death and umbilical cord magnesium concentration. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S302. RobbinsLS , BlanchardCT , BiasiniFJ , PowellMF , CaseyBM , TitaAT , et al. General anesthesia for cesarean delivery and childhood neurodevelopmental and perinatal outcomes: a secondary analysis of a randomized controlled trial. International Journal of Obstetric Anesthesia2020;45:34-40. RobbinsLS , BlanchardCT , SinkeyRG , HarrisSL , TitaAT , HarperLM . Prenatal tobacco exposure and childhood neurodevelopment among infants born prematurely. American Journal of Perinatology2020;38(3):218-23. RobertsR , Ankumah N-A, ViteriO , Mendez-FigueroaH , ChauhanS , SibaiB . Significance of the absence of amniotic fluid from the cervical os with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S223. RouseD , HirtzD , ThomE , VarnerM , AlexanderJ , SpongC , et al. Magnesium sulfate for the prevention of cerebral palsy. New England Journal of Medicine2008;359:895-905. RouseD . A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. American Journal of Obstetrics and Gynecology2007;197(6):S2. RouseD . Magnesium sulfate (MGSO4) dose and timing, umbilical cord MG++ concentration: relationship to cerebral palsy. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S46. SagaramD , HaarEV , MillerR , Gyamfi-BannermanC . Birth order does not offer a neurologic advantage in twin pregnancy. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S427. SiegelAM , HeineRP , Dotters-KatzSK . The effect of non-penicillin antibiotic regimens on neonatal outcomes in preterm prelabor rupture of membranes. American Journal of Obstetrics and Gynecology2018;219(6):637. SonM , GrobmanWA , MillerES . Is mode of delivery associated with the risk of necrotizing enterocolitis?American Journal of Obstetrics and Gynecology2016;214(1 Suppl 1):S204-5. TuritzAL , TooGT , Gyamfi-BannermanC . Proximity of magnesium exposure to delivery and neonatal outcomes. American Journal of Obstetrics and Gynecology2016;215(4):508.e1-6. TwicklerD , McIntireD , AlexanderJ , LevenoK . Effects of magnesium sulfate on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S112. TwicklerDM , McIntireDD , AlexanderJM , LevenoKJ . Effects of magnesium sulfate on preterm fetal cerebral blood flow using Doppler analysis: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):21-5. Vander HaarE , GoldbergerA , Gyamfi-BannermanC . Mild intraventricular hemorrhage is not associated with low bayley scores at age 2. Reproductive Sciences2017;24(1 Suppl 1):83A. VilchezG , DaiJ , KumarK , MundyD , KontopoulosE , SokolRJ . Racial/ethnic disparities in magnesium sulfate neuroprotection: a subgroup analysis of a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(17):2304-11. VilchezG , DaiJ , LagosM , SokolRJ . Maternal side effects &amp; fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(2):178-83. WoodAM , PostAL , SwamyGK , GrotegutCA . Neonatal outcomes associated with noncephalic presentation at delivery in preterm birth. American Journal of Perinatology2018;35(12):1131-7. YadavaS , GarabedianM , SitA , El-SayedY . Use of magnesium sulfate and labor outcomes in PPROM at less than 37 weeks. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S203. YangM , VarnerMW , YoderB . Cord blood magnesium levels and nonneurologic outcomes in neonates less than 27 weeks gestational age. Journal of Investigative Medicine2019;67(1):86-7. ">Rouse 2008</a> </p> </td> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Inclusion criteria</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women at high risk of spontaneous birth because of ROM, or advanced preterm labour with cervical dilatation of 4 to 8 cm and intact membranes, or an indicated preterm birth anticipated within 2 to 24 h; birth &lt; 2 h or cervical dilatation &gt; 8 cm, and ROM &lt; 22 weeks' gestation excluded </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Singleton or twin pregnancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 to 31 completed weeks’ gestation (&lt; 32 weeks' gestation)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Population characteristics, magnesium sulphate vs placebo, N (%) unless stated</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Qualifying eligibility criterion</b> </p> <p>PROM: 947 (86.4) vs 995 (86.9)</p> <p>Advanced preterm labour: 116 (10.6) vs 114 (10.0)</p> <p>Indicated preterm delivery: 33 (3.0) vs 36 (3.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Twin pregnancy: 92 (8.4) vs 111 (9.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) gestational age at randomisation: 28.3 (2.5) vs 28.2 (2.4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a> </p> </td> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Inclusion criteria</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women expected to give birth preterm within 2 to 24 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Singleton or twin pregnancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 + 0 to 31 + 6 weeks’ gestation</p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Population characteristics, magnesium sulphate vs placebo, N (%) unless stated</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary reason for preterm birth</b> </p> <p>Advanced preterm labour: 183 (64.7) vs 174 (62.8)</p> <p>Antepartum haemorrhage: 19 (6.7) vs 22 (7.9)</p> <p>Chorioamnionitis: 11 (3.9) vs 7 (2.5)</p> <p>Fetal distress: 5 (1.8) vs 4 (1.4)</p> <p>Pre‐eclampsia, eclampsia, HELLP: 3 (1.1) vs 4 (1.4)</p> <p>PPROM: 42 (14.8) vs 37 (13.4)</p> <p>Severe IUGR: 20 (7.1) vs 29 (10.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Twin pregnancy: 60 (21.2) vs 60 (21.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) gestational age at randomisation: 28.6 (2.3) vs 28.7 (2.2)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><b>Abbreviations:</b> HELLP: haemolysis, elevated liver enzymes, low platelet count; IQR: interquartile range; IUGR: intrauterine growth restriction; PPROM: preterm prelabour rupture of membranes; PROM: prelabour rupture of membranes; RCT: randomised controlled trial; ROM: rupture of membranes; SD: standard deviation </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Participant characteristics related to planned subgroup analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/full#CD004661-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004661-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Treatment characteristics related to planned subgroup analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RCT</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mode of administration</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Loading‐dose regimen</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Maintenance dose regimen</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Repeat treatment permitted</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Time of starting treatment prior to birth</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD004661-bbs2-0001" title="CrowtherCA , HillerJE , Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4. CrowtherCA , HillerJE , DoyleLW , Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA2003;290(20):2669-76. CrowtherCA , HillerJE , DoyleLW , HaslamRR . Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. In: Pediatric Academic Societies Annual Meeting; 2003 May 3-6; Seattle, Washington, USA. 2003. DoyleLW , AndersonPJ , HaslamR , LeeKJ , CrowtherC . School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA2014;312(11):1105-13. ParadisisM , EvansN , OsbornD , KluckowM , ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research2004;55 Suppl:114. ParadisisM , OsbornDA , EvansN , KluckowM . Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery neonatal cardiovascular effects. Journal of Perinatology2012;32(9):665-70. PoprzecznyAJ , OakeyH , CrowtherCA . Effect of infant gender on outcomes after antenatal administration of magnesium sulphate for neuroprotection prior to preterm birth from the ACTOMgSO4 trial. Journal of Paediatrics and Child Health2011;47(Suppl 1):101. ShepherdE , McIntyreS , Smithers-SheedyH , AshwoodP , SullivanTR , Te VeldeA , et al. Linking data from a large maternal perinatal clinical trial with the Australian cerebral palsy register for long-term follow up. Journal of Paediatrics and Child Health2020;56(Suppl 1):43. ShepherdE , McintyreS , AshwoodP , MiddletonP , MakridesM , CrowtherC . Comparison of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. Developmental Medicine and Child Neurology2020;62:27. SmithCA , CrowtherCA , WillsonK , HillerJE , DoyleLW . Placental transfer of magnesium sulphate: a randomised placebo controlled trial. In: Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48. ">Crowther 2003</a> </p> </td> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Treatment intended</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 g over 20 min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 g/h until birth (if within 24 h) or up to 24 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women eligible if birth was planned or expected within 24 h</p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Treatment as received, magnesium sulphate vs placebo, N (%) unless stated</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Started: 522 (97.5) vs 509 (96.6)</p> <p>Completed: 484 (90.5) vs 495 (93.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Started:</p> <p>451 (84.2) vs 459 (87.1)</p> <p>Completed:</p> <p>70 (13.1) vs 77 (14.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD004661-bbs2-0002" title="ACTRN12611000491965. MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: neuroprotection trial [Does antenatal magnesium sulphate given to women at risk of imminent preterm birth (defined as planned or definitely expected in the next 24 hours) between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children at 2 years corrected age? - a randomised controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000491965 (first received 11 May 2011). CrowtherCA , AshwoodP , MiddletonPF , McPheeA , TranT , HardineJE , et al. Prenatal intravenous magnesium at 30-34 weeks’ gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial. JAMA2023;330(7):603-14. CrowtherCA , MiddletonPF , WilkinsonD , AshwoodP , HaslamR . Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) - study protocol. BMC Pregnancy and Childbirth2013;13(1):91. PoppeT , ThompsonB , BoardmanJP , BastinME , AlsweilerJ , DeibG , et al. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: the MagNUM Study. EBioMedicine2022;78:103923. ">Crowther 2023</a> </p> </td> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Treatment intended</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 g over 30 min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women eligible if birth was planned or definitely expected within 24 h</p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Treatment as received, magnesium sulphate vs placebo, N (%) unless stated</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Received: 690 (94.7) vs 667 (94.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD004661-bbs2-0003" title="ChollatC , EnserM , HouivetE , ProvostD , BenichouJ , MarpeauL , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. Journal of Pediatrics2014;165(2):398-400. ChollatC , MarretS . Magnesium sulfate given before very-preterm birth to protect infant brain: the first long-term follow-up (PREMAG randomized trial). In: Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington DC, USA. 2013. MarretS , MarpeauL , AstrucD , CambonieG , FolletC , BenichouJ . Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. MarretS , MarpeauL , BenichouJ . Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics2008;121(1):225-6. MarretS , MarpeauL , Follet-BouhamedC , CambonieG , AstrucD , Delaporte B et al, for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique &amp; Fertilité2008;36:278-88. MarretS , MarpeauL , Zupan-SimunekV , EurinD , LévêqueC , Hellot MF et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology2007;114(3):310-8. MarretS , ZupanV , MarpeauL , Adde-MichelC , BenichouJ , the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005. NCT00120588. Neuroprotection by magnesium sulfate given to women at risk of very preterm birth [Effect of magnesium sulfate on the incidence of periventricular leukomalacia in the very preterm neonate]. clinicaltrials.gov/show/NCT00120588 (first received 18 July 2005). ">Marret 2006</a> </p> </td> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Treatment intended</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 g over 30 min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women eligible if birth was expected or planned within 24 h</p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Treatment as received, magnesium sulphate vs placebo, N (%) unless stated</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Started: 266 (93.0) vs 257 (92.4)</p> <p>Completed: 259 (90.6) vs 249 (89.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Interval from infusion to delivery, median (range): 1 h 38 min (5 min to 25 h 5 min) vs 1 h 30 min (8 min to 61 h 30 min) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD004661-bbs2-0004" title="MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , BesingerR , SantillanM , GianopoulosJ . When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S65. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeKS , SieglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?Lancet1997;350(9090):1517-8. MittendorfR , CovertR , ElinR , PrydeP , KhoshnoodB , Sun-LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics &amp; Gynecology2001;98:75-8. MittendorfR , DambrosiaJ , DammannO , PrydePG , LeeKS , Ben-Ami TE et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140(5):540-6. MittendorfR , DambrosiaJ , KhoshnoodB , Lee K-S, PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeKS , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , Besinger RE et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111-8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , Karlman R et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101-7. MittendorfR , PrydeP , KhoshnoodB , LeeKS . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?Obstetrics &amp; Gynecology1998;92(2):308-11. MittendorfR , PrydeP , Lee K-S, BesingerR , MacMillanW , Karlman R et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S131. MittendorfR , PrydeP , LeeKS , BesingerR , MacmillanW , Karlman R et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S74. MittendorfR , PrydePG , GianopoulosJG , LeeKS . Relationships between increased exposures to magnesium sulfate in preterm labor and total pediatric mortality. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S40. SantillanM , BesingerRE , GianopoulosJG , MittendorfR . An inverse correlation between umbilical cord blood ionized magnesium (IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S183. ">Mittendorf 2002</a> </p> </td> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Treatment intended</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 g bolus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Treatment as received, magnesium sulphate vs placebo, N (%) unless stated</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD004661-bbs2-0005" title="BrookfieldKF , O'MalleyK , Yeaton-MasseyA , ButwickAJ . Does magnesium sulfate exposure attenuate the effect of steroids administered for fetal lung maturation? In: Society for Obstetric Anesthesia and Perinatology (SOAP) 48th Annual Meeting; 2016 May 18-22; Boston USA. 2016:SA-32. BuhimschiCS , JablonskiKA , RouseDJ , VarnerMW , ReddyUM , MercerBM , et al. Cord blood haptoglobin, cerebral palsy and death in infants of women at risk for preterm birth: a secondary analysis of a randomised controlled trial. Eclinicalmedicine2019;9:11-8. CostantineMM , WeinerSJ , RouseDJ , HirtzDG , VarnerMW , SpongCY , et al. Umbilical cord blood biomarkers of neurologic injury and the risk of cerebral palsy or infant death. International Journal of Developmental Neuroscience2011;29(8):917-22. CostantineMM . Cord blood biomarkers and the risk of cerebral palsy or death. Reproductive Sciences2010;17(3 Suppl 1):65A. DeihlTE , SimhanHN . Antenatal magnesium sulfate and ponderal index from birth to age 2 in preterm male and female infants. Reproductive Sciences2017;24(Suppl 1):130A. DeihlTE , SimhanHN . Antenatal magnesium sulfate exposure and ponderal index in preterm infants. American Journal of Perinatology2019;36(3):329-34. DenobleAE , WuJ , MitchellCJ , HughesBL , Dotters-KatzSK . Chorioamnionitis versus intraamniotic infection among preterm deliveries-is postpartum infectious morbidity different?American Journal of Obstetrics and Gynecology MFM2020;2(3):100176. DrassinowerD , FriedmanAM , LevinH , ObicanSG , Gyamfi-BannermanC . Does magnesium exposure affect neonatal resuscitation? Presented as a poster at the 35th annual meeting of the society for maternal-fetal medicine, San Diego, CA, Feb. 2-7, 2015. American Journal of Obstetrics and Gynecology2015;213(3):424e1-5. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm prelabour rupture of membranes and neurodevelopmental outcomes: a secondary analysis. BJOG: an international journal of obstetrics and gynaecology2016;123(10):1629-35. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of cerebral palsy. Journal of Maternal-Fetal &amp; Neonatal Medicine2016;29(17):2748-52. DrassinowerD , FriedmanAM , ObicanSG , LevinH , Gyamfi-BannermanC . Prolonged latency of preterm premature rupture of membranes and risk of neonatal sepsis. American Journal of Obstetrics and Gynecology2016;214(6):743.e1-6. DrassinowerD , LevinH , ObicanS , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on cerebral palsy. American Journal of Obstetrics and Gynecology2015;212(1):S310-1. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . Immediate neonatal outcomes in infants exposed to magnesium sulfate at the time of delivery. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S90. DrassinowerD , ObicanS , LevinH , Gyamfi-BannermanC . The effect of prolonged latency of preterm premature rupture of membranes on neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1):S161-2. EdwardsJ , EdwardsL , SwamyG , GrotegutC . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S215-6. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Effect of cord blood magnesium level at birth on non-neurologic neonatal outcomes. American Journal of Perinatology2019;36(1):3-7. EdwardsJM , EdwardsLE , SwamyGK , GrotegutCA . Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. Journal of Maternal-Fetal &amp; Neonatal Medicine2018;31(9):1156-60. FaucettAM , MetzTD , DeWittPE , GibbsRS . Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2016;214(2):287.e1-5. HaarEV , Gyamfi-BannermanC , Coletta-LucasJ . Sepsis but not chorioamnionitis is associated with cerebral palsy. Reproductive Sciences2015;22:372A. HaarEV , Gyamfi-BannermanC , RandisTM . Abnormal brain imaging in infants exposed to chorioamnionitis and sepsis. American Journal of Obstetrics and Gynecology2016;214(1 Suppl. 1):S11-2. HaarEV , LucasJC , D'AltonM , Gyamfi-BannermanC . The effect of chorioamnionitis on neurocognitive development at age 2. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S139-40. HerreraC , SilverRM , MajorH , VarnerMW , ClarkEAS . Triple I criteria and adverse neonatal and childhood outcomes after early preterm birth. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S250. HirtzDG , WeinerSJ , BulasD , DiPietroM , SeibertJ , RouseDJ , et al. Antenatal magnesium and cerebral palsy in preterm infants. Journal of Pediatrics2015;167(4):834-9.e3. HirtzDG . Effect of prenatal MgSO4 on head ultrasound imaging in preterm infants. Annals of Neurology2011;70(Suppl 15):S110. HortonA . The effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S209. HortonL , YingleiL , RouseJ , SpongY , LevenoJ , VarnerW , et al. Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. American Journal of Perinatology2015;32(4):387-92. JohnsonLH , MappDC , RouseDJ , SpongCY , MercerBM , LevenoKJ , et al. Association of cord blood magnesium concentration and neonatal resuscitation. Journal of Pediatrics2012;160(4):573-7.e1. KachikisA , WalkerC , McAdamsR , WaldorfKA , Gyamfi-BannermanC . Influence of preterm premature rupture of membranes on neonatal respiratory complications. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S215. KachikisA , WalkerCL , McAdamsRM , Gyamfi-BannermanC , Adams WaldorfKM . Phenotypic overlap in neonatal respiratory morbidity following preterm premature rupture of membranes versus spontaneous preterm labor. Journal of Maternal-fetal &amp; Neonatal Medicine2021;34(12):1941-8. KamyarM , ClarkEA , YoderBA , VarnerMW , ManuckTA . Antenatal magnesium sulfate, necrotizing enterocolitis, and death among neonates &lt; 28 weeks gestation. AJP Reports2016;6(1):e148-54. KamyarM , ClarkEAS , VarnerMW , ManuckTA . Chorioamnionitis prevents protective effect of magnesium sulfate in the preterm infant. Reproductive Sciences2014;21(3 Suppl 1):78A. KamyarM , ManuckTA , StoddardGJ , VarnerMW , ClarkEAS . Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. BJOG: an international journal of obstetrics and gynaecology2016;123(7):1161-6. KamyarM , VarnerM , ClarkE . Magnesium sulfate neuroprophylaxis and the effect of infant sex. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S144. ManuckA , ShengX , YoderA , VarnerW . Correlation between initial neonatal and early childhood outcomes following preterm birth. American Journal of Obstetrics &amp; Gynecology2014;210(5):426.e1-9. ManuckT , ShengX , YoderB , VarnerM . Correlation between initial neonatal and early childhood outcomes among children delivered &lt;34 weeks gestation. American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S23. ManuckT , VarnerM . Is bigger better? Neonatal and childhood outcomes of large for gestational age (LGA) infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341-2. ManuckT , VarnerM . Neonatal and childhood outcomes following early vs later preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S340-1. ManuckT , VarnerM . Neonatal and childhood outcomes of small for gestational age infants delivered following preterm premature rupture of membranes (PPROM). American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S341. ManuckTA , VarnerMW . Neonatal and early childhood outcomes following early vs later preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2014;211(3):308.e1-6. MarrsC , Mendez-FigueroaH , ChauhanS . Periventricular leukomalacia with PPROM: Obstetric antecedents and infants' outcomes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S85. MarrsCC , Mendez-FigueroaH , HammadIA , ChauhanSP . Differential morbidity in preterm small versus appropriate for gestational age: perhaps unverifiable. American Journal of Perinatology2015;32(13):1251-6. McPhersonJ , SmileyS , StamiloD . Magnesium sulfate neuroprotection and obesity: Is efficacy affected by obesity. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S218. McPhersonJA , RouseDJ , GrobmanWA , PalatnikA , StamilioDM . Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. Obstetrics and Gynecology2014;124(4):749-55. McPhersonJA , SmileyS , StamilioDM . Maternal obesity and neuroprotective magnesium sulfate. American Journal of Obstetrics and Gynecology2015;213(4):582.e1–6. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate &lt; 12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S252. MeintsL , EdwardsA , LiuM . Value of magnesium sulfate for &gt;12 hours to prevent cerebral palsy and death. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S104-5. Mendez-FigueroaH , ChauhanSP , PedrozaC , RefuerzoJS , DahlkeJD , RouseDJ . Preterm cesarean delivery for nonreassuring fetal heart rate: neonatal and neurologic morbidity. Obstetrics and Gynecology2015;125(3):636-42. Mendez-FigueroaH , DahlkeJD , ViteriOA , ChauhanSP , RouseDJ , SibaiBM , et al. Neonatal and infant outcomes in twin gestations with preterm premature rupture of membranes at 24-31 weeks of gestation. Obstetrics and Gynecology2014;124(2 Pt 1):323-31. MoussaH , Hosseini NasabS , FournieD , OntiverosA , AlkawasR , ChauhanS , et al. The impact of time of delivery on gestations complicated by preterm premature rupture of membranes: daytime versus nighttime. Journal of Maternal-Fetal &amp; Neonatal Medicine2019;32(20):3319-24. NCT00014989. Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) [Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)]. clinicaltrials.gov/show/NCT00014989 (first received 18 April 2001). NussEE , SpiegelmanJ , TuritzAL , Gyamfi-BannermanC . Childhood neurodevelopment after spontaneous versus indicated preterm birth. American Journal of Obstetrics and Gynecology MFM2020;2(2):100082. ObicanS , DrassinowerD , LevinH , Gyamfi-BannermanC . Mode of delivery at periviability and early childhood neurodevelopment. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S124. OvertonE , BaptisteC , Gyamfi-BannermanC . 546: neurodevelopmental outcomes in late preterm and early term deliveries following antenatal corticosteroid exposure. American Journal of Obstetrics and Gynecology2019;220(1):S365-6. PalatnikA , RouseD , StamiloD , McPhersonJ , GrobmanW . The association between cerebral palsy or death and umbilical cord magnesium concentration. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S302. RobbinsLS , BlanchardCT , BiasiniFJ , PowellMF , CaseyBM , TitaAT , et al. General anesthesia for cesarean delivery and childhood neurodevelopmental and perinatal outcomes: a secondary analysis of a randomized controlled trial. International Journal of Obstetric Anesthesia2020;45:34-40. RobbinsLS , BlanchardCT , SinkeyRG , HarrisSL , TitaAT , HarperLM . Prenatal tobacco exposure and childhood neurodevelopment among infants born prematurely. American Journal of Perinatology2020;38(3):218-23. RobertsR , Ankumah N-A, ViteriO , Mendez-FigueroaH , ChauhanS , SibaiB . Significance of the absence of amniotic fluid from the cervical os with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S223. RouseD , HirtzD , ThomE , VarnerM , AlexanderJ , SpongC , et al. Magnesium sulfate for the prevention of cerebral palsy. New England Journal of Medicine2008;359:895-905. RouseD . A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. American Journal of Obstetrics and Gynecology2007;197(6):S2. RouseD . Magnesium sulfate (MGSO4) dose and timing, umbilical cord MG++ concentration: relationship to cerebral palsy. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S46. SagaramD , HaarEV , MillerR , Gyamfi-BannermanC . Birth order does not offer a neurologic advantage in twin pregnancy. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S427. SiegelAM , HeineRP , Dotters-KatzSK . The effect of non-penicillin antibiotic regimens on neonatal outcomes in preterm prelabor rupture of membranes. American Journal of Obstetrics and Gynecology2018;219(6):637. SonM , GrobmanWA , MillerES . Is mode of delivery associated with the risk of necrotizing enterocolitis?American Journal of Obstetrics and Gynecology2016;214(1 Suppl 1):S204-5. TuritzAL , TooGT , Gyamfi-BannermanC . Proximity of magnesium exposure to delivery and neonatal outcomes. American Journal of Obstetrics and Gynecology2016;215(4):508.e1-6. TwicklerD , McIntireD , AlexanderJ , LevenoK . Effects of magnesium sulfate on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S112. TwicklerDM , McIntireDD , AlexanderJM , LevenoKJ . Effects of magnesium sulfate on preterm fetal cerebral blood flow using Doppler analysis: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):21-5. Vander HaarE , GoldbergerA , Gyamfi-BannermanC . Mild intraventricular hemorrhage is not associated with low bayley scores at age 2. Reproductive Sciences2017;24(1 Suppl 1):83A. VilchezG , DaiJ , KumarK , MundyD , KontopoulosE , SokolRJ . Racial/ethnic disparities in magnesium sulfate neuroprotection: a subgroup analysis of a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(17):2304-11. VilchezG , DaiJ , LagosM , SokolRJ . Maternal side effects &amp; fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2018;31(2):178-83. WoodAM , PostAL , SwamyGK , GrotegutCA . Neonatal outcomes associated with noncephalic presentation at delivery in preterm birth. American Journal of Perinatology2018;35(12):1131-7. YadavaS , GarabedianM , SitA , El-SayedY . Use of magnesium sulfate and labor outcomes in PPROM at less than 37 weeks. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S203. YangM , VarnerMW , YoderB . Cord blood magnesium levels and nonneurologic outcomes in neonates less than 27 weeks gestational age. Journal of Investigative Medicine2019;67(1):86-7. ">Rouse 2008</a> </p> </td> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Treatment intended</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 g over 20 to 30 min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 g/h until birth or for up to 12 h (resumed if &lt; 6 h had passed and birth again appeared imminent) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If ≥ 6 h had passed since discontinuation, another loading dose was given.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clear, although women were not eligible if delivery was anticipated within less than 2 h; women with indicated preterm deliveries were eligible if birth was anticipated within 24 h </p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Treatment as received, magnesium sulphate vs placebo, N (%) unless stated</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Did not receive treatment:</p> <p>18 (1.6) vs 20 (1.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Received treatment for &lt; 3 h: 996 (90.9) vs 1024 (89.4)</p> <p>Received treatment for ≥ 3 h: 82 (7.5) vs 101 (8.8)</p> <p>Median (IQR) total dose: 31.5 g (29.0 to 44.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eligible for retreatment (total population): 1602 (71.5)</p> <p>Of eligible for retreatment, receiving drug at delivery (total population): 947 (59.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD004661-bbs2-0006" title="HuusomLD , BrokJ , HegaardHK , PrydsO , SecherNJ . Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? the final trial?Acta Obstetricia et Gynecologica Scandinavica2012;91(11):1346-7. LarsenML , KrebsL , RackauskaiteG , Hoei-HansenCE , GreisenG . Re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: at which gestational ages should magnesium sulphate be given to women at risk of preterm birth?BJOG: an international journal of obstetrics and gynaecology2020;127(10):1295-6. NCT01492608. Magnesium Sulphate for Preterm Birth (MASP Study) [Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)]. clinicaltrials.gov/show/nct01492608 (first received 15 December 2011). WolfH , HuusomL , PinborgA , HegaardH . Administration of antenatal magnesium sulphate for prevention of cerebral palsy and death in preterm infants-a double blind randomised placebo controlled parallel group multicentre trial. Journal of Perinatal Medicine2019;47(Suppl 1):eA167-8. WolfHT , BrokJ , HenriksenTB , GreisenG , SalvigJD , PrydsO , et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1217-25. WolfHT , BrokJ , HenriksenTB , HegaardHK , GreisenG , WeberT , et al. Authors' reply re: antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: time range for treatment with magnesium sulphate. BJOG: an international journal of obstetrics and gynaecology2020;127(10):1296-7. ">Wolf 2020</a> </p> </td> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Treatment intended</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 g over 10 to 30 min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 g/h until birth, or for 24 h if birth had not occurred</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loading dose repeated if ≥ 6 h had passed since discontinuation of treatment and birth was again imminent &lt; 32 weeks' gestation. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women eligible if expected to give birth within 2 to 24 h</p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Treatment as received, magnesium sulphate vs placebo, N (%) unless stated</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Started: 273 (96.5) vs 268 (96.7)</p> <p>Completed: 268 (94.7) vs 266 (96.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Started: 235 (83.0) vs 230 (83.0)</p> <p>Completed: 116 (41.0) vs 95 (34.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eligible for repeat loading dose (total population): 147 (26.3)</p> <p>Of those eligible for repeat loading dose, received it (total population):</p> <p>78 (53.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>Abbreviations:</b> IQR: interquartile range; IV: intravenous; N/A: not applicable; RCT: randomised controlled trial </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Treatment characteristics related to planned subgroup analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/full#CD004661-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004661-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Magnesium sulphate versus placebo: primary outcomes</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Death (fetal, neonatal, or later (up to 2 years' corrected age)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.82, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Cerebral palsy (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.57, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Death or cerebral palsy (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.77, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Major neurodevelopmental disability (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.83, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Death or major neurodevelopmental disability (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.85, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Death (fetal, neonatal, or later (up to school age)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.66, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Cerebral palsy (school age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.69, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Death or cerebral palsy (up to school age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.67, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Major neurodevelopmental disability (school age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>940</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.53, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Death or major neurodevelopmental disability (up to school age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.59, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Adverse effects severe enough to stop treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4736</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.21 [1.88, 5.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Magnesium sulphate versus placebo: primary outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004661-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Fetal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.46, 1.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Neonatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Variously defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6751</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.80, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Defined, where possible, as up to hospital discharge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6751</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.80, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Birthweight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Birthweight (grams)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.63 [‐18.85, 30.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Birthweight (z‐scores)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1679</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.08, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Length at birth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Length (cm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.04, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Length (z‐scores)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.05, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Head circumference at birth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Head circumference (cm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.10, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 Head circumference (z‐scores)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.12, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Gestational age at birth (weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.02, 0.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Apgar score less than 7 at 5 minutes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.89, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Use of active resuscitation at birth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 Any</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3776</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.96, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.2 Supplementary oxygen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3093</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.96, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.3 Intubation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3093</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.80, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.4 Chest compressions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3093</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.78, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Intraventricular haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.85, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Severe intraventricular haemorrhage (grade 3 or 4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5885</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.60, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Cystic periventricular leukomalacia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.65, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.12 Ventriculomegaly <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1776</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.53, 1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.13 Neonatal encephalopathy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1679</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.06, 15.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.14 Neonatal convulsions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6689</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.63, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.15 Neonatal hypotonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.77, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.16 Necrotising enterocolitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6689</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.98, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.17 Retinopathy of prematurity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3639</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.86, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.18 Patent ductus arteriosus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4771</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.73, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.19 Respiratory distress syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4777</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.83, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.20 Chronic lung disease/bronchopulmonary dysplasia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6689</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.77, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.21 Use of respiratory support (endotracheal intubation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.58, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.22 Use of respiratory support (mechanical ventilation or continuous positive airway pressure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.91, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.23 Use of inotropic support <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3092</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.50, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.24 Air leak syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1679</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.23, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.25 Early‐ or late‐onset sepsis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.25.1 Maternal‐fetal infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [1.09, 2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.25.2 Sepsis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.81, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.25.3 Early onset sepsis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1679</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.29, 5.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.25.4 Late onset sepsis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1679</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.49, 2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.26 Severe adverse neonatal outcome composite <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>863</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.72, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Magnesium sulphate versus placebo: secondary outcomes for fetuses/neonates/infants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004661-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Later death (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6646</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.66, 1.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Cerebral palsy severity (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Mild</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.53, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.50, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Any neurodevelopmental disability (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.84, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Death or any neurodevelopmental disability (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.83, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Blindness (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3633</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.39, 6.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Deafness (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3633</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.32, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Developmental delay/intellectual impairment (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.1 Any</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.90, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.2 Mild</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4639</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.84, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.3 Moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4639</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.91, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Gross motor dysfunction (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.1 Any</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1648</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.72, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.2 Substantial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1648</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.41, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Psychomotor dysfunction (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.1 Any</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.72, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.2 Moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.82, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.10 Death or substantial gross motor dysfunction (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5097</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.74, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.11 Growth (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.1 Weight (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.22, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.2 Height (cm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.75, 0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.3 Head circumference (cm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.21, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.4 Weight (z‐score)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.09, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.5 Height (z‐score)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.08, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.6 Head circumference (z‐score)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.13, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.12 Respiratory function (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.1 Childhood respiratory morbidity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.80, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.2 Asthma or wheezing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.78, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.13 Blood pressure (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.1 Systolic hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>679</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.76, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.2 Diastolic hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.81, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.3 Hypertension (any)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.83, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.14 Blood pressure (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14.1 Systolic blood pressure (mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>679</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐1.52, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14.2 Diastolic blood pressure (mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.93 [‐2.46, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14.3 Systolic blood pressure (z‐score)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>679</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.15, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14.4 Diastolic blood pressure (z‐score)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.22, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.15 Behaviour (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15.1 Child Behavior Checklist, total (scores in clinical range (&gt; 97.5th percentile))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>768</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [1.00, 2.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15.2 Child Behavior Checklist, anxiety (scores in clinical range (&gt; 97.5th percentile))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>793</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.14 [1.18, 3.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15.3 Child Behavior Checklist, withdrawal (scores in clinical range (&gt; 97.5th percentile))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>791</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [1.06, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15.4 Child Behavior Checklist, sleeping problem (scores in clinical range (&gt; 97.5th percentile)) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>795</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.54 [1.14, 5.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15.5 Child Behavior Checklist, somatic problem (scores in clinical range (&gt; 97.5th percentile)) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>785</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.59, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15.6 Child Behavior Checklist, aggressive behaviour (scores in clinical range (&gt; 97.5th percentile)) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>786</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.34 [0.94, 19.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15.7 Child Behavior Checklist, destructive behaviour (scores in clinical range (&gt; 97.5th percentile)) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>796</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.06, 15.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15.8 Child Behavior Checklist, other (scores in clinical range (&gt; 97.5th percentile))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.92 [1.00, 63.00]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Magnesium sulphate versus placebo: secondary outcomes for children (up to 2 years' corrected age)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004661-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Magnesium sulphate versus placebo: secondary outcomes for children (school age)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Later death (school age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1738</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.12, 1.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Cerebral palsy severity (school age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1065</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.72, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.34, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Any neurodevelopmental disability (school age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 Mild</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.63, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>940</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.87, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.3 Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>940</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.50, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.4 Any</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>940</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.85, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Death or any neurodevelopmental disability (school age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.86, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Blindness (school age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.86, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Deafness (school age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.38, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Developmental delay/intellectual impairment (school age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.1 Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.88, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.2 Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.35, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 Gross motor dysfunction (school age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.1 Motor dysfunction/deficits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.82, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.2 Motor deficits: no cerebral palsy, other motor disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.73, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.3 Gross Motor Function Classification System (GMFCS): levels I‐V</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.73, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.4 Movement Assessment Battery for Children (MABC): suspect/abnormal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>598</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.82, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.9 Death or substantial gross motor dysfunction (school age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.80, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.10 Growth (school age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10.1 Weight (SD scores)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>614</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐0.45, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10.2 Head circumference (SD scores)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>609</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.40, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10.3 Height (SD scores)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.16 [‐0.35, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10.4 BMI (SD scores)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>612</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.41, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.11 Respiratory function (school age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>424</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.51, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.12 Behaviour (school age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.12.1 'Behavioral and psychiatric disorder' (moderate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.67, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.12.2 Borderline and abnormal Total Difficulties Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.55, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.12.3 Borderline and abnormal Emotional Symptoms Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.76, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.12.4 Borderline and abnormal Conduct Problem Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.76, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.12.5 Borderline and abnormal Hyperactivity Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.61, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.12.6 Borderline and abnormal Peer Problems Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.67, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.12.7 Borderline and abnormal Prosocial Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.49, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.13 Behaviour (school age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.13.1 CADS parent T scores: ADHD index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [‐0.75, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.13.2 CADS parent T scores: DSM‐IV inattentive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [‐1.05, 2.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.13.3 CADS parent T scores: DSM‐IV hyperactive‐impulsive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐1.71, 2.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.13.4 CADS parent T scores: DSM‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [‐1.20, 2.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.13.5 CADS teacher T scores: ADHD index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [‐1.32, 2.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.13.6 CADS teacher T scores: DSM‐IV inattentive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [‐0.82, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.13.7 CADS teacher T scores: DSM‐IV hyperactive‐impulsive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [‐0.96, 2.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.13.8 CADS teacher T scores: DSM‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [‐0.81, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.13.9 BRIEF teacher T scores: global executive composite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>507</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [‐1.14, 2.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.13.10 BRIEF teacher T scores: metacognition index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>495</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [‐1.59, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.13.11 BRIEF teacher T scores: behavioral regulation index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>537</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [‐1.42, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.14 Educational achievement (school age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.14.1 Schooling: specialised class room</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.32, 2.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.14.2 Schooling: specialised institution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.25, 3.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.14.3 Schooling: repeated grades</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.24, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.14.4 Schooling: specific education assistance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.40, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.14.5 Schooling: home education services</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.17, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.14.6 Language disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.53, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.15 Educational achievement (school age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.1 Academic skills: reading</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>588</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [‐2.24, 3.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.2 Academic skills: spelling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [‐1.31, 3.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.3 Academic skills: arithmetic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>587</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐2.35, 2.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.4 General cognitive function: full scale IQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.10 [‐3.60, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.5 General cognitive function: verbal comprehension index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>601</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐3.00, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.6 General cognitive function: perceptual reasoning index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>601</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.50 [‐3.95, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.7 General cognitive function: working memory index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>592</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.30 [‐3.68, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.8 General cognitive function: processing speed index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>585</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐1.97, 2.77]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Magnesium sulphate versus placebo: secondary outcomes for children (school age)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004661-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Magnesium sulphate versus placebo: secondary outcomes for women</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Cardiac arrest <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Respiratory arrest <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Side effects of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.49 [2.53, 7.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Side effect: respiratory depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.1 As defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4736</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.82, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.2 As defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.83, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Side effect: hypotension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3059</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [1.29, 2.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 Side effect: tachycardia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1062</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [1.03, 2.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.8 Side effect: warmth over body/flushing <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.13 [4.28, 11.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.9 Side effect: arm discomfort with infusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4736</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.64 [7.85, 11.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.10 Side effect: mouth dryness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2495</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.26 [1.31, 8.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.11 Side effect: nausea or vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.99 [2.05, 7.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.12 Side effect: sleepiness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1062</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.49 [1.82, 3.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.13 Side effect: sweating <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4736</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.12 [2.86, 13.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.14 Side effect: dizziness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2495</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.16 [1.50, 6.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.15 Side effect: blurred vision <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2495</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.33 [1.05, 17.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.16 Side effect: tendon reflex abolition <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.94 [0.18, 21.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.17 Side effect: "curarisation" <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.92 [0.12, 71.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.18 Side effect: headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.89 [0.44, 34.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.19 Mode of birth: caesarean birth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5861</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.91, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.20 Chorioamnionitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.81, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.21 Postpartum haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.21.1 Postpartum haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2495</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.80, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.21.2 Severe postpartum haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3059</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.90, 2.05]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Magnesium sulphate versus placebo: secondary outcomes for women</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004661-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Magnesium sulphate versus placebo: secondary outcomes for health services</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Maternal admission to the intensive care unit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1062</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Length of postnatal hospitalisation for women (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1062</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.18, 0.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Length of neonatal/infant hospitalisation (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [‐2.62, 6.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Hospital admissions (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.79, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 Postdischarge service (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.83, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.6 Hospital admissions (school age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.69, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Magnesium sulphate versus placebo: secondary outcomes for health services</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004661-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Subgroup analysis: gestational age at randomisation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Death (fetal, neonatal, or later (up to 2 years' corrected age)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.82, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 &lt; 30 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1466</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.68, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.2 &lt; 32 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2913</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.83, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.3 &lt; 34 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.68, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Cerebral palsy (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.57, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.1 &lt; 30 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.53, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.2 &lt; 32 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2876</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.42, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.3 &lt; 34 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.55, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Death or cerebral palsy (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.77, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.1 &lt; 30 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1466</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.70, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.2 &lt; 32 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2913</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.70, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.3 &lt; 34 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.71, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Death or major neurodevelopmental disability (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.85, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.1 &lt; 30 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.80, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.2 &lt; 32 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1771</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.79, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.3 &lt; 34 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.76, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.5 Death (fetal, neonatal, or later (up to school age)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.66, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5.1 &lt; 30 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.62, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5.2 &lt; 34 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.58, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.6 Cerebral palsy (school age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.69, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.1 &lt; 30 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>609</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.66, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.2 &lt; 34 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.56, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.7 Major neurodevelopmental disability (school age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>940</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.53, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7.1 &lt; 30 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.75, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7.2 &lt; 34 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.39, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.8 Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.8.1 &lt; 30 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1062</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.8.2 &lt; 32 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.8.3 &lt; 34 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.9 Adverse effects severe enough to stop treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4736</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.21 [1.88, 5.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.9.1 &lt; 30 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1062</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.74 [1.81, 4.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.9.2 &lt; 32 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.94 [1.67, 5.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.9.3 &lt; 34 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1433</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>19.31 [2.60, 143.53]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Subgroup analysis: gestational age at randomisation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004661-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Subgroup analysis: loading‐dose regimen</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Death (fetal, neonatal, or later (up to 2 years' corrected age)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.82, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.1 4 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.70, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.2 &gt; 4 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.85, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Cerebral palsy (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.57, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.1 4 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3055</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.62, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.2 &gt; 4 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.43, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Death or cerebral palsy (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.77, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.1 4 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.73, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.2 &gt; 4 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.72, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.4 Death or major neurodevelopmental disability (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.85, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4.1 4 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.84, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4.2 &gt; 4 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1771</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.79, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.5 Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5.1 4 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3059</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5.2 &gt; 4 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.6 Adverse effects severe enough to stop treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4736</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.21 [1.88, 5.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6.1 4 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2495</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.74 [0.83, 39.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6.2 &gt; 4 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.94 [1.67, 5.17]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Subgroup analysis: loading‐dose regimen</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004661-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Subgroup analysis: maintenance dose regimen</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Death (fetal, neonatal, or later (up to 2 years' corrected age)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.82, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.1 No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.68, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.2 1 g/hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1935</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.65, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.3 2 g/hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.87, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Cerebral palsy (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.57, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.1 No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.55, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.2 1 g/hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.53, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.3 2 g/hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.40, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Death or cerebral palsy (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.77, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.1 No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.71, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.2 1 g/hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1935</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.67, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.3 2 g/hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.73, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.4 Death or major neurodevelopmental disability (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.85, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4.1 No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.76, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4.2 1 g/hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.80, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4.3 2 g/hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1771</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.79, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.5 Death (fetal, neonatal, or later (up to school age)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.66, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5.1 No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.58, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5.2 1 g/hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.62, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.6 Cerebral palsy (school age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.69, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.6.1 No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.56, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.6.2 1 g/hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>609</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.66, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.7 Major neurodevelopmental disability (school age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>940</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.53, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7.1 No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.39, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7.2 1 g/hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.75, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.8 Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.8.1 No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.8.2 1 g/hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1062</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.8.3 2 g/hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.9 Adverse effects severe enough to stop treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4736</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.21 [1.88, 5.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.9.1 No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1433</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>19.31 [2.60, 143.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.9.2 1 g/hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1062</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.74 [1.81, 4.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.9.3 2 g/hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.94 [1.67, 5.17]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Subgroup analysis: maintenance dose regimen</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004661-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Subgroup analysis: repeat treatment permitted</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Death (fetal, neonatal, or later (up to 2 years' corrected age)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.82, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.1 No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.70, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.2 Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.85, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Cerebral palsy (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.57, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.1 No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3055</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.62, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.2 Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.43, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.3 Death or cerebral palsy (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.77, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3.1 No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.73, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3.2 Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.72, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.4 Death or major neurodevelopmental disability (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.85, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4.1 No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.84, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4.2 Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1771</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.79, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.5 Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5.1 No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3059</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5.2 Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.6 Adverse effects severe enough to stop treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4736</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.21 [1.88, 5.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.6.1 No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2495</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.74 [0.83, 39.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.6.2 Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.94 [1.67, 5.17]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Subgroup analysis: repeat treatment permitted</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004661-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Sensitivity analysis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Death (fetal, neonatal, or later (up to 2 years' corrected age)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.81, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 Cerebral palsy (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.55, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.3 Death or cerebral palsy (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.74, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.4 Death or major neurodevelopmental disability (up to 2 years' corrected age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.84, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.5 Cerebral palsy (school age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.79, 1.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Sensitivity analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004661.pub4/references#CD004661-tbl-0016">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004661.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD004661-note-0010">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD004661-note-0020">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004661-note-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD004661-note-0018">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD004661-note-0016">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD004661-note-0014">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD004661-note-0015">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD004661-note-0019">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD004661-note-0013">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD004661-note-0011">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD004661-note-0012">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004661\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004661\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004661\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004661\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004661\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004661\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004661\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004661\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004661\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004661\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004661\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004661\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004661\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004661\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004661\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004661\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004661\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004661\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xcg9958b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004661.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004661.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004661.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004661.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004661.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715288701"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004661.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715288707"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004661.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d83702d2ef446',t:'MTc0MDcxNTI4OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 